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Abstract 
Psoriasis represents a complex interplay between genetic predisposition, the 
environment and inflammatory responses, and increasing evidence suggests alterations 
in the epigenome, including histone acetylation, plays a role.  Bromodomain-containing 
proteins regulate gene expression by binding to acetyl-lysine residues on histones and 
recruiting transcription factors to gene regulatory regions.  The development of small 
molecule inhibitors of bromodomain extraterminal (BET) proteins has enabled 
interrogation of this pathway.  Interestingly BET inhibitors demonstrate anti-
proliferative and anti-inflammatory effects in in vitro and in vivo models of cancer and 
inflammation.  An established in-vitro keratinocyte model of cutaneous inflammation 
was further developed to characterise IL-6 and IL-8 (mRNA and protein) responses to 
TNF+ IL-17 stimulation.  Chromatin immunoprecipitation (ChIP) studies showed 
psoriasis-relevant stimuli induced dynamic, gene-specific alterations of the epigenome, 
including histone hyperacetylation, with co-ordinated recruitment of BET proteins 
(Brd2, Brd3 and Brd4) and RNA polymerase II, to the promoter region of IL-6 and IL-
8.  The effects of TNF+ IL-17 stimulation in keratinocytes were validated through 
global gene expression array studies which showed stimulation modulated expression of 
keratinocyte genes known to be differentially expressed in psoriasis and involved in its 
pathogenesis.  The hypothesis that BET proteins are involved in regulating 
inflammatory responses in keratinocytes was tested using a specific BET inhibitor, I-
BET151; this blocked pathogenic inflammatory responses.  In particular, IL-6 and IL-8 
responses to TNF + IL-17 stimulation demonstrated potent sensitivity to I-BET151 
treatment; this could be accounted for by the decreased binding of BET proteins and 
RNA polymerase II to IL-6 and IL-8 gene promoter regions in the presence of the BET 
inhibitor.  Global gene expression array studies showed genes sensitive to BET 
inhibition were primarily involved in the cell cycle and inflammation, with many 
relevant to the pathogenesis of psoriasis.  In addition, ~20% of genes identified in a 
previously published meta-analysis of five psoriasis transcriptomic studies were 
differentially modulated by I-BET151 treatment in TNF + IL-17 stimulated NHEKs.  
Furthermore, acetate, a principle metabolite of ethanol, a factor implicated in the 
development and exacerbation of psoriasis, enhanced IL-6, but not IL-8, responses to 
TNF + IL-17 stimulation through gene-specific epigenetic modifications at the 
promoter region. IFN also enhanced IL-6, but not IL-8, response to TNF + IL-17 
stimulation, suggesting i) IL-6 is more sensitive to enhancement by additional disease 
relevant stimuli and ii) IL-6 and IL-8 are differentially regulated at the transcriptional 
level; ChIP studies showed increased enrichment of Brd4/p65 at the IL-6 promoter 
compared to the IL-8 promoter. 
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1. Introduction 
1.1. Structure and function of the skin 
The skin covers over 2m
2
 in adult humans and is divided into two layers (Figure 1-1A); 
the epidermis which is generally 75-150nm thick, but may be up to 600nm on palms 
and soles; and the dermis which is usually up to 2mm thick, but may be up to 4.5mm on 
the back; below these two layers is the subcutaneous tissue (Tobin, 2006).  
Keratinocytes are the major cell type of the epidermis (approximately 80%), other cell 
types include; T-cells, melanocytes, Langerhans’ cells and monocytes.  The dermis is 
composed mainly of collagen-based connective tissue interspersed with blood vessels 
but also hair follicles, sweat glands, and sebaceous glands.  Below the dermis is 
subcutaneous tissue composed mainly of adipose tissue.  The skin has important barrier 
functions, with protective functions against ultraviolet radiation, infection and excess 
fluid loss; the majority of these functions are provided by the stratum corneum of the 
epidermis. 
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Figure 1-1: Haematoxylin and eosin stain of normal and psoriatic skin 
(40x objective) 
A) Normal skin.  Keratinocytes make up 80% of the epidermis which undergo 
progressive differentiate within the 4 layers of the epidermis.  The basal layer contains 
keratinocyte stem cells; the stratum spinosum contains proliferating cells committed to 
differentiation (transit amplifying cells); the stratum granulosum contains the majority 
of differentiating cells and; the stratum corneum consists of anucleated differentiated 
squames that are eventually shed.  Corneocytes within the stratum corneum have a 
lipid-embedded, crossed-linked protein membrane (termed a “cornified envelope”), 
which effectively forms a physical barrier to prevent e.g. outward water loss and inward 
infection.  The dermis is composed mainly of collagen-based connective tissue 
interspersed with blood vessels  B) In psoriasis the epidermis is thickened (acanthosis), 
with elongation of the rete ridges (papillomatosis), thickening of the stratum corneum 
(hyperkeratotic) and of the stratum spinosum. The stratum granulosom is thinned or 
absent (hypogranulosis) due to the loss of differentiation which normally occurs in this 
layer.  Excess keratinocyte proliferation and abnormal differentiation, results in 
retention of nuclei within the stratum corneum (parakeratosis).  In psoriasis, erythema is 
due to an increased vasculature which reaches into the tips of the dermal papillae and 
becomes dilated.  Epidermal neutrophilic infiltration is also a feature and may localise 
to form microabscesses.  Additional inflammatory infiltrate is composed mainly of 
myeloid dendritic cells and CD4+ T cells within the dermis and CD8+ cells in the 
epidermis.  (Adapted from www.skinpathology.org) 
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1.2. Introduction to psoriasis 
1.2.1. Epidemiology and characteristics of psoriasis 
Psoriasis is a chronic inflammatory dermatosis, which is a category of disease 
encompassing a broad spectrum of dermatological conditions including atopic eczema, 
psoriasis, acne and lichen planus; common features include skin barrier disruption and 
inflammation.  These conditions have high prevalence and severity can range from mild 
to life-threatening.  Psoriasis is a chronic relapsing and remitting inflammatory skin 
disease which typically affects 2-3% of the Western population, although this figure can 
vary between studies (Stern et al., 2004; Gelfand et al., 2005; Parisi et al., 2015).  
Psoriasis affects both sexes equally, although some report that men suffer more severe 
disease than women (Hagg et al., 2013).  In patients with psoriasis, approximately 90% 
will have chronic plaque psoriasis (Figure 1-2) which demonstrates characteristic 
histological features (Figure 1-1B).  Other subtypes of psoriasis include inverse/flexural 
psoriasis, pustular psoriasis, guttate psoriasis, erythrodermic psoriasis and palmo-plantar 
psoriasis.  There may also be nail and joint involvement with each subtype of psoriasis. 
 
 
 
 
 
                                                                           
Figure 1-2: Chronic plaque psoriasis 
Chronic plaque psoriasis is characterised clinically by well-defined plaques of erythema 
with thick silver scale often on extensor surfaces, including elbows and knees.  
(Source: Prof. N.J. Reynolds, Newcastle Upon Tyne Hospitals, NHS Foundation Trust) 
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Chronic plaque psoriasis can itself be subdivided into type I, in which onset is <40 years 
old, there is a strong family history and accounts for approximately 75% of patients 
with chronic plaque psoriasis; and type II, in which onset is ≥40 years old and accounts 
for approximately 25% of patients with chronic plaque psoriasis.  Recently, the concept 
of disease endotype has been applied to complex multi-factorial diseases; an endotype 
can be defined by a genetic signature (e.g. IL-36RN in pustular psoriasis or HLA-Cw6 
in plaque psoriasis (Gudjonsson et al., 2003; Onoufriadis et al., 2011) or by a molecular 
signature (e.g. high IFN in systemic lupus erythematosus (Niewold et al., 2010) 
(section 1.2.4).  There is currently great interest in the association of disease endotypes 
with clinical presentation and course of disease, as well as their potential to inform 
therapeutic stratification. 
Clinical severity of psoriasis can be assessed using the psoriasis activity and severity 
index (PASI), which includes assessment of erythema (redness), desquamation (scale), 
induration (thickness) and body sites affected, with a maximum total score of 72.  In 
clinical trials, a baseline PASI score (measured prior to treatment) is usually compared 
to repeated PASI scores undertaken during treatment.  Most clinical trials consider an 
intervention to be effective if it leads to a 75% improvement in PASI compared baseline 
(PASI75).  A major criticism of this is that patients with very severe disease could still 
have a high PASI score/disease severity even after PASI75 is achieved.  In addition to 
PASI or as an alternative, disease severity can be measured using Physician Global 
Assessment (PGA) and impact of disease on a patient’s quality of life can be measured 
by Dermatology Life Quality Index (DLQI). 
1.2.2. The financial burden of psoriasis and impact on quality of life  
Psoriasis can have a significant impact on a patient’s quality of life, with some patients 
rating the impact of skin disease as highly as some major medical diseases, including 
cancer and heart disease (Rapp et al., 1999).  In addition, it is reported that some 
patients with psoriasis consume more alcohol following diagnosis to cope with the 
impact of disease (Braathen et al., 1989), reflecting the negative impact that chronic 
inflammatory dermatoses can have on quality of life (Kirby et al., 2008).  Patient with 
severe psoriasis are also more likely to suffer from depression with an adjusted hazard 
ratio (HR) for depression of 1.72 in those with severe psoriasis compared to an HR of 
1.38 in those with mild disease.   In addition to effects on patients, psoriasis can be a 
considerable financial burden for the wider society; a European study showed the 
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economic cost of patients with moderately severe psoriasis to be ~£4500 per patient per 
year, while the economic cost of patients with severe disease was ~£10000 per patient 
per year (Colombo et al., 2008), with time out of work accounting for ~40% of these 
costs (Fowler et al., 2008).  A more recent 2015 study in the US showed the cost of 
treating moderate to severe psoriasis was ~£15000 per patient per year (Schaefer et al., 
2015). 
1.2.3. Current therapies and unmet needs in psoriasis 
Current available treatments for psoriasis tends to progress in a step-wise fashion 
(Figure 1-3).  Approximately 70-80% of patient with psoriasis will have mild disease 
which may respond to topical treatment alone (Schon and Boehncke, 2005). However 
topical treatments are often time consuming to apply or cosmetically unacceptable (for 
example being greasy, smelly or stain clothing/bedding) and may not lead to complete 
resolution of disease; resulting in poor compliance (Jabbar-Lopez et al., 2014).  
Systemic therapy, for moderate to severe disease, often carries the risk of significant 
side effects, including renal and hepato-toxicity, increased risk of life-threatening 
infections and cancer; and not all patients will respond to treatment (Jabbar-Lopez et al., 
2014).  Interestingly the field of pharmacogenetics, with respect to psoriasis, is 
expanding with some groups reporting, in a small preliminary study, genetic 
polymorphisms associated with response to biologic therapy (Tejasvi et al., 2012).  This 
may have important implications for the selection of the most appropriate treatments for 
patients.   However, despite these advances there is a significant unmet therapeutic 
need, not all patients will respond to currently available treatments which may have 
many side-effects and there are no predictive biomarkers of response or failure.  In 
addition, even in patients who do show an initial response to biologic therapy, loss of 
efficacy over time remains a challenge.  Furthermore, none of the current therapies offer 
a potential cure or very long-term remission. 
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Figure 1-3: Psoriasis treatment ladder 
The choice of therapy will be determined by a variety of factors including severity and 
site of psoriasis.  Generally, the greater the severity of disease, the further up the 
treatment ladder, but patients may receive treatment from several rungs of the ladder 
and do not necessarily have to transition through each step, e.g. if a patient presents 
with very severe disease for the first time, then topical treatment alone may be 
inappropriate.  (Adapted from Jabbar-Lopez et al., 2014) 
 
1.2.4. Genetic studies in psoriasis 
It is unknown what regulates the pattern of psoriasis seen clinically; for example, the 
boundary between lesional and non-lesional skin, the typical sites of chronic plaque 
psoriasis or the relapsing/remitting nature of the disease, although it is known that there 
is a genetic component.  Evidence for genetic involvement in psoriasis initially came 
from twin studies demonstrating higher concordance between monozygotic twins (65–
72% concordance) compared to dizygotic twins (15–30%  concordance)  (Bowcock and 
Cookson, 2004).  
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More recently our knowledge of the genetic susceptibility of psoriasis has increased and 
genome wide association studies have increased the number of psoriasis susceptibility 
loci in individuals of European ancestry to 45 (Tsoi et al., 2012; Tsoi et al., 2015).  
Each susceptibility loci may contain sequences for several candidate genes and, while it 
is currently unknown what all these genes are and which might contribute to disease, 
deep sequencing in the future may identify these genes.   However, some loci are known 
to include candidate genes involved in, for example, i) T-cell regulation, e.g. STAT3 
which is involved in downstream signalling of numerous cytokines implicated in 
psoriasis including IL-6, IL-22 and IL-23; ii) innate immune response, e.g. SOCS1 
which regulates STAT3 transcriptional activity and CARD14 which is involved in 
activation of the NF-kB pathway; and iii) cell signalling, e.g. KLF4 which is involved in 
macrophage activation (Tsoi et al., 2012; Tsoi et al., 2015).  36 of the previously 
discovered psoriasis associated genetic regions were predicted to account for only 
approximately 14% of the total variance of psoriasis risk or approximately 22% of its 
estimated heritability (Tsoi et al., 2012), which together with the observation that 
monozygotic twins do not show complete concordance for psoriasis, suggests that non-
genetic factors must also contribute to disease. 
Interestingly different genetic associations have been made with particular subtypes of 
psoriasis.  For example, type I chronic plaque psoriasis (section 1.2.1) is most strongly 
associated with the PSORS1 locus, a 220-kb region in the major histocompatibility 
complex (MHC) on chromosome 6 which is known to contain at least 10 genes 
(Trembath et al., 1997). Within the PSORS1 locus there is consensus that HLA-C is the 
most likely gene involved in psoriasis pathogenesis (Elder, 2006). Specifically, the 
HLA-Cw0602 allele is believed to confer the greatest risk of developing psoriasis; up to 
60% of patients with psoriasis carry the HLA-Cw0602 allele and homozygosity confers 
a relative risk of developing psoriasis of approximately 20 and a relative risk of 
approximately 10 in heterozygotes (Gudjonsson et al., 2003).  Despite strong 
association with psoriasis, the role of HLA-Cw0602 in the pathogenesis of psoriasis 
remains unknown.  Interestingly HLA-Cw0602 is known to interact genetically with the 
endoplasmic reticulum aminopeptidase-1 (ERAP1) such that variants of ERAP1 are 
only associated with psoriasis in those also carrying the HLA-Cw6 risk allele (Strange 
et al., 2010).  This is of particular biological interest as ERAP is involved in antigen 
binding to MHC class I proteins including HLA-C.   Type II plaque psoriasis (section 
1.2.1), on the other hand is not associated with HLA-Cw0602, different disease 
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pathways may therefore feature more prominently in particular disease subtypes.  
Furthermore, different ethnic groups may show unique genetic susceptibility factors 
(Sun et al., 2010).   
With the observation that i) there is discordance in psoriasis between monozygotic 
twins and ii) in patients with chronic plaque psoriasis, there are both affected and 
unaffected areas, despite all cells generally harbouring the same underlying genetic 
sequences and mutations, it is clear that psoriasis cannot be a purely genetic disease.  In 
this respect it is known that environmental factors can also contribute to disease; 
alcohol, streptococcal throat infection, stress and drugs, such as beta-blockers and 
lithium, are associated with psoriasis (section 1.4).  It is, however, unknown how the 
environment interacts with genetic components and adaptive and innate immune 
systems to produce the disease phenotype in psoriasis, although epigenetics may play a 
role (section 1.3.5). 
1.2.5. Pathophysiology of psoriasis 
The pathogenesis of psoriasis is not fully understood but the most widely accepted 
model of psoriasis is that proliferation of keratinocytes, which themselves may be 
dysfunctional or hypersensitive to stimuli (section 1.2.6), is driven by over-active 
adaptive and innate immune systems, involving T cells, dendritic cells, neutrophils, 
mast cells, natural killer (NK) cells, and macrophages, with at least 3 key cytokine 
networks/axes having prominent roles: 
i. IFN/TNF/T helper 1 cells (TH1 cells) 
ii. IL-23/IL-17/T helper 17 cells (TH17 cells) 
iii. IL-22/T helper 22 cells (TH22) 
In addition to key roles for TNF, IL-17, IL-23 and IFN in disease pathogenesis, IL-6, 
IL-7, IL-8, IL-12, IL-18 and vascular endothelial growth factor (VEGF) also have 
important roles and their serum levels are elevated in patients with psoriasis compared 
to healthy controls (Takahashi et al., 2010).  Although cytokine networks/axes will be 
discussed individually, for simplicity, psoriasis represents a complex interplay between 
these networks with multiple positive feedback loops between networks and different 
cell types driving disease. 
Psoriasis can be triggered by a variety of stimuli including injury/trauma (known as 
Koebner phenomenon), drugs, alcohol, and infections.  Exactly how these stimuli may 
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influence psoriasis is unknown but it is thought that environmental insults to 
keratinocytes cause cell death and release of epidermal products including anti-
microbial peptide LL37 (cathelicidin)/nucleic acid complexes which bind to toll-like 
receptors on plasmacytoid dendritic cells (Gilliet and Lande, 2008).  This is thought to 
lead to dendritic cell activation and production of type I interferons IFNand, TNF 
and IL-2, which skews the maturation of naïve T cells into TH1 cells which are known 
to produce IFN, TNF, IL-1 and IL-18 (Gilliet and Lande, 2008).  TNFis a pro-
inflammatory cytokine that acts as a chemoattractant for immune cells and is an 
activator of T-cells and dendritic cells; thus a positive feedback loop between 
keratinocytes and dendritic cells is created.  TNFis also produced by a wide variety of 
other cells in psoriasis, including keratinocytes, macrophages, lymphocytes and 
endothelial cells.  IFN is a type II interferon and drives further recruitment of 
lymphocytes as well as further stimulating dendritic cells to produce IL-23 and IL-1.  
The IFN/TNF/TH1 cytokine axis is considered one of the main divers of psoriasis 
pathogenesis (Perera et al., 2012). 
Dendritic cells are also known to be the main producers of IL-23 in psoriatic skin (Lee 
et al., 2004).  IL-23, together with IL-6 and IL-12, triggers activation and differentiation 
of T cells into IL-17 producing TH17 cells.  IL-6-dependent activation of STAT3 leads 
to TH17 differentiation, by activating transcription of IL-23R, IL-17 family members 
and RORC (retinoic acid receptor-related orphan receptor C), and subsequent TH17 
proliferation (Hirahara et al., 2010).  Once activated, TH17 cells produce key cytokines 
including IL-17A (IL-17), IL-17F and IL-22 which are increased in psoriatic skin and 
known to drive keratinocyte proliferation (Johansen et al., 2009).  IL-17 is also 
produced by CD4+/8+ T cells, neutrophils, mast cells, NK cells and macrophages 
(Baliwag et al., 2015). This second cytokine axis, IL-23/IL-17/TH17, is also considered 
key to disease pathology (Perera et al., 2012).  TNF and IL-17 act on many cells types, 
although keratinocytes are the main cell type to express the IL-17 receptor, causing 
them to produce antimicrobial peptides (e.g. -defensins and S100 proteins) chemokines 
(e.g. CXCL-5, CXCL-6, CXCL10 and CCL-20) and cytokines (e.g. IL-6, IL-8, IL-17, 
IL-23)  which act as chemoattractants for immune cell infiltration into the skin 
(Nograles et al., 2008; Chiricozzi et al., 2011).  The positive feedback loop between IL-
17-induced  production of IL-6 from non-immune cells (e.g. keratinocytes and 
fibroblasts) and IL-6-induced differentiation/activation of naïve T-cells into TH17 cells, 
resulting in further IL-17 release, plays a key role in linking immune and non-immune 
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tissues (Saggini et al., 2014).  IL-17 is also known to link the innate and adaptive 
immune systems, through recruitment and activation of neutrophils (Weaver et al., 
2007). Neutrophil recruitment and activation is further enhanced by IL-6, IL-8 and 
CXCL-5 release from keratinocytes in response to IL-17 (and TNF) stimulation 
(Saggini et al., 2014), thus demonstrating complex interplay between non-immune and 
immune (adaptive and innate) tissues as well as key roles for both IL-6 and IL-8.   
In addition to TH17 cells secreting IL-22, more recently a subset of T-cells were found 
to secrete IL-22 and TNF but not IFN IL-4 or IL-17; these were termed TH22 cells 
and are known to infiltrate the epidermis in patients with psoriasis (Eyerich et al., 2009) 
and differentiation of naive T cells to TH22 cells was previously found to be dependent 
on both dendritic cells as well as IL-6 and TNF (Duhen et al., 2009).  NK cells also 
secret IL-22, as well as TNF and IFN(Lowes et al., 2014.   Interestingly, the IL-22 
receptor is expressed only in non-immune cells, including epidermal keratinocytes, 
which could explain why IL-22 stimulation previously was shown to have no effect on 
T-cells (Wolk et al., 2010).  IL-22 can induce a variety of responses in keratinocytes 
which are known to be important in psoriasis.  For example, IL-22 can stimulate 
production of anti-microbial peptides in keratinocytes, including S100 proteins, -
defensins and LL-37, which are over-expressed in psoriasis and have roles in recruiting 
immune cells and potentially initiating psoriasis in response to keratinocyte injury, as 
discussed above (Wolk et al., 2004; Gilliet and Lande, 2008).  Furthermore, IL-22 can 
also induce keratinocyte proliferation and inhibit differentiation, two key features of 
psoriatic epidermis (Boniface et al., 2005).  IL-17 secretion from TH17 cells may also 
drive epidermal hyperplasia (Rizzo et al., 2011) 
Cytokine signalling plays a clear role in linking complex networks and regulating 
different cell types.  This signalling is tightly regulated and relies on multiple positive 
feedback loops, thus inhibiting key cytokine pathways has the potential to disrupt 
pathogenesis leading to disease remission.  This is supported by the finding that 
monoclonal antibodies to individual key cytokines are effective treatments for psoriasis.  
Monoclonal antibodies to both TNFand IL-23/12 are both widely used clinically and 
the central role of IL-17 in psoriasis is supported by the observation that IL-17 receptor 
antagonism reverses the psoriatic phenotype (Hueber et al., 2010) and a monoclonal 
antibody against IL-17 has recently been licensed for treating moderate-severe psoriasis 
(section 1.2.6).  In addition to targeting TNF, IL-23/12 and IL-17,  IL-6 has also been 
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evaluated as a potential target for treatment (Saggini et al., 2014).  In addition to 
antibody-targeting of specific cytokines, more recently small molecule inhibitors have 
been developed which either inhibit production of cytokines or inhibit downstream 
signalling pathways.  For example, a phosphodiesterase 4 inhibitor (apremilast) has 
recently been licensed for moderate-severe psoriasis and is known to downregulate 
production of TNF, IFN and IL-23 in inflammatory cells, while a Janus kinase 3 
inhibitor (tofacitinib, currently in phase III clinical trials) blocks signal transduction of 
IL-2/-7/-15 and -21 which are involved in T-cell development (Mansouri and 
Goldenberg, 2015). 
1.2.6. In vitro keratinocyte models/studies of psoriasis 
Although there is strong evidence for the role of both the adaptive and innate immune 
system in the pathogenesis of psoriasis, there is also good evidence to support the role 
of defects or alterations in keratinocyte functions in psoriasis (Al-Daraji et al., 2002).  
For example, psoriasis can present in distinct linear patterns often with a sharp, midline 
cut off; this is known as linear psoriasis and is characterised by a linear distribution of 
psoriatic lesions along Blaschko's lines (Brinca et al., 2011).  Blaschko’s lines represent 
the routes of embryological keratinocyte migration and do not follow any known 
nervous, vascular or lymphatic structures in the skin (Jackson, 1976).  Linear psoriasis 
is hypothesised to arise from either somatic mutations or crossing over in embryonic 
keratinocyte stem cells (resulting in exchange of genetic material between homologous 
chromosomes and therefore recombination of genes), which may therefore harbour a 
predisposing gene in daughter cells within a Blaschkoid migratory segment (Happle, 
1991).  In addition to predisposing genes, as with chronic plaque psoriasis, 
environmental factors are also thought to be necessary for the linear psoriasis phenotype 
to develop, this could explain why disease presents later in life and not at birth  (Happle, 
1991).  In addition to potential keratinocyte defects in linear psoriasis, these may also 
exist in keratinocytes from chronic plaque psoriasis.  For example, keratinocytes from 
psoriatic patients have been shown to undergo abnormally rapid proliferation; injection 
of radiolabelled thymidine into skin 1h prior to skin biopsy showed that the ratio of 
mitotic count to number of labelled cells was higher in involved psoriatic skin compared 
to normal healthy skin, with uninvolved psoriatic skin having an intermediate number 
(Goodwin et al., 1973).  Furthermore, keratinocytes derived from psoriasis patients are 
also more resistant to apoptosis compared to ones derived from normal skin and could 
contribute to the excess keratinocyte number observed in psoriasis (Wrone-Smith et al., 
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1997).  Finally, keratinocytes have also been shown to have altered intracellular 
signalling, including activated STAT3, which is known to have roles in cell survival and 
proliferation (Sano et al., 2005).  Interestingly, Sano et al. demonstrated that transgenic 
mice with constitutively active STAT3 developed a psoriatic phenotype in the presence 
of activated T-cells (Sano et al., 2005). 
In addition to the above, psoriasis therapies targeting keratinocytes can lead to disease 
remission which further suggests that keratinocytes have an important role in the 
pathogenesis of psoriasis.  For example, it is known that treatment with narrow band 
ultraviolet B (UVB) can induce remission (Kirke et al., 2007; Chen et al., 2013).  
Although phototherapy has a complex mechanism of action, targeting keratinocytes and 
skin immune cells, it has been shown that keratinocyte apoptosis is an important 
mechanism of psoriatic plaque remodelling and clearance in response to UVB 
(Weatherhead et al., 2011; Zhang et al., 2015).  Together these findings suggest 
keratinocytes are not innocent/passive bystanders but may be genetically predisposed to 
be hyper-responsive to endogenous or exogenous inflammatory stimuli.  Furthermore, 
correction of keratinocyte dysfunction could lead to long-term clearance of psoriasis.  In 
order to explore the role of keratinocytes in psoriasis further, this thesis will focus on 
keratinocyte models/studies of psoriasis. 
Although a variety of cytokines, chemokines and growth factors are upregulated in 
psoriasis, it remains unclear which are the key mediators of disease and therefore which 
of these potential stimuli are the most important for reproducing an in vitro keratinocyte 
model of psoriasis to further understand the pathogenesis.  Perhaps the most relevant 
factors are those which correlate with disease activity and also respond to therapy.  In 
one of the largest studies of its kind, involving 122 patients, serum cytokine and growth 
factors levels in patients with psoriasis were compared to healthy controls and also 
correlated to disease activity, measured by PASI, both before and after psoriasis 
treatment (Takahashi et al., 2010).  Psoriasis patients showed increased serum levels of 
TNFα, IFNγ, IL-6, IL-7, IL-8, IL-12, IL-17, IL-18 and vascular endothelial growth 
factor (VEGF) compared to healthy controls but decreased IL-10 compared to healthy 
controls (Takahashi et al., 2010).   Furthermore, apart from IL-6, IL-7 and IL-8, all 
factors correlated with PASI and were downregulated with psoriasis treatment, except 
IL-10 which was inversely correlated, suggesting that increased levels of TNFα, IFNγ, 
IL-12, IL-17, IL-18 and VEGF may be most relevant to disease activity. 
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Interestingly monoclonal antibodies to a number of these cytokines (TNF,IL-17 and 
IL-12/23) are currently licensed and are effective for the treatment of psoriasis, 
reinforcing the hypothesis that these particular stimuli are key mediators of disease and 
therefore potentially most relevant to a model of psoriasis.  For example, currently in 
widespread use for the treatment of psoriasis are monoclonal antibodies against TNF 
(e.g. etanercept, adalimumab and infliximab) and IL-23/12 (ustekinumab).  
Furthermore, an anti-IL17, secukinumab, antibody has recently received approval for 
the treatment of psoriasis.  A further monoclonal antibody against IL-17 (ixekizumab) 
and one against IL-17 receptor A (IL-17RA) (brodalumab), are both currently in phase 
III clinical trials with promising results to date (Leonardi et al., 2012; Papp et al., 2012).  
As we will focus on keratinocyte-based studies/models of psoriasis, and IL-23/12 act 
through stimulation of T cells, further discussion of in vitro keratinocyte models of 
psoriasis will be around the effects of TNF and IL-17.  
IL-17 belongs to the IL-17 family, composed of 6 isoforms: IL-17A (IL-17), IL-17B, 
IL-17C, IL-17D, IL-17E and IL-17F.  The isoforms share 20-50% sequence homology, 
with IL-17F being the most homologous to IL-17 (Johansen et al., 2009).  However 
only expression of IL-17, IL-17C and IL-17F is increased in psoriatic skin (Martin et 
al., 2013). As expression of IL-17B, IL-17D and IL-17E are not increased in lesional 
psoriatic skin compared to non-lesional skin, these members of the IL-17 family are less 
likely to play a key role in psoriasis, compared to IL-17, IL-17C and IL-17F (Johansen 
et al., 2009).    
It has previously been reported that stimulation of primary keratinocytes with a 
combination of TNF (10ng/ml) and IL-17 (200ng/ml), both key cytokines in the 
pathogenesis of psoriasis as previously discussed (section 1.2.5), had a synergistic effect 
on the upregulation of 160 genes and an additive effect on the upregulation of 196 
genes, compared to stimulation with either cytokine on their own (Chiricozzi et al., 
2011).  Interestingly synergistically upregulated genes included some of the most highly 
over expressed genes in psoriasis including IL-8, IL-23, S100 calcium binding proteins, 
human -defensin and serpin peptidase inhibitors.  Furthermore, synergy between 
TNF and IL-17 may have therapeutic relevance, as analysis of data from psoriasis 
patients treated with etanercept (a monoclonal antibody against TNF) showed that 
there was a statistically significant greater reduction in expression of genes 
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synergistically regulated by TNF and IL-17 compared to genes regulated by 
TNFalone (Zaba et al., 2009; Chiricozzi et al., 2011).     
Underlying the synergy between TNF and IL-17, it has been shown that TNF 
stabilised IL-17 induced transcripts thereby potentiating its effects (Hartupee et al., 
2007).  There is also potential synergy in downstream signalling pathways.  TNF is 
known to signal via a number of pathways, including NF-B.  In unstimulated cells, 
NF-B is localised to the cytoplasm and is inhibited by its binding to inhibitory B 
(IB).  Binding of TNF to its receptor, for example on keratinocytes, leads to a 
signalling cascade which ultimately results in nuclear translocation of NF-B and 
subsequent binding to DNA and transcriptional activation.  NF-B can be activated by 
many other stimuli, plays a major role in psoriasis and mutations in genes whose protein 
products are involved in signalling NF-B have been identified as psoriasis 
susceptibility loci e.g. CARD14 and CARM1 (Tsoi et al., 2012).  CARD14 is of 
particular interest as it is known to be upregulated by >2.5 fold in the psoriasis 
transcriptome and a do novo CARD14 mutation has been identified in a child with 
severe psoriasis, without a family history of the disease (Jordan et al., 2012).  CARD14 
encodes caspase recruitment domain-containing protein 14, a scaffolding protein which 
interacts with and activates Bcl10, which in turn activates NF-B. CARD14 is expressed 
in keratinocytes and psoriasis-associated CARD14 mutations lead to enhanced NF-B 
activation and increased expression of inflammatory cytokines and chemokines (Jordan 
et al., 2012; Harden et al., 2014).  Mutations in CARD14 are also implicated in 
pityriasis rubra pilaris, another type of chronic inflammatory dermatoses which is less 
common than psoriasis (Fuchs-Telem et al., 2012). 
IL-17 signalling pathways are not fully resolved, but it is known that IL-17 can activate 
NF-B and mitogen-activated protein kinase (MAPK) pathways; IL-17 binding to its 
receptor results in recruitment of the signalling adaptor protein ACT1, also known as 
TRAF3 interacting protein 2, which is encoded by TRAF3IP2, and is involved in IL-17-
mediated NF-B activation (Gaffen et al., 2014; Harden et al., 2015).  ACT1 mediates 
ubiquitylation of TRAF6 (TNF receptor-associated factor 6) which activates the NF-B 
canonical pathway (through TAK1 activation) as well as MAPK pathway (including 
ERK, extra-cellular signal-regulated kinase; p38; and JNK, JUN N-terminal kinase) 
(Gaffen et al., 2014), thus synergy between TNFand IL-17 could be mediated in part 
through NF-B activation and interestingly variant in TRAF3IP2 are associated with 
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psoriasis (Huffmeier et al., 2010).  In addition to signalling through NF-B, TNFcan 
also activate MAPK kinase (e.g. JNK) pathways, through TRAF (Gaur and Aggarwal, 
2003), therefore providing further potential interactions between TNF and IL-17 
signalling, which could underlie their synergistic effects.  
Interestingly although anti-IL-17 therapy is very effective for the treatment of psoriasis 
and has recently been licensed for this indication, surprisingly stimulation of monolayer 
keratinocytes with IL-17 alone altered the expression of only 47 genes, compared to 459 
genes with TNF stimulation (Chiricozzi et al., 2011).  In addition to signalling through 
NF-B and MAPK pathways, IL-17 acts through ERK and GSK-3 (glycogen synthase 
kinase 3) to phosphorylate the transcription factor C/EBPβ (C/CAAT-enhancer-
binding proteins β) (Gaffen et al., 2014).  Therefore IL-17 mediates some of its effects 
through C/EBPβ, which is upregulated in psoriasis. TNF may also play a role in its 
regulation, thus providing a further node of interaction between TNF and IL-17.  In 
this respect, keratinocytes grown in monolayer demonstrate relatively low expression of 
C/EBPβ, which may explain the limited effect of IL-17 stimulation on keratinocytes 
grown in monolayer (Chiricozzi et al., 2014).  Stimulation of monolayer keratinocytes 
with TNF and IL-17 enhanced C/EBP expression, which is known to form 
heterodimers with C/EBPβ (Chiricozzi et al., 2011).  This may partly explain the 
synergistic effects of stimulation with a combination of TNF and IL-17 on 
keratinocytes grown in monolayer.  Of note, immuno-staining of C/EBPβ in psoriatic 
skin (lesional and non-lesional) showed expression was considerably higher compared 
to expression in normal health skin, where C/EBPβ was only slightly detectable 
(Chiricozzi et al., 2014). 
In summary TNF and IL-17 could mediate its synergistic effects through mRNA 
stabilisation and interactions of signalling pathways involving NF-B and MAPK as 
well as upregulation of downstream transcription factors which mediate their effects on 
target genes. 
Although there was an impressive overlap between genes which were synergistically or 
additively regulated by TNF and IL-17 stimulation and the psoriasis gene signature, as 
well as being seemingly therapeutically relevant, this data may need to be interpreted 
with caution.  Firstly, experiments were performed in primary keratinocytes from only 
healthy 4 donors and it is unclear what the variation between donors was and whether 
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similar results would be observed in keratinocytes derived from patients with psoriasis.  
Secondly, keratinocytes were harvested for mRNA only at a single timepoint (24h) after 
stimulation, therefore immediate and early gene responses may have been missed.  
Finally, Chiricozzi et el. reported all genes with a false discovery rate (FDR) <0.3, 
therefore some of these observations may be due to chance.  Of note, the authors refer 
only to genes which were upregulated by TNF and IL-17 stimulation, thus there may 
be a further set of genes which were synergistically or additively downregulated by this 
combination of stimuli.  
Interestingly stimulation of keratinocytes with TNF and IL-17 resulted in >50 fold 
increase in IL-17C mRNA expression (Chiricozzi et al., 2011) and the potential role for 
IL-17C in psoriasis has been recently investigated.  IL-17C shares 23% sequence 
homology to IL-17, although they are located on different chromosomes (Li et al., 
2000).  Both IL-17C and IL-17 mRNA expression were found to be significantly 
increased in lesional psoriatic skin, compared to non-lesional, whereas expression of IL-
17B and IL-17D were both decreased in lesional psoriasis skin (Johnston et al., 2013), 
in keeping with previous findings (Johansen et al., 2009).  Johnston et al. showed that 
while IL-17 transcript levels were approximately 10-fold more abundant than IL-17C 
transcript levels, in contrast IL-17C protein was ~125 higher than IL-17 protein in 
lesional psoriasis skin.  Similarly in normal healthy skin IL-17C protein levels were 
~100 fold higher compared to IL-17 protein levels.  Therefore, overall, upregulation of 
both IL-17 and IL-17C protein was similar each demonstrating ~2-2.5 fold elevation in 
lesional psoriatic skin compared to normal healthy skin (or non-lesional psoriatic skin) 
(Johnston et al., 2013).  Stimulation of primary human keratinocytes with IL-17C 
(200ng/ml) had little effect on pro-inflammatory gene expression but in combination 
with TNF (2ng/ml) increased expression of some genes previously shown to be 
additively or synergistically regulated by TNF and IL-17 stimulation, including TNF, 
IL-8, IL-1, S100 calcium binding proteins and human -defensin genes, amongst 
others (Johnston et al., 2013).  Johnston et al. also demonstrated that over-expression of 
IL-17C in mice resulted in a psoriasiform phenotype.  Although these findings are 
interesting, there were few direct comparisons between IL-17C and IL-17 within the 
same system.  For example, in comparing effects of IL-17 and IL-17C in keratinocytes, 
the effects of IL-17 stimulation were inferred from a different laboratory using 
keratinocytes derived from different donors and the IL-17 versus IL-17C protein 
expression data reported by Johansen et al. was not consistent with previously published 
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data (Johansen et al., 2009).  Johansen demonstrated that IL-17C protein expression was 
only ~4 fold higher compared to IL-17 in lesional psoriatic skin; but, there was actually 
greater upregulation of IL-17 protein (~10 fold) compared to IL-17C (~4 fold) in 
lesional psoriatic skin compared to non-lesional psoriatic skin.  There are several 
possible explanations for these discrepancies.  Patient numbers were low in both 
studies; 3 (Johnston et al., 2013) and 5 (Johansen et al., 2009); differences could 
represent patient variability.  From the methods in the Johnston et al. study it was 
unclear how some of the data was derived. For example the protein concentrations of 
IL-17 in skin (<10pg/ml for lesional psoriasis and <5pg/ml for non-lesional psoriasis 
and normal skin) were below the sensitivity for the ELISA kit (~15pg/ml according to 
Manufacturer’s, R&D Systems, protocol) quoted to be used in their methods (Johnston 
et al., 2013) and levels were lower than the Johansen et al. study.  In a separate study, 
stimulation of keratinocytes with IL-17C produced a concentration dependent increase 
in human -defensin 2 and granulocyte colony-stimulating factor, but again no direct 
comparison was made with IL-17 (Ramirez-Carrozzi et al., 2011).  The relative 
expression of IL-17 and IL-17C therefore remains unclear as does the biological 
relevance of increased IL-17C expression, in psoriasis.   
Although IL-17F shows 50% sequence homology to IL- 17, the effect of IL-17F in 
keratinocytes is less studied (Johansen et al., 2009).  However, IL-17F has previously 
been shown to upregulate expression of both IL-6 and IL-8 protein to a greater degree, 
than an equivalent concentration of IL-17 in human keratinocytes, ~4 fold and ~ 8 fold 
differences respectively. (Watanabe et al., 2009; Fujishima et al., 2010) Although the 
same concentrations of IL-17 and IL-17F were used in these experiments, expression of 
IL-17F protein is ~6 fold higher in lesional psoriatic skin compared to IL-17 protein 
expression (Johnston et al., 2013). 
Although the precise roles of elevated IL-17, IL-17C and IL-17F in psoriasis remains to 
be elucidated, perhaps most tellingly, blockade of IL-17 alone compared to combined 
blockade of IL-17, IL-17C and IL-17F have similar effects on psoriasis endpoints in 
phase II clinical trials (Leonardi et al., 2012; Papp et al., 2012).  Ixekizumab is a 
humanized IgG4 monoclonal antibody that is known neutralise IL-17 and in a 
randomised, double-blinded placebo controlled trial of 142 patients with moderate-to-
severe plaque psoriasis, PASI75 was achieved in ~83% of patients and a 90% reduction 
in PASI (PASI90) was achieved by ~71% of patients, both at week 12  (Leonardi et al., 
2012).  In comparison, brodalumab is a human monoclonal antibody against the IL-17 
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receptor A (IL-17RA).  IL-17RA is known to bind IL-17, IL-17C and IL-17F of the IL-
17 family (Chang et al., 2011; Song et al., 2011; Papp et al., 2012).  In a brodalumab 
randomised, double-blinded placebo controlled trial of 198 patients with moderate-to-
severe plaque psoriasis, PASI75 was achieved in ~82% of patients and PASI90 was 
achieved by ~75% of patients, both at week 12 (Papp et al., 2012).  Although these 
trials were not direct head-to-head comparisons, the finding that blockade of IL-17 
alone vs. blockade of IL-17, IL-17C and IL-17F binding had similar functional 
consequences in psoriasis clinical trial endpoints, could suggest that IL-17 is the main 
mediator (of IL-17 family members) of psoriasis and that IL-17C and IL-17F have 
redundant roles.  Alternatively, blockade of a single member of the IL-17 family had a 
maximal effect and further blockade of additional family members has no additional 
effect. 
1.2.7. Gene array studies in psoriasis 
Psoriasis represents a complex interaction between genetic predisposition, 
environmental factors and an altered immune profile. While the most widely accepted 
model of psoriasis suggest that proliferation of keratinocytes, which themselves may be 
dysfunctional or hypersensitive to stimuli, is driven by an over-active immune system, 
with T cells, dendritic cells, macrophages and inflammatory cytokines playing key roles 
(section  1.2.5), the underlying changes in signalling pathways are not understood.  
With improvements and increased validation of microarray technology, transcriptomic 
data has become a valuable tool to study disease.  Using this data, many groups have 
compared lesional psoriatic skin (PP) to non-lesional psoriatic skin (PN) to define a list 
of differentially expressed genes (DEG), which can be used to help understand psoriasis 
pathogenesis, treatment response and identify novel targets for therapy. Although global 
gene expression array studies have been performed in psoriatic tissues samples other 
than skin, e.g. peripheral blood mononuclear cells (Palau et al., 2013), this discussion 
will focus on array studies performed in skin as these are most relevant to our array 
study (chapter 6).  
Although a number of psoriasis microarray studies have been reported, there is often 
little overlap in DEG between studies.  An explanation for this could be due to the 
heterogeneity in methodologies adopted by different groups.  For example, skin biopsies 
were taken from different anatomical sites e.g. buttock area (Swindell et al., 2012), arm 
(Kulski et al., 2005) and in many studies the body site or specific area of the plaque 
(edge or centre) was not defined (Yao et al., 2008), which could affect results due to the 
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differences in relative thickness of different layers of the skin and therefore contributing 
cell types.  In theory this may have little effect provided that PP and PN biopsies are 
taken from similar sites. In practice, however, in some studies PN samples were taken 
adjacent to psoriatic lesions (Kulski et al., 2005) and in other studies PN samples were 
taken further away (Swindell et al., 2012).  Laser capture micro-dissection is a 
technique which can be used to isolate subpopulations of cells from tissue, thus 
avoiding the pitfalls associated with using mixed populations of cells (Mitsui et al., 
2012).   Furthermore, the location within psoriatic lesions that the PP sample was taken 
also varied between studies; in some studies samples being taken from the edge (Reischl 
et al., 2007) and in other studies the sample was taken from the centre of the lesion 
(Swindell et al., 2012).  This could affect results as there is evidence that psoriatic 
plaques have a “leading edge” which behaves differently to the centre, with potentially 
differential responses to treatment (Goodfield et al., 1994).  For some studies it was 
unclear whether samples were taken from patients with chronic plaque psoriasis or 
another subtype of psoriasis, furthermore the severity of disease was often not reported.  
Finally sample preparation also varied with some investigators placing samples in 
“RNA later” (Reischl et al., 2007) and others “snap freezing” samples in liquid nitrogen 
(Suarez-Farinas et al., 2012) prior to RNA extraction.  Although most studies utilised 
Qiagen RNAesy kits for RNA extraction, not all documented assessment of RNA 
quality prior to analysis.  One study commented that some of the RNA samples obtained 
were unsuitable for microarray analysis, although it was unclear how these samples 
were prepared and whether the same RNA extraction methods were used for all samples 
(Yao et al., 2008).  Finally in addition to the biological and experimental differences 
discussed, there were also technical differences including array platforms and both 
computational and statistical analyses also varied between studies.  In order to improve 
the comparability between transcriptomic studies, standardisation of methodologies has 
previously been suggested (Cahan et al., 2007). 
To take into account these differences in methodologies, various approaches have been 
used to compare transcriptomic data sets, the underlying premise being that key 
pathways will be conserved across different donors despite different sampling and 
analytical techniques.  The main advantage of comparing data sets from different 
studies is the improved statistical power to detect significant and reproducible changes; 
heterogeneity between samples means larger sample numbers are required to detect 
significant changes.   
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As previously discussed, taking a traditional Venn diagram to understand overlapping 
DEG sets, often yields few results (Suarez-Farinas et al., 2010), partly due to the 
variability in sample preparation as described above.  Instead other approaches have 
been taken.  The first is Gene Set Enrichment Analysis (GSEA), where a reference gene 
list from one study is used to compare against DEG lists from other studies.  Instead of 
comparing the expression of individual genes across transcriptomes, GSEA compares 
differential expression patterns of groups of genes which have similar functions or 
pathways, thus GSEA demonstrates which cellular pathways are altered in psoriasis 
(Suarez-Farinas et al., 2010).  A disadvantage of the GSEA approach is that it relies on 
the reference gene list to be complete and it becomes difficult to compare datasets 
where there are less probes in the reference dataset compared to the data sets to be 
compared.  Furthermore, GSEA does not provide weighting according to the size of the 
study; some studies had as few as 4 psoriatic patients (Kulski et al., 2005).  To 
overcome these disadvantages in GSEA analysis, more recently a “meta-analysis” 
approach to comparing transcriptomic studies has been used (Tian et al., 2012).  
Essentially this method compared DEGs across similar transcriptomic studies (e.g. 
studies of chronic plaque psoriasis using particular microarray platforms), but weighted 
these studies according to the sample sizes of the individual studies.  The main 
disadvantage to the meta-analysis approach is that small changes in gene expression 
within a smaller dataset may not be significant in other larger studies, with the potential 
that this information could be lost/ignored in comparative studies.  Using this approach, 
with a false-discovery rate (FDR) of <0.05 and fold change (FCH) >2, Tian et al. 
reported that across 5 transcriptomic studies analysed, there were 677 upregulated and 
433 downregulated genes, which the authors termed the meta-analysis derived (“MAD-
5”) transcriptome.  Within the 5 studies analysed, there were 3 studies which used a 
microarray platform (Affymetrix HGU133aPlus) with twice the number of probes as the 
microarray platform (Affymetrix HGU133a and HGU133a2) used in the other 2 studies.  
Interestingly when meta-analysis of these 3 studies were compared to meta-analysis of 
the 5 studies, there was good correlation: the top 10 up-regulated genes in each meta-
analysis had 8 genes in common (SERPINB4, S100A12, TCN1, SPRR2C, DEFB4A, 
AKR1B10, PI3 and IL-8); and the top 10 down-regulated genes in each meta-analysis 
had 6 genes in common (WIF1, HSD11B1, CCL27, ZBTB16, MSMB and GAL) 
suggesting this method provided reproducible concordance across studies (Tian et al., 
2012).  Using Ingenuity Pathway Analysis, Tian et al. were able to identify pathways 
which were over-represented in the DEG data set, these pathways included interferon 
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signalling, role of IL-17 in psoriasis as expected but also not-immediately obvious 
pathways including atherosclerosis signalling, which is of interest as psoriasis is 
increasingly recognised as an independent risk factor for cardiovascular disease 
(Armstrong et al., 2013).  To date the MAD-5 data set represents the best comparative 
transcriptomic study. 
It should be noted that microarray studies in general can have limitations.  For example, 
the “snap-shot” approach of investigating gene expression at a single timepoint could 
make it difficult to understand the evolution and resolution of disease, although 
different approaches to predict either upstream regulators or downstream responses are 
possible.  It is also important to understand that microarrays can have poor sensitivity 
for low abundance transcripts resulting in under estimation of fold-changes which could 
account for why key cytokines including IL-6, IL-17, IL-22 and IFN were not included 
as DEGs in the MAD-5 transcriptome (Suarez-Farinas et al., 2010; Tian et al., 2012).  
However if other related genes are also differentially regulated then pathway analysis 
(e.g. using IPA) should conclude that a particular pathway is disrupted even if not all 
genes within that pathway demonstrate significant change.  Although studies of global 
gene expression have traditionally been array based, more recently direct RNA-
sequencing has been used, which may show increased sensitivity for low abundance 
transcripts (Li et al., 2014) as well as greater ability to detect transcript isoforms and 
greater dynamic range of detection.  However the relatively high cost of RNA-
sequencing compared to arrays as well as the more challenging analysis required, are 
current factors in preventing more wide-spread adoption of this technology (Zhao et al., 
2014). 
1.3. Introduction to epigenetics  
1.3.1. Overview 
Although there is disagreement over the precise definition of epigenetics, it is generally 
accepted that this describes heritable changes in gene expression or cellular phenotype 
caused by mechanisms other than changes in the underlying DNA sequence (Bird, 
2007). The principle epigenetic mechanisms are histone modifications and DNA 
methylation and recent evidence suggests epigenetics playing a role in psoriasis and 
disease resolution (section 1.3.5).   
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Nucleosomes are the fundamental units of chromatin structure, comprising a core of 8 
histones which DNA is wrapped around.  Chromatin functions include: packaging DNA 
into nuclei, there is over 2m of DNA in each nucleus; strengthening DNA during 
mitosis/meiosis; providing mechanisms to control gene expression and DNA 
replication, through post-translational histone modifications.  
 
Chromatin exists in two states; heterochromatin (“compacted/closed”) and euchromatin 
(“extended/open”).  In its inactive state, chromatin that is not being actively transcribed 
is found tightly associated with structural proteins and highly compacted into tertiary 
structures (heterochromatin).  In the heterochromatin state DNA is relatively 
inaccessible to polymerases, transcription factors and polymerases although the N-
terminus of histone tails protrudes from these structures and are subject to covalent 
modifications (section 1.3.2).  During gene activation, chromatin undergoes 
conformational changes from its compacted/closed heterochromatin state to a more 
loosely packaged extended/open, euchromatin state in which the DNA template is more 
accessible to transcription factors and polymerases.  Although the underlying 
mechanisms which account for these changes are not fully understood, the effects of 
lysine acetylation on chromatin structure is the most studied and understood (section 
1.3.2).  DNA methylation is also known to contribute to these changes (section 1.3.3).  
In addition to histone modifications and DNA methylation, some investigators also 
consider microRNAs a form of epigenetic change and these are often included as an 
epigenetic mechanisms in reviews (Zhang et al., 2011a).  MicroRNAs are non-coding 
RNAs approximately 22 nucleotides in length which target mRNAs in a sequence 
specific manner and normally results in gene silencing by translational repression or 
target degradation.  Other investigators, make a distinction between mircoRNAs from 
histone modifications and DNA methylation (Chuang and Jones, 2007).   Detailed 
investigation and discussion about microRNAs are beyond the scope of this thesis but 
interestingly there appears to be considerable interaction between microRNAs and more 
widely accepted epigenetic changes; expression of microRNAs can be affected by DNA 
methylation and histone modifications and microRNAs can themselves target mRNA 
transcripts coding proteins involved in regulating traditional epigenetic modifications 
e.g. DNA methylating enzymes and histone deacetylases (Chuang and Jones, 2007).  In 
addition, microRNAs are also implicated in the pathogenesis of psoriasis, with some 
microRNAs being under expressed and others being over expressed. For example, miR-
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125b is abnormally decreased in psoriasis; miR-125b normally targets TNFfor post-
translational repression, hence downregulation of miR-125b may be lead to over-
production of TNF in psoriasis (Zhang et al., 2011a).  On the other hand miR-203 is 
over expressed in psoriatic lesional skin; miR-203 targets cytokine signalling-3 (SOC-3) 
which is a known to negatively regulate STAT3 (Sonkoly et al., 2007). Over expression 
of miR-203 would therefore lead to excess STAT3 signalling (a feature of psoriasis), 
via decreased SOC-3 levels.   
1.3.2. Histone modifications: writers, erasers and readers 
Core histones are predominantly globular in structure except for their N-terminus 
(sometimes referred to as the “histone tail”), which is flexible and protrudes from the 
nucleosome surface.  Histones are subject to at least 16 different enzyme-catalysed 
covalent modifications at specific amino acid residues mostly in the histone tail e.g. 
acetylation of lysines; methylation of lysines and arginines; phoshorylation of serines, 
threonines and tyrosines; citrullination of lysines and arginines; sumoylation of lysines;  
succinylation of lysines; formylation of lysines; ubiquitylation of lysines; butyrylation 
of lysines; propionylation of lysines; isomerisation of prolines; ADP ribosylation of 
glutamines; and deamination of arginines etc (Kouzarides, 2007; Sanchez and Zhou, 
2009; Tessarz and Kouzarides, 2014).  These covalent modifications are dynamic, occur 
post-replication and are generated, removed and recognised by distinct families of 
enzymes; “writers”, “erasers” and “readers” respectively (Table 1-1) (Kouzarides, 
2007). In humans there are over 108 histone tails which can all potentially be modified, 
but the functional consequences of histone modifications or how they are integrated is 
not well understood  (Rakyan et al., 2011).   
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Modification Target amino 
acid 
Writer Eraser Reader 
Acetylation Lysine Acetylase Deacetylase Bromodomain 
Methylation Lysine, 
Arginine 
Methylase Demethylase Chromodomain 
Phosphorylation Serine, 
Threonine 
Tyrosine 
Kinase Phosphorylase PHD finger, 
WD40 repeat 
Table 1-1: Examples of common histone modifications, their regulators and 
binding partners 
Amino acid residues on histones tails are subject to covalent modifications.  These-
enzyme-catalysed modifications are regulated by the balance between specific but 
opposing “writers” and “erasers”.  Specific histone modifications function as binding 
sites for specific chromatin “readers”, which in turn orchestrate the recruitment of other 
transcription factors and co-activators.  For example, lysine acetylation is catalysed by 
histone acetyltransferases, the epitope is recognised by bromodomain-containing 
proteins and removed by histone deacetylases. 
 
Histone acetylation of lysine residues is the most widely studied histone modification 
and was first reported in 1964 (Allfrey et al., 1964).  Since then, it is recognised that 
lysine acetylation is regulated by the balance of opposing histone acetyltransferase 
(HAT) and histone deacetylase (HDAC) activity (Figure 1-4).  Although all core 
histones are acetylated, acetylation of histone-H3 and histone-H4 has been more 
extensively studied than acetylation of histone-H2A and histone-H2b.  HATs are a 
family of enzymes which transfer the acetyl group from acetyl-coA onto lysine residues.  
The negatively charged acetyl group counteracts the positive charge on the histones, 
thereby decreasing the affinity of histones with the negatively charged phosphate groups 
of DNA (Bannister and Kouzarides, 2011). As a result, tightly condensed 
heterochromatin undergoes a conformational change into the more relaxed structure of 
euchromatin, thereby increasing the accessibility of transcriptional regulators and RNA 
polymerase to the chromatin template, thus facilitating gene transcription (Struhl, 1998).  
In the reverse, deacetylation, reaction, HDACs remove acetyl groups from lysine 
residues so that chromatin resumes back to its condensed heterochromatin resting state; 
increased HDAC activity is usually associated with repression of transcription (Kimura 
et al., 2005).  Individual members of both the HAT and HDAC families can 
demonstrate distinct specificities for particular lysine residues and different histones.  
For example, CBP and P300 of the HAT family are known to acetylate the lysine 14 
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and 18 residues on histone H3 (H3K14 and H3K18), whereas TIP60 is known to 
acetylate the lysine 5, 8, 12 and 16 residues on histone H4 (H4K5, H4K8, H4K12, 
H4K16) (Kouzarides, 2007).  This may reflect particular biological functions of 
different family members but the mechanisms regulating these specificities are not well 
understood (Turner, 2000).  
 
 
Figure 1-4: Histone acetylation is regulated by the balance between histone acetyl 
transferase and histone deacetylase activity  
 
Interestingly a particular amino acid position can be subject to a variety of different 
covalent modification.  For example, the lysine 27 residue of histone-H3 can be mono-, 
di- or tri-methylated (H3K27me1, H3K27me2 and H3K27me3 respectively) as well as 
acetylated (H3K27ac), although methylation and acetylation are mutually exclusive 
epitopes i.e. the same lysine 27 residue cannot be both acetylated and methylated at the 
same time (Tie et al., 2009).  In fact, the change from H3K27 tri-methylation 
(H3K27me3) to acetylation (H3K27ac) has been shown to act as an important switch 
from gene repression to transcriptional activation (Pasini et al., 2010).  Within a single 
nucleus, there may be both tri-methylation and acetylation of the lysine 27 residue on 
different H3 histones; in hepatocellular carcinoma, it has been shown that H3K27me3 
localised to the heterochromatin-rich peripheral region of nuclei whereas H3K27ac 
localized to the euchromatin-rich central region (Hayashi et al., 2014). 
In addition to writers and erasers having specificity for histone modification on 
particular amino acid residues, histone marks on specific amino acid residues are also 
known to have specific effects.  These effects can depend on whether the histone 
modification is associated with the promoter or enhancer region of a gene (section 
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1.3.4).  Furthermore although lysine acetylation is considered a permissive histone 
modification, which generally signifies actively transcribed genes, the effects of other 
histone modifications are less well studied and it is unknown how cell-type specific 
these modifications are.  In the most comprehensive study of its kind, the Bernstein 
group analysed 9 chromatin marks, across 9 different human cell types (including 
normal epidermal keratinocytes), in different chromatin states e.g. 
repressed/poised/active promoter or strong/weak enhancers (section 1.3.4) and revealed 
some intriguing findings (Ernst et al., 2011).  For example, some epitopes demonstrated 
very defined effects e.g. acetylation of the lysine 9 or lysine 27 residue on histone-H3 
(H3K9ac and H3K27ac) was associated with an active promoter in >95% of cases and a 
strong enhancer in 97% of cases for H3K27ac and 86% of cases for H3K9ac.  Ernst et 
al. showed that the level of methylation at a particular residue affected the function: 
mono-methylation of the lysine 4 of histone-H3 (H3K4me1) was associated with an 
active promoter in only 17% of cases, whereas di-methylation (H3K4me2) was 
associated with an active promoter in 93% of cases and tri-methylation (H3K4me3) was 
associated with an active promoter in 99% of cases.  Interestingly, the effect of a 
particular histone modification was dependent on the regulatory region it was associated 
with: although H3K4me1 was associated with an active promoter in only 17% of cases, 
the same epitope was associated with a strong enhancer in 96% of cases (Ernst et al., 
2011).  
Although, some epigenetic epitopes are known to have co-operative effects (Figure 
1-5), it is unknown exactly how multiple histone modifications interact to regulate gene 
expression although there are several theories including; charge neutralization (Dion et 
al., 2005) and the histone code (Jenuwein and Allis, 2001).  There is on-going debate of 
exactly how multiple histone modifications are integrated to regulate gene expression, 
with constantly evolving viewpoints.  For example, previously one group wrote “the 
recruitment of proteins and complexes with specific enzymatic activities is now 
accepted dogma of how (histone) modifications mediate their function” (Bannister and 
Kouzarides, 2011) but more recently the same group suggested the role of histone 
modifications in regulating chromatin structure may be equally important (Tessarz and 
Kouzarides, 2014).  Histone modification might, indeed, mediate effects through several 
mechanisms and these might not be mutually exclusive.  For example, it has already 
been discussed that histone acetylation can lead to recruitment of bromodomain-
containing proteins but can also lead to changes in chromatin conformation from 
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heterochromatin to euchromatin, potentially through “charge neutralisation”, allowing 
greater accessibility of the DNA template, thus acetylation can have multiple, co-
operative functions to regulate gene expression. 
1.3.3. DNA methylation 
DNA methylation involves covalent transfer of a methyl group from S-adenosyl-
methionine onto the 5’-carbon position of a cytosine ring (5mC), almost exclusively 
within cytosine/guanine dinucleotide pairs (CpG), and is traditionally considered to be a 
repressive epigenetic mark when present near gene regulatory regions (Bestor and 
Coxon, 1993).  DNA methylation is involved in regulating imprinted genes and X-
chromosome inactivation (Jones and Takai, 2001).  In human somatic cells, 
approximately 70-80% of CpG dinucleotide are methylated and primordial germ cells 
show lower levels of DNA methylation (Bird, 2002).  Unmethylated cytosine residues 
are often grouped in cytosine/guanine repeats/clusters, termed CpG islands, which are 
resistant to methylation; approximately 70% of mammalian gene promoters are linked 
to CpG islands and the remaining 30% contain a low CpG content (Saxonov et al., 
2006).  Approximately 50% of CpG islands are associated with gene transcription start 
sites (Bird, 2002) and methylation of these sites are typically inversely correlated to the 
level of expression of the associated gene (Bell et al., 2011).  The mechanism by which 
DNA methylation silences gene expression is unknown but two possible hypotheses 
exist (Bird, 2002).  The first proposes that the methyl group of 5mC interferes with 
binding of proteins onto CpG sequences, in this respect it is known that binding of the 
CTCF protein onto DNA can be blocked by methylation.  The second hypothesis 
proposes that, rather than blocking binding, the methyl group of 5mC increases affinity 
of binding of particular repressive proteins, for example methyl CpG binding protein 2 
(MECP2) (Figure 1-5). 
Cytosine methylation is catalysed by DNA methyltransferase (DNMT) enzymes (Figure 
1-6) and in order to preserve DNA methylation, maintenance methylation activity is 
necessary after each DNA replication cycle; as the replication machinery itself is unable 
to methylate DNA, resultant daughter strands are unmethylated.  In humans, 3 DNMTs 
together are responsible for maintaining and establishing DNA methylation: DNMT1 is 
thought to be responsible for maintaining DNA methylation by preferentially binding 
hemi-methylated DNA and copying DNA methylation patterns to the daughter strands 
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during DNA replication, Figure 1-6, whereas DNMT3a and DNMT3b are thought to be 
responsible for  de novo DNA methylation patterns early in development (Bird, 2002). 
More recently there has been some focus on 5-hydroxymethylcytosine (5hmC) which 
results from the oxidation of 5mC to 5hmC, catalysed by ten eleven translocation 
proteins. However, in contrast to the gene silencing effects associated with 5mC, 5hmC 
has generally been associated with increased gene expression.  Unlike 5mC, mapping of 
5hmC has not yet been performed in psoriasis, for this reason this epitope will not be 
discussed further. 
 
 
Figure 1-5: Epigenetic epitopes can have co-operative effects   
Methyl CpG binding protein 2 (MECP2) binds methylated DNA, recruiting a histone 
deacetalyse enzyme (HDAC) which deacetylates a histone lysine residue.  Methylated 
DNA and de-acetylation of lysines residues on histones is associated with gene 
silencing. 
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Figure 1-6: DNA methylation in maintained by DNA methyltransferase 1 
The semi-conserved nature of DNA replication results in initially hemi-methylated 
daughter strands of DNA. DNA methyltransferase 1 (DNMT1) preferentially binds 
hemi-methylated DNA, thus methylation only occurs on a CG sequence paired with a 
methylated CG.  A CG sequence not paired with methylated CG will not be 
methylated.  Hence, the original pattern can be maintained after DNA replication.  
(Adapted from www.web-books.com) 
1.3.4. Epigenetic modifications at gene regulatory regions 
In humans, gene expression is a highly regulated process which determines the fate and 
function of a cell.  A key early event is transcription initiation which involves the 
assembly of transcriptional machinery including RNA polymerase II at the gene 
promoter region, at or near the transcriptional start site (TSS).  In addition, gene 
expression can be further regulated by enhancer regions, potentially located far from the 
TSS. 
A promoter is a region of DNA which initiates transcription of a gene and is typically 
100-1000bp long, although the “core promoter” is defined as the minimum DNA 
sequence to that directs initiation of transcription (Danino et al., 2015).  Promoters tend 
to be located at or just upstream of the TSS.  Distal promoters are DNA sequences 
further upstream of the gene that may contain additional regulatory elements, with 
Methylation  
by DNMT1 
Methylation  
by DNMT1 
Not recognised   
by DNMT1 
DNA 
replication 
Unmethylated cytosine 
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generally weaker effects on gene expression than more proximal promoters.  Active 
promoters are associated with reduction or depletion of nucleosomes, DNAseI 
hypersensitivity, and enrichment of specific epigenetic marks including di- and tri- 
methylation of lysine 4 residue on histone-H3 (H3K4me2 and H3K4me3) and 
acetylation of lysine 4, 9 and 27 on histone-H3 (H3K4ac, H3K9ac, H3K27ac) (Ernst et 
al., 2011; Danino et al., 2015). 
In contrast to promoters which tend to be at or near the TSS, enhancers are regulatory 
regions of DNA which are capable of regulating/activating expression of genes that are 
potentially hundreds of bases and even megabases away (Heinz et al., 2015).  In their 
active state, enhancers are bound by RNA polymerase II, transcription factors and co-
activators important in the regulating expression of the target gene (Calo and Wysocka, 
2013).  The exact mechanisms by which enhancers regulate expression of genes long-
distances away are unknown but there are 2 main theories: “tracking” and “looping” 
(Bulger and Groudine, 2011).  The “tracking” model proposes that RNA polymerase II, 
transcription factors and co-activators track/move along the length of DNA to the target 
gene, whereas the “looping” model proposes that conformational changes in chromatin 
and “looping out” of intervening DNA, allows the close association of an enhancer 
region and its target gene so that proteins can move directly between the two regions 
(Bulger and Groudine, 2011).  Of the two the “looping” hypothesis is more widely 
accepted and more easily explains how enhancer regions can be megabases away from 
target genes (Calo and Wysocka, 2013).  Interestingly, enhancer regions can be 
characterised by a number of epigenetic characteristics including presence of high levels 
H3K27ac and H3K4me1 (with a high ratio of H3K4me1 to H3K4me3; this ratio tends 
to be reversed at promoter regions) as well as DNAseI hypersensitivity, binding of co-
activators, transcription factors and RNA polymerase II  and relative depletion of 
nucleosomes when enhancers are in their active state (Calo and Wysocka, 2013).  
Although the human genome contains millions of potential enhancers, it is said that 
only a subset are active in a particular type of cell and that cell-specific enhancers, 
through regulation of gene expression, may themselves define the cell type; a major 
challenge is to determine which cell-type defining enhancers connect to which genes 
(Heintzman et al., 2009; Heinz et al., 2015).   
On the basis of the characteristics used to define enhancer regions, a given cell type is 
said to have between 10,000 – 150,000 enhancers, suggesting that there are potentially 
more enhancers in a given cell compared to the number of expressed genes (Pott and 
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Lieb, 2015).  However, although a single enhancer can potentiate the expression of a 
target gene, the concept of super-enhancers had been suggested; these are typically large 
regions of DNA (often tens of kilobases in length) which are enriched with a high 
density of multiple “typical” enhancer loci.  Super-enhancer can be further characterised 
by H3K27 acetylation, binding of Mediator (a multi-protein coactivator that may 
facilitate interactions between transcription factors and RNA polymerase II) and, 
interestingly, binding of bromodomain containing protein Brd4 (Brown et al., 2014; 
Heinz et al., 2015; Pott and Lieb, 2015).  Most cell types contain 300-500 super-
enhancer regions, which can regulate expression of multiple genes and the combined 
function of “typical” enhancers within these regions, are associated with genes encoding 
cell type-specific transcription factors and co-activators, which are central to defining 
cell lineage (Hnisz et al., 2013; Heinz et al., 2015).  Interestingly, DNA sequence 
variations in cancer have been shown to occur within super-enhancer regions or lead to 
the acquisition of super-enhancer regions known to regulate multiple cancer-related 
genes, within specific cell types relevant to disease (Hnisz et al., 2013).  Defining 
enhancer and super-enhancer regions within individual cell types is of considerable 
interest as is the observation that super-enhancers may mediate their effects partly 
through Brd4; inhibiting Brd4 binding to this region may represent a strategy for cancer 
treatment (section 1.3.7). 
1.3.5. Epigenetic studies in psoriasis 
Traditionally the study of human disease has focused on determining genetic 
contributions to disease and in some cases, environmental and age-related factors.  
However, it is now increasingly understood that epigenetics could provide the link to 
explain how environmental factors and age interact with the genome to precipitate 
disease (Grolleau-Julius et al., 2010).  Furthermore, while genetic susceptibility may be 
unavoidable and potentially irreversible, epigenetic abnormalities are potentially 
dynamic and reversible through the use of pharmacological inhibitors to target 
regulators of the epigenome (Egger et al., 2004), for example through the use of 
inhibitors to target writers, erasers or readers of the epigenome, Table 1-1. 
In addition to the rapidly expanding evidence that epigenetics plays a role in many 
diseases including autoimmune diseases and cancer, there is increasing evidence that 
epigenetics plays a role in psoriasis and therapies that are currently used in the treatment 
of psoriasis have been shown to have effects on the epigenome (reviewed below).  
33 
 
Furthermore, early evidence suggests that pharmacological agents targeting regulators 
of the epigenome may lead to promising treatments for psoriasis. 
There have been a limited number of studies examining histone modifications in 
psoriasis and these suggest histone modifications are aberrant in psoriasis.   Zhang et al.  
reported global histone H4 hypoacetylation in peripheral blood mononuclear cells 
(PBMCs) from patients with psoriasis compared to unaffected controls, with negative 
correlation between degree of histone H4 acetylation and psoriasis disease activity 
(Zhang et al., 2011a; Trowbridge and Pittelkow, 2014).    Zhang et al. also reported that 
expression of specific HATs (e.g. p300 and CBP) were decreased in PBMCs from 
patients with psoriasis, which also showed increased expression of some HDACs (e.g. 
HDAC-1); this could account for the hypoacetylation observed in psoriatic PBMCs 
(Zhang et al., 2011a; Zhang et al., 2011b).  Interestingly, downregulated of the HDAC 
Sirtuin-1 (SIRT1) was reported, which has previously been shown to inhibit 
keratinocyte proliferation and promote differentiation, and it is suggested that decreased 
expression of SIRT1 could account for phenotypic changes in psoriatic keratinocytes 
(Blander et al., 2009; Zhang et al., 2011b).  Recently, a SIRT1 activator has been 
evaluated in a clinical trial for the treatment of moderate to severe psoriasis, although 
the results are not yet available (ClinicalTrials.gov Identifier: NCT01154101). 
Most studies investigating epigenetic factors in psoriasis have focused on DNA 
methylation, initially at the promoter region of specific genes relevant to psoriasis.   
Psoriasis is characterised by excess keratinocyte proliferation which may arise as a 
result of resistance to apoptosis of keratinocytes derived from patients with psoriasis, 
compared with healthy patients (Wrone-Smith et al., 1997).  In keeping with this 
hypothesis, DNA methylation of the p16
INK4a 
promoter was found in the epidermis of 
30% of patient with psoriasis (Chen et al., 2008).  p16
INK4a
 is a tumour suppressor 
protein with anti-proliferative effects, whose down-regulation has previously been 
associated with increased promoter methylation in squamous cell carcinoma and  
enhanced cellular self-renewal (Brown et al., 2004).  Patients with methylation at the 
p16
INK4a
 promoter showed significantly lower expression of p16
INK4a
 mRNA and greater 
psoriasis severity, compared to psoriasis patients with an unmethylated p16
INK4a
 
promoter.  Interestingly the promoter of p14
ARF
, a gene homologous to p16
INK4a
, is also 
hypermethylated, with corresponding decreased expression, in keratinocytes derived 
from patients with psoriasis (Zhang et al., 2010).  Together these findings suggest that 
aberrant methylation of specific genes, including the promoter region of both p16
INK4a
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and p14
ARF
, has a potential role in the pathogenesis of psoriasis.  However, in addition 
to aberrant hypermethylation of these genes, hypomethylation of other genes has been 
observed in psoriasis.  For example, SHP-1 is a regulator of cell growth and 
proliferation, with 2 functional promoters and psoriatic keratinocytes show 
demethylation of the SHP-1 promoter 2 compared to keratinocytes from normal skin or 
from eczema (Ruchusatsawat et al., 2006).  Ruchusatsawat et al. also demonstrated that 
psoriatic skin had higher expression of SHP-1 compared to normal skin, suggesting that 
aberrant hypomethylation is at least partly involved in regulating SHP-1 in psoriasis. 
In addition to investigation of DNA methylation changes of single genes, global DNA 
methylation changes in psoriasis have more recently been investigated.  Roberson et al., 
were the first to investigate global DNA methylation changes in psoriatic skin and 
found that psoriatic skin had a greater number of hypermethylated regions than 
hypomethylated regions and that DNA methylation states at ~1100 (out of a total of 
~27500 CpG sites examined) differentiate psoriatic lesional skin from normal skin.  
Interestingly, 12 of these sites mapped to the epidermal differentiation complex, which 
contains a large number of genes involved in epidermal differentiation and function.  
All 12 sites showed decreased methylation in psoriatic lesional skin compared to normal 
skin and mapped near to genes which are known to be upregulated in psoriasis, e.g. 
S100 genes (Roberson et al., 2012).  The greatest differences in methylation were 
between psoriatic lesional skin and normal skin (i.e. from non-psoriatic individuals) and 
the top 50 differentially methylated sites (25 with increased methylation and 25 with 
decreased methylation) could be used to separate psoriatic lesional skin and normal 
skin, with non-lesional psoriatic skin showing intermediate levels of methylation.  
Furthermore, treatment of patients with anti-TNF therapy resulted in a reversion of 
DNA methylation from the lesional state towards the non-lesional state even prior to the 
resolution of psoriatic plaques (Roberson et al., 2012).  This finding suggests restoration 
of aberrant DNA methylation to its normal state could drive the resolution of psoriasis, 
rather than being a consequence of resolution.   
More recently methylated DNA immunoprecipitation followed by sequencing (MeDIP-
Seq) has been used to compare involved and uninvolved psoriatic skin and it was 
reported that there was significantly higher hypermethylated than hypomethylated 
regions in affected skin (Zhang et al., 2013), consistent with previously published data 
(Roberson et al., 2012).  Zhang et al. demonstrated that differentially methylated 
regions were enriched for genes involved in immunity, cell cycle and apoptosis i.e. 
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functions known to be dysregulated in psoriasis. Gene expression inversely correlated 
with levels of DNA methylation for a number of genes including TIMP2, a matrix 
metalloproteinase inhibitor, whose loci was hypermethylation and expression 
downregulated in lesional psoriatic skin, although the function of this gene has not yet 
been characterised in psoriasis (Zhang et al., 2013).  In addition to DNA methylation 
studies in skin, MeDIP-Seq has been used to investigate DNA methylation status of 
circulating immune cells (CD4+ T cells) in patients with psoriasis compared to healthy 
controls and, as with lesional skin, overall DNA methylation values were higher in 
psoriatic CD4+ T cells patients compared to those derived from healthy controls (Park 
et al., 2014).  In addition, hypermethylated regions were enriched at gene promoter 
sites, and this correlated with expression of associated genes (Park et al., 2014) in 
CD4+ T cells.  In the most recent study of DNA methylation in psoriatic skin, lesional 
psoriasis samples compared to normal healthy skin showed over 3600 differentially 
methylated regions, determined by bisulphite sequencing, with psoriatic samples 
demonstration overall hypomethylation (Gu et al., 2015).  Differentially methylated 
regions enriched for genes with functions relevant to the pathogenesis of psoriasis 
including inflammation, regulation of cell motion and regulation of programmed cell 
death (Gu et al., 2015).  However, the overall hypomethylation observed by Gu et al. 
was in contrast to the overall hypermethylation observed in other studies (Roberson et 
al., 2012; Zhang et al., 2013).  This discrepancy may have arisen due to differences in 
sample preparation; in this latest study, DNA methylation of only the epidermal part of 
skin (by separation from the dermis using ammonium thiocyanate) was determined, (Gu 
et al., 2015) whereas previous studies examined whole-skin biopsies i.e. epidermis, 
dermis and any underlying sub-cutaneous tissue (Roberson et al., 2012; Zhang et al., 
2013).  Whole-skin biopsies of psoriatic tissue vs. normal skin may have contained 
relatively more inflammatory infiltrate compared to epidermis-only samples, and the 
hypermethylation observed in psoriatic CD4+ T cells, discussed above (Park et al., 
2014), may have contributed to the overall hypermethylation pattern when whole-skin 
biopsies were sampled. 
Interestingly, therapies that are currently used in the treatment of psoriasis have been 
shown to have effects on the epigenome.  For example, methotrexate is a folate 
antagonist used in the treatment of psoriasis (Figure 2-1), and treatment lead to the 
reversal of global DNA hypomethylation observed in PBMCs derived from patients 
with psoriatic arthritis, indicating that DNA methylation changes in psoriasis are 
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dynamic (Kim et al., 1996).  As previously discussed, anti-TNF psoriasis therapy 
resulted in reversion of DNA methylation from lesional skin towards the non-lesional 
state (Roberson et al., 2012).  Furthermore, narrow-band UVB phototherapy has also 
been shown to reverse aberrant DNA methylation changes in psoriasis (Gu et al., 2015).  
In addition to current therapies in psoriasis reversing aberrant changes in the 
epigenome, compounds targeting readers or regulators of the epigenome may also have 
therapeutic value in the treatment of psoriasis (section 1.3.7).  Collectively these 
findings suggest a role for epigenetics in the pathophysiology of psoriasis and also 
provide some evidence that underlying epigenetic processes may be potential 
therapeutic targets. 
However the epigenetics studies described do have a number of caveats which could 
influence the interpretation or indeed the results of investigations.  Firstly epigenetic 
studies utilising whole tissue, including skin, will be affected by the relative proportions 
of different cell types which will have differences in their epigenome, this becomes 
particularly complex when the state of disease itself influences the composition of cells 
within tissue.  For example, in psoriasis it is known that there is an increased 
inflammatory infiltrate within the skin, therefore epigenetic differences between 
psoriatic skin biopsy samples and normal healthy samples could simply represent these 
differences in cell types.  Secondly the state of differentiation of a cell will be governed 
by changes in the epigenome and in psoriasis, where for example keratinocytes 
demonstrated excess proliferation and abnormal proliferation, comparisons of the 
epigenome between involved and uninvolved epidermis may simply reflect these 
changes in cellular phenotype or proliferation.   Thirdly, variations in the epigenome 
may cause disease or be a consequence of it and deciphering these differences could 
prove difficult, but functionally important to determine especially when considering 
potential therapeutic targets.  Finally, although epigenetic epitopes are dynamic and 
potentially reversible, it is unknown how processing of samples affects these regulatory 
marks.  Overcoming these challenges is fundamental for understanding the role of 
epigenetics in disease pathogenesis and resolution. 
1.3.6. Bromodomains and the bromodomain extraterminal  protein family 
Bromodomain (BRD)-containing proteins are reader proteins known to bind to 
acetylated lysine residues, Table 1-1.  The human genome encodes 61 distinct 
bromodomains (BRDs) each ~110 amino acids long, contained within 46 BRD-
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containing proteins, with each protein containing between 1 – 6 BRDs (Basheer and 
Huntly, 2015).  The BRD structure consists of 4  helices separated by a variable loop 
regions; together these form a hydrophobic binding cavity and is the only domain 
known to specifically recognise acetylated lysine residues (Dhalluin et al., 1999; 
Filippakopoulos and Knapp, 2012).  BRD-containing proteins are grouped into families 
based on sequence homology and are known to have very diverse functions e.g. as 
histone acetyl transferases, methyltransferases, transcriptional co-activators and nuclear 
scaffolding proteins etc (Filippakopoulos et al., 2012).  The bromodomain extraterminal 
(BET) family of BRD-containing proteins (namely Brd2, Brd3, Brd4 and BrdT), 
contains two tandem amino-terminal BRDs (known as BD1 and BD2) and a conserved 
extraterminal domain (Figure 1-7).  Brd2, 3, and 4 are ubiquitously expressed across 
multiple cell types and tissues, whereas BrdT has only been found in testes (Jones et al., 
1997; Basheer and Huntly, 2015).   
BET proteins are known to have essential, non-redundant roles in growth and 
development.  For example,  homozygous Brd2 or Brd4 knockout mouse embryos fail 
to develop after implantation and Brd4 heterozygotes have pre- and post-natal defects 
including head malformations, absence of subcutaneous fat and cataracts showing that 
Brd4 heterozygosity demonstrates haploinsufficiency (Houzelstein et al., 2002; Shang 
et al., 2009).  
 
Figure 1-7: Bromodomain extraterminal (BET) protein structures  
Numbers indicate the position of amino acids.  BD = bromodomain, ET = extraterminal, 
CTM = C-terminal motif.   (Adapted from Basheer et al., 2015) 
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Interestingly BET proteins are also known to be involved in disease pathogenesis.  For 
example, NUT midline carcinoma is a rare but aggressive form of squamous cell 
carcinoma in which tumours arise from midline anatomical structures, especially the 
upper aerodigestive tract and mediastinum.  Most patients have a chromosomal 
translocation t(15;19) involving Brd4 (or less commonly Brd3) and NUT (nuclear 
protein in testes) resulting in a Brd4-NUT (or Brd3-NUT) fusion oncoprotein, which 
contain BET tandem BRDs, the extraterminal domain and virtually the whole of the 
NUT protein.  The fusion protein is targeted to chromatin by BET BRDs and the NUT 
protein is known to recruit HAT enzymes (p300/CBD) leading to histone 
hyperacetylation which is known to drive gene expression (French, 2012).  BET 
inhibitors are currently in clinical trials for the treatment of this life-threatening disease 
(section 1.3.7). 
BET proteins have been shown to associate primarily with euchromatin, and rarely with 
heterochromatin, suggesting early on that these proteins play a role in regulating gene 
expression (Dey et al., 2003).  It is now recognised that, through their BRDs, BET 
proteins bind acetylated lysine residues commonly found on histones and non-histone 
targets and orchestrate recruitment of other proteins involved in transcriptional 
activation/inactivation, thus regulating gene transcription (Figure 1-8)  (Sanchez and 
Zhou, 2009).  It has previously been calculated that there are over 24,000 lysine 
acetylation sites in human cells (Filippakopoulos and Knapp, 2014), but it unknown 
how BRD-containing proteins achieve their binding specificity.  Investigations into 
BET protein binding specificities have previously been undertaken  and, although there 
are no systematic studies comparing specificities and affinities for individual BET 
proteins and particular acetyl-lysine residues, results across several studies suggest that 
binding of  BET protein is highly regulated and complex and is currently poorly 
understood.   
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Figure 1-8: Bromodomain (BRD) containing proteins 
These proteins bind acetylated lysine residues found on histones and stabilise and 
recruit transcription factors (TFs) to chromatin, thereby regulating gene transcription.  
In addition to histone targets, BRDs can also bind acetyl-lysine residues on non-histone 
targets.  
 
Most studies investigate binding in-vitro to acetylated histone-tail peptides, and BET 
proteins are known to bind with greater affinity when exposed to multiple acetylated 
lysine residues on the same (cis) histone tail rather than single acetylated lysines, 
although these proteins can also bind acetylated lysine residues on different (trans) 
histone tails that are in close proximity to each other  (Filippakopoulos and Knapp, 
2012; Basheer and Huntly, 2015).  Published substrate affinities are usually low and 
have been determined by a variety of methods, including pull-down assays and peptide 
arrays.  Even when similar methods were used, conditions often varied e.g. different 
peptide length used in peptide binding assays; these factors make direct comparisons of 
specificity and affinity between studies difficult. Comparisons within a single study are 
more straight-forward; one study demonstrated that Brd4 did not bind to non-acetylated 
H3 or H4 and binding of Brd4 to mono-acetylated H3 was lysine residue specific; there 
was weak binding to H3K14ac but not to H3K9ac (Dey et al., 2003).  In certain 
circumstances, acetylation of multiple lysine residues within a short amino acid span 
can enhance BET protein binding. Dey et al. demonstrated that histone di-acetylation 
can enhance Brd4 binding in a lysine-residue specific manner; di-acetylated H3 
(H3K9acK14ac) and di-acetyl H4 (H4K5acK12ac) enhanced Brd4 binding compared to 
mono-acetylation at each lysine residue alone but an alternative di-acetyl H4 
(H4K8acK16ac) had no effect on Brd4 binding and tetra-acetyl H4 
(H4K5acK8acK14acK16ac) resulted in enhanced binding of Brd4; compared to mono-
acetylation at each lysine residue alone but less than binding to di-acetyl H4 
(H4K5acK12ac).  In addition to lysine acetylation affecting BET protein binding 
interestingly other, non-acetylation, histone modifications can also affect binding.  For 
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example, in peptide binding studies, the association of Brd4 to di-acetyl H3 
(H3K4acK9ac) was enhanced by the phosphorylation of the H3 threonine residue at 
position 3 (H3T3pK4acK9ac) (Filippakopoulos et al., 2012).    These findings suggest 
that although BET proteins can bind single acetyl-lysine residues on histones, binding is 
enhanced by specific patterns of histone modifications, suggesting a co-operative role of 
neighbouring sites for substrate binding.  However it remains unknown how these 
multiple covalent histone modifications are integrated into a single output to active, 
suppress or pause gene expression.  Furthermore, the role of each of the tandem BRDs 
(BD1 and BD2) remain unknown although they are said to have different substrate 
affinities (Filippakopoulos and Knapp, 2012), and deletion of BD1 in BrdT in mice 
caused sterility by inhibiting sperm maturation, suggesting BD1 at least has a non-
redundant role (Shang et al., 2007). 
BRD-mediated interactions with acetylated residues on histones results in localisation 
of BET proteins to specific regions of chromatin where they are associated with other 
proteins involved in regulation of gene expression.  This is accomplished through 
protein interactions with i) the other BRD if not bound to a second acetylated lysine 
residue, ii) the conserved extra-terminal domain of BET proteins  or iii) the carboxy-
terminal (C-terminal) domain, thus BET proteins exert their multiple functions through 
the association with other proteins (Basheer and Huntly, 2015).  In this respect Brd4, 
through the BRDs, is known to bind p65/RelA in an acetylated lysine-310 dependent 
manner, leading to mutual co-activation and recruitment of Brd4/p65 to the promoters 
of NF-B regulated genes (Huang et al., 2009).  Furthermore, Brd4 also recruits cyclin-
dependent kinase 9 (CDK9), which phosphorylates the serine 2 residue of RNA 
polymerase II of its carboxy-terminal domain (pol II S2P) leading to its activation, thus 
facilitating the initiation of transcription of NF-B dependent genes (Huang et al., 
2009).  BET proteins play a further role in initiation of transcription through the 
interaction with Mediator, which Brd4 has been shown to bind;  Mediator is a multi-
protein coactivator that may facilitate interactions between transcription factors and 
RNA polymerase II (Wu and Chiang, 2007).  Brd4/Mediator complexes stabilise each 
other’s occupancy at regulatory regions and have been identified at the transcription 
start site and enhancers of many genes across the genome (Loven et al., 2013). 
The functions of BET proteins do not rest solely on their BRDs, BET proteins also 
interact with other proteins through the BET C-terminal domain, which is unique to 
Brd4 and BrdT and not present in Brd2 nor Brd3 (Basheer and Huntly, 2015).  For 
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example, Brd4 is used as an adaptor by papillomaviruses and the C-terminal domain of 
Brd4 is known to interact with the E2 protein encoded by these viruses, this interaction 
tethers viral DNA to mitotic chromosomes of the host cell for segregation of the viral 
genome into daughter cells (You et al., 2004; Wu and Chiang, 2007).  Positive 
transcription elongation factor b (pTEFb, a complex of cyclin T1 and CDK9) is also 
known to interact with the C-terminal domain and BD2 of Brd4 (Schroder et al., 2012).  
pTEFb (along with SEC, super elongation complex) promotes transcription elongation, 
by phosphorylation of the negative elongation factors DSIF (5,6-dichloro-1--D-
ribofuranosylbenzimidazole sensitivity-inducing-factor) and NELF (negative 
transcription elongation factor) (Bartholomeeusen et al., 2012).   After transcription 
initiation and promoter clearance, DSIF and NELF assemble on RNA polymerase II, 
blocking its movement; phosphorylation of DSIF and NELF inhibits their repressive 
function and also converts DSIF into an elongation promoting factor (Bartholomeeusen 
et al., 2012).  pTEFb itself exists in either a kinase-inactive form, when bound to its 
negative regulators (HEXIM1 and 7SKsnRNA complex), and an active form (free 
pTEFb) (Yang et al., 2005).  In this respect, Brd4 is known to displace the negative 
regulators from pTEFb, thus activating pTEFb which can then phosphorylate DSIF and 
NELF as well as RNA polymerase II (Yang et al., 2005; Bartholomeeusen et al., 2012).  
Therefore in addition to their role in initiation of transcription, BET proteins also play a 
role in transcriptional elongation. 
The extraterminal domain of BET proteins is less studied and little is known about the 
functions of this domain compared to the BET bromo- and C-terminal domains.  All 
BET proteins have been linked to transcriptional regulation.  However, only Brd4 and 
BrdT possess the C-terminal domain which is known to recruit pTEFb, therefore BET 
proteins may possess transcriptional regulatory functions which are independent of the 
C-terminal domain.  Using transfected tagged fragments of Brd4 regions of interest and 
a nuclear localisation signal, the extraterminal domain of Brd4 (and also Brd2/3) was 
shown to interact with NSD3, JMJD6, CHD4, GLTSCR1 and ATAD5.  Furthermore 
NSD3, JMJD6 and CHD4 were found to be involved in transcriptional activation, as 
determined by the effect of siRNA knockdown on transcriptional activation in a 
luciferase reporter assay (Rahman et al., 2011).  Interestingly CHD4 (chromodomain 
helicase DNA binding protein 4) is known to be involved in chromatin remodelling 
suggesting that Brd4 could be involved in chromatin remodelling via its interaction with 
CHD4, although its downstream effects on gene expression are unknown. 
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1.3.7. Epigenetic modifications as therapeutic targets: bromodomain 
extraterminal (BET) protein inhibitors 
In 2010, two separate groups reported the development of small molecules 
(GSK525762A (I-BET762), and JQ1) which specifically bind to the BRDs (BD1 and 
BD2) of the BET family of proteins, with high affinity over BRDs contained within 
other families of BRD-containing proteins (Filippakopoulos et al., 2010; Nicodeme et 
al., 2010). These compounds competitively bind within the acetyl-lysine binding pocket 
of the tandem BRDs of  
Brd2, Brd3, Brd4 and BrdT and block association with acetylated proteins, including 
histone (Figure 1-9) and non-histone targets (Zou et al.); they represent a novel drug 
target class (Nicodeme et al., 2010).   
 
 
 
Figure 1-9: BET inhibitors  
These inhibitors, e.g. I-BET151 target the acetyl-lysine binding pocket of BET proteins 
and block association with acetylated lysine containing proteins which are mainly 
involved in transcriptional complex formation thereby modulating gene expression 
(shown here are histone targets and the effect of gene silencing). (Source of I-BET151 
structure: Epinova, GlaxoSmithKline) 
 
I-BET762 was demonstrated to inhibit the secondary inflammatory response in 
lipopolysaccharide-stimulated mouse macrophages in-vitro and mouse models of sepsis 
in-vivo (Nicodeme et al., 2010).  I-BET762 treatment of lipopolysaccharide-stimulated 
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macrophages lead to the inhibition of expression of LPS-sensitive genes important in 
the  inflammatory response, for example cytokines, IL-6 and IL-1b; and chemokines, 
Cxcl9 and Ccl-12; as well as transcription factors, Rel and Irf4 (Nicodeme et al., 2010); 
chromatin immunoprecipitation (ChIP) studies demonstrated that inhibition of BET 
binding to promoters of affected genes correlated with their decreased expression.  
However, in addition to I-BET762 reducing BET binding to promoter region of LPS-
sensitive genes, I-BET762 treatment also resulted in reduction in histone acetylation 
associated with LPS-sensitive genes which could have been as a result of either i) 
increased accessibility of HDACs to acetyl-lysine residues no longer bound by BET 
proteins and/or ii) inability of coactivators (including HATs) to be recruited to acetyl-
lysine residues to maintain acetylation, in the absence of BET binding (Nicodeme et al., 
2010).  This shift in balance between HDAC and HAT activity could thus favour 
histone deacetylation.  This study provided the first demonstration of efficacy for a BET 
inhibitor in models of inflammation and sepsis.  The potential use of BET inhibitors in 
treating inflammatory diseases was further supported by the finding that JQ1 prevented 
differentiation of naïve CD4+ T cells into IL-17 producing T helper 17 cells (TH17 
cells) and inhibited activation of previously differentiated TH17 cells (Mele et al., 2013) 
with associated suppression of TH17 cell-associated genes including IL-17 and IL-22, 
which are central to the pathogenesis of psoriasis, amongst other auto-inflammatory 
diseases (section 1.2.5).  In addition to effects on immune cells, BET inhibitors have 
been shown to suppress the inflammatory response in other cell types.  For example, I-
BET151 suppressed IL-6 and IL-8 gene expression in response to either TNF or IL-1 
stimulation in patient-derived rheumatoid arthritis synovial fibroblasts (Klein et al., 
2014).  
As well as inhibiting inflammatory responses, BET inhibitors have also been shown to 
have anti-proliferative effects in models of cancer.  In the first of these cancer studies 
JQ1 demonstrated efficacy in a pre-clinical cancer model of NUT midline carcinoma 
which, as previously discussed, results from the formation of a Brd4-NUT or Brd3-
NUT oncoprotein, due to chromosomal translocation, whose oncogenic function lies in 
the ability of Brd3/4 to bind acetylated chromatin thus providing a rationale for 
treatment of NUT-midline carcinoma with a BET inhibitor (section 1.3.6).  In vitro 
investigations using NUT-midline carcinoma cell lines, demonstrated that JQ1 
displaced Brd4-NUT from chromatin and resulted in terminal differentiation and 
apoptosis of malignant cells (Filippakopoulos et al., 2010).  Furthermore, in patient-
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derived xenograft mouse models of NUT-midline carcinoma, in vivo administration of 
JQ1 lead to increased survival with minimal toxicity in normal tissue (Filippakopoulos 
et al., 2010).  Although these results clearly demonstrated a potentially exciting 
advancement for the treatment of NUT-midline carcinoma, and BET inhibitors are now 
in phase I/II clinical trials for this aggressive disease (Basheer and Huntly, 2015), the 
majority of other types of cancers do not display chromosomal translocations involving 
BET.  Therefore, since this pivotal study, other investigations have evaluated the effect 
of BET inhibition in cancers that lack BET translocations.  For example, the BET 
inhibitor GSK1210151A (I-BET151) has been shown to inhibit growth of human mixed 
lineage leukaemic-fusion cell lines in-vitro by inducing early cell cycle arrest and 
apoptosis and, in a mouse model of MLL-fusion leukaemia, in-vivo treatment with I-
BET151 lead to increased survival (Dawson et al., 2011).  The inhibition of tumour 
growth by I-BET151 could be explained, at least in part, by the inhibitory effects on 
transcription of key oncogenes including C-MYC and BCL2 as a result of I-BET151 
inhibiting binding of BET proteins to these gene promoters (Dawson et al., 2011).  Of 
great interest was the observation that in models of other types of cancer, treatment with 
BET inhibitors also lead to inhibition of growth, again at least in part by the 
downregulation of C-MYC and/or BCL2 in both haematological and solid organ tumours 
e.g. JQI had an anti-proliferative effect on both multiple myeloma cells lines and 
primary cells derived from patients and in an in vivo mouse model of disease, with 
accompanying decreases in expression of C-MYC expression C-MYC dependent genes 
(Delmore et al., 2011); and I-BET762 inhibited tumour growth in in vitro and in vivo 
models of neuroblastoma, in which down-regulation on BCL2 (and MYCN) was also 
observed  (Wyce et al., 2013).  Over-expression of MYC or BCL2 led to reversal of 
tumour growth inhibition by JQ1 or I-BET151, respectively (Dawson et al., 2011; 
Mertz et al., 2011). Together these findings suggest that a wide variety of 
haematological and solid organ tumours may be sensitive to BET inhibition and these 
compounds may mediate their tumour suppressive effects, at least in part, through 
inhibition of expression of MYC and BCL2.  BET inhibitors are currently in phase I/II 
clinical trials for the treatment for NUT-midline carcinoma and a number of other 
diseases, mainly haematological in origin, including Hodgkin’s and non- Hodgkin’s 
disease, myelodysplastic syndrome and myeloproliferative neoplasm, section 1.3.7 
(Basheer and Huntly, 2015).  BET inhibitors are also being trialled in non-cancer 
diseases, including type II diabetes and atherosclerosis (Filippakopoulos and Knapp, 
2014). 
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Interestingly in the above studies, BET inhibitors decreased expression of only a subset 
of genes, not all genes were affected equally, even though BET proteins are found at the 
transcriptional start site of a wide variety of genes (Loven et al., 2013).  In addition 
BET inhibition appeared to have effects which were cell type specific; as discussed, JQ1 
treatment of leukaemic cells lead to downregulation of MYC, but in contrast had little 
effect on MYC expression in fibroblasts (Zuber et al., 2011).  To account for this, it has 
previously been hypothesised that BET inhibitors might mediate many of their effects 
through displacement of BET proteins at enhancer regions; where there is often high 
levels of cell-type specific BET binding e.g. Brd4 binding at super-enhancers as 
previously discussed (section 1.3.4).  Support for this hypothesis came from the finding 
that a particular multiple myeloma cell line (MM1.S) was found to have a translocation 
so that MYC expression became under the regulation of the IgH enhancer, which 
showed 10-fold greater enrichment of Brd4 compared to Brd4 binding at the MYC 
promoter (Delmore et al., 2011).  In this cell line, MYC expression was highly sensitive 
to BET inhibition by JQ1 (Delmore et al., 2011), suggesting that BET binding to 
enhancer regions might be the main driver of BET-sensitive gene expression.  
Furthermore as enhancer and super-enhancer may be both cell-type specific and 
regulate the expression of a specific subset of genes (Heintzman et al., 2009; Heinz et 
al., 2015), displacement of BET proteins from enhancers and super-enhancers could 
explain the cell-type specific effects of BET inhibition and also why only a subset of 
gene are inhibited by BET inhibitors.  
In addition to BET inhibitors disruption recruitment of transcriptional complexes to 
regulatory regions, either through inhibiting BET binding to acetylated histones or to 
transcription factors and coactivators, BET inhibitors were also found to have additional 
interesting mechanisms of action which could be used to clinical advantage.  For 
example, the HIV transactivator Tat is known to compete with Brd4 for binding to 
pTEFb; Tat binding to pTEFb leads to transactivation of the HIV promoter and viral 
replication. On the other hand Brd4 binding to pTEFb, sequesters pTEFb thereby 
preventing the formation of Tat-pTEFb complexes, leading to HIV latency thus 
allowing the virus to evade clearance with anti-retroviral treatment (Bisgrove et al., 
2007).  BET inhibition (by JQ1) was shown to release pTEFb from Brd4, thereby 
allowing free pTEFb to associate with Tat and reactive viral transcription which could 
increase HIV sensitivity to anti-retroviral therapies (Li et al., 2013). 
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Given that BET inhibitors demonstrate both anti-inflammatory and anti-proliferative 
effects, as well as inhibiting differentiation of naïve CD4+ T cells into TH17 cells, this 
provided rationale for investigating the role of BET proteins and evaluating the effects 
of BET inhibitors in psoriasis, a disease characterised by chronic inflammation and 
excessive proliferation (sections 1.2.1 and 1.2.5) which may be driven by alterations in 
the underlying epigenome (section 1.3.5).  In this respect, in vivo topical application of 
JQ1 was very recently shown to reduce inflammation in an imiquimod-induced mouse 
model of psoriasiform inflammation (Nadeem et al., 2015).  In mice, topical application 
of imiquimod (IMQ, a TLR-7 agonist which leads to induction of NF-B) is known to 
induce psoriasis-like cutaneous inflammation and Nadeem et al. demonstrated that 
topical treatment with a pan-BET inhibitor (JQ1) either before or after application of 
IMQ prevented the psoriasis-like phenotype including reduction in acanthosis, 
hyperkeratosis and elongation of the rete ridges (Figure 1-1B).  There was a 
corresponding reduction in key cytokines relevant psoriasis including IL-17 and IL-22 
(but not other cytokine including IL-23 and TNF; this was mediated by JQ1 inhibiting 
epidermal expression of the retinoic acid receptor-related orphan receptor C (RORC) 
(mRNA and protein), a transcription factor known to regulate expression of IL-17 and 
IL-22 (Nadeem et al., 2015).  
The multitude of potentially useful but diverse effects of BET inhibitors, of course 
raises the question of whether these effects could be due to off-target effects.  To 
address this question,  the effects of pan-BET inhibitors I-BET151 and JQ1 were 
compared in rheumatoid arthritis synovial fibroblasts stimulated with IL-1; it was 
found that patterns of inhibition were almost identical between the two chemically 
unrelated compounds (Klein et al., 2014).  Furthermore, screening with I-BET762 has 
previously not identified any non-BET protein binding partners (Nicodeme et al., 2010). 
Together these findings suggest that the BET inhibitors discussed mediate their effects 
via specific binding and inhibition of BET proteins. 
1.4. Environmental toxins implicated in the pathogenesis of psoriasis. 
In addition to genetic components, environmental factors including alcohol, 
streptococcal throat infection, stress and prescription drugs, such as beta-blockers and 
lithium  may also contribute to the pathogenesis of psoriasis (Peters et al., 2000).  
Although there is strong evidence that these factors play a role in psoriasis, how 
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environment factors interact with genetic components and adaptive and innate immune 
systems to produce or exacerbate the psoriasis phenotype is poorly understood. 
1.4.1. The role of alcohol and its metabolites in the pathogenesis of psoriasis 
Although it is proposed that alcohol abuse is a risk factor for the subsequent 
development and also exacerbation of pre-existing psoriasis, the exact nature of this 
relationship has not always been clearly defined.  Although data from larger population 
studies in Scandinavia suggested that there was increased alcohol consumption in 
patients with psoriasis (Braathen et al., 1989),  some investigators reported that patients 
consumed more alcohol following the diagnosis of psoriasis, reflecting the negative 
impact that chronic inflammatory dermatoses can have on quality of life (Kirby et al., 
2008).  In this respect, increased alcohol consumption after the onset of psoriasis could 
act as a coping mechanism for chronic disease but not necessarily a cause for it.   
Although some early studies did not demonstrate alcohol abuse preceding the onset of 
psoriasis (Grunnet, 1974), there is increasing evidence from large epidemiological 
studies, and it is now generally accepted, that alcohol is a risk factor for development 
(and exacerbation) of psoriasis (Lindegard, 1986), as well as other skin diseases 
including discoid eczema, rosacea, post-adolescent acne, and porphyria cutanea tarda 
(Higgins and Du Vivier, 1994b).  Interestingly some groups that initially reported no 
significant association between alcohol intake and the risk of developing psoriasis 
(Naldi et al., 1992), have more recently reported that alcohol is a significant risk factor 
(Naldi, 1998). 
A common problem with many of the epidemiological studies on this subject was the 
reliance on self-reporting of alcohol intake; an underestimation of alcohol intake was 
likely to occur.  Many studies were retrospective in nature, with recall bias and potential 
under reporting being a problem.  Other studies included cases of self-diagnosed 
psoriasis.   In addition, the control population in studies varied; some had normal 
healthy controls without any skin disease and others had patients with skin diseases 
other than psoriasis (Poikolainen et al., 1990). In one of the largest studies of its kind, a 
prospective study of nurses in the US sought to address some of these issues (Qureshi et 
al., 2010).  The study was based in a cohort of over 115,000 nurses in the US who 
undertook biennial questionnaires which included question regarding the amount of 
alcohol consumed and dermatological diseases, including physician-diagnosed 
psoriasis.  Only participants without a diagnosis of psoriasis at the start of the study 
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were followed up over a 15 year period.  This study found that the relative risk of 
developing psoriasis was 1.73 (95% confidence interval, 1.16–2.58) in those who 
consumed ≥ 2.3 alcoholic drinks/week compared with those who did not drink any 
alcohol (Qureshi et al., 2010).  The strength of the study was its prospective nature and 
the population size.  Perhaps the greatest weakness was that only women were included 
in this study and it is unknown if the same conclusions could be made about male 
subjects, although it has previously been reported that alcohol may be a greater risk 
factor for psoriasis in males compared to females  (Higgins, 2000). 
In addition to alcohol consumption being a risk factor for the development of psoriasis, 
many investigators also reported that alcohol exacerbated pre-existing psoriasis 
(Higgins, 2000), is associated with poor treatment response (Gupta et al., 1993) and that 
abstinence can induce remission (Vincenti and Blunden, 1987).  Interestingly, alcohol 
may also affect psoriasis in the long term, beyond the acute phase of alcohol intake; it 
has previously been shown that in patients who abstain from alcohol during in-patient 
treatment for psoriasis, their previous alcohol intake can predict treatment outcome 
(Gupta et al., 1993).  
As the role of alcohol in the development and exacerbation of psoriasis becomes clearer, 
there is also evidence that patients with high alcohol intake have a tendency towards  
more severe, widespread, inflamed psoriasis (Monk and Neill, 1986; Higgins and Du 
Vivier, 1994b). They may also have distinct psoriatic phenotypes; the first type being a 
highly inflammatory form, with minimal scale, mainly confined to the flexures and face 
and the second type being characterised by intensely thick scale (hyperkeratosis) in an 
acral distribution e.g. hands and feet (Higgins and du Vivier, 1992).   
In addition to alcohol being a risk factor for the development and exacerbation of 
psoriasis, excess alcohol consumption can also decrease the efficacy of systemic 
treatments for psoriasis, as well as being associated with poorer patient compliance 
(Gupta et al., 1993; Higgins and du Vivier, 1994a).  Furthermore, alcohol can increase 
the potential toxicity of systemic treatments.  For example, alcohol can increase the 
esterification of acitretin, a systemic retinoid used to treat psoriasis, to etretinate which, 
as a result of its slow elimination and accumulation in adipose tissue, increases possible 
side effects of acitretin including its teratogenicity (Larsen et al., 1993).   
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1.4.2. Ethanol metabolism 
In humans, ingested alcohol is absorbed mainly in the duodenum, by passive diffusion. 
Following absorption, ethanol diffuses rapidly throughout water-based compartments of 
the body.  For example, in human sweat ethanol concentration is ~80-95% of that found 
in blood (Buono, 1999) and in rats, skin ethanol levels reached 12–18% of blood values 
2h after a single oral ingestion of ethanol (Brand et al., 2006).  During metabolism, 
ethanol is initially oxidised to acetaldehyde, mostly by cytoplasmic alcohol 
dehydrogenase (ADH), (Figure 1-10) which is then oxidised to acetate, mostly by 
mitochondrial aldehyde dehydrogenase (ALDH); conversion of ethanol to acetate 
occurs predominantly in the liver (Crabb et al., 2004).  Acetate itself can be oxidised to 
carbon dioxide and water, alternatively acetate can freely circulate in plasma to 
peripheral tissue where it can be metabolised to acetyl-coA, by acetyl coenzymeA 
synthetase (ACSS).  Acetyl-coA is involved in many biochemical reactions, including 
the Krebs cycle, but can also be used as a substrate for histone acetyl transferase 
enzymes (e.g. for acetylation of lysine residues on histones) or be converted to acetone, 
through ketosis (Yamashita et al., 2001).  
 
 
 
Figure 1-10: Ethanol metabolism   
 
 
In humans there are six classes of ADH (1-6), each with different substrate specificities, 
although class I ADH (consisting of ADH1A, ADH1B and ADH1C) is the main 
ethanol-metabolising isoenzyme (Cheung et al., 1999).  In comparison, there are 3 
classes of ALDH (1-3), each with different substrate specificities, but ALDH1 and 
ALDH2 are the main acetaldehyde-metabolising isoenzymes (Cheung et al., 2003) 
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Although metabolism of acetate occurs in peripheral tissue, oxidation of ethanol to 
acetate occurs predominantly in hepatocytes where ADH and ALDH enzymes are 
principally expressed (Crabb et al., 2004).  In comparison, it has previously been shown 
that expression of ADH and ALDH in skin was ~12-30 fold lower than in liver (Cheung 
et al., 1999; Cheung et al., 2003).  In addition to skin showing low expression of 
enzymes involved in ethanol metabolism, enzyme activities and affinity for ethanol has 
also been found to be low.  For example, comparisons of substrate utilisation rates of 
ADH derived from human skin for 7 different primary alcohols (ethanol, propranolol, 
butanol, pentanol, 2-methylpropranolol, 3-methylbutanol and 2,2-demethyl-propranolol) 
showed that, apart from 2,2-demethyl-propranolol, ethanol showed the lowest rate of 
substrate utilisation (Wilkin and Stewart, 1987).  In addition the specific enzyme 
activity of ADH from different tissues, using ethanol as a substrate, has previously 
shown that ADH activity in skin is approximately ~190 fold lower than in liver (Saleem 
et al., 1984).  Furthermore while it is clearly not possible to measure total ADH activity 
in the whole human body or in individual organs, total ADH activity in individual 
organs has been calculated using data from ADH activity/gram in organ-specific 
samples and the average total weight of these organs in the human body; these 
calculations showed that ~96 to 98.8% of total ADH activity in the human body is 
confined to the liver and only 0.05% occurs in the whole of the skin (Saleem et al., 
1984).  Together these findings suggest that very little ethanol metabolism occurs in 
skin as a whole and even less in individual keratinocytes. 
1.4.3. Potential, non-epigenetic, mechanisms of alcohol involvement in the 
pathogenesis of psoriasis 
Although there is mounting evidence that alcohol is a causal factor in the development 
and exacerbation of psoriasis, the mechanism(s) by which alcohol might contribute to 
disease remains unknown.  However, a number of studies support the hypothesis that 
ethanol, and a number of its metabolites (Figure 1-10), contributes to the psoriasis 
phenotype through a variety of potential mechanisms.   
Firstly ethanol and its downstream metabolite, acetone (Figure 1-10), have both 
previously been shown to induce proliferation in HaCaT cells, an immortalised 
keratinocyte cell line (Farkas et al., 2003). Excess keratinocyte proliferation is a key 
feature in psoriasis (Goodwin et al., 1973) and ethanol and acetone were both shown to 
upregulate expression  of genes characteristic of keratinocyte proliferation including 5 
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integrin, keratinocyte growth factor receptor and cyclin D1; which have all been shown 
to be upregulated in lesional psoriatic tissue (Farkas et al., 2003).   
Another mechanism proposes that metabolism of ethanol to acetylaldehyde leads to the 
generation of  reactive oxygen species (ROS), which activates pro-inflammatory 
signalling pathways including mitogen-activated protein kinase/activator protein 1 
(MAPK/AP1), NF-B and Janus kinase signal transducers and activators of 
transcription (JAK-STAT) leading to upregulation of pro-inflammatory cytokines 
including TNF, IL-1, IL-6, IL-8 and IFNcausing a shift towards a predominantly 
Th1 response seen in psoriasis (Farkas and Kemeny, 2010).  
As well as potential effects on epidermal proliferation and the immune response, 
alcohol may also affect the skin’s barrier function.  In rats, oral ethanol intake can affect 
the skin’s barrier function, as determined by transdermal absorption of topically applied 
agents; the authors proposed this may be due to enhanced solubility, physical alteration 
in the skin barrier and/or changes in the skin due to ethanol or its metabolites (Brand et 
al., 2006).  Impaired barrier function can also increase susceptibility to infection and 
have effects on the skin microbiome, which may contribute to inflammatory skin 
disease.  As previously described, ethanol concentration in sweat is ~80-95% of that in 
blood (Buono, 1999) and skin ethanol levels are ~12–18% of blood (Brand et al., 2006). 
In addition to local cutaneous effects, alcohol can have more generalised effects which 
could have an impact on the development or exacerbation of psoriasis.  For example, 
alcohol abuse can cause nutritional deficiencies either because of a primary deficiency 
due to lack of intake or a secondary deficiency due to, for example, malabsorption or 
inability to metabolise or store nutrients normally; this could result from pancreatic 
insufficiency or small bowel dysmotility as a result of alcohol abuse.  Heavy abusers of 
alcohol may be deficient in protein and vitamins, including A,B, C and E as well as 
micronutrients including magnesium, zinc and selenium (Smith and Fenske, 2000).  
Many nutritional deficiencies are known to have cutaneous manifestations, for example; 
protein deficiency can lead to scaling of the skin and flexural fissures; vitamin B3 
deficiency can lead to dermatitis (as part of the pellagra); vitamin C deficiency can lead 
to peri-follicular haemorrhages and corkscrew hair and zinc deficiency can lead to 
impaired wound healing, angular stomatitis and pustular paronychia.  Nutritional 
deficiencies, as a result of alcohol abuse, could therefore play a role in the pathogenesis 
of psoriasis. 
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1.4.4. Potential, epigenetic, mechanisms of alcohol involvement in the 
pathogenesis of psoriasis 
As previously discussed, psoriasis is characterised by hyper-proliferative and 
abnormally differentiated keratinocytes, driven in part by intrinsically dysfunctional 
keratinocytes (Goodwin et al., 1973) but also by an altered immune system with excess 
expression of growth factors and cytokines (Takahashi et al., 2010).  As epigenetic 
modifications, section 1.3.2, by definition, regulate gene expression (Bird, 2007) and 
there is increasing evidence that these are aberrant is psoriasis (Gudjonsson and 
Krueger, 2011; Zhang et al., 2011b), section 1.3.5, it is plausible that alcohol interacts 
with the epigenome to influence the development, exacerbation and phenotype of 
psoriasis. 
To date, there have been no publications investigating the potential epigenetic effects of 
alcohol, or its metabolites, in psoriasis.  However, studies outside of the field of 
psoriasis suggest that alcohol or its metabolites can poise a cell into a pro-inflammatory 
state through alterations of the epigenome and its regulators. 
Park et al. were one of the earliest investigators to demonstrate that ethanol treatment, in 
rat derived hepatocytes, resulted in histone hyperacetylation (Park et al., 2003).  The 
same group have since demonstrated that ethanol effects on the epigenome may be 
tissue specific; ingestion of alcohol in rats in vivo lead to enhanced histone acetylation 
in liver and spleen but not in brain or kidney (effects in skin were not investigated) 
(Kim and Shukla, 2006).  The balance between opposing writer (e.g. HAT) and eraser 
(e.g. HDAC) activity governs the state of epigenetic marks and ethanol has previously 
been shown to enhance HAT activity and decrease HDAC activity in vitro, thus 
promoting a state of hyperacetylation (Choudhury and Shukla, 2008), and in keeping 
with evidence of ethanol-induced hyperacetylation of histones in vivo (Kim and Shukla, 
2006).  In vivo, ethanol undergoes zero-order metabolism and it has previously been 
shown that ethanol could mediate its (epigenetic) effects through one of its principle 
metabolites, acetate. In nuclear extracts prepared from rat derived hepatocytes, both 
ethanol and acetate exposure lead to the selective enhancement of acetylation of H3 at 
lysine 9 (H3K9ac) (Park et al., 2005) and inhibition of enzymes involved in ethanol 
metabolism decreased ethanol-induced histone-H3 acetylation (Park et al., 2003). 
In addition to generalised effects on histone acetylation, ethanol has also been shown to 
enhance acetylation of histones associated with the promoter region of genes 
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upregulated in alcohol-associated diseases.  For example in a macrophage model of 
acute alcoholic hepatitis, ethanol enhanced cytokine responses to LPS through 
hyperacetylation of histones at the promoter region of target response genes e.g. IL-6 
and TNF (Kendrick et al., 2010).  The hyperacetylation (greater for histone-H3 
compared to histone-H4) could be explained by the observation that both ethanol and 
acetate increased HAT activity, decreased HDAC activity and up-regulated expression 
of ACSS (Kendrick et al., 2010).  In this system acetate had similar effects to ethanol, 
supporting the earlier hypothesis that ethanol’s effects on the epigenome could be 
mediated through this metabolite (Park et al., 2003; Park et al., 2005). 
In addition to ethanol driving increased acetylation of histone-H3 over histone-H4 
(Kendrick et al., 2010), ethanol has been shown to preferentially induce acetylation of 
particular lysine residues on histone-H3 over others.  For example, in rat-derived 
hepatocytes, ethanol selectively enhanced acetylation of H3 at lysine 9 (H3K9ac) but 
had no significant effect on H3K14ac, H3K18ac nor H3K23ac, these results were also 
observed in the liver of rats treated with ethanol in vivo (Park et al., 2005).  Although it 
is known that histone acetylation is regulated by the family of HAT and HDAC 
enzymes, the specificity of particular family members for individual lysine residues and 
different histones is not fully understood.  Therefore, whilst Park et el. demonstrated 
that ethanol modulated the activity of HAT(s), which demonstrated selectively for 
H3K9ac, they could not elucidate which member(s) of the HAT family were activated 
by ethanol or indeed whether specific HDACs were also involved (Park et al., 2005).  
More recently, ethanol has been shown to regulate recruitment of specific HATs.  In a 
model of alcohol-induced cardiac hypertrophy, ethanol-exposed mice demonstrated an 
ethanol-induced increase in H3K9ac at the NKX2.5 promoter and increased expression 
of the NKX2.5 gene, which encodes a transcription factor involved in and upregulated 
in cardiac development and hypertrophy (Peng et al., 2015).  In contrast there was no 
increased H3K9ac acetylation at the RPL13A promoter, a gene for which the expression 
was not enhanced with ethanol treatment (Peng et al., 2015).  Furthermore Peng et al. 
demonstrated that specific members of the HAT family (p300, CBP, PCAF, SRC1 and 
GCB5) bound to the NKX2.5 promoter and that ethanol enhanced the binding of a 
specific subset of these (p300, CBP, PCAF and SRC1 but not GCB5) (Peng et al., 
2015).  Although Peng et al. did not investigate the effects of ethanol on HDAC binding 
to the NKX2.5 promoter, it was demonstrated that the pan-HAT inhibitor, anacardic 
acid, reduced binding of p300 and PCAF with corresponding attenuation of H3K9ac.  
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Together these findings suggest ethanol can induce acetylation of individual lysine 
residues on histones associated with particular promoter regions of target genes through 
the recruitment of specific HATs, which potentially play a greater role than HDACs in 
ethanol-enhanced expression (of NKX2.5). Although this is a novel and intriguing 
finding, it is unknown if similar mechanisms regulate other ethanol-sensitive genes in 
this system or other alcohol-related diseases or whether HDACs play a greater role in 
different conditions.   
Although the effects of ethanol on histone acetylation have been the most widely 
studied epigenetic modification, ethanol has also been shown to have effects on other 
types of histone modifications.  For example, treatment of rat-derived hepatocytes has 
been shown to alter the methylation status of lysine residues on histones (Pal-Bhadra et 
al., 2007).  Interestingly, Pal-Bhadra et al. demonstrated that ethanol affected 
methylation patterns in a lysine-residue specific manner; ethanol induced an increase in 
global dimethylation on lysine 4 on histone-H3 (H3K4me2) but a decrease in global 
dimethylation on lysine 9 on histone-H3 (H3K9me2).  Furthermore, in ChIP studies, 
H3K4me2 was enriched at the promoter region of genes which were upregulated with 
ethanol treatment, whereas H3K9me2 was enriched at the promoter region of genes 
which were downregulated with ethanol treatment (Pal-Bhadra et al., 2007).  These 
findings support the hypothesis that ethanol can regulate recruitment of specific 
epigenetic writers and potentially erasers to particular histone modifications associated 
with specific genes, but in addition to affecting recruitment of regulators of histone 
acetylation (Peng et al., 2015), the findings by Pal-Bhadra et al. suggest that ethanol 
could also affect regulators of histone methylation (methylases and demethylases), 
although the exact mechanism remains unknown. 
In summary, it is known that alcohol abuse is associated with increased risk of organ 
specific diseases especially inflammation and cirrhosis of liver with mounting evidence 
for a role in psoriasis pathogenesis, amongst other dermatological diseases.   As 
described above, investigations of the epigenetic effects of ethanol in non-
dermatological diseases/models suggest that ethanol can have organ specific epigenetic 
effects and has been shown to affect both histone acetylation and methylation.  By 
regulating the recruitment of specific epigenetic writers (and potentially erasers), 
ethanol can modulate individual histone modifications at the promoter region of 
particular disease-related genes, thereby regulating their expression, potentially 
precipitating or exacerbating disease.  Furthermore, it was shown that acetate often had 
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similar effects to ethanol suggesting that ethanol could mediate its effects through 
acetate, one of its principle metabolites.   
1.4.5. Lithium and beta-blockers in the pathogenesis of psoriasis 
In addition to alcohol, there is very strong evidence and it is widely accepted that non-
recreational drugs including lithium and beta-blockers can also trigger and exacerbate 
pre-existing psoriasis (Peters et al., 2000; Rongioletti et al., 2009). 
Lithium is a mood stabiliser and is licensed, as lithium carbonate and lithium citrate, for 
the treatment of bipolar disorder and depression (BNF, 2015).  It is well recognised that 
lithium can both exacerbate pre-existing psoriasis and, less commonly, provoke it in 
patients with or without a previous personal or family history of psoriasis; although not 
all patients exposed to lithium will develop psoriasis (Sasaki et al., 1989; Brauchli et 
al., 2009).  Incidence of exacerbation or induction of psoriasis ranges between 3.4 – 
45% and is not necessarily dose related and latency periods of  20 weeks (mean) for 
exacerbation and 48 weeks (mean) for induction of psoriasis are reported (Rongioletti et 
al., 2009; Hampton et al., 2012).  A case-control analysis of over 36,000 newly 
diagnosed cases of psoriasis using the UK-based General Practice Research Database, 
showed that patients who received 5 or more prescriptions of lithium had an odds ratio 
of 1.68 (95 confidence interval: 1.18-2.39) for developing psoriasis compared to those 
who did not receive lithium (Brauchli et al., 2009).  In addition to a link between 
lithium and plaque psoriasis, lithium has also been reported to precipitate pustular 
psoriasis in a patient with pre-existing plaque psoriasis and this occurred again on re-
challenge with lithium (Lowe and Ridgway, 1978).  Although the majority of case 
studies involved a limited number of patients, it has been previously reported that 
lithium provoked psoriasis was reversed after withdrawal of the drug and that re-
challenging these patients with lithium resulted in a return of their psoriasis within a 
shorter period of time (Skoven and Thormann, 1979). Although this suggests a causal 
relationship between lithium and psoriasis, the underlying mechanism of lithium 
provoked or lithium exacerbated psoriasis remains uncertain.   
Interestingly, previously published data has shown that lithium did not potentiate 
release of IL-6 or IL-8 protein in unstimulated keratinocytes derived from patients with 
psoriasis or healthy controls, although levels of transforming growth factor alpha 
(TGF) were increased  (Ockenfels et al., 1996).  Furthermore, lithium treatment in 
patients with bipolar disorder has previously been shown to down regulate expression of 
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key psoriasis inflammatory cytokines, including IL-6 and TNF, in patient derived 
monocytes (Padmos et al., 2008).   This is in contrast with the potentiation effects of 
ethanol on IL-6, IL-8 and TNF responses to LPS stimulation, as previously discussed.  
It has previously been reported that lithium can increase T-cell proliferation and, more 
recently, keratinocyte proliferation, key features of psoriasis, through inhibition of 
glycogen synthase kinase 3 (GSK-3) (Ohteki et al., 2000; Hampton et al., 2012).  In 
keratinocytes, it was demonstrated that clinically relevant concentrations of lithium lead 
to increased keratinocyte proliferation and that this could be reproduced by either 
pharmacological inhibition of GSK-3 or retroviral transduction of GSK-binding protein, 
a known endogenous inhibitory binding partner of GSK-3, which resulted in both 
increased nuclear translocation of Nuclear factor of activated T cells 2 (NFAT2) and 
transcriptional activation of NFAT (Hampton et al., 2012).   
In addition to lithium being strongly implicated as a causal factor in the precipitation or 
exacerbation of psoriasis, beta-blockers (-blockers) which are licensed to treat 
hypertension, amongst other indications (BNF, 2015) are also widely accepted to both 
provoke and exacerbate existing psoriasis and latency can be over 1 year (Rongioletti et 
al., 2009).  As with lithium, not all patients exposed to -blockers will develop psoriasis 
and discontinued use of the offending drug will induce remission of -blocker-induced 
psoriasis in the majority of patients (Arntzen et al., 1984).  A retrospective study of 
nearly 600 patients with psoriasis suggested that in those patients prescribed -blockers, 
over 70% experienced exacerbations of their psoriasis over a 1 year period (Gold et al., 
1988).   
Although the underlying mechanism for -blocker-exacerbated or induced psoriasis is 
uncertain it has been suggested that this may be through decreased levels of cyclic 
adenosine monophosphate, as a direct result of beta-blockade, leading to decreased 
levels of intracellular calcium and therefore reduced cellular (keratinocyte) 
differentiation and increased proliferation, as observed in psoriasis (Wu et al., 2014).  
Therefore, as potentially the case with lithium, -blockers could influence the psoriasis 
phenotype through promoting keratinocyte proliferation, although through a different 
mechanism to lithium; rather than through enhanced effects on inflammation which may 
be the underlying mechanism, at least in part, for ethanol-exacerbated or induced 
psoriasis. 
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In summary psoriasis is a common, complex chronic inflammatory dermatosis, whose 
pathogenesis is not fully understood.  While the most widely accepted model of 
psoriasis suggests hyperproliferation of keratinocytes (which themselves may be 
dysfunctional or hypersensitive to stimuli) is driven by an over-active immune system 
and environmental insults, the underlying changes which regulate intracellular 
signalling and inflammation are not fully understood, but increasing evidence suggests 
alterations in the epigenome, including histone acetylation, plays a role.  Bromodomain 
containing proteins bind acetyl-lysine residues on histones and recruit transcription 
factors, thereby regulating gene expression.  Small molecule inhibitors of bromodomain 
extraterminal (BET) proteins demonstrate anti-proliferative and anti-inflammatory 
effects in in vitro and in vivo models of cancer and inflammation.  There is little 
documentation about the function of BET proteins or the effects of BET inhibition in 
keratinocytes.  However, given that psoriasis is characterised by chronic inflammation 
and excessive keratinocyte proliferation, it is hypothesised that epigenetic modifications 
and BET proteins are involved in regulating cutaneous inflammatory responses and that 
BET inhibitors could block pathogenic inflammatory responses in keratinocytes. 
1.5. Study aims 
Psoriasis represents a complex interplay between genetic predisposition, the 
environment and inflammatory responses.  The central hypothesis of this project is that 
epigenetics plays a role in the regulation of cutaneous inflammation and inflammatory 
skin disease.  There is significant interest in utilising and further developing models of 
skin inflammation which can be used to increase understanding about the pathogenesis 
of inflammatory skin disease, including the role of epigenetics. Additionally, these 
studies aim to establish models amenable to pre-clinical testing of potential therapeutic 
compounds, including topical treatments.   
Cytokine-stimuli relevant to the pathogenesis of psoriasis may alter gene-regulating 
epigenetic epitopes, resulting in a primed/pro-inflammatory state.  In addition, it is 
known that exogenous factors can precipitate and exacerbate the psoriasis phenotype 
and we hypothesised that these may modify the epigenome to further promote 
expression of pro-inflammatory and psoriatic genes.   
The main aims of this project were to develop a model of cutaneous inflammation in 
human keratinocytes using pro-inflammatory cytokines and various stimuli of the innate 
immune system that can be used for: 
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 Further understanding the pathogenesis of inflammatory skin disease and the 
role of epigenetics, including acetylation of lysine residues on histones and 
bromodomain-containing proteins that recognise these particular epitopes. 
 Investigating how exogenous factors, including alcohol, might exacerbate 
responses to stimuli relevant to inflammatory skin disease; and to understand 
whether any potentiation of pro-inflammatory responses may be through an 
epigenetic mechanism. 
 In-vitro, pre-clinical, evaluation of potential therapeutic compounds, including 
those targeting proteins known to bind to the epigenetic epitopes.  
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2. Materials and Methods 
2.1. General principles 
2.1.1. Laboratory work 
All experimental procedures were carried out according to the Control of Substances 
Hazardous to Health (COSHH) regulations.  All laboratory work at Newcastle 
University was conducted in accordance with Newcastle University Health and Safety 
regulations and in a sterile containment level 2 safety hood, where appropriate.  
MesoScale Discovery
®
 Platform cytokine analysis and chromatin immunoprecipitation 
(apart from stimulation and fixation of cells) were both carried out at GlaxoSmithKline 
Pharmaceutical Research and Development Facility, Stevenage, according to 
GlaxoSmithKline Health and Safety regulations and with relevant training. 
2.1.2. Ethical approval 
The study adhered to the code of ethics of the world medical association (Declaration of 
Helsinki) for medical research involving human subjects, was approved by Newcastle 
and North Tyneside Research Ethics Committee (Ref 08/H0906/95+5_Lovat) and was 
sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust (trust 
approval for R&D project ref 4775).  Written informed consent was obtained from all 
subjects and the research performed was in accord with the terms of the informed 
consents.  All patient samples were obtained from Newcastle Upon Tyne Hospitals, 
NHS Foundation Trust. 
2.1.3. Sources of materials 
All chemical were supplied by Sigma-Aldrich, Gillingham, UK, unless otherwise stated. 
2.2.  Primary keratinocyte cell culture 
2.2.1. Primary human keratinocytes isolation and culture 
After obtaining informed consent from patients undergoing elective surgery, non-
psoriatic human skin samples which would normally be discarded after surgery (e.g. 
circumcision, breast or abdominal reductions) were used to extract and culture normal 
human epidermal keratinocytes (NHEKs) (Todd and Reynolds, 1998).  Immediately 
following surgical removal, skin samples were placed in 10ml Epilife
®
 keratinocyte 
medium (Invitrogen, Paisley, UK) supplemented with 2% penicillin streptomycin 
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amphotericin B (PSA) (Lonza Biologics, Switzerland). Prior to transfer from theatre to 
the Newcastle University Dermatological Sciences Laboratories, samples were stored at 
4°C.  Upon receipt, samples were stored at 4°C and processed the same day.  In a sterile 
containment level 2 safety hood, samples were washed in phosphate buffered saline 
(PBS) (Sigma-Aldrich, Gillingham, UK) with added PSA.  Forceps and scissors were 
washed in 100% ethanol and flame sterilised and under clean conditions sub-cutaneous 
tissue (fat, connective tissue and blood vessels) was removed; the remaining tissue 
(epidermis and dermis) was scored with a scalpel then incubated in dispase II (1ml) 
(Roche Diagnostics, Burgess Hill, UK), PSA (1ml) and PBS (8ml) at 4°C, overnight.  
Dispase II is a protease, produced in Bacillus polymyxa, which hydrolyses the N-
terminal peptide bonds of non-polar amino acid residues, which are found at a high 
frequency in collagen. Overnight incubation of the sample in dispase II, allows the 
separation of the epidermis from the dermis the following day, using flamed utensils.  
Isolated epidermis was placed in a universal tube containing 0.05% trypsin ethylene 
diamine tetraacetic acid (TE) (Sigma-Aldrich, Gillingham, UK) and incubated at 37°C 
for 5 min, shaking vigorously half way through, prior to TE neutralisation with fetal calf 
serum (FCS) (Sigma-Aldrich, Gillingham, UK).  The sample was centrifuged at 3000g 
for 5mins at room temperature.  The resulting pellet was resuspended in Epilife
® 
medium with human keratinocyte growth supplement (HKGS) (Invitrogen, Paisley, 
UK) and 1% PSA then placed into a T175cm
2
 tissue culture flask (T175) (Corning, New 
York, USA). Cells were cultured in a 37°C, 5% CO2, 95% humidity incubator. Culture 
medium was changed every two days until cells reached approximately 80% 
confluency.   
2.2.2. Cell passaging 
At required confluency, typically 80%, cells were washed twice in PBS, then TE added 
and incubated at 37
o
C for 5-7mins until NHEKs detached. Cells were centrifuged in 
FCS and PSA supplemented Dulbecco’s Modified Eagle Medium (DMEM) (Lonza 
biologics, Switzerland) for 5mins at 3000g.  After resuspending in Epilife
®
/HKGS 
media, cells were split 1 in 3 or 1 in 4, depending on proliferation efficiency of 
individual donors. Culture medium was changed every 2 days until cells reached 80% 
confluency.  All cells used for experiments within this project were passage 1-4.  
62 
 
2.2.3. Ethanol, acetate, lithium and propranolol culture conditions  
In experiments investigating the effects of ethanol, acetate, lithium or propranolol 
exposure on inflammatory responses, these were used at clinically relevant 
concentrations.  The ethanol concentration (86mM, 0.5%, 400mg/dl) used was 
equivalent to five times the legal blood ethanol concentration for driving in the UK and 
equivalent to heavy alcohol consumption in humans (Jones, 1999).  1mM acetate 
concentration was equivalent to the corresponding serum concentration seen in 
individuals metabolising ethanol at the concentration used (86mM) (Mascord et al., 
1992) (Nuutinen et al., 1985).  The concentration of lithium (1mM) was equivalent to 
the therapeutic concentration used clinically (BNF, 2015) and the concentration of 
propranolol (150ng/ml) was equivalent to the concentration required to achieve 
physiological beta-receptor blockade (Duff et al., 1986).   
Ethanol (VWR, Poole, UK) was added to Epilife
®
 culture media (to a final 
concentration of 0.5% v/v). Additionally as ethanol is a volatile substance, evaporation 
could lead to changes in ethanol concentration.  To overcome this problem, several 
options were considered.  Firstly sealing the culture flasks/plates, but this would have 
led to impaired gas exchange.  Secondly to frequently replace the culture media but in 
experiments involving measurement of secreted cytokines over a 48h period, this would 
not be practical.  The use of ethanol in an incubator’s water reservoir at twice the 
concentration as added to the culture media has previously been described as a solution 
to this problem (Zhang et al., 2001).  The concept is that ethanol in the water reservoir 
evaporates, filling the incubator with ethanol vapour which equilibrates with the ethanol 
dissolved in the media; the vapour pressure of the ethanol in the incubator thus 
maintains the ethanol concentration in the media, provided the circuit remains closed.  
This method was adopted for the experiments involving ethanol, control or acetate 
treated cells were grown in a different incubator.  A concentration of 0.5% ethanol was 
added to the media and a concentration of 1% ethanol was used in the reservoir in the 
incubator, which was replaced every 48h and each time the incubator door was opened 
(personal communication Dr. Stuart Kendrick, Newcastle University).  In experiments 
investigating the effects of acetate exposure on inflammatory responses, 1mM sodium 
acetate (Sigma-Aldrich, Gillingham, UK) was added to culture media and replaced 
every 48h, similarly for experiments involving lithium and propranolol. 
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In experiments where cells were exposed to ethanol, acetate, lithium carbonate (Sigma-
Aldrich, Gillingham, UK), lithium chloride (Sigma-Aldrich, Gillingham, UK) or 
propranolol hydrochloride chloride (Sigma-Aldrich, Gillingham, UK), the time 
indicated is the total time of exposure to these reagents prior to stimulation.  As shown 
in Figure 2-1, cells were exposed to 1mM acetate while being cultured in T175 flask for 
6 days, then seeded into 12 or 48-well plates and left for a further 1 day in 1mM acetate 
prior to stimulation (with TNF + IL-17A (IL-17), again in 1mM acetate).  A similar 
protocol was used for testing effects of ethanol, lithium carbonate, lithium chloride or 
propranolol hydrochloride and for testing different stimulation conditions.  Control cells 
were treated in the exactly the same way, apart from excluding acetate/ethanol/lithium 
carbonate/lithium chloride/propranolol hydrochloride where relevant from Epilife
®
 
media, i.e. NHEKs were cultured in T175 flasks with Epilife
®
 media for 6 days, prior to 
being re-seeded into 12 or 48-well plates and 1 day later, cells were stimulated (with 
treatments diluted in Epilife
®
).   
The only exceptions to this were ChIP (chromatin immunoprecipitation) studies.  Due to 
the large number of cells required for ChIP, cells were grown in T175 flasks for the 
total duration indicated (7 days) in the presence of media or media + 1mM acetate, 
before being stimulated (with TNF + IL-17) in these T175 flasks (again treatments 
were diluted in media or media + 1mM acetate as relevant). 
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Figure 2-1: Experimental set-up to investigate the effects of pre-incubation with 
specified agents (e.g. acetate) for 7 days, on keratinocyte responses to pro-
inflammatory stimuli 
Cells were grown in media or media + specified agent (e.g. 0.2-1mM acetate, 86mM 
ethanol) in T175 flasks for 6 days.  Cells were then seeded into 12-well or 48-well 
plates, for mRNA or protein studies respectively, in media or media + specified agent.  
1 day later, i.e. after a total of 7 days’ exposure to media or media + specified agent, 
cells were stimulated with TNF + IL-17 (diluted in media or media + specified agent, 
as relevant).  Cells were harvest at timepoints indicated in results chapters e.g. 6h post-
stimulation for RNA.  Media supernatants were collected at 48h post-stimulation for 
secreted proteins. 
2.3. Treatment of keratinocytes  
2.3.1. Stimulation of keratinocytes 
Except where otherwise stated, for experiments investigating effects on secreted protein, 
NHEKs were seeded into 48-well plates at a density of 18,000 cells/well in 200l 
Epilife
®
 media.  The following day, when cells were approximately 70% confluent, 
Epilife
®
 media was removed and replaced with Epilife
®
 media containing the following 
stimuli or pharmacological compounds, at concentrations as described in individual 
experiments (see results section).  
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 TNF(Immunotools, Friesoythe, Germany) 
 IL-17A (IL-17) (Immunotools, Friesoythe, Germany) 
 IL-22 (Immunotools, Friesoythe, Germany) 
 IFN(Immunotools, Friesoythe, Germany) 
 Pam3Cys-Ser-(Lys)4 trihydrochloride (Pam3Cys) (MerckMillipore, 
Massachusetts, USA) 
 Peptidoglycan derived from Staphylococcus aureus (PGN) (Sigma-Aldrich, 
Gillingham, UK) 
 Pam2CGDPKHPKSF (FSL-1) (Invivogen, California, USA) 
 Heat-killed Staphylococcus aureus (HKSA) (Invivogen, California, USA) 
 Lipoteichoic acid (LTA) (Sigma-Aldrich, Gillingham, UK) 
 Polyinosinic:polycytidylic acid (Poly:IC) (Sigma-Aldrich, Gillingham, UK) 
 Lipopolysaccharide derived from Escherichia coli K235 (LPS) (Sigma-Aldrich, 
Gillingham, UK) 
 Ciclosporin (MerckMillipore, Massachusetts, USA) 
 GSK1210151A (I-BET151, batch ID # P10633-080-PJ1) (GlaxoSmithKline, 
Stevenage, UK) 
 Sodium acetate (Sigma-Aldrich, Gillingham, UK) 
 Ethanol (VWR, Poole, UK) 
 Dimethyl sulfoxide (DMSO, vehicle) (Sigma-Aldrich, Gillingham, UK) 
For the “unstimulated” control, mock-stimulation was performed i.e. Epilife® media 
was replaced with fresh Epilife
®
 media at the same time as treatment with stimuli or 
compounds in other wells.  For the “vehicle” control, cells were stimulated with vehicle 
diluted in Epilife
®
 media at the same concentration as the vehicle dilution for 
compound.  For example, I-BET151 was initially dissolved in DMSO and then diluted 
in Epilife
®
 media so that the final concentration of DMSO was consistently 1:1200, 
regardless of the final concentration of I-BET151.  Therefore for I-BET151, the vehicle 
control was DMSO 1:1200 diluted in Epilife
®
 media.  For ciclosporin, the vehicle was 
ethanol (at a final dilution of 1:2000, 0.05%).  Note, apart from ciclosporin and I-
BET151, all other compounds were dissolvable in aqueous solution/media, abrogating 
the need for a separate vehicle control for these conditions.  Unless otherwise stated, 
media supernatants were collected at 48h post-stimulation and stored at -20
o
C, until 
analyte concentrations were measured.  Quantitative measurements of secreted 
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cytokines were performed by Enzyme-linked immunosorbent assay (ELISA) or 
MesoScale Discovery
®
 (MSD) Platform (section 2.4). 
For mRNA analysis, NHEKs were seeded in 12-well plates at a density of 100,000 
cells/well in 1ml Epilife
®
 media. One day later, when cells were approximately 90% 
confluent, cells were treated as described above and in individual experiments.  Unless 
otherwise stated, cells were harvested at 6h post stimulation and RNA was extracted 
using the ReliaPrep
TM
 RNA Cell Miniprep System (Promega, Wisconsin, USA) 
according to the manufacturer’s protocol (section 2.6). 
In experiments comparing the effects of isolating and culturing NHEKs in Epilife
®
 
media vs. MCDB 153 media (Sigma-Aldrich, Gillingham, UK), keratinocytes were 
extracted from skin samples (section 2.2.1) and cultured separately in either Epilife
®
 
media or MCDB 153 media, both supplemented with HKGS, for 2 passages.  Cells were 
seeded and stimulated with TNF and/or IL-17 (diluted in Epilife® media or MCDB 
153 media) at passage 3, as above, and media supernatants collected 48h  post-
stimulation and secreted protein concentrations measured by ELISA (section 2.4.1). 
Where possible wells at the edges of culture plates were filled with PBS and not used to 
seed keratinocytes.  This was to minimise potential evaporation effects, which could 
have altered the concentration of compounds. 
2.3.2. Treatment of keratinocytes with compounds 
In experiments investigating effects of I-BET151 concentrations on keratinocyte 
responses to TNF + IL-17 stimulation, NHEKs were seeded (section 2.3.1) and I-
BET151 (at concentrations indicated in results) or vehicle (DMSO, 1:1200) was added 
1h prior to stimulation with TNF + IL-17, to allow equilibration of the compound 
across cell membranes.  In experiments investigating effects of ciclosporin on 
keratinocyte responses to TNF + IL-17 stimulation, NHEKs were seeded (section 
2.3.1) and ciclosporin (1M) or vehicle (ethanol, 1:2000, 0.05%) was added 1h prior to 
stimulation with TNF + IL-17.  Cells were harvested at 6h post stimulation and RNA 
was extracted using the ReliaPrep
TM
 RNA Cell Miniprep System (Promega, Wisconsin, 
USA) according to the manufacturer’s protocol (section 2.6).  Media supernatants were 
collected at 48h post-stimulation and secreted cytokines concentrations measured by 
Enzyme-linked immunosorbent assay (ELISA) (section 2.4.1).  
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In experiments investigating effects of timing of I-BET151 addition on keratinocyte 
responses to TNF + IL-17 stimulation, NHEKs were seeded (section 2.3.1) and treated 
with I-BET151 before, during or after stimulation (Figure 2-2).  Cells were harvest at 6h 
post stimulation for RNA (section 2.6).  Media supernatants were collected at 48h post-
stimulation and secreted cytokines concentrations measured (section 2.4.1). 
 
Figure 2-2: Experimental set-up to investigate of timing of I-BET151 addition on 
keratinocyte responses to TNF + IL-17 stimulation 
NHEKs were seeded and treated with I-BET151 (1M) or vehicle (DMSO, 1:1200) 
either 1h before stimulation with TNF + IL-17, at time of stimulation or at various 
times after (1, 2 or 4h after stimulation for mRNA studies and 1, 2, 4, 10 or 24h after 
stimulation for protein studies).  Cells were harvested for mRNA 6h post-stimulation 
and media supernatants collected for secreted cytokines 48h post-stimulation. 
2.4.  Protein determination by immunoassays 
Quantitative measurements of media supernatants (see section 2.3 for details of 
preparation) for secreted cytokines were performed using MesoScale Discovery
®
 
(MSD) Platform (at GlaxoSmithKline, Stevenage) or Enzyme-linked immunosorbent 
assay (ELISA) (at Newcastle University) as indicated in results sections. 
2.4.1. Enzyme-linked immunosorbent assay 
Measurement of secreted protein concentration was performed by ELISA
 
using the 
DuoSet ELISA Development kit (R&D Systems
®
, Minnesota, USA) according to the 
manufacturer’s protocol.  Briefly, a “capture” antibody was coated onto a clear-flat 
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bottomed well and incubated at room temperature overnight, prior to washing 3 times 
(0.05% Tween
®
20 (Sigma-Aldrich, Gillingham, UK) in PBS was used for all washing 
steps).  Non-specific protein binding was blocked using 1% bovine serum albumin 
(Sigma-Aldrich, Gillingham, UK) in PBS, incubating at room temperature for 2h, prior 
to washing 3 times.  Sample media supernatant was incubated in the well at 4°C 
overnight, to allow binding of the protein of interest to the “capture” antibody, before 
the media was removed and the well washed 3 times.  A biotinylated “detection” 
antibody was then added, which binds to a different epitope of the protein of interest 
(which is now bound to the “capture” antibody), incubating at 37°C for 2h before 
washing 3 times.  Streptavidin-horseradish peroxidase (HRP) was added which binds 
the biotinylated “detection” antibody; the plate was sealed and incubated at room 
temperature for 20mins before washing 3 times.  Substrate solution was added and 
incubated for 20mins at room temperature.  Bound-HRP catalyses a colour change in 
the substrate (tetramethylbenzidine) solution and a blue colour develops in proportion to 
the amount of analyte present in the sample. Colour development was terminated using 
sulphuric acid (Sigma-Aldrich, Gillingham, UK), turning the colour in the wells from 
blue to yellow. Optical density was read at 450nm and a correction wavelength at 
540nm using a SpectraMax M250 plate reader (Molecular Devices, UK).  The 
correction wavelength reading at 540nm was subtracted from the 450nm reading and 
compared against a set of standard controls (run at the same time as test media 
supernatants) using a four parameter logistic (4-PL) curve-fit to determine cytokine 
concentrations.  Wavelength-specific absorbance is proportional to the concentration of 
analyte of interest in each sample.  The R&D Systems
® 
ELISA Duoset range of 
detection was 9.38 - 600 pg/ml for IL-6 and 31.20 - 2,000 pg/ml for IL-8, according to 
the manufacturer.  Where concentrations were above the upper limit of detection, 
further stored media supernatant samples were diluted before being assayed again. 
2.4.2. MesoScale Discovery® Platform 
During the initial phase of development of the cutaneous model of inflammation 
secreted protein concentrations were determined by MesoScale Discovery
®
 Platform 
(MSD) (MesoScale, Rockville, Maryland, USA) at GlaxoSmithKline (Stevenage, UK).  
MSD is a proprietary technology, based on a similar principle to ELISA, and uses 
electrochemiluminescent labels (SULFO-TAG
TM
) that are coupled to detection 
antibodies. It also facilitates the assay of multiple analytes in one sample by a multiplex 
format. In MSD platforms, the “capture” antibody is bound to a carbon electrode on the 
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bottom of the well and each well can contain several “capture” antibodies in distinct 
areas (“spots”) of the well allowing for multiple analytes to be detected from the same 
media supernatant sample (Figure 2-3).  “Detection” antibodies/SULFO-TAGTM bind to 
analytes bound to capture antibody and generate light when stimulated by electricity in 
the appropriate buffer environment.  Electricity is applied to the plate electrodes at the 
bottom of the well, leading to light emission by SULFO-TAG
TM
 labels, which is 
measured by a charge-coupled camera within an MSD analyser and, through 
comparison against a set of standard controls (run at the same time as test media 
supernatants), the concentration of an analyte can be determined.   
Media supernatant samples were analysed by MSD, according to the manufacturer’s 
protocol.  Briefly, 25l of test supernatant (or standards) was added to each well and 
incubated at room temperature on an orbital shaker for 2h.  “Detection” antibodies 
coupled to SULFO-TAG
TM 
were added and incubated for a further 2h at room 
temperature on an orbital shaker.  After washing, read buffer was added and samples 
analysed on an MSD sector S 600 analyser (MesoScale, Rockville, Maryland, USA). 
Analyte concentrations were determined, by comparison against the standard set of 
controls, using MSD Workbench software (MesoScale, Rockville, Maryland, USA). 
 
 
 
 
Figure 2-3: Cytokine analysis by MesoScale Discovery
®
 Multi-Spot
®
 Human 
ProInflammatory-7
®
 platform 
Each well contains seven spots, each pre-coated with a defined capture antibody.  A 
specific cytokine binds to its corresponding capture antibody. The SULFO-TAG
TM
 
emits quantifiable light upon electrostimulation at the electrode surface of the plate.  
Typical lower limits of detection are 0.5-10pg/ml.  (Adapted from 
www.mescoscale.com) 
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2.5. Measurement of cell viability 
2.5.1. SRB assay 
Total cellular protein content was determined using the Sulforhodamine B (SRB) assay 
which is based on the ability of SRB to bind to basic amino acids of cellular proteins 
(Voigt, 2005) and has been shown to be highly correlated with cell density (Skehan et 
al., 1990).  NHEKs were seeded into 48-well plates at a density of 18,000 cells/well in 
200l Epilife® media.  The following day, when cells were approximately 70% 
confluent, Epilife
®
 media was removed and replaced with Epilife
®
 media containing 
stimuli or pharmacological compounds, at concentrations as described in individual 
experiments (see section 2.3 and results sections).  48h after treatment, media was 
removed and cells fixed with 200l of 10% trichloroacetic acid in water for 1h at 4oC.  
After fixing, plates were washed in water 5 times and allow to air-dry.  200l of 0.4% 
(w/v) SRB (Sigma-Aldrich, Gillingham, UK) dissolved in 1% glacial acetic acid 
(Sigma-Aldrich, Gillingham, UK) was added to each well and incubated for 30mins at 
room temperature.  Plates were washed five times in 1% glacial acetic acid, until 
residual dye was removed.  Plates were dried at 60
o
C for 1h, then 400l 10mM Tris 
base pH10.0 (Sigma-Aldrich, Gillingham, UK) was added to each well and incubated 
for 15mins at room temperature on an orbital shaker.  Absorbance was read at 490nm, 
using a SpectraMax M250 plate reader (Molecular Devices, UK). 
2.5.2. MTT assay 
Cellular metabolism was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium-bromide (MTT) assay.  Yellow MTT is reduced to purple formazan 
when mitochondrial reductase enzymes are active; therefore if the reduction takes place 
the cell is considered to be metabolically active and viable (van Meerloo et al., 2011).  
Keratinocytes were seeded and treated as described previously for SRB assays (section   
2.5.1).  48h after treatment, 40l of 5mg/ml of MTT dissolved in PBS was added to 
each well and incubated at 37
o
C for 3.5h.  MTT solution was then removed and 300l 
MTT solvent (4mM HCL, 0.1% Nonident P-40 in isopropanol) was added and 
incubated in the dark on an orbital shaker for 15mins. Absorbance was read at 590nm 
using a SpectraMax M250 plate reader (Molecular Devices, UK).  
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2.6. Gene expression determination by quantitative reverse transcriptase 
polymerase chain reaction (PCR) 
Gene expression was assayed by quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR).  mRNA extracted from samples (section 2.6.1) was first converted 
to cDNA by reverse transcription (section 2.6.3).  Polymerase chain reaction (PCR), of 
the newly synthesised cDNA, was then undertaken, using primers specifically designed 
to the region of interest (section 2.6.4).  In comparison to standard PCR, where the 
product of the reaction is detected at the end e.g. by ethidium bromide agarose gel, real 
time PCR is made quantifiable by incorporating fluorescent markers into the reaction.  
As the reaction progresses a detectable signal, proportional to the number of amplicons 
formed, is generated; amplified DNA can therefore be detected as the reaction 
progresses in "real time".  Samples which initially had a higher number of mRNA 
transcripts (higher gene expression), will produce more amplicons and therefore more 
detectable signal, after a given number of PCR cycles.   
There are two main methods used in quantitative PCR.  The first uses a dye (SYBR
®
 
green) which binds to dsDNA; SYBR
®
 dye-dsDNA complexes emit quantifiable light.  
A caveat with this method is that SYBR
®
 green will bind to any dsDNA present; it is 
therefore important to control for non-specific PCR products, double stranded DNA 
contamination in the PCR assay mix and primer dimers.  Alternatively, amplicon-
specific DNA probes consisting of an oligonucleotide sequence that is labelled with a 
fluorophore marker and quencher can be used (e.g. Taqman
®
 probe).  While the probe is 
intact, fluorescence emitted by the fluorophore (after laser excitation) is quenched by 
the quencher molecule, by fluorescence resonance energy transfer (FRET).  However 
during PCR extension, when Taq polymerase copies the (cDNA) template from 3’ to 5’, 
the 5’ exonuclease activity of Taq polymerase hydrolyses the sequence-bound probe.  
Degradation of the probe releases the fluorophore from the locality of the quencher, thus 
releasing the emission of a detectable fluorescence upon excitation.  The fluorescence 
detected in quantitative PCR is proportional to the fluorophore released and the amount 
of cDNA template initially present in the PCR reaction. 
In quantitative PCR studies, using either of the above methods, the Ct (cycle threshold) 
is defined as the number of cycles required for the fluorescent signal/PCR amplification 
curve to cross the threshold (i.e. exceed background level). Ct values are inversely 
proportional to the amount of target nucleic acid in the sample i.e. the greater the 
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amount of starting cDNA template (which reflects gene expression) the lower the Ct 
value. 
2.6.1. RNA extraction 
All water used in RNA work was nuclease-free (Integrated DNA Technologies, 
Coralville, Iowa, USA).  Contamination from RNAses was minimised by careful 
technique, use of RNAse-free plasticware, regular changing of gloves and cleaning all 
equipment and work surfaces routinely with RNAseZap
TM
 (Sigma-Aldrich, Gillingham, 
UK). 
For mRNA analysis, NHEKs were seeded and treated as per section 2.3 and, unless 
otherwise stated, harvested at 6h post-stimulation for RNA.  RNA extraction was 
undertaken using the ReliaPrep
TM
 RNA Cell Miniprep System (Promega, Wisconsin, 
USA) according to the manufacturer’s protocol.  The standard protocol supplied with 
the ReliaPrep
TM
 RNA Cell Miniprep System was followed as below:   
i. To each well of a 12-well plate, 150l BL+TG buffer (Promega, Wisconsin, 
USA) was added (or 250l to each well of a 6-well plate) and pipetted up and 
down 5 times to lyse cells. 
ii. The lysate was transferred to a ReliaPrep™ minicolumn and centrifuged at 
14000g for 30secs at room temperature.  
iii. 500μl of RNA Wash Solution (Promega, Wisconsin, USA) was added to the 
minicolumn and centrifuged at 14000g for 30secs.   
iv. To each minicolumn membrane the following was added: 24μl of Yellow Core 
Buffer (Promega, Wisconsin, USA), 3μl 0.09M MgCl2 and 3μl of DNase I 
enzyme and incubated for 15mins at room temperature. 
v. 200μl of column wash solution (Promega, Wisconsin, USA) was added and 
centrifuged at 14000g for 15secs.  
vi. 500μl of RNA wash solution was added and centrifuged at 14000g for 30secs. 
vii. The minicolumn was placed into a new collection tube and 300μl of RNA wash 
solution added and centrifuged at 14000g for 2mins. 
viii. The minicolumn was transferred to an elution tube, and nuclease-free water 
added directly onto the membrane (20l for RNA from a 12-well plate, 30l for 
RNA from a 6-well plate) and incubated for 1min. 
ix. The minicolumn was centrifuged at 14000g for 1min to elute RNA. 
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2.6.2. Nucleic acid quantification 
The concentration of nucleic acid solutions can be determined spectrophotometrically at 
260nm, where 1 absorbance unit (A260) equals 40μg of single-stranded RNA/ml.  
Nucleic acid purity was estimated by spectrophotometry from the relative absorbances 
at 230, 260 and 280nm.  Proteins have a peak absorbance at 280nm and an A260/A280 
ratio of 1.8-2.0 suggests that protein contamination is relatively low.  Phenol, 
Ethylenediaminetetraacetic acid (EDTA) and carbohydrates and have peak absorbance 
near 230nm and an A260/A230 ratio of 2.0-2.2 suggests that contamination from these is 
relatively low.  After extraction, RNA yield was quantified and purity determined using 
a NanoDrop 2000 Spectrophotometer (ThermoScientific, Illinois USA) with 1l sample 
and referenced to a blank sample of nuclease-free water, without nucleic acid.   
2.6.3. cDNA preparation 
Reverse transcription was performed using SuperScript
TM
 III Reverse 
Transcriptase/First-strand synthesis system (Invitrogen, Paisley, UK) according to the 
manufacturer’s protocol, using a standardised amount of RNA in each reaction (Table 
2-1). Where possible “master cocktails” were made up to minimise variations in 
volumes of components.  Reactions mixes were sealed and briefly centrifuged before 
being transferred to an Applied Biosystems GeneAmp
®
 PCR System 9700 Machine 
(Invitrogen, Paisley, UK) using standard PCR cycle conditions as per Table 2-1:  
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Process Reagents Vol. per 
reaction 
(l) 
Temp 
(
o
C) 
Time (mins) 
Denature Total RNA (up to 500ng) 
100M random primers 
10mM dNTP mix 
Water 
10 (max) 
1 
1 
to 12 
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4 
5 
 
 
1 
Anneal To RNA/primer mix add: 
5X First-strand buffer 
0.1M DTT 
RNaseOUT
TM 
(40 U/l) 
M-MLV RT (200 U/l) 
Water 
 
4 
2 
0.125 
0.5 
to 20 
25 10 
cDNA 
synthesis 
  37 50 
Inactivation 
of reaction 
  70 15 
Table 2-1: Summary of reverse transcription/cDNA preparation, prior to real time 
polymerase chain reaction 
 
2.6.4. Real time PCR 
All primer/probes sets used were TaqMan® Gene Expression Assay (Invitrogen, 
Paisley, UK); except IL-6, Brd2/3/4 and RPL13A primer/probes (sequences and optimal 
running concentrations kindly supplied by Dr N.R. Harker, GlaxoSmithKline, 
Stevenage, UK) which were synthesised by Integrated DNA Technologies (Coralville, 
Iowa, USA) (Table 2-2).  Primers used span exon-exon junctions; complementary 
sequences to exon-spanning primers only appear in cDNA and not in (contaminating) 
genomic DNA, therefore only cDNA is amplified.  RPL13A was selected as a 
reference/housekeeper gene for “loading control” as this gene has previously been 
identified as a suitable reference/housekeeper gene in human keratinocytes (Minner and 
Poumay, 2009).  Furthermore, RPL13A demonstrated the least variation in cycle 
threshold values determined by qRT-PCR (section 2.6.5) in samples treated with TNF 
+ IL-17 stimulation as well as I-BET151, compared to other candidates assayed e.g. 
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18S, keratin14, and histone H4.  Negative control wells (containing no DNA) were used 
for each primer/probe to ensure the system was free of DNA contamination 
Real-time quantitative polymerase chain reaction (qPCR) was performed with GoTaq 
Probe qPCR Master Mix (Promega, Wisconsin, USA) according to the manufacturer’s 
protocol, adjusted to a 10l reaction with a standardised amount of cDNA in each 
reaction (typically ~200ng).   “Master cocktails” were made up to minimise variations 
in volumes of PCR buffer, probe and primers in each well.  Reaction were set up in 
optical 96-well plates (Invitrogen, Paisley, UK) on a pre-chilled rack, sealed and briefly 
centrifuged before being transferred to an Applied Biosystems Step One Plus Machine 
(Invitrogen, Paisley, UK) using standard PCR cycle conditions as follows:  
1. 50
o
C for 2mins 
2. 95
o
C for 10mins  
3. 95
o
C for 15secs 
4. 60
o
C for 60secs 
5. Plate read   
6. Repeat steps 3-5 x 40 times  
In the conditions above, DNA polymerase was activated by incubation at 95
o
C for 
10mins, followed by 40 cycles of denaturation at 95
o
C for 15secs and 
annealing/extension at 60
o
C for 60secs.  Heating DNA to 95oC denatures the DNA 
allowing the two strands to separate and cooling to 60
o
C allows primers to anneal to 
complementary strands. This process was repeated 40 times. 
2.6.5. Analysis of real time PCR 
A cycle threshold (Ct) value (section 2.6) was measured by qRT-PCR for each reaction, 
and RPL13A was used as a “housekeeper gene/loading control” to calculate a fold 
change correction for each sample.  After correction of the “housekeeper gene/loading 
control”, the Delta-Delta Ct method was used for analysis (i.e. the difference between 
the two Ct values) (Livak and Schmittgen, 2001). The difference was expressed as a 
fold change (equivalent to 2
Delta-Delta Ct
).  
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Target Assay ID/sequence Concentration used in qPCR 
IL-8 Hs00174103_m1 
(Applied Biosciences) (FAM/NFQ-MGB) 
Primers: 900nM 
Probe: 100nM 
ADH1A Hs00605167_g1 
(Applied Biosciences) (FAM/NFQ-MGB) 
Primers: 900nM 
Probe: 100nM 
ADH1B Hs00605175_m1 
(Applied Biosciences) (FAM/NFQ-MGB) 
Primers: 900nM 
Probe: 100nM 
ADH1C Hs02383872_s1 
(Applied Biosciences) (FAM/NFQ-MGB) 
Primers: 900nM 
Probe: 100nM 
ALDH1 Hs00946916_m1 
(Applied Biosciences) (FAM/NFQ-MGB) 
Primers: 900nM 
Probe: 100nM 
ALDH2 Hs01007998_m1 
(Applied Biosciences) (FAM/NFQ-MGB) 
Primers: 900nM 
Probe: 100nM 
ACSS1 Hs00287264_m1 
(Applied Biosciences) (FAM/NFQ-MGB) 
Primers: 900nM 
Probe: 100nM 
ACSS2 Hs00218766_m1 
(Applied Biosciences) (FAM/NFQ-MGB) 
Primers: 900nM 
Probe: 100nM 
IL-6 Forward: AATGGAAAGTGGCTATGCAG    
Reverse: GTTAGCCATTTATTTGAGGTAAGC   
Probe: TGTTTCAGAGCCAGATCATTTCTTGGA  (FAM/TAMRA)    
Forward: 900nM 
Reverse: 400nM 
Probe:100nM 
Brd2 Forward: GAAGCTGGGCCGAGTTGT 
Reverse: CGTAGGCAGGAAAGGACATAG 
Probe: CCAAGCCAGGGAGCCCTCTTTACGTGA  (FAM/TAMRA)    
Forward: 400nM 
Reverse: 900nM 
Probe:100nM 
Brd3 Forward: AGCAGCTCCTCCGAGTCTGG 
Reverse: TCCGAAGCCAGTTCATTCTGAG 
Probe: AGCGGGTCCAGCTCTGACAGCAGTGA  (FAM/TAMRA)    
Forward: 900nM 
Reverse: 900nM 
Probe:100nM 
Brd4 Forward: GCAGCTGAGGATTGCAGAGC    
Reverse: GCTCGTAACAAGGCGTGTGC  
Probe: CTTACGGCCAGTCGGACAG  (FAM/TAMRA)    
Forward: 900nM 
Reverse: 900nM 
Probe:100nM 
RPL13A Forward: GGGACTGCAGGTGGTGAC 
Reverse: GGCCTCAGATGGTAGTGCAT 
Probe: AGTTTCCCGACCATGAGATG  (FAM/TAMRA) 
Forward: 900nM 
Reverse: 900nM 
Probe:100nM 
Table 2-2: Primer/probe sets used in real time polymerase chain reactions 
All primer/probe sets were TaqMan® Gene Expression Assay (Invitrogen, Paisley, 
UK); except IL-6, Brd2/3/4 and RPL13A (sequences and optimal running 
concentrations kindly supplied by Dr N.R. Harker, GlaxoSmithKline, Stevenage, UK) 
which were synthesised by Integrated DNA Technologies (Coralville, Iowa, USA).  All 
probes contained a FAM reporter dye and a non-fluorescent quencher. 
 
2.7. Dual-luciferase assays 
NF-B activity after stimulation with TNF and/or IL-17 was measured using a NF-B 
firefly luciferase reporter (gift from Dr D J McKean, Mayo foundation, Rochester, MIN, 
USA).  Keratinocytes were seeded into a 48-well plate at a density of 16000 cells/well. 
24h later, when ~60% confluent, cells were transfected with 0.2μg NF-B firefly 
construct and 0.005μg renilla using TransIT-Keratinocyte specific transfection reagent 
(Geneflow, Litchfield, UK), according to manufacturer’s instructions, with renilla as an 
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internal control vector (Flockhart et al., 2008).  The next day, cells were stimulated with 
TNF(10ng/ml) and/or IL-17 (100ng/ml).  At the times indicated for each experiment 
post-stimulation, cells were harvested using 40μl passive lysis buffer (Promega, 
Wisconsin, USA), incubating at room temperature on an orbital shaker for 15mins then 
stored at -80
o
C.  Luciferase activity was measured using Dual-luciferase reporter system 
(Promega, Wisconsin, USA) following the manufacturer’s protocol.  Briefly, 20μl of 
defrosted lysate was added to a blacked-out 96-well plate suitable for luminescence 
assays.  Using a Glomax 96 Microplate reader (Promega, Wisconsin, USA), 60μl LAR 
and 60μl S+G was added to each well using two injectors built into the luminometer.  
Values were presented as a ratio of firefly to renilla, then normalised to 
mock/unstimulated control. 
2.8. Gene array 
2.8.1. Study design 
The following conditions were considered to be the most valuable in order to 
understand the effects of i) TNF + IL-17 stimulation in keratinocytes and ii) BET 
inhibition in this system:   
1. Mock/unstimulated (i.e. media change) 
2. TNF (10ng/ml) + IL-17 (100ng/ml) 
3. TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 vehicle (DMSO (1:1200)) 
4. TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 (1M) 
A number of valuable comparisons could be considered.  For example, comparison of 1 
vs. 2 would determine which genes were regulated by TNF + IL-17 stimulation in the 
model. The set of differentially expressed genes (DEGs) could then be compared to a 
psoriasis transcriptome to determine the overlap and understand their relevance to 
psoriasis.  2 vs. 3 would determine which genes, in TNF + IL-17 stimulated NHEKs, 
were affected by DMSO and 4 vs. 3 would  determine which genes, in TNF + IL-17 
stimulated NHEKs, were affected by I-BET151.  I-BET151 sensitive genes could in 
turn be compared to a psoriasis disease set of genes and a variety of psoriasis-treatment 
transcriptomes, respectively.  
As we were interested in early/primary response genes and IL-6 and IL-8 mRNA 
responses to TNF + IL-17 stimulation were maximal at 6h post-stimulation (section 
78 
 
3.3.2), it was decided to stimulate NHEKs with TNF + IL-17 for 6h prior to harvesting 
cells for mRNA/microarray analysis.  However, late response genes may not show 
changes as early as 6h.  Furthermore, Chiricozzi et al. had chosen a timepoint of 24h 
after stimulation with TNF + IL-17, in studying the effects of these stimuli on 
inflammatory responses in human keratinocytes (Chiricozzi et al., 2011).  For these 
reasons, it was decided that in addition to a 6h timepoint, NHEKs would also be 
stimulated under the above conditions for 24h in order to study effects on late gene 
response, to allow for easier comparison to published data set (Chiricozzi et al., 2011) 
and also to understand dynamic gene expression changes in responses at 6h vs. 24h. 
Such data may also allow clustering of distinct response patterns.  Thus there were 4 
treatment conditions, each at 2 timepoints for each donor. 
Power calculations were undertaken in collaboration with Dr. Erika Cule 
(GlaxoSmithKline, Stevenage, UK), to determine the number of donors required to 
detect statistically significant changes in gene expression in response to TNF + IL-17 
stimulation and also inhibition by I-BET151.   Power calculations were based on pilot 
qRT-PCR data (N=8) for IL-6 and IL-8 in the TNF (10ng/ml) + IL-17 (100ng/ml) 
stimulated human keratinocyte model, and also considering the effects of I-BET151 
(1M) on these endpoints.  Based on this analysis, it was calculated that, for example, 5 
donors would have 80% statistical power (with type-I error of 5%) to detect a ~6-fold 
change in gene expression in stimulated compared to unstimulated NHEKs and ~85% 
inhibition by I-BET151, based on variability in IL-6 mRNA responses across donors 
(IL-8 showed similar variability to IL-6).  In comparison, 20 donors would have 80% 
power (with type-I error of 5%) to detect a ~2-fold change in gene expression in 
stimulated compared to unstimulated NHEKs and ~50% inhibition by I-BET151, based 
on variability in IL-6 mRNA responses across donors. 
The final consideration was the microarray platform and provider.  After cost 
effectiveness analysis, it was decided that the Illumina human HT-12 v4.0 microarray 
platform (Illumina, San Diego, California, USA), outsourced to Central Biotechnology 
Services, Cardiff University, Cardiff, UK (http://centralbioserv.co.uk/) would provide 
the most cost effective and reliable service.  Each Illumina human HT-12 v4.0 
BeadChip allowed 12 samples to be run; although empty runs are wasted.   
In summary it was decided that the 4 treatment conditions, each at 2 timepoints would 
be run in 12 donors which, based on power calculation from pilot data, would have 80% 
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power (with type-I error of 5%) to detect a ~2.85-fold change in gene expression after 
stimulation with TNF + IL-17 and ~60% inhibition by I-BET151, based on variability 
in IL-6 mRNA responses across donors.  These power calculations were based solely on 
variability in IL-6 and IL-8 responses (which both demonstrated similar variability), 
with RPL13A as a reference/loading control.  If other gene responses show greater 
variability, the power to detect significant changes will be reduced for these genes. 
2.8.2. Sample preparation 
For microarray studies, NHEKs were seeded in 6-well plates at a density of 150,000 
cells/well in 2ml Epilife
®
 media. 24h later, when NHEKs were approximately 80% 
confluent, cells were stimulated as follows: 
1. Mock/unstimulated (i.e. media change), 6h stimulation 
2. TNF (10ng/ml) + IL-17 (100ng/ml), 6h stimulation 
3. TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 vehicle (DMSO (1:1200)), 6h 
stimulation 
4. TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 (1M), 6h stimulation 
5. Mock/unstimulated (i.e. media change), 24h stimulation 
6. TNF (10ng/ml) + IL-17 (100ng/ml), 24h stimulation 
7. TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 vehicle (DMSO (1:1200)), 
24h stimulation 
8. TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 (1M), 24h stimulation 
 
Note that stimulation times were staggered so that conditions 5-8 were set up first and 
18h later conditions 1-4 were set up.  Cells from all conditions were therefore harvested 
at the end of the experiment, at a single timepoint.  This was to ensure a similar number 
of cells were harvested for each condition and to minimise any differences in harvesting 
of cells.  Harvested cells from each donor were “snap frozen” in liquid nitrogen and 
stored at -80

C.  Once all donors were stimulated and cells harvested, RNA was 
extracted from all donors over a 2-day period (section 2.6, eluting into 30l of nuclease-
free water), in order to minimise variations in handling.  In total NHEKs from 14 
consecutive donors were stimulated (over a period of approximately 3 months, each at 
passage 3) and harvested for RNA.  qRT-PCR for IL-6 and IL-8 were undertaken 
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(section 2.6) for each of the 14 donors and their 8 conditions.  12 of the 14 donors were 
selected for microarray analysis (section 6.3.1). 
2.8.3. Array processing on Illumina human HT-12 v4.0 microarray platform 
To avoid unnecessary freeze/thawing of samples, 2 aliquots of each sample of RNA (at 
a concentration of 100ng/l, in nuclease free water) was transferred on dry ice by 
Biocair (Cambridge, UK) to Central Biotechnology Services (Cardiff University, UK).  
One aliquot (containing 2l of RNA) was used for analysis RNA quality and verify 
quantity and the other aliquot (containing 5l of RNA) was used for microarray analysis 
on an Illumina human HT-12 v4.0 microarray platform (Illumina, San Diego, 
California, USA).  RNA quality and quantity was analysed  using Agilent RNA 6000 
Nano kit (Agilent, Santa Clara, California, USA) on an Agilent on an Agilent 2100 
Bioanalyzer (Agilent, Santa Clara, California, USA), using 1l of sample; 4 of the 96 
samples had (RNA integrity number) RIN values between 8.6 - 8.9, all remaining 
samples had RIN values which were above 9.  RIN values are a measure of RNA 
degradation and range between 1 - 10, where 10 indicates completely intact RNA.  RIN 
values above 7 are recommended for microarrays, but values above 8 are preferable; 
therefore all 96 samples had RIN values suitable for microarray analysis. 100ng of RNA 
per sample was labelled using Ambion Illumina TotalPrep-96 RNA Amplification Kit 
(Invitrogen, Paisley, UK) and resulting cRNA hybridised onto one of eight Illumina 
human HT-12 v4.0 BeadChip microarray platforms.  The Illumina human HT-12 v4.0 
microarray platform contains over 47,000 probes/oligonucleotides, coated onto beads 
which are mapped onto an array surface and each probe is represented, typically on over 
30 beads (http://www.illumina.com/products/humanht_12_expression_beadchip_kits_v4.html). 
After hybridisation, washing and staining steps, BeadChips were scanned using iScan 
system (Illumina, San Diego, California, USA).   
Note samples were randomised at Newcastle University prior to shipment to Central 
Biotechnology Services, who were blinded to the randomisation.  Samples from 
different conditions and different donors were therefore allocated at random to different 
BeadChips to minimise any sampling differences due to RNA labelling, BeadChip or 
date of BeadChip hybridisation/analysis (Central Biotechnology Services advise that 
this was performed on 2 separate days). 
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2.8.4. Array analysis 
After BeadChips were scanned, data was imported by Central Biotechnology Services 
into GenomeStudio
®
 (Illumina, San Diego, California, USA), background correction 
was applied and values for missing probes imputed.  Output intensity data files (.idat 
files) were transferred to Newcastle University for further analysis.  Microarray analysis 
was performed in collaboration with Dr. Simon Cockell (Bioinformatics Support Unit, 
Newcastle University, UK) 
Expression values were derived from SampleProbeProfile.txt. files imported in R 
Software  using the lumi package.  Expression values were initially log transformed (log 
base 2) using a Variance Stabilising Transformation (Lin et al., 2008) which takes 
advantage of the technical replication present in the Illumina human HT-12 v4.0 
microarray platform.  Data was then normalised using the Robust Spline Normalisation 
algorithm designed for BeadChip data (Du et al., 2008).  Three different methods were 
used for the quality assessment of arrays.  Firstly, the mean absolute difference of each 
array from all other arrays was considered - a threshold for outlier detection was 
determined from the distribution of mean absolute differences.  Secondly, the principal 
component analysis was considered for outlier detection - outliers being determined by 
visual inspection and expert judgement.  Finally, the array intensity distribution was 
assessed - an array will be marked as an outlier by this method if the distribution tests 
are significantly different from the pooled intensity distribution of the other arrays 
(by the Kolmogorov-Smirnov statistic).   
After quality control, a number of initial analyses were performed in R software, e.g. 
principle component analysis and hierarchical clustering.  These analyses revealed 
variance between samples was primarily due to the effect of I-BET151, although effects 
of TNF + IL-17 stimulation and donor were also apparent.  Following these initially 
analyses and decisions on cut off values for fold change and p value (section 6.3.1), 
comparisons were made, in R software, between the following groups of conditions 
(section 6.3): 
i. TNF + IL-17 stimulation compared to mock stimulation at 6h  
 i.e. condition 1 vs. 2 (section 2.8.2) 
ii. TNF + IL-17 stimulation compared to mock stimulation at 24h  
 i.e. condition 5 vs. 6 (section 2.8.2) 
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iii. TNF + IL-17 compared to TNF + IL-17 + DMSO at 6h   
 i.e. condition 2 vs. 3 (section 2.8.2) 
iv. TNF + IL-17 compared to TNF + IL-17 + DMSO at 24h   
 i.e. condition 6 vs. 7 (section 2.8.2) 
v. TNF + IL-17 + I-BET151 compared to TNF + IL-17 + DMSO at 6h 
 i.e. condition 3 vs. 4 (section 2.8.2) 
vi. TNF + IL-17 + I-BET151 compared to TNF + IL-17 + DMSO at 24h 
 i.e. condition 7 vs. 8 (section 2.8.2) 
vii. Comparison between i. and ii 
viii. Comparison between v. and vi. 
ix. Comparison between vii. and viii 
x. A previously published data set of the effects of TNF + IL-17 stimulation in 
NHEKs (Chiricozzi et al., 2011) was compared to ii. 
xi. A previously published meta-analysis of psoriasis transcriptomic studies (Tian et 
al., 2012) was also compared i., ii, v., v. and ix. 
 
Lists of differentially expressed genes (DEGs) derived from the above analyses were 
further interrogated using Ingenuity
®
 Pathway Analysis (IPA) Summer 2015 release 
software (Qiagen, Hilden, Germany).  IPA enables analysis of gene-to-gene interactions 
by creating networks which link DEGs by identifying relationships and relevant 
connections between genes e.g. upstream signalling pathways, targets of kinases etc.  
This allows DEGs to be grouped into pathways, diseases or biological functions, for 
example, allowing the biological relevance of changes in gene expression to be better 
understood.  IPA also enables predictions of upstream regulators or downstream effects 
of DEGs to be made.  DEGs were also compared to a meta-analysis of psoriasis 
transcriptomic datasets (Tian et al., 2012) and an IPA-defined psoriasis network.  The 
information within IPA is derived from data in primary literature, in e.g. journal articles, 
review articles and textbooks, as well as publicly available databases.  Furthermore as 
the information in IPA is manually curated, analysis in IPA can give reliable meaning to 
DEGs. 
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2.9. Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) is a method used to study interactions between 
specific proteins of interest (e.g. particular transcription factors or modified histones) 
and genomic DNA.  The method involves several steps:  
i. Cross-linking of proteins to DNA (this step is excluded in “native” ChIP) 
(section 2.9.2). 
ii. Lysis of cells and shearing of chromatin into smaller fragments (section 
2.9.3). 
iii. Selective enrichment of chromatin, using an antibody to a particular protein 
of interest (sections 2.9.4 and 2.9.5). 
iv. Purification and identification of immunoprecipitated DNA fragments e.g. 
by sequencing or PCR using primers designed to particular DNA regions of 
interest.  Enrichment of a particular region of DNA reflects the extent to 
which this region was associated with the protein of interest (sections 2.9.6 
and 2.9.7). 
The following ChIP protocol was kindly supplied by Dr N.R. Harker 
(GlaxoSmithKline, Stevenage, UK) then optimised for use in keratinocytes. 
2.9.1. Stimulation of cells 
A) For ChIP experiments investigating binding of BET proteins to gene regulatory 
regions, NHEKs were grown in T175 culture flasks and, when ~90% confluent, 
stimulated as follows, timepoints were chosen based on maximal IL-6 and IL-8 
mRNA expression (section 3.3.2): 
1) TNF (10ng/ml) + IL-17 (100ng/ml) + DMSO (1:1200) (stimulated for 3h) 
2) TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 (3M) (stimulated for 3h) 
3) TNF (10ng/ml) + IL-17 (100ng/ml) + DMSO (1:1200) (stimulated for 4.5h) 
4) TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 (3M) (stimulated for 4.5h) 
5) TNF (10ng/ml) + IL-17 (100ng/ml) + DMSO (1:1200) (stimulated for 6h) 
6) TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 (3M) (stimulated for 6h) 
 
NB:  As indicated, DMSO or I-BET151 was added to cells at the same time as 
stimulation with TNF + IL-17.  
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B) For ChIP experiments investigating effects of TNF + IL-17 stimulation and pre-
treatment with acetate, NHEKs were grown in T175 culture flasks with or without 
1mM acetate for 7 days (section 2.2.3), when ~90% confluent, before being 
stimulated as follows, timepoints were chosen based on maximal IL-6 and IL-8 
mRNA expression (section 3.3.2):  
1) Media, mock/unstimulated 
2) Media + 1mM acetate, mock/unstimulated 
3) Media + TNF (100ng/ml) + IL-17 (100ng/ml) (stimulated for 1h) 
4) Media + 1mM acetate + TNF (100ng/ml) + IL-17 (100ng/ml) (stimulated for 
1h) 
5) Media + TNF (100ng/ml) + IL-17 (100ng/ml) (stimulated for 4h) 
6) Media + 1mM acetate + TNF (100ng/ml) + IL-17 (100ng/ml) (stimulated for 
4h) 
 
NB:  In conditions where NHEKs were cultured with 1mM acetate for 7 days prior 
to stimulation, subsequent stimulation was also performed in 1mM acetate/media 
(i.e. conditions B2, B4 and B6 above). See section 2.2.3 for further details. 
 
Note that stimulations were performed in a total volume of 15ml and stimulation times 
were staggered so that conditions with the longest stimulation times were stimulated 
first (including the mock/unstimulated control) followed by conditions with shorter 
periods of stimulation.  For each experiment, cells from all conditions were therefore 
fixed and harvested at the end of the experiment, at a single timepoint.  This was to 
ensure a similar number of cells were harvested for each condition and to minimise any 
differences in fixation and harvesting of cells (section 2.9.2).  1x10
6
 keratinocytes was 
used in each immunoprecipitation (section 2.9.4).  A T175 culture flask contains 
approximately 5x10
6
 keratinocytes, therefore the number of T175 flasks stimulated was 
increased accordingly, to accommodate for the number of immunoprecipitations. 
2.9.2. Fixation 
After stimulation for the indicated times, 1/10th volume (1.67ml) fix solution (10% 
formaldehyde, 0.1M NaCl, 1mM EDTA, 0.5mM EGTA, 10mM Tris-HCl pH8) was 
added drop wise to the flask and incubated for 10mins at room temperature. Fixation 
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was terminated by the addition of 875l glycine (125mM final concentration) and 
incubated at room temperature for 5mins.  Cells were scraped and pelleted by 
centrifuging at 1200rpm at 4C for 5mins.  The pellet was washed twice with ice cold 
PBS, centrifuging at 1200rpm at 4C for 5 minutes after each wash.  The cell pellet was 
“snap frozen” in liquid nitrogen and stored at -80°C.  Cell pellets were transferred on 
dry ice by Biocair (Cambridge, UK) to GlaxoSmithKline, Stevenage, UK, where the 
remainder of the ChIP protocol and qPCR was performed. 
2.9.3. Sonication 
The cell pellets were defrosted on ice and resuspended in 100l of lysis buffer (1% 
SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8, protease inhibitor cocktail (Roche 
Diagnostics, Burgess Hill, UK) per 1x10
6
 NHEKs, incubating on ice for 10mins with 
intermittent mixing.  Cell lysate were aliquoted into pre-chilled polystyrene sonication 
tubes (Active Motif, Carlsbad, California, USA) and sonicated for 15mins (30secs on 
and 30secs off, on high power) using Bioruptor
®
Pico waterbath sonicator (Diagenode, 
Seraing, Belgium). Cell debris was removed by centrifugation (8°C, 10mins at 
13000rpm).  As primary keratinocytes from different donors had previously shown 
variable responses to sonication, 25l of test sample was assayed to ensure adequacy of 
sonication.  This sample was eluted, cross-links reverse and DNA was purified (section 
2.9.6) and run on a 2% agarose gel (Invitrogen, Paisley, UK) to ensure the majority of 
DNA was sonicated to 200-500bp.  If sonication was inadequate, sonication was 
repeated on all conditions from that donor (further sonication time was dependent on the 
efficiency of initial sonication).  A further 25l of test sample was assayed to ensure 
adequacy of any further sonication. 
2.9.4. Incubation with antibody 
Chromatin was aliquoted into 100l aliquots (1x106 cells) and diluted 1:10 with dilution 
buffer (0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl pH 8, 
167mM NaCl, protease inhibitor cocktail).  Samples were incubated at 4
o
C with rotation 
overnight with 5μg antibody (Table 2-3 and Table 2-4).  IgG was selected as a negative 
control and -pan H3 a positive control.  25l of chromatin (250,000 cells) was 
reserved as input and stored at -20°C. 
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Antibody Company/Cat No. Lot and conc
n
 Vol for 5ug 
Rabbit IgG Abcam ab37415 GR164350-1 5mg/ml 1ul 
Rabbit -pan H3 Abcam ab1791 GR125634-1 1mg/ml 5ul 
Rabbit -Pol II S2P Abcam Ab5095 GR154006-2 1mg/ml 5ul 
Rabbit -Brd2 Bethyl  
A302-583A 
A302-583A-1 
0.2mg/ml 
25ul 
Rabbit -Brd3 Bethyl  
A302-368A 
A302-368A-1 
0.2mg/ml 
25ul 
Rabbit -Brd4 Bethyl  
A301-985A 
A301-985A-1 
1mg/ml 
5ul 
Rabbit -NF-Bp65  Abcam7970 GR150309-4 
0.2mg/ml 
25ul 
Table 2-3: Antibodies used in chromatin immunoprecipitation studies, section 
2.9.1A 
 
 
Antibody Company/Cat No. Lot and conc
n
 Vol for 5ug 
Rabbit IgG  Abcam ab37415 GR164350-1 5mg/ml 1ul 
Rabbit -pan H3 Abcam ab1791 GR182539-1 1mg/ml 5ul 
Rabbit -pol II (S2P) Abcam Ab5095 GR154006-2 1mg/ml 5ul 
Rabbit -Acetyl H3 Millipore 06-599 2430399 1mg/ml 5ul 
Rabbit -H3K9ac Abcam Ab4441 GR196840-1 
1mg/ml 
5ul 
Rabbit -H3K27ac Abcam Ab4729 GR184557-1 
1mg/ml 
5ul 
Rabbit -H3K4me3 Abcam Ab8580 GR188707-1 
1mg/ml 
5ul 
Rabbit -H3K4me1 Millipore ABE1353 Q2464806 1.5mg/ml 3.3ul 
Rabbit -H3K27me3 Abcam ab108245 161273-2 1mg/ml 5ul 
Table 2-4: Antibodies used in chromatin immunoprecipitation studies, section 
2.9.1B 
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2.9.5. Immunoprecipitation and wash 
Protein A + G magnetic beads (Millipore, Massachusetts, USA and Invitrogen, Paisley, 
UK) were washed twice in dilution buffer (section 2.9.4) and resuspended in their 
original volume.  20l Protein A + G magnetic beads were added to each sample and 
incubated with rotation for 5h at 4C.  Samples were washed once in low salt buffer 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150mM NaCl, 20 mM Tris-HCl pH 8), 
once in high salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500mM NaCl, 20 
mM Tris-HCl pH 8), once in lithium chloride buffer (0.25M LiCl, 1% NP40, 1% Na 
Deoxycholate, 1mM EDTA, 10mM Tris-HCl pH8) and twice in Tris-EDTA buffer 
(10mM Tris-HCl pH8, 1mM EDTA).  All washes were performed at room temperature.  
After the final wash, samples were centrifuged at 13000rpm for 30secs and remaining 
traces of Tris-EDTA buffer removed prior to addition of elution buffer, below. 
2.9.6. Elution, reversal of cross links and DNA purification 
Chromatin bound to protein A + G magnetic beads were resuspended in 100l elution 
buffer (1% SDS, 100mM NaHCO3) and incubated at RT with rotation for 15mins. 
Eluted chromatin was removed, and the beads were incubated for 15mins with a further 
100l elution buffer, then 65°C for 5mins.  The two eluates were then combined.  8l 
5M NaCl was added to the combined eluates and incubated at 65°C overnight to reverse 
protein-DNA cross-links. The samples were then incubated with 0.25l 20mg/ml 
RNaseA for 1h at 37°C then with 4l 0.5M EDTA, 8l 1M Tris-HCl pH6.5 
(MerckMillipore, Massachusetts, USA) and 0.4l 20mg/ml Proteinase K (Invitrogen, 
Paisley, UK) for 1h at 60°C.  The DNA was purified using Zymo ChIP DNA Clean & 
Concentrator Kit (Cambridge Bioscience, Cambridge, UK). Following the 
manufacturer’s instructions, 1ml DNA binding buffer was added to each sample, mixed 
and the samples loaded onto the purification columns in 2 batches with a 13000 rpm 
30secs centrifugation in between. The columns were washed twice with 200l DNA 
wash buffer with a 13000 rpm 30secs centrifugation in between.  100l of elution buffer 
was added directly onto the membrane of each column and after 1min incubation at 
room temperature, the column was centrifuged at 13000rpm for 1min to elute DNA.  
Samples were stored at -20°C. 
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2.9.7. Real time PCR 
Real-time PCR (qPCR) was undertaken using specifically designed primers to the IL-6 
promoter, IL-8 promoter and to a region previously described as an IL-6 enhancer in 
macrophages (Table 2-5).  All primers were optimised for SYBR-based qPCR using 
genomic standards (1 – 1x105 copies). qPCR was performed, in triplicate technical 
repeat, in 10l reactions each containing the following: 3l DNA template or human 
genomic standard (1 – 1x105 copies) (Promega, Wisconsin, USA), 5l SYBR green 
master mix (Invitrogen, Paisley, UK), 0.1l forward primer, 0.1l reverse primer and 
1.8l water, and run on an Applied Biosystems 9700HT Machine (Invitrogen, Paisley, 
UK) using standard PCR cycle conditions as follows:  
1. 50
o
C for 2mins 
2. 95
o
C for 10mins  
3. 95
o
C for 15secs 
4. 60
o
C for 60secs 
5. Plate read   
6. Repeat steps 3-5 x 40 times 
 
Target Assay ID/sequence Concentrations 
IL-6 
Promoter 
(Qiao et al., 
2013)  
Forward: ACCCTCACCCTCCAACAAAG  
 
Reverse: GCAGAATGAGCCTCAGACATC  
 
Forward: 250nM 
 
Reverse: 250nM 
 
IL-6 
Enhancer 
(Qiao et al., 
2013) 
Forward: GGACACACACAGGACTCTCACA  
 
Reverse: GAGGTAGATTTGGTTCTCCCATT  
Forward: 250nM 
 
Reverse: 250nM 
 
IL-8 
Promoter 
(Costa et 
al., 2013) 
Forward: GGGCCATCAGTTGCAAATC 
 
Reverse: TTCCTTCCGGTGGTTTCTTC 
 
Forward: 900nM 
 
Reverse: 900nM 
 
Table 2-5: Sequences of real time primers used in chromatin immunoprecipitation 
qPCR studies 
All primers were synthesised by Sigma-Aldrich (Gillingham, UK). 
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2.9.8. Analysis of chromatin immunoprecipitation real time PCR 
Based on comparisons of Ct values from samples vs. genomic standards used to obtain a 
standard curve, the quantity of DNA following amplification was determined using 
Applied Biosystems SDS Software (Invitrogen, Paisley, UK) and  a mean of the 
triplicate qPCR technical repeats was calculated, excluding any obvious outliers e.g. 
due to pipetting errors.  Values from immunoprecipitated DNA samples were expressed 
as a percentage of values from non-immunoprecipitated input sample, which represents 
the amount of chromatin initially used in the ChIP, prior to immunoprecipitation with 
antibody.  The calculated percentage input value from the negative control (IgG) was 
subtracted from the calculated percentage input values obtained using specific 
antibodies to proteins/histone modifications of interest.  Enrichment of a particular 
region of DNA (e.g. IL-6 promoter) reflects the extent to which this region was 
associated with the protein or histone modification of interest. 
2.10.  Measurement of epigenetic writer and eraser activity 
The balance between epigenetic writer and eraser activity regulates epigenetic histone 
modifications; in the case of lysine acetylation this balance is between histone acetyl 
transferase (HAT) and histone deacetylase (HDAC) activity.  The effects of acetate on 
HAT and HDAC activity, in NHEKs nuclear extracts, were measured after exposure to 
1mM acetate, or media alone, for 7 days. 
2.10.1. Preparation and quantification of keratinocyte nuclear extracts 
NHEKs were grown in T175 culture flasks with or without 1mM acetate for 7 days, 
reaching 90% confluency.  Flasks were washed twice with ice-cold PBS, then scraped 
with a cell-scraper into of ice-cold PBS and transferred into 1.5ml microcentrifuge tube 
and pelleted by centrifugation at 500g for 3mins at 4
0
C.  Supernatant was removed and 
the cell pellet “snap-frozen” in liquid nitrogen and stored at -800C before nuclear 
extraction was performed using NE-PER
®
 nuclear and cytoplasmic extraction reagents 
(CER) (ThermoScientific, Rockford, Illinois, USA) according to the manufacturer’s 
instruction as follows: 
1. 300l ice-cold cytoplasmic extraction reagent (CER) I (ThermoScientific, 
Rockford, Illinois, USA) was added to the cell pellet. 
2. The sample was vortexed for 15secs then incubated on ice for 10mins. 
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3. 16.5l ice-cold CER II (ThermoScientific, Rockford, Illinois, USA) was 
added to the sample, then vortexed for 5secs, incubated on ice for 1min and 
vortexed again for 5secs before centrifugation for 5mins at 16000g at 4
0
C. 
4. The supernatant (cytoplasmic extract) was transferred to a clean pre-chilled 
tube, “snap-frozen” in liquid nitrogen and stored at -800C. 
5. 150l ice-cold nuclear extraction reagent (NER) (ThermoScientific, 
Rockford, Illinois, USA) was added to the cell pellet. 
6. The sample was vortexed for 15secs then incubated on ice with further 
15secs vortexing every 10mins for a total of 40mins before centrifugation for 
10mins at 16000g at 4
0
C. 
7. The supernatant (nuclear extract) was transferred to a clean pre-chilled tube, 
“snap-frozen” in liquid nitrogen and stored at -800C. 
Quantification of nuclear extracts was undertaken using Pierce
®
 BCA protein assay kit 
(ThermoScientific, Rockford, Illinois, USA) according to the manufacturer’s 
instructions, using 5l of nuclear extract and incubating the samples and standards (each 
in triplicate repeat) at 37
0
C for 30mins.  Absorbance of samples were read at 562nm 
using a SpectraMax M250 plate reader (Molecular Devices, UK) and compared against 
the set of standard controls using a four parameter logistic (4-PL) curve-fit to determine 
nuclear extract concentrations. 
2.10.2. Measurement of histone acetyl transferase enzyme activity 
HAT activity was measured using HAT activity colorimetric assay kit (Sigma-Aldrich, 
Gillingham, UK) that detects acetylation of a substrate by HAT enzymes, using acetyl-
coA as a substrate; which releases of co-A.  Co-A acts as a co-enzyme for the 
production of NADH, which can be detected as a colour change after reaction with a 
tetrazolium dye.  HAT activity, using 50g of keratinocyte nuclear extract in 40l 
water, was measured according to the manufacturer’s protocol. Each sample also 
contained 50l 2x HAT assay buffer, 5l HAT substrate I, 5l HAT substrate II and 8l 
NADH generating enzyme and samples were incubated at 37
0
C for 4h.  Absorbance of 
samples was read at 440nm using a SpectraMax M250 plate reader (Molecular Devices, 
UK).  Background absorbance reading (obtained by running the reaction with water but 
no nuclear extracts) was subtracted from samples readings. 
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2.10.3. Measurement of histone deacetylase enzyme activity 
HDAC activity was measured using HDAC assay kit, colorimetric (Active Motif, 
Carlsbad, California USA) and HDAC assay kit, fluorescent (Active Motif, Carlsbad, 
California USA) that detects deacetylation of an acetylated lysine residue; in subsequent 
reactions the deacetylated lysine residue results in release of either i) a chromophore, 
which can be detected by a quantifiable colour change or ii) a fluorophore which can be 
detected by fluorescence, depending on the kit used.  According to the manufacturer, the 
colorimetric kit measures total activity of HDAC 1,2,6,10,11, whereas the fluorescence 
kit measures total activity of HDAC 1,2,6,8,10,11.    
For each of the protocols, 45g of keratinocyte nuclear extract in 30l water was used.   
Each reaction also contained 10l HDAC assay buffer (for colorimetric or fluorescent 
kit) and 10l HDAC substrate (for colorimetric or fluorescent kit).  Samples were 
incubated at 37
0
C for 1h, 50ul HDAC assay developing solution (for colorimetric or 
fluorescent kit) was then added and incubated at room temperature for 15mins.  For the 
colorimetric assay, absorbance of samples was read at 440nm using a SpectraMax 
M250 plate reader (Molecular Devices, UK).  For the fluorescent assay, fluorescence 
was read with an excitation wavelength of 360nm and emission wavelength of 460nm 
using a NanoDrop 2000 Spectrophotometer (ThermoScientific, Illinois USA).  For both 
assays, background absorbance reading (obtained by running the reaction with water but 
no nuclear extracts) was subtracted from samples readings. 
2.11. Statistical analysis 
All initial analysis was carried out using Microsoft Excel (Microsoft Corporation, 
Redmond, Washington) and all statistical analysis was carried out using Prism 5.0 
(GraphPad version 5.0 software, San Diego, CA). 
Data is generally presented as the mean of data points ± SEM.  N depicts the number of 
independent donors and n indicates the total number of independent data points 
(typically representing data obtained from independent wells). Thus N=3 indicates that 
the experiment was conducted in 3 independent donors.  For all figures:  *p<0.05, 
**p<0.01, ***p<0.001 and where results were analysed by two statistical methods (e.g. 
section 7.3.9), the second statistical anaylsis is shown as 
+
p<0.05, 
++
p<0.01, 
+++
p<0.001; 
statisitical significance was taken at p<0.05, thus non-significant (ns) was p>0.05. 
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Data was tested for normal distribution before statistical analysis was performed.  
Where appropriate, results show pooled data from multiple donors presented as mean ± 
standard error of the mean (SEM).  In experiments where there was large variability in 
absolute values between donors (e.g. of secreted cytokines), values were normalised to 
control (e.g. unstimulated) within each donor before data was pooled.  This was done to 
prevent responses in some donors, which showed greater absolute values, masking the 
responses of other donors, which showed lower absolute values, if a mean of absolute 
values was calculated.   
 
For I-BET151 concentration-response curves, results were expressed as % inhibition of 
(e.g. IL-6) calculated as follows: 
 
“Best fit curve”, IC50 and maximum inhibition were drawn/derived using 4-parameter 
logistic curve fit software, Prism 5.0 (GraphPad version 5.0 software, San Diego, CA).  
“Mean IC50” was calculated as the mean of IC50 values from individual donors. 
 
The effects of  TNF(10ng/ml)+ IL-17 (100ng/ml) stimulation on the induction of IL-
6 and IL-8, compared to stimulation with TNF (10ng/ml) or IL-17 (100ng/ml) alone 
were classified by the following definitions (Chiricozzi et al., 2011): 
 Synergistic effect: the combined effect of interacting cytokines was greater than 
the sum of their individual effects. 
 Additive effect: the combined effect of interacting cytokines was greater than 
the individual effect for each cytokine, but less than the sum of their individual 
effects. 
 Antagonistic effect: the combined effect of interacting cytokines was less than 
the individual effect for either or both cytokines. 
Using this method of analysis, synergy is defined as a greater than expected additive 
effect, and antagonism is defined as a less than expected additive effect. 
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Two-way ANOVAs were conducted when analysing the effect of two independent 
variables. An example within this project was the effect I-BET151 on BET protein 
recruitment at the IL-6 promoter at different timepoints (section 4.3.4).  A two-way 
ANOVA is useful when one of the variables being compared is a repeated measure.  
The analysis therefore acknowledges that readings from different timepoints are not 
independent readings and therefore provides a more stringent statistical analysis 
between treatments, by taking into account measurements over several timepoints.  A 
Bonferroni post-hoc test was then conducted to determine at which timepoint(s), during 
stimulation with TNF + IL-17, I-BET151 treatment had a significant inhibitory effect 
on BET protein binding at the IL-6 promoter. 
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Chapter 3. 
 
In vitro model of 
cutaneous inflammation 
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3. In vitro model of cutaneous inflammation 
3.1. Introduction 
There is considerable interest in developing in vitro models of cutaneous inflammation 
in order to further understand underlying mechanisms of inflammatory skin diseases 
such as psoriasis, and for pre-clinical evaluation of potential therapeutic compounds.  
This chapter focuses on the development of in vitro models of cutaneous inflammation, 
including the further development of an existing model in which normal human 
epidermal keratinocytes (NHEKs) were stimulated with a combination of TNF + IL-
17A (IL-17); this combination of cytokine stimulation was previously found to regulate 
expression of key keratinocyte genes central to the pathogenesis of psoriasis (Chiricozzi 
et al., 2011).   
Additionally, we investigated the effects of compounds used clinically to treat psoriasis 
in this in vitro model, in part to further validate the utility of the model for pre-clinical 
evaluation of potential therapeutic compounds.   
3.2. Aims 
 To develop in vitro model(s) of cutaneous inflammation for further 
understanding the pathogenesis of inflammatory skin disease and the role of 
epigenetics, including acetylation of lysine residues on histones, in the 
regulation of genes relevant to psoriasis. 
 To evaluate the model(s) of cutaneous inflammation for in-vitro, pre-clinical, 
testing of potential therapeutic compounds, including those targeting epigenetic 
epitopes. 
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3.3. Results 
3.3.1. Stimulation of keratinocytes with a combination of TNF + IL-17 produced 
the most robust level of secreted IL-6 and IL-8, with no significant effect on 
cellular metabolism or total cellular protein 
Initial data obtained during the MRes preceding this PhD project showed robust 
secretion of IL-6 and IL-8 by NHEKs in response to TNFα and/or IL-17 stimulation. 
Responses were dependent on TNF concentrations up to 10ng/ml and the effect of 
stimulation with IL-17 was maximal at the lowest concentration tested of 100ng/ml.  
Maximal IL-6 and IL-8 responses were achieved with a combination of 10ng/ml TNF 
+100ng/ml IL-17.  The combination of TNF + IL-17 was previously reported to have a 
synergistic effect on keratinocyte IL-6 and IL-8 mRNA expression, compared to 
stimulation with either cytokine on their own (Chiricozzi et al., 2011).   We extended 
this model by investigating the effects of TNF + IL-17 stimulation on secreted IL-6 
and IL-8 protein in NHEKs.  We found that this combination of stimuli also exerted a 
synergistic effect on secreted IL-6 and IL-8 protein.  In addition, the absolute level of 
secreted IL-8 protein was greater than that of secreted IL-6.  Levels of secreted IL-10, 
IL-12, IL-1 and IFN protein were at or below the lowest limit of detection for the 
MSD
®
 Multi-Spot
® 
platform (typically 0.5-10ng/ml); therefore these cytokines were not 
explored in future studies.  It was thus concluded that a combination of 10ng/ml TNF 
+100ng/ml IL-17 would produce optimal stimulation of NHEKs and determined that 
data could only be reliably obtained from secreted IL-6 and IL-8 protein in this model. 
To explore the specificity of the IL-6 and IL-8 responses and to develop further models 
of cutaneous inflammation, NHEKs were stimulated with a variety of cytokines and 
toll-like receptor (TLR) ligands, at concentrations previously described in the literature: 
IL-22, IFN, Pam3Cys-Ser-(Lys)4 trihydrochloride (Pam3Cys), peptidoglycan derived 
from Staphylococcus aureus (PGN), Pam2CGDPKHPKSF (FSL-1), heat-killed 
Staphylococcus aureus (HKSA), lipoteichoic acid (LTA), polyinosinic:polycytidylic 
acid (Poly:IC) or lipopolysaccharide derived from Escherichia coli (LPS) (Kollisch et 
al., 2005; Begon et al., 2007; Donnarumma et al., 2011).  Supernatants were collected 
48h after stimulation and IL-6 and IL-8 concentrations measured by ELISA. 
As shown in Figure 3-1, the combination of TNF + IL-17 stimulation induced 
significant secreted IL-6 and IL-8 protein responses; approximately 27-fold and 17-fold 
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changes respectively compared to unstimulated cells (p<0.001 for both IL-6 and IL-8 
induction).  Interestingly the addition of IFNto TNF+ IL-17 stimulation enhanced 
the IL-6 response (p<0.001) but inhibited the IL-8 response (p<0.05) compared to 
stimulation with TNF+ IL-17 in NHEKs, suggesting IL-6 and IL-8 are differentially 
regulated. TNF+ IL-17 + IFNinduced ~120-fold increase in IL-6 secreted protein  
and ~10-fold increase in IL-8 secreted protein compared to unstimulated (p<0.001 for 
both IL-6 and IL-8 induction).  IL-17 stimulation of NHEKs resulted in a significant IL-
8 response (p<0.001) but not IL-6.  The remaining stimuli had no significant effect on 
IL-6 and IL-8 secreted cytokine production.   
Having established that both TNF (10ng/ml) + IL-17 (100ng/ml) and TNF (10ng/ml) 
+ IL-17 (100ng/ml) + IFN (10ng/ml) produced the most robust and reproducible IL-6 
and IL-8 responses, the effects of these stimuli on cellular metabolism and total protein 
were investigated.  NHEKs were stimulated with combinations of TNF, IL-17 and 
IFN. The effects of cytokine stimulation on cellular metabolism and total protein were 
determined at 48h by thiazolyl blue betrazolium bromide (MTT) and Sulphorhodamine 
B (SRB) assays respectively.   
As shown in Figure 3-2, NHEKs stimulation with TNF, IL-17 or TNF + IL-17 for 
48h had no significant effects on cellular metabolism or total protein.   IFNtreatment 
inhibited cellular metabolism, by approximately 30% (p<0.05), and total protein, by 
approximately 25% (p<0.01).  However, the combination of TNF+ IL-17 + 
IFNtreatment had the greatest and most significant effect on cellular metabolism and 
total protein, with reduction of approximately 31% (p<0.01) and 42% (p<0.001) 
respectively.  Although NHEKs stimulation with TNF+ IL-17 + IFN resulted in 
significant secretion of IL-6 and IL-8 protein, the interpretation of this was difficult due 
to the corresponding inhibition of both cellular metabolism and total protein; it was 
unclear if the IL-6 and IL-8 responses to TNF + IL-17 + IFNstimulation were 
products of non-inflammatory pathways, e.g. cytotoxicity, rather than inflammatory 
responses per se.  Furthermore it appeared that negative effects on cellular metabolism 
or total protein could be attributed to IFN, as both IFNand TNF+ IL-17 + IFNhad 
similar effects in the MTT and SRB endpoints.  For these reasons, only effects of 
TNF, IL-17 or TNF + IL-17 on inflammatory responses were subsequently 
investigated. 
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Figure 3-1: IL-6 and IL-8 secreted protein responses by NHEKs in response to a 
variety of cytokine and TLR agonists.  Stimulation with TNF + IL-17 and TNF 
+ IL-17 + IFN produced the greatest secreted IL-6 and IL-8 responses. 
NHEKs were stimulated with TNF (10ng/ml), IL-17 (100ng/ml), IFN (10ng/ml), 
TNF (10ng/ml) + IL-17 (100ng/ml), TNF (10ng/ml) + IL-17 (100ng/ml) + IFN 
(10ng/ml), IL-22 (100ng/ml), Pam3Cys (10g/ml), PGN (20g/ml), FSL-1 (100ng/ml), 
HKSA (1x10
7
/ml), LTA (20g/ml), Poly:IC (0.1g/ml), LPS (1g/ml) or mock 
stimulated. Compounds were soluble in aqueous solution/media; therefore vehicle 
controls were not necessary.  Supernatants were harvested 48h post-stimulation and IL-
6 (A) and IL-8 (B) protein concentration measured by ELISA.   (N=3, with each donor 
performed in triplicate repeat) Analysis by two-way ANOVA with Bonferroni post-test; 
*p<0.05, **p<0.01, ***p<0.001.  Graphs show mean of data points (normalised to 
unstimulated) ± SEM. 
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Figure 3-2: TNF and/or IL-17 stimulation had no significant effect on NHEK 
metabolism or total protein, in contrast to addition of IFN alone or in 
combination which reduced NHEK metabolism and total protein. 
NHEKs were stimulated with TNF (10ng/ml), IL-17 (100ng/ml), IFN (10ng/ml), 
TNF (10ng/ml) + IL-17 (100ng/ml), TNF (10ng/ml) + IL-17 (100ng/ml) + IFN 
(10ng/ml) or mock stimulated.  The effects of cytokine stimulation on cellular 
metabolism were measured at 48h by MTT (A) and total protein determined by SRB 
(B).  (N=6, with each donor performed in triplicate repeat) Analysis by one-way 
ANOVA with Dunnett’s post-test; *p<0.05, **p<0.01, ***p<0.001.  Graphs show mean 
of data points (normalised to unstimulated control) ± SEM. 
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3.3.2. IL-6 and IL-8 mRNA expression was maximal at 6h after TNF + IL-17 
stimulation whereas secreted protein levels were cumulative up to 48h 
From the data on cellular metabolism and total protein, and TNF + IL-17’s effects on 
IL-6 and IL-8 production, we concluded that the combination of TNF (10ng/ml) + IL-
17 (100ng/ml) produced the most robust inflammatory stimulus for use as an in vitro 
model of cutaneous inflammation in order to study the role of epigenetics in the 
regulation of inflammatory responses and for in vitro evaluation of potential therapeutic 
compounds.  These two cytokines have central roles in psoriasis pathology, they induce 
expression of key genes central to psoriasis pathogenesis (Chiricozzi et al., 2011) and 
anti-IL-17 and anti-TNFα biological therapies are licensed and effective for the 
treatment of psoriasis. 
To characterise the kinetics of expression of IL-6 and IL-8 in the TNF + IL-17 model 
of cutaneous inflammation, IL-6 and IL-8 mRNA levels were measured (by qRT-PCR) 
at 1, 3, 6, 10 and 24h after stimulation with TNF, IL-17 or TNF + IL-17 and secreted 
protein levels were measured (by ELISA) at 10, 24 and 48h after stimulation.   
Both IL-6 and IL-8 mRNA expression was maximal at 6h post-TNF + IL-17 
stimulation (Figure 3-3), whereas secreted IL-6 and IL-8 protein was cumulative up to 
48h (Figure 3-4).  Measuring secreted protein production beyond 48h is difficult owing 
to the need to feed cells with fresh media, thereby altering the inflammatory milieu.  
Subsequent investigations, e.g. compound inhibition and chromatin 
immunoprecipitation (ChIP) studies were designed around these optimised time points 
i.e. 6h post- TNF + IL-17 stimulation for studies concerning mRNA expression and 
48h post-stimulation for protein studies.   
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Figure 3-3: NHEK IL-6 and IL-8 mRNA expression was maximal at 6h after 
TNF + IL-17 stimulation. 
NHEKs were stimulated with TNF (10ng/ml), IL-17 (100ng/ml), TNF (10ng/ml) + 
IL-17 (100ng/ml) or mock stimulated.  Cells were harvested for mRNA at timepoints 
indicated and expression of IL-6 (A) and IL-8 (B) determined by qRT-PCR.   (N=3, 
with each donor performed in duplicate repeat) Analysis by two-way ANOVA with 
Bonferroni post-test; *p<0.05, **p<0.01, ***p<0.001.  Graphs show mean of data 
points (normalised to unstimulated control within individual timepoints) ± SEM. 
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Figure 3-4: Secreted IL-6 and IL-8 protein by NHEKs was cumulative up to 48h 
after TNF + IL-17 stimulation. 
NHEKs were stimulated with TNF (10ng/ml) + IL-17 (100ng/ml) or mock stimulated.  
Supernatants were harvested at timepoints indicated post-stimulation and IL-6 (A) and 
IL-8 (B) protein concentrations measured by ELISA.   (N=3, with each donor performed 
in triplicate repeat) Analysis by one-way ANOVA with Dunnett’s post-test; *p<0.05, 
**p<0.01, ***p<0.001.  Graphs show mean of data points ± SEM. 
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3.3.3. TNF + IL-17 induced expression of IL-6 and IL-8 in keratinocytes, with a 
reproducible synergistic effect for IL-6 protein and a donor-dependent 
synergistic effect for IL-8 protein 
As shown in Figure 3-1, TNF+ IL-17 exerted a synergistic effect on IL-6 secretion 
into the medium but not IL-8 secretion (N=3).  Data obtained during the MRes 
preceding this PhD project, showed that for some donors TNF + IL-17 also had a 
synergistic effect on IL-8 induction. To understand the potential effect of donor 
variability, we investigated TNFand/or IL-17 stimulation on IL-6 and IL-8 secretion 
in further donors.  Effects of TNF+ IL-17 stimulation compared to stimulation with 
TNF or IL-17 alone were classified according to the following definitions (Chiricozzi 
et al., 2011): 
 Synergistic effect: the combined effect of interacting cytokines was greater than 
the sum of their individual effects. 
 Additive effect: the combined effect of interacting cytokines was greater than 
the individual effect for each cytokine, but less than the sum of their individual 
effects. 
 Antagonistic effect: the combined effect of interacting cytokines was less than 
the individual effect for either or both cytokines. 
NHEKs were stimulated with TNF (10ng/ml), IL-17 (100ng/ml) or TNF (10ng/ml) + 
IL-17 (100ng/ml).  For IL-6 and IL-8 mRNA expression studies, NHEKs were 
harvested for mRNA extraction at 6h post-stimulation and expression was measured by 
qRT-PCR.  Supernatants were harvested 48h post-stimulation and IL-6 and IL-8 protein 
concentration measured by ELISA.    
As shown in (Figure 3-5), there was considerable variability in IL-6/-8 mRNA and 
protein expression between donors.  Basal levels of secreted IL-8 protein (Figure 3-5D) 
were higher than IL-6 protein (Figure 3-5B).  The magnitude of IL-8 mRNA and protein 
responses (Figure 3-5C and Figure 3-5D) to stimulation were greater than IL-6 mRNA 
and protein responses (Figure 3-5A and Figure 3-5B).  Stimulation with either TNF or 
IL-17 alone induced IL-6/-8 (mRNA and protein) to a similar degree.  TNF + IL-17 
stimulation had a robust effect on IL-6/-8 mRNA and protein induction, although there 
was considerable variability between donors in terms of both magnitude of responses 
104 
 
and to the combined effects of TNF + IL-17 stimulation compared with stimulation 
with either cytokine alone (i.e. synergistic, additive or antagonistic).  
As shown in Table 3-1, TNF + IL-17 stimulation had a synergistic effect on IL-6 
mRNA induction in 65% of donors and an additive effect in 35% of donors; whereas for 
IL-6 secreted protein, synergy between  TNF + IL-17 was observed in 94% of donors.  
On the other hand, TNF + IL-17 stimulation had a synergistic effect on IL-8 mRNA 
induction in all donors, but a synergistic effect on IL-8 protein production in only 70% 
of donors, an additive effect in 17% and antagonistic effect in 13% of donors.  
The effects of TNF + IL-17 stimulation in NHEKs for individual donors are shown in 
Figure 3-6.  In some donors stimulation with TNF + IL-17 had similar effects on both 
IL-6 and IL-8 protein production.  For example, in donor A, TNF+ IL-17 stimulation 
had a synergistic effect on both IL-6 and IL-8 expression, (Figure 3-6A and Figure 
3-6B, respectively); whereas in donor B, TNF+ IL-17 stimulation had an antagonistic 
effect on IL-6 and IL-8 expression, (Figure 3-6C and Figure 3-6D, respectively).  In 
other donors the IL-6 and IL-8 responses to TNF + IL-17 stimulation differed.  For 
example, in donor C, TNF+ IL-17 stimulation had a synergistic effect on IL-6 
production but an additive effect on IL-8 production (Figure 3-6E and Figure 3-6F, 
respectively); whereas in donor D, TNF+ IL-17 had a synergistic effect on IL-6 
production but an antagonistic effect on IL-8 production (Figure 3-6G and Figure 3-6H, 
respectively).  Furthermore, the absolute level of secreted IL-6 or IL-8 protein in 
response to TNF + IL-17 stimulation was variable across different donor.  For 
example, IL-6 production in response to TNF + IL-17 stimulation in donor D (Figure 
3-6G) was ~ 10 fold higher than in donors A, B or C (Figure 3-6A, Figure 3-6C, Figure 
3-6E, respectively) and IL-8 production in response to TNF + IL-17 stimulation in 
donor A (Figure 3-6B) was ~ 5 fold higher than in donors B, C or D (Figure 3-6D, 
Figure 3-6F, Figure 3-6H, respectively).  Furthermore, the absolute levels of secreted 
proteins were not dependent on whether TNF and IL-17 had a synergistic effect or not. 
For example, TNF + IL-17 stimulation induced similar levels of IL-6 protein in donor 
B (Figure 3-6C) and C (Figure 3-6E), despite TNF and IL-17 having an antagonistic 
effect in donor B but a synergistic effect in donor E.  Similarly, TNF + IL-17 
stimulation induced comparable levels of IL-8 protein in donor C (Figure 3-6F) and D 
(Figure 3-6H), despite TNF and IL-17 having an additive effect in donor C but an 
antagonistic effect in donor D. 
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In some donors, the effects of TNF+ IL-17 on IL-6 and IL-8 protein were also 
observed at the mRNA level; in donor E (Figure 3-7A, B, C, D) TNF+ IL-17 had a 
synergistic effect on IL-6 and IL-8 protein which was also evident at the mRNA level.  
However in other donors this was not the case; in donor F (Figure 3-7E, F, G, H), 
TNF+ IL-17 had a synergistic effect on IL-6 and IL-8 secreted protein and IL-8 
mRNA but an additive effect on the IL-6 mRNA response.   
The different effects of TNF + IL-17 stimulation on IL-6 and IL-8 mRNA expression 
suggest these two cytokines are differentially regulated at a transcriptional level and the 
differential effects of stimulation on IL-6/-8 mRNA vs. protein suggests both cytokines 
are subject to post-transcriptional regulation.  In order to understand whether donor-
dependent effects could be related to underlying disease, for example, clinical notes 
were extensively analysed; the donor dependent IL-6 and IL-8 responses to TNF + IL-
17 stimulation were not correlated with donor age, personal or family history of medical 
illness, or current medications. 
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Figure 3-5: TNF + IL-17 stimulation of NHEKs induced IL-6 and IL-8 responses, 
with considerable variability in magnitude of responses between donors 
NHEKs were stimulated with TNF (10ng/ml), IL-17 (100ng/ml), TNF (10ng/ml) + 
IL-17 (100ng/ml) or mock stimulated.  Cells were harvested for mRNA at 6h post-
stimulation and expression of IL-6 (A) and IL-8 (C) mRNA determined by qRT-PCR.  
Supernatants were harvested 48h post-stimulation and secreted IL-6 (B) and IL-8 (D) 
protein concentration measured by ELISA.  Graphs show the effect TNF and/or IL-17 
stimulation in individual donors represented by different colours/symbols, black line 
shows the mean ± SEM.  (for mRNA, N=17; for protein, N=30).  
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Effect of 
TNF + IL-17 
stimulation  
IL-6 mRNA 
Donor N (%) 
IL-6 protein 
Donor N (%) 
IL-8 mRNA 
Donor N (%) 
IL-8 protein 
Donor N (%) 
Synergistic 11 (65%) 28 (94%) 17 (100%) 21 (70%) 
Additive 6 (35%) 1 (3%) 0 5 (17%) 
Antagonistic 0 1 (3%) 0 4 (13%) 
Total 17 30 17 30 
 
Table 3-1: TNF + IL-17 had a reproducible synergistic effect on NHEK IL-6 
protein and IL-8 mRNA induction and donor-dependent effects on IL-6 mRNA 
and IL-8 protein.  TNF + IL-17 effects on IL-6/-8 mRNA were not always 
comparable to effects on IL-6/-8 protein 
Table shows number of donors and proportion of donors with synergistic, additive or 
antagonistic effects in response to TNF + IL-17 stimulation, compared to stimulation 
with either TNF or IL-17 individually.  Data derived as described in Figure 3-5.  (for 
mRNA, N=17, with each donor performed in duplicate repeat; for protein, N=30, with 
each donor performed in triplicate repeat). 
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Figure 3-6: Donor dependent effects of TNF + IL-17 stimulation on IL-6 and IL-8 
secreted protein responses 
NHEKs from donors A (graphs A and B), B (C and D), C (E and F) and D (G and H) 
were stimulated with TNF (10ng/ml), IL-17 (100ng/ml), TNF (10ng/ml) + IL-17 
(100ng/ml) or mock stimulated.  Supernatants were harvested 48h post-stimulation and 
IL-6 (A, C, E, G) and IL-8 (B, D, F, H) protein concentration were measured by 
ELISA.   (for each graph: N=1, with each donor performed in triplicate repeat) Analysis 
by one-way ANOVA with Dunnett’s post-test; *p<0.05, **p<0.01, ***p<0.001.  
Graphs show mean of data points. 
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Figure 3-7: Donor dependent effects of TNF + IL-17 stimulation on IL-6 and IL-8 
mRNA and secreted protein responses 
NHEKs from donor E (graphs A, B, C, D) and F (E, F, G, H) were stimulated with 
TNF (10ng/ml), IL-17 (100ng/ml), TNF (10ng/ml) + IL-17 (100ng/ml) or mock 
stimulated.  Cells were harvested for mRNA at 6h post-stimulation and expression of 
IL-6 (A, E) and IL-8 (C, G) determined by qRT-PCR.  Supernatants were harvested 48h 
post-stimulation and IL-6 (B, F) and IL-8 (D, H) protein concentration were measured 
by ELISA.  (for each graph: mRNA, N=1; protein, N=1, with each donor performed in 
triplicate repeat) Analysis by one-way ANOVA with Dunnett’s post-test; *p<0.05, 
**p<0.01, ***p<0.001.  Graphs show mean of data points (for mRNA, normalised to 
unstimulated).  
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3.3.4. The synergistic effect of TNF + IL-17 on IL-6 and IL-8 induction were 
reproducible and not dependent on cell density, type of growth media or cell 
passage 
Having observed that TNF + IL-17 stimulation appeared to have donor dependent 
effects on IL-6 and IL-8 responses, the consistency of these findings over different cell 
passage numbers and potential impact of culture conditions were investigated. 
Initially NHEKs density was investigated; NHEKs were seeded at a density of either 16,000 or 18,000 cells per 
well of a 48 well plate prior to stimulation with TNF, IL-17 or TNF+ IL-17.  Supernatants were harvested 
48h post-stimulation and IL-6 and IL-8 protein concentration measured by ELISA.  At the time of 
supernatant harvesting, wells originally seeded with 16,000 cells had reached ~70% confluency whereas those 
seeded with 18,000 cells had reached ~100% confluency.  As shown in  
Figure 3-8, the density of NHEKs did not affect the pattern of response to TNF and/or 
IL-17 stimulation.  However, as expected, absolute values of IL-6 and IL-8 were greater 
where there were higher densities of NHEKs, reflecting the greater number of cells at 
the end of the experiment. 
Next the potential effect of cell passage on NHEKs responses to TNF + IL-17 
stimulation were investigated; NHEKs isolated from a single donor were stimulated at 
passage 3 with TNF, IL-17 or TNF+ IL-17.  Supernatants were harvested 48h post-
stimulation and IL-6 and IL-8 protein concentration measured by ELISA.  The same 
experiment was repeated on NHEKs from the same donor at passage 4, with a delay of 
5 days between passage 3 and passage 4 growth/stimulation.  As shown in Figure 3-9, 
there were no significant difference between passage 3 and passage 4 responses to 
TNF, IL-17 or TNF+ IL-17 and effects were reproducible on different days of 
stimulation/supernatant harvest. 
Finally, different growth media were investigated.  NHEKs were cultured in either 
Epilife
®
 or MCDB 153, both supplemented with human keratinocyte growth 
supplement, prior to stimulation with TNF, IL-17 or TNF+ IL-17.  Supernatants 
were harvested 48h post-stimulation and IL-6 and IL-8 protein concentrations measured 
by ELISA. Growth of NHEKs in Epilife
®
 or MCDB 153 produced no significant 
differences in inflammatory responses to TNF, IL-17 or TNF+ IL-17 (Figure 3-10). 
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Figure 3-8: The synergistic effects of TNF + IL-17 on IL-6 and IL-8 induction 
were independent of NHEK cell density 
NHEKs from donor H were seeded at a density of either 16,000 NHEKs per well of a 
48 well plate (A) and (C) or 18,000 NHEKs per well of a 48 well plate (B) and (D) then 
stimulated with TNF (10ng/ml), IL-17 (100ng/ml), TNF (10ng/ml) + IL-17 
(100ng/ml) or mock stimulated.  Supernatants were harvested 48h post-stimulation and 
IL-6 (A and B) and IL-8 (C and D) and protein concentration were measured by 
ELISA.  At the end of the experiment A and C, NHEKs had reached 70% confluency 
whereas NHEKs in experiment B and D had reached 100% confluency.  (N=1, with 
each donor performed in triplicate repeat) Analysis by one-way ANOVA with 
Dunnett’s post-test; *p<0.05, **p<0.01, ***p<0.001.  Graphs show mean of data points. 
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Figure 3-9:  Synergistic effects of TNF + IL-17 on IL-6 and Il-18 induction were 
independent of NHEK cell passage and reproducible on different days 
NHEKs from donor I were cultured to passage 3 or 4 then stimulated with TNF 
(10ng/ml), IL-17 (100ng/ml), TNF (10ng/ml) + IL-17 (100ng/ml) or mock stimulated, 
the delay between passage 3 and 4 was 5 days. Supernatants were harvested 48h post-
stimulation, for each of passage 3 and 4; IL-6 (A) and IL-8 (B) protein concentration 
were measured by ELISA.  (N=1, with each donor performed in triplicate repeat) 
Analysis by two-way ANOVA with Bonferroni post-test.  Graphs show mean of data 
points. 
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Figure 3-10: Induction of IL-8 by TNF + IL-17 stimulation was not dependent on 
the type of growth media used  
NHEKs from donor J were isolated and cultured for 2 passages in either Epilife
®
 or 
MCDB 153, each supplemented with Human Keratinocyte Growth Supplement, prior to 
stimulation with TNF (10ng/ml), IL-17 (100ng/ml), TNF (10ng/ml) + IL-17 
(100ng/ml) or mock stimulated.  Supernatants were harvested 48h post-stimulation and 
IL-6 (A) and IL-8 (B) protein concentration were measured by ELISA.  (N=1, with each 
donor performed in triplicate repeat) Analysis by two-way ANOVA with Bonferroni 
post-test.  Graphs show mean of data points. 
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3.3.5. TNF + IL-17 stimulation had an additive effect on upstream NF-B 
signalling  
Having observed that TNF and IL-17 could have a synergistic effect on IL-6 and IL-8 
mRNA expression, it was hypothesised that this might be through synergistic effects on 
upstream signalling pathways.  Nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-B) is known to be a key regulator of inflammatory responses in psoriasis, 
including IL-6 and IL-8, and both TNFand IL-17, have been shown to signal through 
NF-B (Libermann and Baltimore, 1990; Hoffmann et al., 2002; Gaffen et al., 2014; 
Harden et al., 2015).  This raised the hypothesis that TNF + IL-17 stimulation in 
NHEKs would have a synergistic effect on NF-B activation.  The effects of stimuli 
were therefore investigated in an NF-B dual luciferase reporter system (Sherf et al., 
1996).   NHEKs were transiently transfected with an NF-B luciferase reporter and 
stimulated with TNF, IL-17 or TNF + IL-17.  As expression of IL-6 and IL-8 mRNA 
were maximal at 6h after TNF + IL-17 stimulation, we reasoned that activation of 
upstream signalling pathways would precede maximal transcription.  Luciferase activity 
was therefore measured at 2 and 4h post-stimulation. 
As shown in Figure 3-11, TNF and IL-17 produced an at least additive effect on NF-
B signalling which was more evident at 4h post-stimulation.  TNF stimulation 
appeared to have a greater effect on NF-kB activation, compared to IL-17 stimulation, 
although this was not significant. 
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Figure 3-11: TNF + IL-17 stimulation had an additive effect on NF-B activation 
NHEKs were transfected with NF-κB firefly and renilla luciferase constructs prior to 
stimulation with TNF (10ng/ml), IL-17 (100ng/ml), TNF (10ng/ml) + IL-17 
(100ng/ml) or mock stimulated.  Cells were lysed at 2h (A) or 4h (B) post-stimulation 
and luciferase activity measured using a luminometer.   (N=3, with each donor 
performed in triplicate repeat)  Analysis by one-way ANOVA with Dunnett’s post-test; 
*p<0.05, **p<0.01, ***p<0.001.  Graphs show mean of relative luminescence 
(firefly/renilla ratio) ± SEM. 
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3.3.6. Induction of IL-6 and IL-8 by TNF + IL-17 stimulation was inhibited by 
ciclosporin 
To explore whether the TNF + IL-17 model of cutaneous inflammation could be used 
for in vitro testing of potential therapeutic compounds, the effect of ciclosporin, a 
compound used clinically to treat psoriasis  (Jabbar-Lopez et al., 2014), on IL-6 and IL-
8 responses to TNF + IL-17 was investigated.  NHEKs were treated with ciclosporin 
for 1h prior to stimulation with TNF + IL-17. Forty eight hours after stimulation, 
supernatants were collected and secreted IL-6 and IL-8 concentrations were measured 
by ELISA. 
Consistent with the effects of ciclosporin on keratinocyte calcineurin/NFAT signalling, 
ciclosporin significantly inhibited IL-6 and IL-8 responses to TNF + IL-17 stimulation 
(Figure 3-12) compared to the vehicle control (p<0.01 and p<0.001 for IL-6 and IL-8, 
respectively), suggesting that the model could be used for in vitro, pre-clinical, 
evaluation of potential therapeutic compounds for the treatment of psoriasis.  
Ciclosporin did not significantly affect basal IL-6 or IL-8 levels in unstimulated 
NHEKs.  In comparison DMSO, a commonly used drug vehicle, had no significant 
effects on basal IL-6/-8 levels or on IL-6/-8 responses to TNF + IL-17 stimulation. 
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Figure 3-12: Ciclosporin inhibited IL-6 and IL-8 induction by TNF + IL-17 
stimulation 
NHEKs were incubated with ciclosporin (1M), vehicle (ethanol, 0.05%) or DMSO 
(1:1200) for 1h prior to stimulation with TNF (10ng/ml) + IL-17 (100ng/ml) or mock 
stimulated.  Supernatants were harvested 48h after stimulation and IL-6 (A) and IL-8 
(B) concentrations were determined by ELISA.  (N=3, with each donor performed in 
triplicate repeat)  Analysis by two-way ANOVA with Bonferroni post-test.  Graphs 
show mean of data points (normalised to unstimulated control) ± SEM. 
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3.4. Discussion 
An existing model of cutaneous inflammation, in which NEHKs were stimulated with 
TNF + IL-17 (Chiricozzi et al., 2011), was extended to show that secreted pro-
inflammatory cytokines were significantly increased after TNF + IL-17 stimulation.  
In addition it was demonstrated that inflammatory responses could be inhibited by 
ciclosporin, a compound used clinically to treat psoriasis.  TNF and IL-17 are key 
cytokines in the pathogenesis of psoriasis, whose serum levels correlate with disease 
severity and are known to regulate the expression of keratinocyte genes relevant to the 
pathogenesis of psoriasis (Takahashi et al., 2010; Chiricozzi et al., 2011).  Together 
these findings suggest the in vitro TNF + IL-17 model of cutaneous inflammation, 
relevant to psoriasis, can be used to i) investigate the regulation of inflammatory skin 
disease and ii) be used for pre-clinical evaluation of potential therapeutic compounds.  
Furthermore, in the first time using a model relevant to psoriasis, it was demonstrated 
that there were donor-dependent inflammatory responses to TNF + IL-17 stimulation, 
in terms of both magnitude of responses and synergism, or lack of, between TNF and 
IL-17 stimulation.   
It was observed that IL-6 and IL-8  mRNA expression was maximal at 6h after TNF + 
IL-17 stimulation, whereas secreted protein was cumulative up to 48h post-stimulation.  
The kinetics of expression were in keeping with previously published effects of TNF + 
IL-17 stimulation in synovial fibroblasts on IL-6 and IL-8 mRNA induction (Katz et al., 
2001) and also the effects of  oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-
phosphorylcholine (Ox-PAPC) stimulation in human endothelial cells on IL-8 mRNA 
and protein induction (Yeh et al., 2001).  The absolute concentrations of secreted IL-6 
and IL-8 we observed in response to TNF + IL-17 stimulation were approximately 5-
10 fold higher than co-culture of keratinocytes with Staphylococci (Sasaki et al., 2003).   
Compared to stimulation with each cytokine individually, the combination of TNF + 
IL-17 stimulation had a consistently synergistic effect on IL-8 mRNA induction in all 
donors but donor dependent effects (synergistic or additive) on IL-6 mRNA induction.  
Overall TNF + IL-17 had a synergistic effect on IL-6 mRNA induction in only 65% of 
donors and an additive effect in 35% of donors (N=17) (Table 3-1).  Donor effects did 
not correlate with donor age, medical history, family history of illness, or medications.  
In NHEKs, Chiricozzi et al. previously described TNF + IL-17 having synergistic 
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effects on both IL-6 and IL-8 mRNA induction (Chiricozzi et al., 2011).  A number of 
differences in experimental set up exist and these were considered with respect to this 
discrepancy. Firstly the concentration of IL-17 used by Chiricozzi et al. was 200ng/ml, 
compared to 100ng/ml in these investigations (the same concentration of TNF, 
10ng/ml, was used in both studies).  However, results obtained during the MRes 
preceding this PhD showed that NHEKs stimulation with TNF (10ng/ml) plus IL-17 at 
either 100ng/ml, 200ng/ml or 400ng/ml had no significant difference in the magnitude 
of IL-6 and IL-8 protein responses (i.e. IL-6 and IL-8 responses were maximal with IL-
17 100ng/ml). Furthermore, Katz et al. previously demonstrated that in primary 
synovial fibroblasts the synergistic effects of TNF and IL-17, on IL-6 and IL-8 mRNA  
production, could be observed for all concentrations and combinations of TNF and IL-
17 assayed; up to 10ng/ml and 100ng/ml respectively (Katz et al., 2001).    Differences 
in concentration of IL-17 were therefore unlikely to account for the discrepancy in 
results.  Secondly Chiricozzi et al. investigated effects on mRNA expression 24h after 
stimulation, whereas the experiments described above investigated effects at 6h, when 
expression of IL-6 and IL-8 was maximal (Figure 3-3).  The kinetics of IL-6 and IL-8 
mRNA expression in our model were in keeping with the effects of TNF + IL-17 
stimulation in synovial fibroblasts, which demonstrated maximal IL-6 and IL-8 mRNA 
responses at 4-18h after stimulation with a peak at around 7h (Katz et al., 2001) and 
Figure 3-3, demonstrates that maximal synergistic response to TNF + IL-17 
stimulation occurred at 6h for both IL-6 and IL-8; differences in timepoints are 
therefore also unlikely to account for the discrepancy in results.  Finally, primary 
keratinocytes were used in these experiments, therefore donor variability may account 
for some of these differences.  As our dataset had over 4 times the number of donors it 
is likely to be more robust (N=4 in Chiricozzi et al.’s dataset and N=17 in our dataset); 
subtle effects of TNF + IL-17 stimulation on IL-6 mRNA responses may have only 
been detectable with greater donor numbers.  
To begin to investigate potential underlying mechanisms of synergy between TNF and 
IL-17, we studied the effects of stimulation on NF-B signalling, which TNFand IL-
17 have both been shown to signal through (Gaffen et al., 2014; Harden et al., 2015) 
(section 1.2.6).  Using a NF-B luciferase reporter assay, combined TNF + IL-17 
stimulation was found to have at least an additive effect on NF-B signalling.  This is 
consistent with the synergistic effects of TNF + IL-17 on NF-B nuclear translocation 
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observed in rheumatoid arthritis synoviocytes; similar synergistic effects on nuclear 
translocation of other transcription factors, including c-FOS and c-JUN, were also 
observed (Granet et al., 2004).  It would have been interesting to correlate the effects of 
TNF and/or IL-17 stimulation on NF-B signalling, with effects on IL-6 and IL-8 
induction in individual donors. However, as NHEKs demonstrated differential effects of 
TNF + IL-17 stimulation on IL-6 and IL-8 induction in some donors (for example in 
donor F, Figure 3-7, TNF + IL-17 stimulation had an additive effect on IL-6, but a 
synergistic effect on IL-8 gene expression), the effect on NF-B signalling alone, which 
is known to regulate both IL-6 and IL-8 (Libermann and Baltimore, 1990; Hoffmann et 
al., 2002), is unlikely to account for the different responses of downstream effector 
genes entirely.  In addition to signalling through NF-B, both TNFand IL-17 have 
been shown to activate mitogen-activated protein kinase (MAPK) pathways (e.g. JUN 
N-terminal kinase (JNK)), through TNF receptor-associated factor (TRAF) (Gaur and 
Aggarwal, 2003; Gaffen et al., 2014) (section 1.2.6).  It may therefore be informative to 
understand the effects of TNF + IL-17 stimulation on MAPK signalling pathways on 
NHEKs.   
It was observed that TNF + IL-17 stimulation of NHEKs had a consistently synergistic 
effect on IL-8 mRNA induction, but a more variable effect on IL-6 mRNA, and the 
magnitude of IL-8 mRNA response to TNF + IL-17 stimulation was greater than IL-6 
mRNA response.  In comparison, the addition of IFN enhanced IL-6, but inhibited IL-
8, response to TNF + IL-17 stimulation.  Interestingly IFN has also previously been 
shown to enhance IL-6 mRNA response to histamine in keratinocytes, but had an 
inhibitory effect on histamine-induced IL-8 mRNA (Kohda et al., 2002).  Together 
these findings suggest IL-6 and IL-8 are differentially regulated at the transcriptional 
level.  In support of this, in Jurkat T cells stimulated with phorbol 12-myristate 13-
acetate (PMA) (an analogue of diacylglycerol and activator of protein kinase C, which 
activates nuclear factor of activated T cells (NFAT)) showed IL-8, but not IL-6, was 
closely associated with the activation pattern of NFAT (Khalaf et al., 2013).  
Furthermore in a model of HIV-associated neurotoxicity, stimulation of astrocytes with 
methamphetamine and HIV-1 glysoproein120 had a synergistic effect on IL-6, but not 
IL-8, induction, and the synergistic effect was shown to be mediated through 
phosphatidylinositol 3'-kinase/ protein kinase B  (PI3/Akt) pathways (Shah et al., 2012).  
Interestingly, epigenetic changes are implicated in mechanisms underlying synergistic 
effects of combined stimulation; in macrophages, pre-treatment with IFN 
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synergistically upregulated subsequent LPS-induced responses of effector cytokines 
including IL-6 (Qiao et al., 2013).  Qiao et al. demonstrated IFN treatment resulted in 
increased acetylation of the lysine 27 residue on histone H3 (H3K27ac) at the promoter 
and enhancer region of IL-6 and TNF, which was associated with increased 
recruitment of histone acetyl transferase (HAT) enzymes to these regions.  IFN-
induced priming of IL-6 regulatory regions did not activate IL-6 transcription but 
subsequent LPS stimulation led to enhanced and prolonged recruitment of transcription 
factors (including p65) and RNA polymerase II to IL-6 promoter and enhancer regions, 
which accounted for IFN-induced potentiation of IL-6 response to LPS stimulation 
(Qiao et al., 2013).  It would be very interesting to investigate whether similar 
epigenetic mechanisms underlie the synergy between TNF + IL-17 stimulation in 
NHEKs, especially as IFN enhanced IL-6 response to TNF + IL-17 stimulation 
(Figure 3-1A).  It would also be interesting to understand if the magnitude of synergism, 
or lack of, between TNF + IL-17 on IL-6 induction correlates with epigenetic changes 
at the IL-6 promoter in NHEKs and whether similar epigenetic changes occur at the IL-
8 promoter. 
Although Chiricozzi et al. did not investigate effects of TNF + IL-17 stimulation on 
IL-6 and IL-8 protein responses (Chiricozzi et al., 2011), importantly, we extended the 
model of NHEKs stimulation with TNF + IL-17 by investigating effects of stimulation 
on secreted IL-6 and IL-8 protein.  TNF + IL-17 stimulation had a reproducible 
synergistic effect on secreted IL-6 protein production (94% of donors, N=30) (Table 
3-1).  In contrast, the effects on secreted IL-8 protein were indicative of  TNF + IL-17 
stimulation having a synergistic effect on IL-8 protein production in only 70% of 
donors, an additive effect in 17% and antagonistic effect in 13% of donors (N=30) 
(Table 3-1).  The donor dependent effects  of  TNF + IL-17 stimulation (synergistic, 
additive or antagonistic) could not be accounted for by tissue culture conditions e.g. cell 
density, type of growth media or cell passage and effects were reproducible on different 
days of stimulation.  As shown in Figure 3-7, the effect of TNF + IL-17 stimulation on 
IL-6 mRNA expression did not necessarily translate to effects on secreted IL-6 protein, 
suggesting that there is post-transcriptional regulation for both IL-6 and IL-8. This 
suggestion is supported by findings by Katz et al. who showed that in primary synovial 
fibroblasts, TNF and IL-17 had a greater synergistic effect on secreted protein 
responses compared to mRNA expression, for both IL-6 and IL-8 (Katz et al., 2001).  It 
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has previously been shown that stimulation with TNF + IL-17 can have co-operative 
effects on target gene mRNA stability, in human colonic myofibroblasts (Hata et al., 
2002).  Hata et al. showed that co-stimulation  of  myofibroblasts with TNF + IL-17 
enhanced IL-6 mRNA stability compared to stimulation with either TNF or IL-17 
alone and observed that enhancement of IL-6 protein responses to TNF + IL-17 
stimulation was dependent on IL-6 mRNA stability (Hata et al., 2002).  In contrast IL-8 
mRNA was more stable than IL-6 mRNA and the stability of TNF-induced IL-8 was 
not modulated by the addition of IL-17 (Hata et al., 2002).   Similar post-transcriptional 
mechanisms could exist in NHEKs and these may account for the differential effects of 
TNF + IL-17 on mRNA vs. protein in response to stimulation.  
With regard to the variability in magnitude of IL-6 and IL-8 responses to stimulation 
and the donor dependent effects of synergy between TNF and IL-17, it has previously 
been demonstrated that primary cells from different donors can show considerable 
variability in the amount of proteins they secrete including cytokines, chemokines and 
growth factors in both basal/unstimulated cells and also in response to inflammatory 
stimuli, including TNF and IL-1 (Zhukareva et al., 2010).  Interestingly Zhukareva et 
al, demonstrated donor dependent IL-8 responses (to IL-1 stimulation).  Donor 
heterogeneity in response to TNF, IL-17 or combined stimulation has also previously 
been reported, in fibroblast-like synoviocytes (FLS).  Fischer et al. demonstrated that 
TNF + IL-17 stimulation of FLS from different donors tended to have an additive 
effect on both IL-6 and IL-8 protein production in the majority of donors, but in some 
donors a synergistic effect was observed (Fischer et al., 2015). Our understanding of 
individual donor responses to stimuli is increasing and a genetic component is likely to 
be involved in the underlying mechanism, this is perhaps unsurprising given that 
different culture or stimulation conditions could not account for the donor variability 
demonstrated in NHEKs.   Dombroski et at. previously investigated  B cell responses to 
endoplasmic reticulum (ER) stress and found that, in a sample of 60 donors, some genes 
(e.g. RNASE4, which encodes a protein that plays a  role in mRNA cleavage) showed 
large variations in responses across donors, but other genes demonstrated less variation 
(e.g. EIF3B, which encodes a protein involved in initiation of protein synthesis)  
(Dombroski et al., 2010).  Although highly variable genes did not demonstrate 
enrichment for any particular functions, Dombroski et al. assessed whether there were 
genetic components underlying this variance by investigating ER stress responses in 
immortalised B cells derived from monozygotic (MZ) twins compared to unrelated 
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individuals.  Immortalised B cells derived from MZ twins were found to be more 
similar in their responses to ER stress compared to unrelated individuals, suggesting a 
genetic component could account for donor variability to stimuli.  Interestingly 
correlation between MZ twins varied for different responses induced by ER stress,  and 
the lack of complete correlation between MZ twins suggested other, non-genetic factors, 
were also involved in mechanisms underlying donor variability (Dombroski et al., 
2010). 
Recently the concept of expression quantitative trait loci (eQTLs) has emerged.  
Genome wide association studies (GWAS) of gene expression have identified genetic 
loci associated with the expression of specific genes, these loci have been termed 
eQTLs (Ding et al., 2010).  Most eQTLs in humans map to within a few hundred 
kilobases of the associated gene, theses have been termed cis-eQTLs, and eQTLs which 
map further away have been termed trans-eQTLs (Ding et al., 2010).  eQTLs have been 
identified for a wide variety of genes involved in disease pathogenesis (Cookson et al., 
2009) and interestingly donor heterogeneity of IL-6 responses to lipopolysaccharide 
(LPS) have been mapped to eQTLs (Fairfax et al., 2010).  Fairfax et al. showed that IL-
6 mRNA expression correlated with single nucleotide polymorphisms (SNPs) in a 
number of genes including LEP (encoding leptin, an adipokine secreted mainly by 
adipocytes), in both unstimulated and LPS stimulated peripheral blood mononuclear 
cells (PMBCs).   For example, heterozygous carriers of a thymine to cytosine mutation 
at position 3030 (3030T>C) of the LEP gene had 7-fold higher expression of basal IL-6 
mRNA compared to those not carrying this mutation.  In addition, after LPS stimulation 
donors with the 3030T>C mutation in LEP demonstrated 2.3-fold higher expression of 
IL-6 (Fairfax et al., 2010).  The 3030T>C mutation in LEP was associated with a 5.5-
fold higher expression in LEP mRNA expression and basal expression of leptin 
correlated with the magnitude of IL-6 responses to LPS stimulation in PMBCs (Fairfax 
et al., 2010).  The mechanisms underlying LEP associated enhancement of IL-6 
production are unknown, but does not appear to be through non-specific, pro-
inflammatory responses, as expression of other cytokines (e.g. IL-12) are no affected 
(Fairfax et al., 2010).  Interestingly, leptin has been shown to increase secreted IL-6, IL-
8 and TNF in keratinocytes (Xue et al., 2013).  Of further note, a recent meta-analysis 
of 11 studies, comprising 773 patients with psoriasis and 579 controls, showed 
significantly elevated leptin levels in serum samples from psoriasis patients (weighted 
mean difference 7.24ng/ml, p<0.0001), although this was less significant when plasma 
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was analysed (weighted mean difference 12.47ng/ml, p<0.02) (Zhu et al., 2013).  It 
would be very interesting to understand if any eQTLs (including in LEP) correlate with 
increased IL-6 or IL-8 responses to TNF + IL-17 stimulation in NHEKs or to 
synergistic effects of TNF + IL-17 stimulation on IL-6 or IL-8 mRNA and protein 
induction and whether these are also associated with an increased risk of developing 
psoriasis, or indeed whether any of the currently identified psoriasis susceptibility loci 
(Tsoi et al., 2012; Tsoi et al., 2015) can predict IL-6 or IL-8 responses to TNF + IL-17 
stimulation. 
In the final investigation of the TNF + IL-17-stimulated NHEKs model of cutaneous 
inflammation, the model was evaluated for in vitro pre-clinical testing of potential 
therapeutic compounds.  Ciclosporin is a an effective treatment for psoriasis (Ellis et al., 
1986) and is known to inhibit calcineurin and therefore block phosphorylation and 
subsequent translocation of NFAT (Flanagan et al., 1991).  In addition to inhibition of 
the NFAT pathway, ciclosporin has more recently been shown to have inhibitory effects 
on NF-B signalling (Nishiyama et al., 2005).  In TNF + IL-17 stimulated NHEKs, 
ciclosporin inhibited both IL-6 and IL-8 responses.  This result is consistent with the in 
vivo inhibitory effects of ciclosporin on cytokine production in psoriatic patients treated 
with this drug (Elder et al., 1993).  More recent studies have shown ciclosporin can 
inhibit IL-6 and IL-8 production in keratinocytes in vitro, consistent with our findings 
(Kobayashi et al., 2007; Takei-Taniguchi et al., 2012).  Other studies have shown that 
ciclosporin can have direct effects on skin independent of T-cells, for example 
ciclosporin has anti-proliferative effects on cultured keratinocytes (Fisher et al., 1988).  
Furthermore, calcineurin/NFAT have  been shown to be expressed in keratinocytes (Al-
Daraji et al., 2002).  This, together with our results, suggests that ciclosporin effects in 
keratinocytes, in addition to its effects in T-cells, may account in part for its 
effectiveness in inflammatory skin disease.   Furthermore, the results suggest that the 
TNF + IL-17 model of cutaneous inflammation could be a valid assay for pre-clinical 
testing of potential therapeutic compounds for psoriasis treatment. 
3.5. Future work 
Our results, combined with Chiricozzi et al.’s data (Chiricozzi et al., 2011) suggest the 
NHEKs model of cutaneous inflammation is a valid in vitro model which can be used to 
further understand the response of epidermal keratinocytes to inflammatory cytokines, 
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the pathogenesis of psoriasis and the role of epigenetics in regulating cutaneous 
inflammation.  A number of key questions, however, remain:   
 In the NHEKs model of cutaneous inflammation which factors govern donor 
dependent responses to TNF + IL-17 stimulation?   Although it has previously 
been shown that TNF and IL-17 can have co-operative effects on several 
levels, e.g. receptor upregulation, upstream signalling pathways and mRNA 
stability of target, it is unknown how these co-operative effects vary between 
donors (Hartupee et al., 2007; Gudjonsson et al., 2012; Gaffen et al., 2014; 
Harden et al., 2015).  Are changes in co-operative effects at different levels 
responsible for differences in magnitude of response and synergism (or lack of) 
between TNF + IL-17 stimulation.  We hypothesise that specific eQTLs 
(Fairfax et al., 2010) are associated with donor variability in response to TNF 
and/or IL-17 stimulation.  Furthermore it would be interesting to investigate 
whether specific eQTLs (Fairfax et al., 2010) associated with increased pro-
inflammatory responses are also associated with specific endotypes of psoriasis 
and potentially to their response to treatment, including anti-TNF/anti-IL-17 
therapy. 
 Combined with increased understanding of eQTLs, further mechanistic studies 
of epigenetic changes and signalling pathways engaged by TNFand IL-17 in 
NHEKs and their potential role in regulating i) inter-individual differences in IL-
6/IL-8 mRNA responses and ii) synergistic responses of IL-8 and IL-6 following 
stimulation with TNF + IL-17 would also be of interest.   
3.6. Conclusions 
 NHEKs stimulation with TNF + IL-17 induced significant IL-6 and IL-8 
mRNA and protein responses, although there were inter-donor differences in the 
magnitude of responses. 
 Combined stimulation with TNF + IL-17, compared to stimulation with either 
cytokine alone, had a reproducible synergistic effect on IL-8 mRNA induction in 
all donors.  On the other hand, TNF + IL-17 stimulation had donor dependent 
responses on IL-6 mRNA expression, with only 65% of donors showing a 
synergistic effect of stimulation. 
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 In contrast to effects on IL-6/-8 mRNA responses; a synergistic effect between 
TNF + IL-17 stimulation on IL-6 protein induction was observed in 94% of 
donors.  On the other hand, TNF + IL-17 stimulation had a synergistic effect 
on IL-8 protein production in only 70% of donors, an additive effect in 17% and 
antagonistic effect in 13% of donors. 
 TNF + IL-17 stimulation resulted in maximal IL-6 and IL-8 mRNA expression 
at 6h after stimulation, whereas protein was cumulative up to 48h post-
stimulation. 
 Ciclosporin, a compound used clinically to treat psoriasis, inhibited TNF + IL-
17 induction of both IL-6 and IL-8.   
 Taken together, these data suggest the NHEKs model of cutaneous inflammation 
could be used to further understand the pathogenesis of psoriasis and also for in 
intro pre-clinical testing of potential therapeutic compounds. 
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4. The role of BET proteins in the in vitro model of cutaneous 
inflammation 
4.1. Introduction 
As discussed in section 1.3.5, differential DNA methylation and histone modifications 
have been associated with psoriasis (Zhang et al., 2011a; Roberson et al., 2012; 
Trowbridge and Pittelkow, 2014).  Lysine acetylation is the most widely studied histone 
modification and is mostly associated with gene expression (Ernst et al., 2011). 
Through their bromodomains, bromodomain extraterminal (BET) proteins (Brd2, Brd3, 
Brd4 and BrdT, although BrdT is only expressed in testes) are known to bind acetylated 
lysine residues on histones and act as adapter proteins to regulate gene expression 
through recruitment of other proteins involved in transcription initiation and also 
elongation  (Basheer and Huntly, 2015). 
Specific and potent inhibitors of BET-bromodomains have been developed 
(Filippakopoulos et al., 2010; Nicodeme et al., 2010) e.g. I-BET151 (Dawson et al., 
2011) (section 1.3.7).  These compounds bind within the acetyl-lysine binding pocket of 
the tandem bromodomains of BET proteins and block association with acetylated 
proteins, including histones (Zou et al.).  In in vitro and in vivo models of inflammation 
and cancer, BET inhibitors demonstrated anti-inflammatory and anti-proliferative 
effects (Filippakopoulos et al., 2010; Nicodeme et al., 2010) and have been shown to 
inhibit differentiation of naïve CD4+ T cells into TH17 cells (Mele et al., 2013). 
There is little documentation about the function of BET proteins or the effects of BET 
inhibition in keratinocytes or skin.  However, given that BET inhibitors have anti-
proliferative and anti-inflammatory effects both in vitro and in vivo (Filippakopoulos et 
al., 2010; Nicodeme et al., 2010) and that psoriasis is characterised by chronic 
inflammation and excessive proliferation, with TH17 cytokines playing key roles in 
driving pathogenesis, we hypothesised that BET proteins may be involved in regulating 
expression of pro-inflammatory cytokines relevant to psoriasis and that BET inhibition 
would block pro-inflammatory responses in keratinocytes. In support of this hypothesis, 
BET inhibition has recently been shown to inhibit psoriasis-like cutaneous 
inflammation in an imiquimod-induced mouse model of psoriasis (Nadeem et al., 
2015).  To test these hypotheses the activity of a specific BET inhibitor, I-BET 151, 
(Dawson et al., 2011) was evaluated in the TNF + IL-17A (IL-17) in vitro model of 
cutaneous inflammation and the results are described in this chapter. 
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4.2. Aims 
 To characterise the role of BET proteins in regulating expression of pro-
inflammatory cytokines, using the TNF + IL-17 in vitro model of 
cutaneous inflammation 
 To test the activity of BET inhibitor I-BET151 in the TNF + IL-17 in vitro 
model of cutaneous inflammation, as a potential therapeutic compound for 
the treatment of psoriasis. 
 To use the specific BET inhibitor, I-BET151, as a tool for further 
understanding the role of BET proteins in regulating inflammatory responses 
in the TNF + IL-17 in vitro model of cutaneous inflammation. 
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4.3. Results 
4.3.1. Keratinocyte expression of BET proteins is not regulated by TNF + IL-17 
stimulation 
To characterise the role of BET proteins in the TNF + IL-17 in vitro model of 
cutaneous inflammation, BET expression in keratinocytes was investigated.  Previously, 
expression of IL-6 and IL-8 mRNAs in TNF + IL-17 stimulated normal human 
epidermal keratinocytes (NHEKs) was found to be maximal at 6h after stimulation 
(section 3.3.2) and it was hypothesised that this would involve recruitment of pre-
formed BET proteins rather than through increased synthesis of BET proteins de novo.  
NHEKs were stimulated with TNF, IL-17 or TNF + IL-17 and Brd2/3/4 mRNA 
expression was measured by qRT-PCR at 1, 3, 6, 10 and 24h after stimulation.  
As shown in Figure 4-1, unstimulated NHEKs expressed Brd2 Brd3 and Brd4, and 
stimulation with TNF and/or IL-17 had no significant effect on their expression.  
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Figure 4-1: TNF + IL-17 stimulation did not affect mRNA BET expression 
NHEKs were stimulated with TNF (10ng/ml), IL-17 (100ng/ml), TNF (10ng/ml) + 
IL-17 (100ng/ml) or mock stimulated.  Cells were harvested after stimulation, at 
timepoints indicated, and expression of Brd2 (A), Brd3 (B) and Brd4 (C) determined by 
qRT-PCR/Taqman
®
 gene expression assays.  (N=3, with each donor performed in 
triplicate repeat) Analysis by two-way ANOVA with Bonferroni post-test, comparing 
against the relevant unstimulated control.  Graphs show mean of data points (normalised 
to unstimulated control within the relevant timepoint) ± SEM.   
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4.3.2. I-BET151 treatment inhibited  induction of IL-6 protein, reduced IL-6 
mRNA expression, but had donor-dependent effects on IL-8 protein and 
mRNA expression in TNFα + IL-17 stimulated NHEKs. 
To understand the effects of BET inhibition on keratinocyte inflammatory responses 
and to further investigate the pharmacology of I-BET151, NHEKs were treated with a 
range of increasing concentrations of I-BET151 for 1h prior to stimulation with TNF + 
IL-17 in-vitro, to allow time for I-BET151 to equilibrate across cell membranes prior to 
stimulation; the effects of addition of compound either at time of or after stimulation 
was also studied (section 4.3.7).  For IL-6 and IL-8 gene expression studies, NHEKs 
were harvested at 6h post-stimulation, when IL-6 and IL-8 mRNA expression was 
maximal (section 3.3.2), and IL-6 and IL-8 mRNA expression was measured by qRT-
PCR.  As IL-6 and IL-8 secreted protein was cumulative up to 48h post-stimulation 
(section 3.3.2), media supernatants were collected at this timepoint and secreted IL-6 
and IL-8 concentrations were determined by ELISA,   
I-BET151 inhibited IL-6 mRNA response to TNFα + IL-17 stimulation in NHEKs in a 
concentration dependent manner, although the activity of I-BET151 on IL-6 mRNA 
response was variable across the three donors; IC50 (half-maximum inhibitory 
concentration) range = 57.6 – 173.4nM and maximum inhibition of IL-6 mRNA range = 
61.0  - 74.9% (Figure 4-2A, C and E).  Across the 3 donors, the mean IC50 = 133.6nM 
(95% confidence interval (95% CI) = 86.5 – 180.7nM) and mean maximum inhibition = 
69.5% (95% CI = 64.2 – 74.8%) (Figure 4-4A and E). 
I-BET151 also inhibited IL-8 mRNA response to TNFα + IL-17 stimulation in NHEKs 
in a concentration dependent manner and, as with the effect on IL-6 mRNA response, 
the activity of I-BET151 on IL-8 mRNA response was variable across the three donors; 
IC50 (half-maximum inhibitory concentration) range = 18.4 – 117.8nM and maximum 
inhibition of IL-6 mRNA range = 44.1  - 76.0% (Figure 4-2B, D and F).  Across the 3 
donors, the mean IC50 = 55.5nM (95% confidence interval (95% CI) = 16.7 – 94.3nM) 
and mean maximum inhibition = 61.4% (95% CI = 49.9 – 72.9%) (Figure 4-4C and E). 
Interestingly, donor 3 showed the most sensitive IL-6 and IL-8 mRNA responses to I-
BET151, IC50 = 57.6% and 64.1%, respectively, (Figure 4-2E and F) and also displayed 
the widest stimulation window (i.e. difference between the positive and negative 
controls for stimulation) for both IL-6 and IL-8 mRNA (Figure 4-2E and F).  In 
comparison, I-BET151 had the greatest maximum inhibitory effect in donor 1 for both 
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IL-6 and IL-8 mRNA responses, although this did not correlate with the stimulation 
window or basal/stimulated levels of IL-6/-8 mRNA (Figure 4-2A and B).  These 
finding could suggest donors with the greatest stimulation window could be most 
sensitive to BET inhibition, although further investigation in additional donors would be 
required to confirm this.    
I-BET151 inhibition of IL-6 protein response to TNFα + IL-17 stimulation in NHEKs 
was concentration dependent and had broadly similar activity across the seven donors; 
IC50 range = 21.1 – 80.2nM and maximum inhibition of IL-6 protein range = 85.2  - 
98.6%)  (Figure 4-3A, C, E, G, I, K and M).  Across the 7 donors, the mean IC50 = 
44.6nM (95% CI = 36.1 – 53.1nM) and mean maximum inhibition = 91.2% (95% CI = 
88.9 – 93.5%) (Figure 4-4C and Figure 4-4E). 
In contrast to the effect on IL-6 protein response, I-BET151 had a variable and weaker 
effect on IL-8 secreted protein response to TNFα + IL-17 stimulation in NHEKs (Figure 
4-3B, D, F, H, J, L, N).  Although all donors assayed demonstrated a degree of IL-8 
protein inhibition in response to I-BET151 treatment, the range of maximum IL-8 
inhibition was variable (42.0 – 89.5%).  Furthermore, only some donors (4, 5 and 8) 
showed concentration-dependent sensitivity to I-BET151.  In these donors, the activity 
of I-BET151 was more variable (IC50  range = 4.5 – 108.4 nM) compared to IL-6 
protein sensitivity (IC50  range = 21.1 – 80.2 nM) and the compound exhibited only 
partial inhibition of IL-8 protein (Figure 4-4D).  As a result of donor variability, the 
mean values of these data points for IL-8 protein, mean IC50 = 59.0nM (95% CI = 29.5 
– 88.5nM) and mean maximum inhibition = 63.3% (95% CI = 49.7 – 76.9%) were not 
representative of any one of the contributing 3 donors (Figure 4-4D and Figure 4-4E).  
The stimulation window for IL-8 protein in different donors could not account for donor 
differences in sensitivity to I-BET151.  For example while  donor 4 and donor 10 had 
broadly similar basal and stimulated levels of IL-8 secreted protein, donor 4 
demonstrated sensitivity to I-BET151 but donor 10 did not (Figure 4-3B and N).  In 
addition the variable effect of I-BET151 on IL-8 protein responses was not dependent 
on the underlying histological diagnosis of donor samples (Table 4-1).   
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Figure 4-2: I-BET151 inhibition of IL-6 and IL-8 mRNA responses to TNF + IL-
17 stimulation in keratinocytes was concentration dependent 
NHEKs were treated with increasing concentrations of I-BET151 for 1 h prior to 
stimulation with TNF (10ng/ml) + IL-17 (100ng/ml). Stimulated and mock stimulated 
cells were also pre-treated for 1h with vehicle (DMSO, 1:1200) as positive and negative 
controls for stimulation, and to determine the stimulation window (S/W).  Cells were 
harvested 6h post-stimulation and expression of IL-6 (A, C, E) and IL-8 (B, D, F) 
mRNA was determined by qRT-PCR.  Coloured lines are mean data for individual 
donors (for each graph: N=1, with each donor performed in duplicate repeat ). Best fit 
curve was fitted using 4-parameter logistic curve fit software (Graphpad Prism); 
maximum inhibition, IC50 and S/W (qRT-PCR cycle threshold (Ct) values for positive 
and negative controls for stimulation) are shown for each graph.  
+
Results expressed as 
“% inhibition of IL-6”, were calculated:  
 
“% inhibition of IL-8” calculated in a similar manner.  
134 
 
Donor 4
max. inhibition = 85.2%
IC50 = 21.1nM
S/W = 0 - 131pg/ml
-9 -8 -7 -6 -5
20
40
60
80
100
A)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-6
 p
ro
te
in
+
  
Donor 4
max. inhibition = 42.0%
IC50 = 64.0nM
S/W = 173 - 6101pg/ml
-9 -8 -7 -6 -5
-40
-20
20
40
60
80
100
B)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-8
 p
ro
te
in
+
 
Donor 5
max. inhibition = 86.0%
IC50 = 39.3nM
S/W = 16 - 131pg/ml
-9 -8 -7 -6 -5
20
40
60
80
100
C)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-6
 p
ro
te
in
+
 
Donor 5
max. inhibition = 58.5%
IC50 = 4.5nM
S/W = 0 - 821pg/ml
-9 -8 -7 -6 -5
-40
-20
20
40
60
80
100
D)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-8
 p
ro
te
in
+
 
Donor 6
max. inhibition = 91.9%
IC50 = 38.3nM
S/W = 0 - 105pg/ml
-9 -8 -7 -6 -5
20
40
60
80
100
E)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-6
 p
ro
te
in
+
 
Donor 6
max. inhibition = N/A
IC50 = N/A
S/W = 36 - 1202 pg/ml
-9 -8 -7 -6 -5
20
40
60
80
100
F)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-8
 p
ro
te
in
+
 
Donor 7
max. inhibition = 98.6%
IC50 = 22.2nM
S/W = 0 - 101pg/ml
-9 -8 -7 -6 -5
20
40
60
80
100
G)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-6
 p
ro
te
in
+
 
Donor 7
max. inhibition = N/A
IC50 = N/A
S/W = 102 - 1771 pg/ml
-9 -8 -7 -6 -5
-20
20
40
60
80
100
H)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-8
 p
ro
te
in
+
 
135 
 
Donor 8
max. inhibition = 98.3%
IC50 = 59.5nM
S/W = 8 - 545pg/ml
-9 -8 -7 -6 -5
20
40
60
80
100
I)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-6
 p
ro
te
in
+
 
Donor 8
max. inhibition = 89.5%
IC50 = 108.4nM
S/W = 151 - 9330pg/ml
-9 -8 -7 -6 -5
20
40
60
80
100
J)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-8
 p
ro
te
in
+
 
Donor 9
max. inhibition = 91.1%
IC50 = 80.2nM
S/W = 87 - 1879pg/ml
-9 -8 -7 -6 -5
20
40
60
80
100
K)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-6
 p
ro
te
in
+
 
Donor 9
max. inhibition = N/A
IC50 = N/A
S/W = 322.3 - 10035 pg/ml
-9 -8 -7 -6 -5
-20
20
40
60
80
100
L)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-8
 p
ro
te
in
+
 
Donor 10
max. inhibition = 87.3%
IC50 = 51.6nM
S/W = 4 - 89pg/ml
-9 -8 -7 -6 -5
50
100
M)
Log 10 [I-BET151, M] %
 i
n
h
ib
it
io
n
 o
f 
IL
-6
 p
ro
te
in
+
 
Donor 10
max. inhibition = N/A
IC50 = N/A
S/W = 113 - 4821 pg/ml
-9 -8 -7 -6 -5
20
40
60
80
100
N)
Log 10 [I-BET151, M]
%
 i
n
h
ib
it
io
n
 o
f 
IL
-8
 p
ro
te
in
+
 
Figure 4-3: Across donors I-BET151 had a concentration-dependent inhibitory 
effect on IL-6 protein response to TNF + IL-17 stimulation in keratinocytes, but 
donor-dependent effects on IL-8 protein response  
See Figure 4-2 for experimental details.  Media supernatants were collected 48h after 
stimulation and secreted IL-6 (A, C, E, G, I, K, M) and IL-8 (B, D, F, H, J, L, N) 
protein concentrations were measured by ELISA. Coloured lines are mean data for 
individual donors (for each graph: N=1, with each donor performed in triplicate repeat). 
Where possible, best fit curve was fitted using 4-parameter logistic curve fit software 
(Graphpad Prism); maximum inhibition, IC50 and stimulation window (S/W) (for 
negative and positive controls for stimulation, in pg/ml) are shown for each graph. 
+
Results expressed as “% inhibition of IL-6 (or IL-8)” calculated as per Figure 4-2. 
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Mean IC50, nM 
(95% confidence interval) 
Mean max. inhibition, % 
(95% confidence interval) 
IL-6 mRNA 133.6  (86.5, 180.7) 69.5  (64.2, 74.8) 
IL-6 protein 44.6  (36.1, 53.1) 91.2  (88.9, 93.5) 
IL-8 mRNA 55.5  (16.7, 94.3) 61.4  (49.9, 72.9) 
IL-8 protein 59.0  (29.5, 88.5) 63.3  (49.7, 76.9) 
Figure 4-4: I-BET151 inhibited IL-6/-8 mRNA expression and IL-8 protein release, 
with a greater maximal inhibitory effect on IL-6 protein in TNF + IL-17 
stimulated keratinocytes 
See Figure 4-2 for experimental details.  Cells were harvested 6h post-stimulation and 
expression of IL-6 (A) and IL-8 (C) mRNA was determined by qRT-PCR. Media 
supernatants were collected 48h after stimulation and secreted IL-6 (B) and IL-8 (D) 
protein concentrations were measured by ELISA.  Coloured lines are mean data for 
individual donors (Figure 4-2 and Figure 4-3), the black line is a composite curve 
derived from mean of normalised % inhibition data points across donors ± SEM; (for 
mRNA: N=3, with each donor performed in duplicate repeat; for protein: N=7, with 
each donor performed in triplicate repeat). Best fit curve was fitted using 4-parameter 
logistic curve fit software (Graphpad Prism).  The mean IC50 was calculated as the mean 
of IC50 values from individual donor curves and the mean maximum inhibition was 
calculated in a similar manner, 95% confidence interval shown in brackets (E).  
+
Results expressed as “% inhibition of IL-6 (or IL-8)”, calculated as per Figure 4-2. 
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Donor Histological diagnosis 
4 Balanitis xerotica obliterans 
5 Balanitis xerotica obliterans 
6 Balanitis xerotica obliterans 
7 Non-specific balanitis 
8 Lichenoid inflammation, consistent with early balanitis xerotica obliterans 
9 Non-specific balanitis 
10 Lichenoid inflammation, consistent with early balanitis xerotica obliterans 
 
Table 4-1: Underlying histological diagnosis of donors   
Table shows the underlying histological diagnosis of tissue samples from which 
keratinocytes were isolated, cultured and assayed in Figure 4-3. 
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4.3.3. I-BET151 inhibited total protein at high concentration, but had no 
significant effect on cellular metabolism 
Having established that I-BET151 inhibited IL-6 and IL-8 responses to TNF + IL-17 
stimulation in NHEKs, the effects of BET inhibition on cell viability were investigated 
by determining the effects of I-BET151 on cellular metabolism and total cellular 
protein.  NHEKs were incubated with I-BET151, vehicle (DMSO, 1:1200) or fresh 
media alone.  48h later, effects on cellular metabolism and total protein were measured, 
by MTT and SRB respectively. 
I-BET151 had no significant effect on cellular metabolism (Figure 4-5A) and although 
there was significant inhibition of total protein at high I-BET151 concentrations (Figure 
4-5B), the effects were relatively modest (~25% inhibition) and could not account for 
the reduction in IL-6 and IL-8 previously observed (Figure 4-4). For example, at 3M I-
BET151 had no effect on cellular metabolism (Figure 4-5A) and inhibited total protein 
by only approximately 25% (p<0.05, Figure 4-5B), but inhibited both the IL-6 secreted 
protein response to TNF + IL-17 stimulation, by approximately 90% (p<0.001, Figure 
4-4B), and the IL-8 secreted protein response, by approximately 60% (p<0.001, Figure 
4-4D).  
In subsequent chromatin immunoprecipitation-experiments, I-BET151 was used at a 
concentration of 3M; this was towards the top/plateau of concentration-response curve 
(Figure 4-4). At this concentration I-BET151 had a maximal inhibitory effect on IL-6 
and IL-8 mRNA and protein responses to TNF + IL-17 stimulation (significance 
values p<0.01 for IL-6 mRNA, p<0.001 for IL-6 protein, p<0.001 for IL-8 mRNA and 
p<0.001 for IL-8 protein responses) (Figure 4-4), without any significant effect on 
cellular metabolism and only a small inhibitory effect on total protein at 48 hours 
(Figure 4-5). 
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Figure 4-5: I-BET151 had no significant effect on keratinocyte cellular metabolism 
but at high concentration did have a small, although significant, inhibitory effect 
on total cellular protein 
NHEKs were incubated with increasing concentrations of I-BET151, vehicle (DMSO, 
1:1200) or media alone (“untreated”). 48h later, I-BET151 effects on cellular 
metabolism were measured by MTT (A) and total protein determined by SRB (B).  
(N=3, with each donor performed in triplicate repeat) Analysis was by one-way 
ANOVA with Dunnett’s post-test comparing to vehicle; *p<0.05, **p<0.01, 
***p<0.001.  Graphs show mean of data points (normalised to vehicle) ± SEM. 
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4.3.4. I-BET151 blocked transient recruitment of Brd4 and RNA polymerase II to 
the IL-6 promoter 
Having demonstrated that I-BET151 blocked TNF + IL-17 induced IL-6 expression, 
we hypothesised that i) BET proteins would be involved in regulating IL-6 transcription 
and ii) TNF + IL-17 stimulation would drive recruitment of BET proteins to the IL-6 
promoter region.   Furthermore, we hypothesised that I-BET151 would inhibit this 
recruitment, as well as the co-recruitment of RNA polymerase II (pol II (S2P)).  To 
investigate these hypotheses, chromatin immunoprecipitation (ChIP) experiments were 
undertaken to evaluate the effects of TNF + IL-17 stimulation on BET protein and pol 
II (S2P) recruitment to the promoter region of target genes, as well as the effects of I-
BET151.  TNF + IL-17 was demonstrated to enhance NF-B upstream signalling 
(section 3.3.5) and as Brd4 is known to bind p65 (Huang et al., 2009), we investigated 
whether p65 would also be recruited to the promoter region of TNF + IL-17 
responsive genes such as  IL-6 and tested whether I-BET151 would inhibit any p65 
binding.   
NHEKs were stimulated with TNF + IL-17 in the presence of I-BET151 or vehicle.  
As maximum expression of IL-6 (and IL-8) occurred at 6h post-TNF + IL-7 
stimulation (section 3.3.2), we reasoned that peak recruitment of BET, pol II (S2P) and 
p65 would occur within 6h of stimulation.  Cells were therefore harvested at 3h, 4.5h 
and 6h post-TNF + IL-7 stimulation for ChIP studies using antibodies to RNA 
polymerase II phosphorylated (and therefore activated) at its serine 2 residue (pol II 
(S2P)), Brd2, Brd3, Brd4 and p65 for selective immunoprecipitation (antibodies to 
histone-H3 and IgG were used as positive and negative controls respectively).  After 
reverse cross-linking, co-immunoprecipitated DNA was purified prior to being assayed 
by real-time PCR (qPCR) for enrichment of the IL-6 promoter region (using specifically 
designed primers directed at the IL-6 promoter region, (Qiao et al., 2013).  Enrichment 
of a particular region of DNA (e.g. IL-6 promoter) reflects the extent to which this 
region was associated with the protein of interest. 
As shown in Figure 4-6, TNF + IL-17 stimulation induced transient, recruitment of pol 
II (S2P), BET proteins and p65 to the IL-6 promoter, maximal at 4.5h post-stimulation.  
I-BET151 appeared to reduce binding of Brd2/3/4, although this inhibition was only 
significant for Brd4 (p<0.05 at 4.5h).  I-BET151 also impaired recruitment of pol II 
141 
 
(S2P) to the IL-6 promoter (p<0.05 taking all timepoints into account), consistent with 
I-BET151’s inhibition of IL-6 expression in response to TNF + IL-17 stimulation 
(Figure 4-4).  Interestingly, binding of Brd4 and p65 at the IL-6 promoter was ~35 fold 
and ~25 fold higher, respectively, than at the Il-8 promoter (Figure 4-7).  Furthermore, 
p65 binding tracked with changes in Brd4 binding at the Il-6 promoter and in addition to 
I-BET151 blocking Brd4 binding to the Il-6 promoter, there was a trend for I-BET151 
inhibiting p65 binding to the IL-6 promoter. 
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Figure 4-6:  I-BET151 blocked transient, TNF + IL-17-induced, recruitment of 
pol II (S2P) and Brd4 to the IL-6 promoter 
NHEKs were stimulated with TNF (10ng/ml) + IL-17 (100ng/ml) in the presence of I-
BET151 (3M) or vehicle (DMSO, 1:1200) and harvested at 3h, 4.5h and 6h post-
stimulation for ChIP studies using antibodies to pol II (S2P) (A), p65 (B) and BET 
proteins (C).  Quantification of co-immunoprecipitated DNA was performed by qPCR, 
using primers to the IL-6 promoter region; (N=3)  p value above each graph shows the 
overall statistical significance of I-BET151 compared to vehicle, taking into account all 
timepoints, two-way ANOVA; Bonferroni post-test, comparing I-BET151 against 
vehicle; *p<0.05, **p<0.01, ***p<0.001.   Data points show mean (after subtracting 
background/non-specific binding and normalised to an input control) ± SEM.  
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4.3.5. I-BET151 blocked transient recruitment of Brd3, Brd4 and RNA 
polymerase II to the IL-8 promoter 
Having observed that I-BET151 inhibited TNF + IL-17-induced recruitment of Brd4 
and pol II (S2P) to the IL-6 promoter (Figure 4-6) and given that I-BET151 also 
inhibited IL-8 transcription induced by TNF + IL-17 (Figure 4-4), we hypothesised 
that I-BET151 would also block recruitment of BET proteins and pol II (S2P) to the IL-
8 promoter in TNF + IL-17 stimulated keratinocytes.  After reverse cross-linking, co-
immunoprecipitated, purified DNA (samples prepared as per section 4.3.4) was assayed 
by qPCR for enrichment of the IL-8 promoter region (using specifically designed 
primers directed at the IL-8 promoter region, (Costa et al., 2013) in I-BET151 treated 
NHEKs and compared to vehicle treated cells. 
TNF + IL-17 stimulation induced, transient, recruitment of pol II (S2P) and BET 
proteins to the IL-8 promoter, maximal at 4.5h post-stimulation for Brd2/3 proteins and 
cumulative up to 6h for pol II (S2P)  (Figure 4-7).  Binding of Brd4 and pol II (S2P) to 
the IL-8 promoter appeared to be more sustained, compared to binding at the IL-6 
promoter.  Although I-BET151 appeared to block binding of Brd2/3/4, this inhibition 
was only significant for Brd3 (p<0.01 taking all timepoints into account and Bonferroni 
post-test showed this was also significant at 4.5h, p<0.01) and Brd4 (p<0.001 taking all 
timepoints into account,).  I-BET151 also inhibited recruitment of pol II (S2P) to the IL-
8 promoter (p<0.05 taking all timepoints into account, Bonferroni post-test showed this 
was also significant at 6h, p<0.01).  This was consistent with inhibition of IL-8 
expression, in response to TNF + IL-17 stimulation, by I-BET151.  I-BET151 had no 
significant effect on p65 binding at the IL-8 promoter.  
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Figure 4-7: At the IL-8 promoter, I-BET151 blocked, TNF + IL-17 induced, 
transient recruitment of pol II (S2P), Brd3 and Brd4 
NHEKs were stimulated with TNF (10ng/ml) + IL-17 (100ng/ml) in the presence of I-
BET151 (3M) or vehicle (DMSO, 1:1200) and harvested at 3h, 4.5h and 6h post-
stimulation for ChIP studies using antibodies to pol II (S2P) (A), p65 (B) and BET 
proteins (C).  Quantification of co-immunoprecipitated DNA was performed by qPCR, 
using primers to the IL-8 promoter region.    (N=3); p value above each graph shows the 
overall statistical significance of I-BET151 compared to vehicle, taking into account all 
timepoints, two-way ANOVA; Bonferroni post-test, comparing I-BET151 against 
vehicle; *p<0.05, **p<0.01, ***p<0.001.   Data points show mean (after subtracting 
background/non-specific binding and normalised to an input control) ± SEM.  
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4.3.6. I-BET151 blocked binding of BET proteins and RNA polymerase II to the 
potential IL-6 enhancer in keratinocytes 
Having observed that I-BET151 inhibited IL-6 induction by TNF + IL-17 and that I-
BET151 significantly inhibited recruitment of Brd4 and pol II (S2P) to the IL-6 
promoter, we hypothesised that I-BET151 would also block BET protein and pol ll 
(S2P) recruitment at the IL-6 enhancer.  Previously prepared co-immunoprecipitated, 
purified DNA samples (section 4.3.4) were assayed by qPCR for enrichment of a region 
previously described as an IL-6 enhancer in macrophages (using specific primers 
directed at this sequence, (Qiao et al., 2013)). 
As shown in Figure 4-8, I-BET151 inhibited binding of Brd2 (p<0.05 at 3h), Brd3 
(p<0.05 taking all timepoints into account), Brd4 (p<0.05 taking all timepoints into 
account, Bonferroni post-test showed this was significant at 4.5h, p<0.05) and pol II 
(S2P) (p<0.01 taking all timepoints into account, Bonferroni post-test showed this was 
significant at 3h, p<0.05).  In contrast, I-BET151 had no significant effect on p65 
binding at the potential IL-6 enhancer in keratinocytes.  
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Figure 4-8: At the IL-6 enhancer, I-BET151 inhibited binding of pol II (S2P), 
Brd2/3/4 
NHEKs were stimulated with TNF (10ng/ml) + IL-17 (100ng/ml) in the presence of I-
BET151 (3M) or vehicle (DMSO, 1:1200) and harvested at 3h, 4.5h and 6h post-
stimulation for ChIP studies using antibodies to pol II (S2P) (A), p65 (B) and BET 
proteins (C).  Quantification of co-immunoprecipitated DNA was performed by qPCR, 
using primers to a region previously described as an IL-6 enhancer in macrophages.    
(N=3); p value above each graph shows the overall statistical significance of I-BET151 
compared to vehicle, taking into account all timepoints, two-way ANOVA; Bonferroni 
post-test, comparing I-BET151 against vehicle; *p<0.05, **p<0.01, ***p<0.001.   Data 
points show mean (after subtracting background/non-specific binding and normalised to 
an input control) ± SEM. 
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4.3.7. I-BET151 remains active if added after TNF + IL-17 stimulation 
Having observed that I-BET151 inhibited IL-6 and IL-8 transcription in response to 
TNF + IL-17 stimulation (Figure 4-4) via reducing binding of BET proteins and pol II 
(S2P) to IL-6 and IL-8 gene regulatory regions in chromatin (Figure 4-6 and Figure 
4-7), the dynamics of BET inhibition were further investigated.   
As BET proteins and pol II (S2P) were recruited to IL-6 and IL-8 gene regulatory 
regions after stimulation with TNF + IL-17, during the phase of active chromatin 
remodelling, it was hypothesised that I-BET151 would retain activity during this phase 
of remodelling, even when added after stimulation with TNF + IL-17.  In previous 
experiments I-BET151 had been added either 1h before (Figure 4-4) or at the same time 
as TNF + IL-17 stimulation (Figure 4-6, Figure 4-7 and Figure 4-8).  The effect of 
timing of I-BET151 treatment in relation to TNF + IL-17 stimulation on IL-6 and IL-8 
mRNA and protein expression was therefore explored.  NHEKs were treated with I-
BET151 (1M) either 1h before stimulation with TNF + IL-17, at time of stimulation 
or at various times after (1, 2 or 4h after stimulation for mRNA studies and 1, 2, 4, 10 or 
24h after stimulation for protein studies).  IL-6 and IL-8 mRNA were measured, by 
qRT-PCR, at 6h after stimulation, when maximal expression of these genes was 
previously observed (section 3.3.2).  Media supernatants were collected for 
determination of secreted IL-6 and IL-8 protein concentrations, by ELISA, at 48h post-
stimulation (section 3.3.2). 
As shown in Figure 4-9, I-BET151 inhibited IL-6 mRNA production when added 
before, during or after stimulation with TNF + IL-17, this was statistically significant 
up to 2h after stimulation (p<0.01) and, interestingly,  I-BET151 appeared to have more 
effect on inhibition of IL6 mRNA when added during or after stimulation.  The effect of 
time of I-BET151 treatment on IL-6 mRNA production translated to inhibitory effects 
on secreted  IL-6 protein; where the compound still had an inhibitory effect even when 
added up to 24h after stimulation (p<0.001).  
I-BET151 also inhibited IL-8 mRNA production when added up to 2h after TNF + IL-
17 stimulation (p>0.01) (Figure 4-10).  As previously observed (Figure 4-3), the effects 
on secreted IL-8 protein were more variable; although there was a trend for inhibition 
when I-BET151 was added after stimulation, this was only significant for 10h 
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(p<0.001).  This was partly due to the variability in donor sensitivity, as shown by the 
larger error bars for effects on IL-8 protein compared to IL-6.   
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Figure 4-9: I-BET151 was pharmacologically active when added after TNF + IL-
17 stimulation 
NHEKs were treated with I-BET151 (1M) or vehicle (DMSO, 1:1200) either 1h prior 
to stimulation with TNF (10ng/ml) + IL-17 (100ng/ml), at time of stimulation or 
afterwards (at timepoints indicated below graphs).  Cells were harvested 6h post-
stimulation and IL-6 mRNA expression (A) determined by qRT-PCR.  Supernatants 
were collected 48h post-stimulation and secreted IL-6 protein (B) concentration 
measured by ELISA.  (for mRNA: N=3; for protein: N=3, with each donor performed in 
triplicate repeat)  Analysis by two-way ANOVA with Bonferroni post-test, comparing 
against the relevant DMSO (vehicle) control and time point; *p<0.05, **p<0.01, 
***p<0.001.  Graphs show mean of data points (normalised to vehicle within relevant 
timepoint) ± SEM.           
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Figure 4-10: I-BET151 was pharmacologically active when added after TNF + 
IL-17 stimulation 
NHEKs were treated with I-BET151 (1M) or vehicle (DMSO, 1:1200) either 1h prior 
to stimulation with TNF (10ng/ml) + IL-17 (100ng/ml), at time of stimulation or 
afterwards (at timepoints indicated below graphs).  Cells were harvested 6h post-
stimulation and IL-8 mRNA expression (A) determined by qRT-PCR.  Supernatants 
were collected 48h post-stimulation and secreted IL-8 protein (B) concentration 
measured by ELISA.  (for mRNA: N=3; for protein: N=3, with each donor performed in 
triplicate repeat)  Analysis by two-way ANOVA with Bonferroni post-test, comparing 
against the relevant DMSO (vehicle) control and time point; *p<0.05, **p<0.01, 
***p<0.001.  Graphs show mean of data points (normalised to vehicle within relevant 
timepoint) ± SEM.           
 
 
 
 
 
 
 
0
50
100
150
Vehicle
I-BET151
TNF + IL-17 stimulated
R
e
la
ti
v
e
 I
L
-8
 m
R
N
A
e
x
p
re
s
s
io
n
(n
o
rm
a
li
s
e
d
 t
o
 v
e
h
ic
le
)
Timing of Vehicle/I-BET151
relative to stimulation
1h
before
At time
of
1h
after
2h
after
4h
after
ns * *** * ns
A)
0
25
50
75
100
125
TNF + IL-17 stimulated
1h
before
At time
of
1h
after
2h
after
4h
after
10h
after
24h
after
**** nsnsnsnsns
IL
-8
 p
ro
te
in
(n
o
rm
a
li
s
e
d
 t
o
 v
e
h
ic
le
)
x
x
B)
Timing of Vehicle/I-BET151
relative to stimulation
Vehicle
I-BET151
151 
 
 
4.4. Discussion 
In this chapter the effects of a specific BET inhibitor, I-BET151, on keratinocyte pro-
inflammatory responses were investigated.  I-BET151 treatment inhibited expression of 
IL-6 and IL-8 genes as well as secretion of IL-6 and IL-8 protein in response to TNF + 
IL-17 stimulation. These effects could not be attributed to relatively minor effects of I-
BET151 on cellular metabolism or total protein.  These data indicate for the first time 
that BET proteins are involved in regulating expression of pro-inflammatory genes in 
keratinocytes and notably, in an in vitro model of cutaneous inflammation relevant to 
psoriasis, we demonstrated that BET proteins were transiently recruited to the promoter 
region of pro-inflammatory genes in response to stimuli directly relevant to disease.  
Furthermore inhibition of IL-6 and IL-8 mRNA induction could be explained by the 
reduction in recruitment of BET proteins and pol II (S2P) to the promoter region of 
these genes in the presence of I-BET151.  These novel findings suggest BET proteins 
are involved in the regulation of genes relevant to psoriasis in keratinocytes and that 
BET proteins could represent novel targets for psoriasis treatment.   
I-BET151 inhibited both IL-6 and IL-8 mRNA expression in TNF + IL-17 stimulated 
NHEKs with statistically similar IC50 and maximum effects.  I-BET151 also inhibited 
IL-6 and IL-8 secreted protein responses with statistically similar potency, IC50 = 
44.6nM (95% CI 36.1 – 53.1) and 59.0nM (95% CI 29.5 – 88.5) for IL-6 and IL-8, 
respectively, in I-BET151 sensitive-donors.  Inhibition of IL-6 inflammatory response 
by I-BET151 has previously been described; in lipopolysaccharide (LPS)-stimulated 
peripheral blood mononuclear cells, I-BET151 inhibited IL-6 secreted protein response, 
with an IC50 = 160nM (Dawson et al., 2011). These findings demonstrate IL-6 secreted 
protein response to TNF + IL-17 stimulation in NHEKs, was more sensitive to I-
BET151 treatment than IL-6 secreted protein response to LPS stimulation in peripheral 
blood mononuclear cells or human whole blood.  Differential sensitivity to I-BET151 
could suggest that, while BET proteins are likely to be involved in the inflammatory 
response in a variety of cell types, they may play in different roles different cell types or 
in response to different stimuli.   
TNF + IL-17 stimulated transient recruitment of Brd2/3/4 proteins as well as pol II 
(S2P) to the promoter region of both IL-6 and IL-8; this is in keeping with the positive 
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effects of TNF + IL-17 stimulation on IL-6 and IL-8 expression (section 3.3.2).  This 
was also consistent with previously published data which showed that Brd2/3/4 proteins 
are recruited to the IL-6 gene promoter after LPS stimulation (Nicodeme et al., 2010).  
In addition Brd4 was previously shown to be recruited to the IL-8 promoter in airway 
smooth muscle cells stimulated with fetal calf serum (FCS) + transforming growth 
factor-beta (TGF-); recruitment of Brd2/3 was not investigated in this model (Perry et 
al., 2015).  In TNF + IL-17 stimulated NHEKs, there appeared to be ~35 fold greater 
enrichment of Brd4 to the IL-6 promoter compared to the IL-8 promoter (~3% input and 
~0.08% input respectively), whereas the IL-8 promoter demonstrated relatively greater 
enrichment of Brd3 (~1% input compared to ~0.03% input at the IL-6 promoter).  
Although it is difficult to make direct comparisons about enrichment of different 
epitopes, as enrichment will be influenced by antibody affinity to the target protein, 
these results suggest differential regulatory roles of Brd2/3/4 for different genes in 
keratinocytes.  These findings are supported by findings in LPS-stimulated 
macrophages, where enrichment of Brd2 at the TNF promoter was approximately 
twice that at the IL-6 promoter (~0.16% and ~0.09% respectively); in comparison 
enrichment of Brd3 at the TNF promoter was 20-times that at the IL-6 promoter 
(~0.4% and ~7%,  respectively) (Nicodeme et al., 2010).   
I-BET151 treatment of TNF + IL-17 stimulated NHEKs, significantly inhibited the 
recruitment of Brd4 and pol II (S2P) to the IL-6 promoter and although there were 
trends for blocking Brd2/3 binding at all timepoints assayed these effects were not 
significant.  At the IL-8 promoter, I-BET151 significantly inhibited binding of Brd3 and 
Brd4 as wells as pol II (S2P), with a non-significant trend for inhibiting Brd2 binding at 
all timepoints assayed.  Similar to our findings in keratinocytes, in LPS stimulated 
macrophages, treatment with a BET inhibitor I-BET762 which is structurally distinct 
from I-BET151, significantly inhibited binding of Brd3, Brd4 and pol II (S2P) to the IL-
6 promoter, but not Brd2 (Nicodeme et al., 2010).  In FCS + TGF- stimulated ASM 
cells with JQ1 (a third BET inhibitor, widely used in research as a preclinical tool 
compound) blocked recruitment of Brd4 to the IL-8 promoter (Perry et al., 2015).  
Although I-BET151 targets Brd2,3,4, the affinities of I-BET151 for Brd2, Brd3 and 
Brd4 differ as determined by ligand displacement assays (Dawson et al., 2011), together 
these results support the hypothesis that BET proteins have different regulatory 
functions for different genes, which are likely to be context dependent (on both stimulus 
and cell type) and could suggest that in keratinocytes Brd4 plays a relatively more 
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important role in regulation of IL-6; whereas at the IL-8 promoter, both Brd3 and Brd4 
play important roles.  It would be interesting to understand if disease states may 
differentially affect recruitment of BET proteins in keratinocytes, as previously 
demonstrated in ASM cells derived from asthmatic and non-asthmatic donors, and 
therefore whether these might represent novel targets for therapy (Perry et al., 2015).   
Tracking with the greater enrichment of Brd4 at the IL-6 promoter, compared to the IL-
8 promoter, there was also greater enrichment of p65 at the IL-6 promoter.  
Furthermore, changes in p65 binding tracked with changes in Brd4 binding to the IL-6 
promoter and I-BET151 inhibited both Brd4 and p65 binding to the IL-6 promoter, 
although this was only a trend for p65.  These findings are consistent with Brd4 being a 
co-factor for p65 binding (Huang et al., 2009); the tandem bromodomains of Brd4 have 
previously been shown to have co-operative effects on binding to acetylalted-lysine-310 
of p65, this in turn leads to the Brd4 induced activation of cyclin dependent kinase 9, 
leading to the phosphorylation and activation of RNA polymerase II which ultimately 
drives transcription (Huang et al., 2009).  As I-BET151 did not block total p65 binding 
to the IL-6 or IL-8 promoter, it may be informative to perform ChIP studies with a 
specific antibody against acetylalted-lysine-310 of p65, although this may be difficult to 
detect if levels are very low.  The differential enrichment of Brd4/p65 and Brd3 at IL-6 
and IL-8 promoters supports the suggestion that IL-6 and IL-8 are differentially 
regulated and the relatively greater enrichment of Brd4/p65 at the IL-6 promoter could 
suggest the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) 
signalling pathway plays a relatively greater role in regulating IL-6 expression 
compared to IL-8 expression.  In support of this, as previously discussed (section 3.4) in 
Jurkat T cells IL-6 expression was closely associated with the activation pattern of NK-
kB, whereas IL-8 expression was more closely associated with the activation pattern of 
nuclear factor of activated T cells (NFAT) (Khalaf et al., 2013).  Our finding that, in 
NHEKs stimulated with TNF + IL-17, ciclosporin had a greater inhibitory effect on 
IL-8 induction compared to IL-6 (section 0), could be in keeping with Khalaf et al.’s 
findings.  It would be interesting to understand, in further ChIP studies of TNF + IL-
18 NHEKs, whether NFAT shows greater enrichment at the IL-8 promoter than at the 
IL-6 promoter. 
The second tandem bromodomain (BD2) of Brd4 is known to bind and direct 
recruitment of a kinase, positive transcription elongation factor b (pTEFb), to RNA 
polymerase II, thus regulating RNA polymerase II-dependent transcriptional elongation, 
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(Jang et al., 2005; Schroder et al., 2012), this may represent an additional mechanism 
through which BET proteins regulate IL-6 and IL-8 responses in keratinocytes.  
Therefore, in addition to I-BET151 inhibiting BET binding to regulatory regions of 
TNF + IL-17-responsive genes in NHEKs, I-BET151 may also act through additional 
mechanisms including disrupting Brd4 binding to acetyl-p65 as well as pTEFb. 
Interestingly, I-BET151 had a more potent  and sensitive effect on IL-6 secreted protein 
compared to its effect on mRNA expression (maximal inhibition of IL-6 protein = 
91.2% (95% CI = 88.9 – 93.5) and IC50 = 44.6nM (95% CI = 36.1 – 53.1) compared to 
maximal inhibition of IL-6 mRNA expression = 69.5% (95% CI = 64.2 – 74.8) and IC50 
= 133.6nM (95% CI = 86.5 – 180.7), whereas I-BET151 had statistically similar effects 
on IL-8 mRNA and protein responses to TNF + IL-17 stimulation, in I-BET151 
sensitive donors (Figure 6-4E).  For the first time, our results demonstrate differential 
effects of I-BET151 on IL-6 mRNA vs. secreted protein and suggest BET inhibition 
may have post-transcriptional effects.  These effects could be through I-BET151 i) 
inhibiting the function of proteins/molecules with post-transcriptional roles e.g. mRNA 
translation or protein trafficking, or ii) inhibiting expression of these proteins/molecules 
(section 6.3.3).  An increased inhibitory effect on protein compared to mRNA has 
previously been observed in compounds targeting regulators of the epigenome.  In a 
model of rheumatoid arthritis trichostatin A (TSA), an histone deacetylase (HDAC) 
inhibitor (HDACi) blocked IL-6 induction by IL-1 in fibroblast-like synoviocytes 
(Grabiec et al., 2012).  Grabiec et al. demonstrated that 1M TSA had a greater 
inhibitory effect on secreted IL-6 protein (over 80% inhibition) compared to the effect 
on IL-6 mRNA (70% inhibition) and it was demonstrated that treatment with TSA (or 
ITF2357, an HDACi) lead to accelerated decay in IL-6 mRNA (Grabiec et al., 2012).  
Grabiec et al. also observed this effect in LPS stimulated monocyte-derived 
macrophages, suggesting accelerated IL-6 mRNA decay could be a common 
mechanism by which IL-6 translation is suppressed by HDAC inhibition and may 
explain the differential effects of HDAC inhibition (and potentially BET inhibition) 
observed on IL-6 mRNA vs. protein responses.  Grabiec et al. hypothesised HDACi 
might modulate the expression of specific microRNAs, which are known to regulate 
mRNA stability, although no specific microRNAs for IL-6 have yet been identified.  
Additionally, Grabiec et al. hypothesised that HDACs might associate with proteins 
involved in selective regulation of IL-6 mRNA stability; Zc3h12 RNAse is known to 
both associate with HDACs and regulate IL-6 mRNA stability (Matsushita et al., 2009).  
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Interestingly it has previously been shown that BET inhibitors and HDAC inhibitors 
both modulate similar genes, with similar overall biological effects and can have 
synergistic effects when assayed in combination (Bhadury et al., 2014; Heinemann et 
al., 2015), therefore there may be shared mechanisms between HDAC inhibitors and I-
BET151 to explain the differential effects of I-BET151 on IL-6 mRNA versus protein. 
Of note, Grabiec at al., reported that their preliminary data suggested HDAC inhibition 
had no effect on IL-8 mRNA stability (Grabiec et al., 2012).   Interestingly, although I-
BET151 had donor-dependent effects on IL-8 protein responses to TNF + IL-17 
stimulation, in I-BET151-responsive donors the effects of I-BET151 on IL-8 mRNA vs. 
protein were more consistent, compared to effects on IL-6;  maximal inhibition of IL-8 
protein = 63.3% and IC50 = 59.0nM compared to maximal inhibition of IL-8 mRNA 
expression = 61.4% and IC50 = 55.5nM.  This could suggest that, unlike the effects on 
IL-6, I-BET151 did not have post-transcriptional regulatory effects on IL-8 mRNA and 
further supports the suggestion that BET and HDAC inhibitors have similar biological 
effects (Grabiec et al., 2012).       
In NHEKs stimulated with TNF + IL-17, it was demonstrated that BET inhibition had 
a consistent effect on IL-6 secreted protein responses across donors, but a more variable 
effect on secreted IL-8.  Some donors showed little IL-8 sensitivity to low 
concentrations of I-BET151, and robust I-BET151 concentration vs. IL-8 protein 
responses could not be generated in these donors.  Even in donors that demonstrated IL-
8 sensitivity to I-BET151, their I-BET151 concentration vs. IL-8 protein responses 
showed considerable donor variability.  A similar observation has been described in 
airway smooth muscle cells (ASM) stimulated with FCS + TGF- in the presence of the 
BET inhibitor, JQ1, which showed donor-dependent effects on secreted IL-8 protein but 
more consistent effects on secreted IL-6 protein across donors (Perry et al., 2015).  For 
example, 10nM JQ1 consistently inhibited secreted IL-6 protein by ~10-15% across 
different groups of donors but inhibited secreted IL-8 protein by ~40% healthy controls, 
~25% in the non-severe asthma group and appeared to enhance IL-8 release by ~15% in 
the severe asthma group (Perry et al., 2015).  In the severe asthma group a JQ1 
concentration of 300nM was required to inhibit secreted IL-8 protein by ~40% (Perry et 
al., 2015).  Interestingly, ASM from asthmatics demonstrated greater basal expression 
of IL-6 and IL-8 compared to healthy controls and in keeping with this observation, 
Perry et al. reported greater enrichment of Brd4 at IL-6 and IL-8 promoters in ASM 
from asthmatic patients compared to healthy controls.  Furthermore ASM from severe 
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asthmatics demonstrated greater IL-6 and IL-8 responses to stimulation with increased 
enrichment of Brd4 to the IL-8 (but not IL-6) promoter, compared to ASM from non-
severe asthmatics, although this difference was a trend and not significant.  Perry et al. 
hypothesised that increased basal recruitment of Brd4 to the IL-8 promoter in severe 
asthmatics could explain the reduced sensitivity and variability of IL-8 responses (but 
not IL-6 responses) to BET inhibition.   
In order to understand if similar findings could explain donor-dependent IL-8 responses 
to I-BET151 treatment in NHEKs, the underlying histological diagnosis of donor 
samples were investigated, but no correlation between severity of underlying 
inflammation  (as determined by histological analysis of donor samples) and NHEKs 
IL-8 sensitivity to I-BET151 could be demonstrated (Figure 4-3 and Table 4-1).  
However, the underlying histological diagnosis of donors may need to be interpreted 
with caution, as typically a macroscopically diseased portion of a sample would be sent 
for histological diagnosis and the remainder of the sample would be donated, with 
patient consent, for research.  Therefore the histological diagnosis of the 
macroscopically diseased portion of a sample might not necessarily reflect pathology, if 
any, present in the portion donated for research and used in these experiments.  It may 
have been informative to perform ChIP studies in NHEKs whose IL-8 response was 
relatively insensitive to I-BET151 treatment, to understand if TNF + IL-17 stimulation 
lead to greater enrichment of BET proteins to the IL-8 promoter compared to NHEKs 
which were more sensitive I-BET151 treatment.   
On the basis of our findings, it can be concluded that TNF + IL-17 stimulation results 
in chromatin remodelling, facilitating histone hyperacetylation and thus transient 
recruitment of BET protein to the promoter region of response genes.  We hypothesised 
that I-BET151 would demonstrate inhibition of IL-6 and IL-8 expression when added 
after stimulation with TNF + IL-17, during the phase of active chromatin remodelling.  
Indeed I-BET151 inhibited IL-6 and IL-8 mRNA expression when added up to 4h after 
TNF + IL-17 stimulation, consistent with the observation that maximal recruitment of 
BET proteins to IL-6 and IL-8 promoters occurred at ~4.5h post-stimulation.  
Interestingly, I-BET151 had a greater inhibitory effect on both IL-6 and IL-8 
transcription when added at time of stimulation, compared to addition 1h before 
stimulation, and the most significant inhibition was observed when I-BET151 was 
added 1h after stimulation.  It is uncertain why this phenomenon was observed but we 
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postulate that in unstimulated cells where there was low IL-6 and IL-8 expression, 
chromatin associated with these promoters would be in a “closed”/inactive state 
(heterochromatin) with little accessibility for BET protein binding.  Therefore when I-
BET151 is added before stimulation, the compound may be sequestered to promoters of 
other actively transcribed genes (where BET proteins are bound) which could limit the 
availability of compound when cells are later stimulated, with TNF + IL-17.   
However if I-BET151 is added at time of or after stimulation, during the phase of 
chromatin remodelling, chromatin associated with IL-6 and IL-8 promoters will be 
expected to rapidly become “open”/active (euchromatin) facilitating binding of BET 
proteins, and I-BET151 might be expected to have most access to actively transcribed 
genes (e.g. IL-6 and IL-8). Therefore addition of compound at time of stimulation or 
shortly afterwards may be expected to have most effect on TNF + IL-17-sensitive 
genes. As it was observed that BET recruitment was maximal 4.5h after TNF + IL-17 
stimulation, it is unlikely that inhibition of IL-6 and IL-8 protein responses, by I-
BET151 added at 10h or 24h after stimulation, would be through inhibiting BET 
binding to IL-6 and IL-8 promoters.  Potential post-transcriptional effects of BET 
inhibition are discussed in sections 6.3.3 and 6.4, and it is perhaps more likely that it is 
through these mechanisms predominate when I-BET151 was added 10h or 24h after 
stimulation.  Interestingly addition of I-BET151 1h before TNF + IL-17 stimulation 
had no significant effect on IL-8 mRNA response in these donors (Figure 4-10), in 
contrast to the significant effects in other donors (Figure 4-2) and the effects on IL-8 
protein response were variable; these findings further confirm that I-BET151 has donor-
dependent effects on IL-8 response to TNF + IL-17 stimulation.  As discussed in 
section 4.3.2, maximal effects and sensitivities to I-BET151 in different donors were not 
clearly related to the stimulation window or to the underlying histological diagnosis in 
donor tissue. 
In NHEKs stimulated with TNF + IL-17, I-BET15 blocked binding of Brd2/3/4 as 
well as pol II (S2P) to a region previously defined as an IL-6 enhancer in macrophages 
(Qiao et al., 2013).  However, as discussed in sections 5.3.3 and 5.4, the epigenetic 
modifications (induced by TNF + IL-17 stimulation) at this region suggest it does not 
function as an IL-6 enhancer in keratinocytes.  In addition to enhancer regions being 
characterised by high levels H3K27ac and H3K4me1 (with a high ratio of H3K4me1 to 
H3K4me3), DNAseI hypersensitivity, binding of co-activators, transcription factors and 
RNA polymerase II when enhancers are in their active state (Calo and Wysocka, 2013) 
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(section 1.3.4), a further characteristic of enhancers, especially “super enhancers”, can 
be the relatively greater enrichment Brd4 (Brown et al., 2014).  Brown et al. 
demonstrated that in human endothelial cells activation via the NF-B pathway by 
TNF stimulation, resulted in increased co-localisation of p65 and Brd4 to 
inflammatory gene promoters as well as H3K27ac-enriched de-novo inflammatory 
enhancers (Brown et al., 2014).  However results in TNF + IL-17 stimulated NHEKs 
demonstrated ~6 fold lower enrichment of Brd4 at the region previous described as an 
IL-6 enhancer in macrophages compared to the IL-6 promoter and p65 enrichment at 
these two regions was broadly comparable.  The relatively poor enrichment of Brd4 and 
p65 together with the lack of enrichment of H3K27ac and H3K4me1 after TNF + Il-17 
stimulation (section 5.3.3), suggest that the region identified as an IL-6 enhancer in 
macrophages does not have the same function in keratinocytes and supports the view 
that enhancer regions are cell-type specific (Heinz et al., 2015).  As this region does not 
appear to function as an IL-6 enhancer in keratinocytes and its function has not been 
defined, it is unclear what the functional relevance of BET recruitment to this region is 
or what the consequences of inhibiting BET protein binding are. 
4.5. Future work 
In summary stimulation of NHEKs with TNF + IL-17 demonstrated BET epigenetic 
reader proteins are recruited to the promoter region of pro-inflammatory genes in 
response to stimuli relevant to the pathogenesis of psoriasis.  Furthermore, using BET 
inhibitor I-BET151 as a pharmacological tool to further understand the relevance of 
BET proteins in regulating expression of pro-inflammatory genes in keratinocytes, we 
showed that  BET bromodomains are involved in mediating the inflammatory cytokine 
responses, confirming the suggestion that BET proteins could represent novel targets in 
the treatment of psoriasis (Nadeem et al., 2015).  Importantly we showed that inhibition 
of IL-6 and IL-8 responses by I-BET151 can be attributed to the blockade of BET 
protein and pol II (S2P) recruitment to hyperacetylated IL-6 and IL-8 promoters 
respectively, demonstrating the tractability of targeting this epigenetic process. 
Additionally I-BET151 profoundly blocked IL-6 protein release suggesting that the 
compound may also modulate post-transcriptional mechanisms to impair protein 
synthesis and or secretory functions. 
A number of key questions remain: 
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 Which proteins/molecules are targeted by I-BET151 to account for the 
differential effects on IL-6 mRNA vs. protein response to TNF + IL-17 
stimulation and which other responses are affected? (section 6.3.3) 
 What factors are responsible for donor-dependent IL-8 protein sensitivity to I-
BET151, which other responses demonstrate this variability and how are these 
relevant to psoriasis? 
 In addition to inhibiting recruitment of BET proteins to regulatory regions of I-
BET151-senstitive genes, does I-BET151 mediate the effects through any 
additional mechanisms e.g. inhibiting Brd4 binding to acetyl-p65 or pTEFb for 
example? 
 In the NHEKs model of cutaneous inflammation, apart from IL-6 and IL-8, 
which other genes are regulated by TNF + IL-17 stimulation, how are these 
relevant to psoriasis, are they regulated by BET proteins and can their 
expression be modulated by BET inhibitors? (section 6.3) 
4.6. Conclusions 
 TNF + IL-17 stimulated transient differential recruitment of BET proteins to 
IL-6 and IL-8 promoter regions with relatively greater enrichment of Brd4 to the 
IL-6 promoter and relatively greater enrichment of Brd3 to the IL-8 promoter.  
 Inhibition of cytokine responses by I-BET151 could not be accounted for by its 
negative effects on cellular metabolism or total protein alone. 
 ChIP studies demonstrated that I-BET151 blocked Brd4 and pol II (S2P) 
recruitment to the IL-6 promoter, and blocked recruitment of both Brd3/4 and 
pol II (S2P) to the IL-8 promoter.  These findings link BET proteins to pol II 
recruitment in keratinocytes and support the hypothesis that BET inhibitors 
mediate their effects on gene transcription through inhibiting binding of BET 
proteins to gene regulatory regions.  These data also support the hypothesis that 
distinct BET proteins regulate expression of IL-6 and IL-8 in TNF + IL-17 
stimulated NHEKs. 
 There was greater enrichment of p65 at the IL-6 promoter, than at the IL-8 
promoter, and p65 tracked with changes in Brd4 binding at the IL-6 promoter 
and, in addition to I-BET151 blocking Brd4 binding to the Il-6 promoter, there 
was a trend for I-BET151 inhibiting p65 binding to the IL-6 promoter.  Together 
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these findings suggest Brd4/p65 make play a relatively greater role in regulating 
expression of IL-6 compared to IL-8. 
 I-BET151 had donor dependent effects on secreted IL-8 responses to TNF + 
IL-17 stimulation and a differential effect on IL-6 mRNA versus secreted 
protein responses to TNF + IL-17 stimulation, suggesting that BET inhibition 
has post-transcriptional effects.  This could be through functional inhibition of 
proteins involved in e.g. mRNA translation/stability or cytokine secretion or, 
alternatively, through inhibiting expression of these proteins. (section 6.3.3)   
 I-BET151 was able to inhibit expression of IL-6 and IL-8 when added after 
TNF + IL-17 stimulation, consistent with chromatin remodelling taking place 
after stimulation.  
 The lack of enrichment of Brd4 and p65  to the IL-6 enhancer defined previously 
in macrophages (Qiao et al., 2013) suggests this region does not perform the 
same function in keratinocytes, supporting the general consensus that enhancer 
functions are cell-type specific. 
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5. Epigenetic regulation in the in vitro model of cutaneous inflammation 
5.1. Introduction 
It is increasingly evident that alterations in the epigenome play an important role in 
regulating inflammatory skin conditions.  As discussed fully in section 1.3.5, 
differential DNA methylation and histone modifications have been associated with 
psoriasis and some epigenetic modifications were shown to correlate with disease 
severity and treatment response (Zhang et al., 2011a; Roberson et al., 2012; Trowbridge 
and Pittelkow, 2014).  
In sections 4.3.3 and 4.3.4, it was demonstrated that stimulation of normal human 
epidermal keratinocytes (NHEKs) with TNF + IL-17A (IL-17) resulted in transient 
recruitment of BET proteins and RNA polymerase II to IL-6 and IL-8 promoters, which 
corresponded to increased expression of these genes.  Furthermore IL-6 and IL-8 
mRNA responses to TNF + IL-17 stimulation were sensitive to a BET inhibitor, I-
BET151, and these findings could be accounted for by the observation that I-BET151 
blocked recruitment of BET proteins and RNA polymerase II to IL-6 and IL-8 
promoters.  As BET proteins are known to bind acetylated lysine residues, this raised 
the hypothesis that histone modifications, including acetylation, plays a role in 
regulating inflammatory responses in keratinocytes.   
Acetylation of lysine residues on histones is considered a permissive histone 
modification, which generally signifies actively transcribed genes; the change from 
H3K27 tri-methylation (H3K27me3) to acetylation (H3K27ac) is an important switch 
from gene repression to transcriptional activation (Pasini et al., 2010).  In general our 
understanding of the effects of different histone modifications is limited, although some 
epitopes have very well defined functions.   For example, acetylation of the lysine 9 or 
lysine 27 residue on histone-H3 (H3K9ac and H3K27ac) is associated with an active 
promoter in >95% of cases (Ernst et al., 2011).  Interestingly the level of methylation at 
a particular residue affects its function: mono-methylation of the lysine 4 of histone-H3 
(H3K4me1) is associated with an active promoter in only 17% of cases, whereas tri-
methylation (H3K4me3) is associated with an active promoter in 99% of cases (Ernst et 
al., 2011).  
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To further understand the role of histone modifications in the regulation of the psoriasis 
phenotype histone modifications, including lysine acetylation, at regulatory regions of 
key effector genes were evaluated in NHEKs stimulated with TNF + IL-17. 
5.2. Aims 
 To use the in vitro keratinocyte model of cutaneous inflammation to understand 
the role of histone modifications, including acetylation of lysine residues on 
histones, in regulating expression of inflammatory genes relevant to psoriasis. 
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5.3. Results 
5.3.1. TNF + IL-17 stimulation induced RNA polymerase II recruitment, global 
histone acetylation and hyperacetylation of specific lysine residues associated 
with active gene expression at the IL-6 promoter  
Having observed that stimulation of NHEKs with TNF + IL-17 increased IL-6 mRNA 
expression and resulted in a transient increase in BET protein and RNA polymerase II 
recruitment to the IL-6 promoter (section 4.3.4), we hypothesised that stimulation 
would lead to chromatin remodelling.  Specifically, we hypothesised a mechanism 
involving hyperacetylation of lysine residues on histones and recruitment of RNA 
polymerase II (RNA pol II); thus promoting IL-6 expression.  To test this hypothesis 
chromatin immunoprecipitation (ChIP) studies were undertaken to investigate the effect 
of TNF + IL-17 on defined histone modifications and RNA pol II recruitment.  As 
expression of IL-6 mRNA was maximal at 6h after TNF + IL-17 stimulation, we 
reasoned that any chromatin remodelling and epigenetic changes would precede 
maximal transcription.  NHEKs were therefore harvested at 1h and 4h post-TNF + IL-
17 stimulation for the ChIP experiments.  The following ChIP assays were conducted 
using antibodies directed to:  
 RNA polymerase II, phosphorylated (and therefore activated) at its serine 2 
residue (pol II (S2P)) 
 epigenetic epitopes known to positively regulate gene expression (global 
acetylation of histone H3, acetyl-H3; acetylation of the lysine 9 residue on 
histone H3, H3K9ac; acetylation of the lysine 27 residue on histone H3, 
H3K27ac; and tri-methylation of the lysine 4 residue on histone H3, H3K4me3) 
 an epigenetic epitope known to have repressive effects on gene expression 
(mono-methylation of the lysine 4 residue on histone H3, H3K4me1)    
 IgG was used as a negative control and anti-pan H3 a positive control 
 ChIP studies were also performed using an antibody to tri-methylation of the 
lysine 27 residue on histone H3 but the data are not shown as the manufacturer 
(Abcam, Cambridge, UK) subsequently advised the antibody was not specific 
(with cross-reactivity to H3K4me3 and H3K9me3 as determined by western blot 
and ELISA), therefore the results were not interpretable. 
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Co-immunoprecipitated DNA was purified as described in methods section (section 
2.9.6) prior to being assayed by qPCR for enrichment of the IL-6 promoter region 
(using specifically designed primers, (Qiao et al., 2013) in TNF + IL-17 stimulated 
NHEKs compared to unstimulated NHEKs.  Enrichment of a particular region of DNA 
(e.g. IL-6 promoter) reflects the extent to which this region was associated with the 
histone modification or protein of interest. 
As shown in Figure 5-1, TNF + IL-17 stimulation resulted in a time-dependent 
increase in pol II (S2P) recruitment to the IL-6 promoter (p<0.05 at 4h).  Furthermore, 
and consistent with the positive effects of TNF + IL-17 on IL-6 expression, there was 
a corresponding increase in global H3 acetylation (p<0.05 at 4h), as well as 
hyperacetylation of specific lysine residues on histone H3 known to positively regulate 
gene expression; H3K9ac (p<0.01 at 4h) and H3K27ac (p<0.05 at 4h).  Although there 
was a trend for an increase in H3K4me3, this was not significant.  In contrast, there was 
no significant increase in the repressive mark H3K4me1 at the IL-6 promoter, again this 
was entirely in keeping with the positive effects of TNF + IL-17 on IL-6 expression. 
  
166 
 
pol II (S2P)
UnStim 1h 4h
0.00
0.05
0.10
0.15
0.20
*
ns
TNF + IL-17
A)
%
 I
n
p
u
t
      
Acetyl-H3
UnStim 1h 4h
0
1
2
3 *
ns
TNF + IL-17
B)
%
 I
n
p
u
t
  
H3K9ac
UnStim 1h 4h
0
1
2
3
4
5 **
ns
TNF + IL-17
%
 I
n
p
u
t
 
 
H3K27ac
UnStim 1h 4h
0
10
20
30
40
*
ns
TNF + IL-17
%
 I
n
p
u
t
 
H3K4me3
UnStim 1h 4h
0
10
20
30
40
ns
ns
TNF + IL-17
%
 I
n
p
u
t
 
 
H3K4me1
UnStim 1h 4h
0
2
4
6
8
10 ns
ns
TNF + IL-17
C)
%
 I
n
p
u
t
   
Figure 5-1: At the IL-6 promoter, TNF + IL-17 stimulation increased active 
epigenetic epitopes and pol II (S2P) recruitment 
NHEKs were stimulated with or without TNF (10ng/ml) + IL-17 (100ng/ml) and 
harvested at 1h and 4h post-stimulation for ChIP studies using antibodies to pol II (S2P) 
(A), epigenetic epitopes that positively regulate gene expression, highlighted in green 
(B) and epigenetic epitopes with repressive effects on gene expression, highlighted in 
red (C).  Quantification of co-immunoprecipitated DNA was performed by qPCR, using 
primers to the IL-6 promoter region.    (N=3)  Analysis by one-way ANOVA with 
Dunnett’s post-test, comparing against the unstimulated media control; *p<0.05, 
**
p<0.01, 
***
p<0.001.  Data points show mean (after subtracting background/non-
specific binding and normalised to an input control) ± SEM. 
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5.3.2. At the IL-8 promoter, TNF + IL-17 stimulation induced RNA polymerase 
II recruitment, global histone hyperacetylation and acetylation of specific 
lysine residues associated with active gene expression  
As TNF + IL-17 increased both IL-6 and IL-8 mRNA expression in NHEKs, we 
hypothesised that, similar to the effects at the IL-6 promoter, TNF + IL-17 stimulation 
would also result in chromatin remodelling and enhance pol II (S2P) recruitment to the 
IL-8 promoter, thus promoting IL-8 expression.  As with IL-6, maximal expression of 
IL-8 mRNA occurred at 6h post-TNF + IL-17 stimulation, therefore NHEKs were 
harvested at 1 and 4h after stimulation with TNF + IL-17 for ChIP experiments. 
Co-immunoprecipitated, purified DNA (samples prepared as per section 5.3.1) were 
assayed by qPCR for enrichment of the IL-8 promoter region using specifically 
designed primers (Costa et al., 2013) in TNF + IL-17 stimulated NHEKs compared to 
unstimulated NHEKs. 
As shown in Figure 5-2, TNF + IL-17 stimulation resulted in a time-dependent and 
transient increase in pol II (S2P) recruitment to the IL-8 promoter (p<0.05 at 1h).  
Similar to the effects at the IL-6 promoter, at the IL-8 promoter, TNF + IL-17 
stimulation resulted in increased global H3 acetylation (p<0.05 at 1h) and H3K27ac 
(p<0.01 at 1h).  There were also trends for increases in other active marks, H3K9ac and 
H3K4me3, although these were not significant.  Post-test analysis for linear trend 
showed the increase in H3K9ac enrichment was not significant.  Interestingly pol II 
(S2P) recruitment was maximal at 1h for IL-8 but cumulative up to 4h for IL-6.  
Furthermore the changes in pol II (S2P) recruitment tracked the general changes in 
active marks at the IL-6 and IL-8 promoter.  There was also greater enrichment of pol II 
(S2P) at the IL-8 promoter than at the IL-6 promoter in both unstimulated and TNF + 
IL-17 stimulated NHEKs.    There were no significant changes in the repressive mark 
H3K4me1 at the IL-8 promoter with TNF + IL-17 stimulation.  These findings were 
consistent with the positive effects of TNF + IL-17 on IL-8 expression.  Of note the 
enrichment of acetyl-H3 and H3K9ac was approximately 5-10 fold lower at the IL-8 
promoter than for the IL-6 promoter, suggesting these genes are differentially regulated. 
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Figure 5-2: At the IL-8 promoter, TNF + IL-17 stimulation increased active 
epigenetic epitopes and pol II (S2P) recruitment 
NHEKs were stimulated with or without TNF (10ng/ml) + IL-17 (100ng/ml) and 
harvested at 1h and 4h post-stimulation for ChIP studies using antibodies to pol II (S2P) 
(A), epigenetic epitopes that positively regulate gene expression, highlighted in green 
(B) and epigenetic epitopes with repressive effects on gene expression, highlighted in 
red (C).  Quantification of co-immunoprecipitated DNA was performed by qPCR, using 
primers to the IL-8 promoter region.    (N=3)  Analysis by one-way ANOVA with 
Dunnett’s post-test, comparing against the unstimulated media control; *p<0.05, 
**
p<0.01, 
***
p<0.001.  Data points show mean (after subtracting background/non-
specific binding and normalised to an input control) ± SEM. 
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5.3.3. At the potential IL-6 enhancer in keratinocytes, TNF + IL-17 stimulation 
had no significant effect on histone modifications or RNA polymerase II 
binding 
Having observed that in ChIP studies of the IL-6 promoter, TNF + IL-17 enhanced 
recruitment of pol II (S2P) as well as an increase in permissive epigenetic epitopes, 
TNF + IL-17 stimulation was hypothesised to have similar effects at a potential IL-6 
enhancer region in NHEKs, thus potentiating IL-6 expression. Although an IL-6 
enhancer region has not previously been described in NHEKs, one has previously been 
identified in primary human macrophages (Qiao et al., 2013)  25kb upstream of the IL-6 
transcriptional start site (TSS).  This region was therefore evaluated as a potential IL-6 
enhancer in NHEKs, by undertaking ChIP studies to investigate the enrichment of 
epitopes characteristic of enhancers (H3K27ac, H3K4me1and RNA polymerase II (Calo 
and Wysocka, 2013)  to this region in NHEKs.  Note, H3K4me1 is associated with 
active enhancer regions, compared to a generally repressive effect at promoter regions 
(Ernst et al., 2011; Calo and Wysocka, 2013). 
Co-immunoprecipitated, purified DNA samples (prepared as per section 5.3.1) were 
assayed by qPCR for enrichment of marks at the IL-6 enhancer region as defined in 
primary human macrophages (forward and reverse primer sequences were as defined in 
(Qiao et al., 2013)). The ChIP experiment was conducted in TNF + IL-17 stimulated 
NHEKs compared to unstimulated NHEKs.   
As shown in Figure 5-3, TNF + IL-17 had no significant effect on pol II (S2P) 
recruitment to the potential IL-6 enhancer in NHEKs or enrichment of epigenetic 
epitopes which normally characterise active enhancers, e.g. H3K27ac and H3K4me1. 
Additionally, there was no significant enrichment of acteyl-H3, H3K9ac or H3K4me3 at 
this region in response to TNF + IL-17 stimulation.  Furthermore, this region 
demonstrated relatively low enrichment of acetyl-H3, H3K9ac and H3K27ac compared 
to levels at IL-6 and IL-8 promoter regions. 
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Figure 5-3: At the potential NHEK IL-6 enhancer, TNF + IL-17 stimulation had 
no significant effect on active epigenetic epitopes and/or pol II (S2P) recruitment 
NHEKs were stimulated with or without TNF (10ng/ml) + IL-17 (100ng/ml) and 
harvested at 1h and 4h post-stimulation for ChIP studies using antibodies to pol II (S2P) 
(A) or epigenetic epitopes that positively regulate gene expression (B).  Quantification 
of co-immunoprecipitated DNA was performed by qPCR, using primers to the potential 
IL-6 enhancer region.    (N=3)  Analysis by one-way ANOVA with Dunnett’s post-test, 
comparing against the unstimulated media control; 
+
p<0.05, 
++
p<0.01, 
+++
p<0.001.  Data 
points show mean (after subtracting background/non-specific binding and normalised to 
an input control) ± SEM. 
 
pol II (S2P)
UnStim 1h 4h
0.00
0.05
0.10
0.15 ns
ns
TNF + IL-17
A)
%
 I
n
p
u
t
171 
 
5.4. Discussion 
The skin and serum of patients with psoriasis are both rich in TNF and IL-17 
(Takahashi et al., 2010) and these cytokines are known to regulate the expression of 
genes relevant to the pathogenesis of psoriasis (Chiricozzi et al., 2011).  TNF + IL-17 
stimulation upregulated IL-6 and IL-8 expression in NHEKs, with maximal expression 
occurring at 6h post stimulation (section 3.3.2).  For the first time in a model relevant to 
psoriasis, and consistent with the observations above, we demonstrated that TNF + IL-
17 stimulation resulted in chromatin remodelling facilitating histone hyperacetylation 
and pol II (S2P) binding at the promoter regions of IL-6 and IL-8.  These changes 
preceded maximal transcription.  There was greater enrichment of pol II (S2P) at the IL-
8 promoter than at the IL-6 promoter, in both unstimulated and stimulated cells; this 
may explain higher expression of IL-8 compared to IL-6, in both the basal state and in 
inflammatory responses.  These findings provide mechanistic insight into how stimuli 
relevant to psoriasis regulate inflammatory responses through changes in the 
epigenome.  As histone acetylation is dynamic and the balance between histone acetyl 
transferase and histone deacetylase activity, which governs the acetylation state of 
histones, can be modulated with pharmacological treatments, these findings could lead 
to the identification of novel targets for psoriasis therapy.      
Although the ChIP results supported the hypothesis that TNF + IL-17 stimulation 
induced chromatin remodelling, the comparative studies also highlighted differences 
between the epigenome at the IL-6 and IL-8 promoters in response to TNFα and IL-17 
stimulation. The results for IL-6 and IL-8 loci are discussed in turn.  
At the IL-6 promoter, there were significant increases in permissive histone 
modifications (acetyl-H3, H3K9ac and H3K27ac, each cumulative up to 4h after 
stimulation), but no significant change in the inhibitory mark H3K4me1 in response to 
TNF + IL-17 stimulation.  Although there was a trend for increased enrichment of 
H3K4me3 at 4h post-TNF + IL-17 stimulation, this was not significant.  Of note, 
TNF + IL-17 induced changes in the epigenome preceded maximal IL-6 expression 
(6h).  Furthermore, pol II (S2P) recruitment to the IL-6 promoter tracked with changes 
in histone acetylation and was also cumulative up to 4h post-stimulation.    Together, 
these findings suggest histone acetylation ultimately drives recruitment of pol II (S2P) 
to the IL-6 promoter, thus regulating IL-6 expression.  Our findings were consistent 
with epigenetic regulation of IL-6 found in other systems.  Sahar et al. demonstrated 
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that angiotensin II treatment of rat vascular smooth muscle cells led to increased 
H3K9ac enrichment at the IL-6 promoter, with a parallel increase in IL-6 expression 
(Sahar et al., 2007).  In neutrophils and monocytes, stimulation with R848 (a 
TLR7/TLR8 agonist) induced increases in H3K27ac, with a corresponding increase in 
IL-6 induction (Zimmermann et al., 2015).  Further in keeping with our results, 
Zimmermann et al. found no significant change in the inhibitory mark H3K4me1 early 
after stimulation (6h) of neutrophils with R848, although there was significant 
enrichment by 20h after stimulation.  It would be interesting in future to understand if 
NHEKs show a similar delayed increase in H3K4me1 at the IL-6 promoter.  Delayed 
enrichment of inhibitory marks, including H3K4me1, could account for the gradual 
decline in IL-6 (and IL-8) mRNA expression 6h after stimulation with TNF + IL-17.  
It would also be informative to evaluate the effects of prolonged TNF + IL-17 
stimulation on permissive histone modifications (including lysine acetylation) at the IL-
6 promoter to investigate the how the balance between permissive and repressive 
epigenetic marks shift with time, to understand the mechanisms responsible for 
switching from gene expression to silencing.  
At the IL-8 promoter, TNF + IL-17 stimulation resulted in significant enrichment of 
acetyl-H3 and H3K27ac, but not H3K9ac.  Of interest, enrichment of permissive histone 
modifications (acetyl-H3 and H3K27ac) at the IL-8 promoter was transient and 
maximal at 1h after TNF + IL-17 stimulation.  Similar to findings at the IL-6 
promoter, pol II (S2P) recruitment to the IL-8 promoter tracked with transient changes 
in histone acetylation and preceded maximal IL-8 expression (6h).  Together, these 
findings suggest histone acetylation drives recruitment of pol II (S2P) to the IL-8 
promoter, thus regulating IL-8 expression.  Furthermore, the decline in permissive 
epigenetic marks and pol II (S2P) recruitment, by 4h post-TNF + IL-17 stimulation, 
may explain the gradual decline in IL-8 mRNA expression after 6h stimulation.  This 
data suggests that an increase and subsequent decline in permissive epigenetic marks 
(rather than changes in repressive epitopes) may be primarily responsible for switching 
on/off IL-8 expression in NHEKs.  However before this conclusion can be drawn, it 
may be informative to undertake longer timecourse studies to understand if there is a 
delayed increase in H3K4me1 at the IL-8 promoter, as demonstrated at the IL-6 
promoter in neutrophils, as discussed above (Zimmermann et al., 2015).  In addition 
further ChIP studies investigating additional repressive epitopes, e.g. H3K27me3, as 
originally undertaken prior to being contacted by the manufacturer about cross-
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reactivity problems with this antibody (section 5.3.1) may aid additional understanding 
of the switch between gene expression and silencing.  In this respect, the change from 
H3K27 tri-methylation (H3K27me3) to acetylation (H3K27ac) has been shown to act as 
an important switch from gene repression to transcriptional activation (Pasini et al., 
2010).   
Our observation that stimulation of NHEKs (with TNF + IL-17) resulted in histone 
hyperacetylation at the IL-8 promoter, which in turn drives gene expression, is 
consistent with previously published findings describing epigenetic regulation of IL-8 
expression in keratinocytes.  For example, stimulation of human keratinocytes with 
Malassezia furfur, a yeast which signals through TLR2 receptors, increased H3 
acetylation with corresponding upregulation of pro-inflammatory cytokine responses 
including IL-8, as well as IL-1, IL-6 and TNF (Angrisano et al., 2013).  However, in 
contrast to the kinetics of IL-8 expression and histone acetylation observed in TNF + 
IL-17 stimulated NHEKs, Angrisano et al. observed maximal IL-8 gene expression at 
4h after stimulation with Malassezia furfur and a transient increase in acetyl-H3, which 
was also maximal at 4h after-stimulation and returned to baseline by 24h.  These 
differences may be due to the different stimuli used, although Angrisano et al. did not 
perform ChIP studies prior to the 4h timepoint, when maximal expression of IL-8 was 
observed, and it is likely that chromatin would undergo remodelling prior to maximal 
IL-8 gene expression.   For these reasons, direct comparisons of kinetics of histone 
modifications would be difficult. 
As described in section 3.3.3, basal expression of IL-8 protein, in unstimulated NHEKs, 
was higher than expression of IL-6 protein and the magnitude of IL-8 mRNA and 
protein responses to TNF + IL-17 stimulation were greater compared to IL-6 
responses.  It was therefore hypothesised that IL-6 and IL-8 genes were under 
differential epigenetic regulation.  In support of this hypothesis, the enrichment of 
acetyl-H3 and H3K9ac was approximately 5-10 fold higher at the IL-6 promoter than at 
the IL-8 promoter.  Furthermore, and consistent with this observation, there was 
approximately 35 fold greater enrichment of Brd4 at the IL-6 promoter compared to the 
IL-8 promoter (sections 4.3.4 and 4.3.5).  Although enrichment of pol II (S2P) tracked 
with histone acetylation at the promoter region of IL-6 and IL-8, as discussed above, the 
increased enrichment of histone modifications (acetyl-H3 and H3K9ac) and Brd4 at the 
IL-6 promoter was not reflected by increased recruitment of pol II (S2P).   The opposite 
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was actually observed i.e. enrichment of pol II (S2P) was greater at the IL-8 promoter 
compared to enrichment at the IL-6 promoter; approximately 2.9 fold higher at the IL-8 
promoter compared to IL-6 promoter in unstimulated cells and approximately 1.6 fold 
higher at the IL-8 promoter compared to IL-6 promoter in TNF + IL-17 stimulated 
cells (Figure 5-1 and Figure 5-2).  Increased recruitment of pol II (S2P) at the IL-8, 
promoter than at the IL-6 promoter, may partly explain the greater expression of IL-8 
versus IL-6 in both unstimulated and TNF + IL-17 stimulated NHEKs.  As differences 
in epigenetic modifications and Brd4 recruitment could not account for differences in 
pol II (S2P) recruitment to IL-6 and IL-8 promoters, it is likely that additional 
epigenetic marks/transcription factors and co-activators are also involved in regulating 
recruitment of pol II (S2P), thus IL-6/-8 expression, in keratinocytes.  In this respect 
increased di-methylation of the lysine 4 of histone-H3 (H3K4me2) is associated with 
increased IL-8 expression in keratinocytes and hyperacetylation of H4 is associated with 
increased IL-6 expression in neutrophils (Angrisano et al., 2013; Zimmermann et al., 
2015).  In addition Brd4 is known to bind Mediator, a multi-protein co-activator that 
may facilitate interactions between transcription factors and RNA polymerase II (Wu 
and Chiang, 2007) and Brd4/Mediator complexes have been identified at the 
transcription start site of many genes across the genome (Loven et al., 2013).  It may 
therefore be informative to direct future investigations towards understanding how these 
additional factors may regulate cutaneous inflammation.  Additional regulatory regions, 
e.g. enhancers, may also be involved in regulating cutaneous inflammatory responses, 
although these have not been previously defined for IL-6/-8 in keratinocytes.  It was 
also noted that the differences in kinetics of histone modifications and pol II (S2) 
recruitment at IL-6 and IL-8 promoters (Figure 5-1 and Figure 5-2) were not reflected 
by differences in kinetics of IL-6 and IL-8 expression (section 3.3.2).  This supports the 
hypothesis that additional factors, or regulatory regions, are also involved in regulating 
cutaneous inflammation, as discussed above.  
It is known that BET proteins bind acetylated lysine residues on protein, including 
histones.  It was shown that in NHEKs stimulation with TNF + IL-17 resulted in 
chromatin remodelling and a significant increase in global acetylation of histone H3 at 
IL-6 and IL-8 promoters, as well as acetylation of specific lysine residues associated 
with active promoters (at the IL-6 promoter H3K9ac and H3K27ac, at the IL-8 promoter 
H3K27ac and a trend for increased H3K9ac).  Furthermore, at the IL-8 promoter 
maximal enrichment of permissive epitopes and pol II (S2P) was at 1h post-stimulation, 
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but lagged at the IL-6 promoter where maximal enrichment was at 4h post-stimulation.  
These differences in kinetics of lysine acetylation at the IL-6 vs. IL-8 promoter did not 
appear to translate to differences in kinetics of BET recruitment to IL-6 and IL-8 
promoters; BET proteins showed transient recruitment, which tended to be maximal at 
4.5h post-stimulation, at both IL-6 and IL-8 promoters.  As the differences in kinetics of 
lysine acetylation at IL-6 and IL-8 promoters was not reflected by differences in timing 
of BET recruitment to these regulatory regions, these findings could suggest that while 
H3K9ac and H3K27ac are both associated with active promoters, they may not be (the 
only) binding targets of BET proteins.  However definitive conclusions may be difficult 
to draw as acetylation of other lysine residues were not investigated.   
Furthermore, ChIP experiments in NHEKs investigating effects on epigenetic 
modification (sections 4.3.4 and 4.3.5) and BET recruitment were performed in 
different donors, which may have shown subtle differences in kinetics as suggested by 
the different binding profiles of pol II (S2P) to IL-6 and IL-8 promoters in these two 
experiments.  Investigations into BET proteins binding targets suggest regulation of 
binding is highly complex and that BET proteins might recognise a pattern of histone 
modifications not simply single acetyl-lysine residue, and modifications other than 
acetylation might also play a role.  For example, histone di-acetylation can enhance 
Brd4 binding in a lysine-residue specific manner; di-acetylated H3 (H3K9acK14ac) and 
di-acetyl H4 (H4K5acK12ac) enhanced Brd4 binding compared to mono-acetylation at 
each lysine residue alone but an alternative di-acetyl H4 (H4K8acK16ac) had no effect 
on Brd4 binding (Dey et al., 2003) and binding of Brd4 to di-acetyl H3 (H3K4acK9ac) 
is enhanced by the phosphorylation of the H3 threonine residue at position 3 
(H3T3pK4acK9ac) (Filippakopoulos and Knapp, 2012).  Investigation of BET binding 
patterns through ChIP in primary donors is therefore unlikely to be a particularly 
efficient method of screening.  Further investigations through ChIP-sequencing could be 
an informative method to discover where, for example, Brd4 (other BET proteins), p65 
or acetyl marks map within the genome in order to further understand their regulatory 
roles.  Advances in technology using low cell numbers could allow this to be performed 
in activated primary keratinocytes in the future (Mundade et al., 2014; Jakobsen et al., 
2015) 
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In contrast to the observations and the IL-6 and IL-8 promoters which were 
transcriptionally activated, TNF + IL-17 stimulation had no significant effect on 
histone modifications or pol II (S2P) recruitment at a region of DNA in NHEKs which 
has previously been defined as an IL-6 enhancer in primary human macrophages; a 
region 25kb upstream of the IL-6 transcriptional starts site (TSS) (Qiao et al., 2013).  In 
primary human macrophages Qiao et al. identified several regions upstream of the IL-6 
TSS, which showed high levels of H3K27 acetylation in response to IFN + LPS 
stimulation.  These regions also demonstrated high DNAseI sensitivity, in keeping with 
them being potential gene enhancers.  These regions included a region 25kb upstream of 
the IL-6 TSS which demonstrated increased recruitment of CREB binding protein 
(CBP, a known histone acetyl transferase co-activator) as well as the transcription 
factor, p65.   Together these findings suggest the region 25kb upstream of the IL-6 TSS 
is an enhancer in primary human macrophages.  In comparison, the findings in NHEKs 
suggest that this region does not perform the same function in keratinocytes following 
TNF + IL-17 stimulation.  For example TNF + IL-17 stimulation did not increase 
recruitment of pol II (S2P) to the IL-6 enhancer region in NHEKs, nor was there any 
increased acetylation of H3K27; stimulation which would be expected to increase both 
pol II recruitment and H3K27ac to a true enhancer region (Calo and Wysocka, 2013).  
Furthermore, in NHEKs the ratio of H3K4me1 to H3K4me3 was lower at the “IL-6 
enhancer” region compared to the IL-6 promoter region, approximately 1:25 and 1:5 
respectively at 4h after TNF+ IL-17 stimulation; true enhancer regions generally 
show greater levels of enrichment of H3K4me1 compared to H3K4me3 (Heintzman et 
al., 2009).  In addition to these findings, it was demonstrated that this region also had 
relatively low enrichment of Brd4 (section 4.3.6).  In contrast enhancers, especially 
“super enhancers”, often demonstrate high levels of Brd4 binding (Brown et al., 2014).  
Although enhancer regions from macrophages and keratinocytes have not been directly 
compared previously, enhancers regions have previously been shown to be cell-type 
specific (Heintzman et al., 2009), therefore it is not unexpected that the same DNA 
sequence may have different regulatory roles in macrophages and keratinocytes. 
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5.5. Future work 
In a model of cutaneous inflammation relevant to psoriasis it was demonstrated that 
TNF + IL-17 stimulation resulted in chromatin remodelling facilitating histone 
hyperacetylation and pol II (S2P) binding at the promoter regions of IL-6 and IL-8.  
These findings provide mechanistic insight into how stimuli relevant to psoriasis 
regulate inflammatory responses through changes in the epigenome and could lead to 
the identification of novel targets for psoriasis therapy.  A number of key questions, 
however, remain:   
 Stimulation with TNF + IL-17 increased acetylation of specific lysine residues 
on histones at IL-6 and IL-8 promoters and pol II (S2P) recruitment traced with 
these changes, but which other epigenetic modifications (permissive or 
repressive) are key regulators of cutaneous inflammation?   
 In addition to changes in the epigenome driving IL-6 and IL-8 expression, what 
changes in the epigenome are responsible for their repression; a decrease in 
permissive marks (as observed with IL-8) or an increased in repressive marks or 
a shift in balance between the two? 
 Which additional factors and co-activators are involved in the recruitment of pol 
II (S2P) to target promoters?  Could inhibition of binding of these factors and 
co-activators to the epigenome represent novel therapeutic targets? 
5.6. Conclusions 
 Consistent with the positive effects of TNF + IL-17 stimulation on IL-6 and 
IL-8 expression in NHEKs, stimulation increased permissive (but not repressive) 
histone modifications, including lysine acetylation, at promoter regions of 
effector genes.   
 Epigenetic changes induced by TNF + IL-17 stimulation preceded maximal IL-
6 and IL-8 expression.  
 Recruitment of pol II (S2P) tracked with changes in histone acetylation at IL-6 
and IL-8 promoters. 
 The decline in histone acetylation at the IL-8 promoter at 4h post-stimulation 
could account for the subsequent decline in IL-8 expression.  
 There was greater enrichment of pol II (S2P) at the IL-8 promoter than at the IL-
6 promoter in both unstimulated and TNF + IL-17 stimulated NHEKs, this 
178 
 
may explain the higher expression of IL-8 compared to IL-6 in both basal and 
inflammatory states. 
 Enrichment of acetyl-H3 and H3K9ac was approximately 5-10 fold higher at the 
IL-6 promoter than for the IL-8 promoter, corresponding with increased binding 
of Brd4 at the IL-6 promoter (sections 4.3.3 and 4.3.4).  This suggests these 
genes are differentially regulated by epigenetic writers and erasers.   
 There were difference in kinetics of histone modifications at IL-6 and IL-8 
promoters, with maximal changes around 4h and 1h respectively.  These 
differences were not obviously reflected in differences in expression of these 2 
genes over time, suggesting additional factors may also be involved in 
regulating their expression.  
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6. Gene array: investigating the effects of BET inhibition in the in vitro model of 
cutaneous inflammation 
6.1. Introduction 
Psoriasis represents a complex interplay between genetic predisposition, the 
environment and inflammatory responses (section 1.2).  While the most widely accepted 
model of psoriasis suggests hyperproliferation of keratinocytes (which themselves may 
be dysfunctional or hypersensitive to stimuli) is driven by an over-active immune 
system, the underlying changes which regulate intracellular signalling and inflammatory 
feedback loops are not fully understood.  Knowledge of differentially expressed genes 
(DEGs) in psoriasis may aid our understanding of the changes in signalling pathways 
between disease and non-disease states and identify candidates for further discovery of 
pathogenesis or treatment targets.  Advances in array technology have transformed this 
field, for example, the Illumina human HT-12 v4.0 BeadChip array allows high 
throughput screening of over 47,000 transcripts simultaneously and comparisons 
between samples (e.g. involved vs. uninvolved psoriatic skin or unstimulated vs. 
stimulated cells) enables DEGs to be identified and potentially candidates for further 
investigation to aid understanding of the pathogenesis of psoriasis or as novel targets for 
therapy.  Although a number of individual psoriasis array studies have previously been 
published (Kulski et al., 2005; Yao et al., 2008; Swindell et al., 2012), more recently a 
robust meta-analysis of 5 studies has been undertaken (Tian et al., 2012).  Tian et al. 
uncovered 677 upregulated and 443 downregulated genes across the 5 transcriptomic 
studies analysed, which the authors termed the meta-analysis derived (“MAD-5”) 
transcriptome. 
Although it is known that BET inhibitors have anti-proliferative and anti-inflammatory 
effects in in vitro and in vivo models of inflammation and cancer, thus providing 
rationale for their use in psoriasis, to date there have been no array studies in 
keratinocytes, skin or models of psoriasis using BET inhibitors.  In section 4.3.2, it was 
demonstrated that I-BET151 blocked induction of IL-6 and IL-8, key cytokines in the 
pathogenesis of psoriasis, in TNF + IL-17A (IL-17) stimulated normal human 
epidermal keratinocytes (NHEKs), which could be accounted for by the inhibition of 
BET protein recruitment to IL-6 and IL-8 promoter regions in the presence of I-
BET151.  TNF + IL-17 stimulation of NHEKs was previously shown to induce 
expression of key genes thought to be central to the pathogenesis of psoriasis 
(Chiricozzi et al., 2011); we hypothesised that BET proteins would be involved in the 
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regulation of some of these genes and that I-BET151 treatment would modulate their 
expression.  We therefore undertook microarray studies to examine the effects of TNF 
+ IL-17 stimulation in NHEKs and the effects of I-BET151 in this model of cutaneous 
inflammation.  Finally, we analysed genes which were differentially regulated with 
TNF + IL-17 stimulation and I-BET151 treatment and compared them to the MAD-5 
transcriptome to determine the overlap and understand their relevance to psoriasis. 
 
6.2. Aims 
 To investigate gene expression responses in keratinocytes following stimulation 
with TNF + IL-17 at early (6h) and late (24h) time points post-stimulation. 
 To determine the effect of I-BET151 on gene expression in keratinocytes 
stimulated with TNF + IL-17 at early (6h) and late (24h) time points post 
stimulation. 
 To understand the overlap of genes which are both sensitive to TNF + IL-17 
stimulation, and also I-BET151 treatment, and how these relate to known DEGs 
in psoriasis and to genes known to be involved in the pathogenesis of psoriasis. 
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6.3. Results 
6.3.1. Data quality assessment and generation of differentially expressed gene lists 
In section 3.3.2, it was demonstrated that stimulation of NHEKs with TNF + IL-17 
induced IL-6 and IL-8 expression, with maximal mRNA levels detected at 6h post-
stimulation.  Furthermore, IL-6 and IL-8 responses could be inhibited by I-BET151 and 
the inhibition could be accounted for by the reduction in BET protein and pol II (S2P) 
binding to the promoter regions of IL-6 and IL-8 (sections 4.3.4 and 4.3.5).  In order to 
understand the effects of TNF + IL-17 stimulation on other early and late gene 
responses and to investigate the effects of I-BET151 treatment in this cell model, 
NHEKs were treated with the following 8 conditions: 
1. Mock/unstimulated (i.e. media change), 6h stimulation 
2. TNF (10ng/ml) + IL-17 (100ng/ml), 6h stimulation 
3. TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 vehicle (DMSO (1:1200)), 6h 
stimulation 
4. TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 (1M), 6h stimulation 
5. Mock/unstimulated (i.e. media change), 24h stimulation 
6. TNF (10ng/ml) + IL-17 (100ng/ml), 24h stimulation 
7. TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 vehicle (DMSO (1:1200)), 
24h stimulation 
8. TNF (10ng/ml) + IL-17 (100ng/ml) + I-BET151 (1M), 24h stimulation 
Based on power calculations, using pilot qRT-PCR data, and cost effectiveness analysis, 
it was determined that array data from 12 donors would yield sufficient power to detect 
meaningful changes in gene expression after stimulation with TNF + IL-17 in the 
presence or absence of I-BET151 (section 2.8).  In total, NHEKs derived from 14 
consecutive donors were treated; excess donors were treated to allow for any problems 
with growth, infections or outlier responses etc.  No donors demonstrated macroscopic 
problems with growth or infection.  RNA was therefore extracted for each condition 
from all 14 donors and qRT-PCR, using primers to IL-6 and IL-8, was undertaken 
(Table 6-1 and Table 6-2).  All 14 donors, demonstrated upregulation of both IL-6 and 
IL-8 at 6h after stimulation with TNF + IL-17, as previously observed (section 3.3.2), 
with many also demonstrating sustained induction of IL-6 and IL-8 at 24h after TNF + 
IL-17 stimulation.  I-BET151 had an inhibitory effect on IL-6 and IL-8 responses to 
stimulation at 6h in all donors, apart from donors XII and XIV in which I-BET151 
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appeared to potentiate the IL-6 response to stimulation at 6h (table 6.1).  It is unknown 
why donors XII and XIV had outlying responses to I-BET151, but for this reason the 
other 12 donors were selected as the 12 for further microarray analysis.   
All 96 samples had RNA integrity number (RIN) values above 8, therefore all samples 
were suitable for microarray analysis which was performed using Illumina human HT-
12 v4.0 microarray platform which contains over 47,000 probes (section 2.8).  Three 
different methods were used for the quality assessment of arrays.  Firstly, the mean 
absolute difference of each array from all other arrays was considered - a threshold for 
outlier detection was determined from the distribution of mean absolute differences.  
Secondly, the principal component analysis (PCA) was considered for outlier detection 
- outliers being determined by visual inspection and expert judgement.  Finally, the 
array intensity distribution was assessed - an array will be marked as an outlier by this 
method if the distribution tests are significantly different from the pooled intensity 
distribution of the other arrays.  Only one array failed any of these quality control 
metrics, and this single case was only considered an outlier by the mean absolute 
difference method, and passed PCA and array intensity distribution quality assessments; 
all 96 arrays were therefore retained for analysis.  There were on average approximately 
33% of probes detectable per array and in total, 23794 probes (50.28% of the total 
number of probes) were retained (detection p value < 0.01 on at least 1 array).   
PCA demonstrated that variance was mainly accounted for by treatment with I-BET151, 
with length of treatment with I-BET151 also contributing to the variance (Figure 6-1A).  
As I-BET151 had such a marked effect, the effect of other components, e.g. TNF + IL-
17 stimulation, was difficult to observe.  For this reason, we undertook a further PCA 
excluding conditions which contained I-BET151 treatment (i.e. conditions 4 and 8).  
This allowed greater separation of other conditions and showed separation between 
TNF + IL-17 stimulated and unstimulated conditions (Figure 6-1B).  Furthermore, 
TNF + IL-17 stimulation with or without DMSO (i.e. conditions 2, 3, 6 and 7, above) 
grouped closely together, suggesting DMSO had very limited effect.   
In keeping with these findings, when formal contrasts were performed, DMSO was 
found not to regulate expression of any transcripts analysed regardless of the cut-offs 
specified (fold change, FCH, and p-value) (Table 6-3).  TNF + IL-17 stimulation 
regulated 46 - 1277 transcripts at 6h and 80 - 2338 transcripts at 24h, depending on the 
cut-offs specified, Table 6-3.  In comparison, and in keeping with results from PCA 
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plots (Figure 6-1), I-BET151 regulated a greater number of transcripts compared to 
TNF + IL-17 stimulation for any given FCH and p-value (Table 6-3).   
There were good reasons to believe that inclusion of genes with equal or greater fold-
changes than IL-6 and IL-8 would be of biological relevance as these cytokines are 
known to play key roles in the pathogenesis of psoriasis (section 1.2.5) and have been 
shown to be regulated by TNF + IL-17 in an in vitro model of cutaneous inflammation 
(Chiricozzi et al., 2011).  Furthermore, I-BET151 was shown to inhibit induction of IL-
6 and IL-8 in response to TNF + IL-17 stimulation in the model (section 4.3.2). It was 
therefore decided to select a cut off threshold so that both IL-6 and IL-8 were included 
in subsequent analyses.   Table 6-4 shows the absolute FCH in IL-6 and IL-8 responses, 
after stimulation with TNF + IL-17 and the effect of I-BET151 treatment in TNF + 
IL-17 stimulated NHEKs, each at 6 and 24h.  A FCH cut-off of 1.3 would capture 
changes in IL-6 and IL-8 for all conditions, except the effect of I-BET151 treatment in 
TNF + IL-17 stimulated NHEKs at 24h (absolute FCH = 1.2995).  However, the I-
BET151 effect on induction of IL-8 after TNF + IL-17 stimulation at 24h was unclear, 
as it appeared to have an overall inhibitory effect as determined by microarray but an 
overall potentiation effect on IL-8 when measured by qRT-PCR, although other results 
generally showed good concordance, (Table 6-4).  For this reason, we chose not to 
lower the cut off threshold further to include this value.  As the threshold for FCH was 
set relatively low (1.3) to include biologically relevant changes in IL-6 and IL-8, we 
chose a stringent threshold for p-value of 0.01 (adjusted for multiple testing) to ensure 
changes were robust.  Table 6-5 shows the number of transcripts with an absolute FCH 
≥ 1.3 and p-value ≤ 0.01; there were approximately 10 times the number of transcripts 
regulated by I-BET151 compared to TNF + IL-17 stimulation at either timepoint 
(3614 and 260, respectively at 6h; and 4289 and 436, respectively at 24h).  I-BET151 
modulated ~ 7.7% and 9.1% of the total number of probes in the array (~47000) at 6 
and 24 h respectively, indicating that effects of the compound were discrete, not global.  
Although more transcripts were upregulated by TNF + IL-17 stimulation than 
downregulated, a similar number of transcripts were either up or downregulated by I-
BET151.   
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IL-6, Fold change (Log2) 
Donor TNF+ IL-17 
6h 
TNF+ IL-17 
24h 
I-BET151 
6h 
I-BET151 
24h 
I 3.36 4.01 -1.82 -0.63 
II 2.00 2.58 -2.05 -0.24 
III 1.88 0.89 -0.93 -1.99 
IV 1.42 2.24 -0.89 -0.16 
V 2.60 0.28 -1.09 -1.56 
VI 3.95 4.41 -1.57 -0.68 
VII 1.87 3.14 -0.04 -2.16 
VIII 3.43 3.64 -0.15 -1.65 
IX 4.53 -0.16 -1.03 -0.62 
X 1.83 3.07 -1.11 -1.53 
XI 2.29 2.95 -1.66 -0.71 
XII 2.29 3.86 0.25 -0.26 
XIII 1.63 3.03 -0.82 -1.08 
XIV 2.98 3.70 0.13 -1.28 
Table 6-1: qRT-PCR analysis of IL-6 expression in TNF + IL-17 stimulated 
human keratinocytes and the effect of I-BET151 
NHEKs derived from 14 donors were treated with TNF (10ng/ml) + IL-17 (100ng/ml) 
or mock stimulated.  NHEKs were also stimulated with TNF (10ng/ml) + IL-17 
(100ng/ml) in the presence of I-BET151 (1uM) or vehicle (DMSO, 1:1200).  Cells were 
harvested at 6h or 24h post-stimulation and expression of IL-6 mRNA determined by 
qRT-PCR.  Columns 2 and 3 show IL-6 fold change (Log2) in stimulated NHEKs 
compared to mock stimulated NHEKs at 6 and 24h after stimulation, respectively.  
Columns 4 and 5 show IL-6 fold change (Log2) in TNF + IL-17 + I-BET151 treated 
NHEKs compared TNF + IL-17 + vehicle treated NHEKs at 6 and 24h after 
stimulation, respectively.   
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IL-8, Fold change (Log2) 
Donor TNF+ IL-17 
6h 
TNF+ IL-17 
24h 
I-BET151 
6h 
I-BET151 
24h 
I 6.24 7.35 -1.46 0.33 
II 5.38 6.07 -2.60 -0.01 
III 7.18 6.89 -0.96 0.72 
IV 5.70 4.88 -1.77 0.67 
V 5.33 5.55 -1.21 0.27 
VI 7.64 8.19 -2.29 -0.44 
VII 5.57 5.18 -1.27 0.83 
VIII 5.14 6.10 -0.27 0.64 
IX 5.73 6.26 -0.95 0.98 
X 4.74 5.31 -2.29 0.11 
XI 7.76 6.61 -2.22 0.38 
XII 6.64 7.75 -0.54 -0.16 
XIII 6.58 6.73 -1.42 0.38 
XIV 6.35 7.26 -0.84 0.24 
Table 6-2: qRT-PCR analysis of IL-8 expression in TNF + IL-17 stimulated 
human keratinocytes and the effect of I-BET151 
NHEKs derived from 14 donors were treated as per Table 6-1 and expression of IL-8 
mRNA determined by qRT-PCR.  Columns 2 and 3 show IL-8 fold change (Log2) in 
stimulated NHEKs compared to mock stimulated NHEKs at 6 and 24h after stimulation, 
respectively.  Columns 4 and 5 show IL-8 fold change (Log2) in TNF + IL-17 + I-
BET151 treated NHEKs compared TNF + IL-17 + vehicle treated NHEKs at 6 and 
24h after stimulation, respectively.   
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Figure 6-1: Principal component analysis (PCA) plots of data 
PCA plot A) containing data from all 96 samples (i.e. 12 donors, each stimulated under 
8 conditions (section 6.3.1).  B) Data from all samples, except conditions containing I-
BET151 treatment. Numbers in PCA plot B, represent different donors. 
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Fold change 
p-value 
 2.0 
0.05 
2.0 
0.01 
2.0 
0.001 
1.5 
0.05 
1.5 
0.01 
1.5 
0.001 
1) TNF + IL-17 stimulation 6h 49 47 46 114 107 101 
2) DMSO 6h 0 0 0 0 0 0 
3) TNF + IL-17 stimulation 
+ I-BET151 minus DMSO 
6h 409 409 409 1601 1600 1594 
4) TNF + IL-17 stimulation 24h 84 82 80 219 211 200 
5) DMSO 24h 0 0 0 0 0 0 
6) TNF + IL-17 stimulation 
+ I-BET151 minus DMSO 
24h 734 734 732 2262 2258 2245 
Table 6-3: Number of differentially regulated probes, for a range of cut-offs, for 
each contrast 
Table shows the number of differentially regulated probes for a given fold change and 
p-value (adjusted for multiple testing) for each contrast, shown in the left column.  
Contrast “TNF + IL-17 stimulation” is the comparison between TNF + IL-17 
stimulated NHEKs compared to mock stimulated NHEKs (i.e. conditions 1 vs. 2 and 5 
vs. 6 (section 6.3.1).  Contrast “DMSO” is the comparison of TNF + IL-17 stimulated 
NHEKs in the presence or absence of DMSO (i.e. conditions 2 vs. 3 and 6 vs. 7 (section 
6.3.1).  Contrast “TNF + IL-17 stimulation + I-BET151 minus DMSO” is the 
comparison of TNF + IL-17 stimulated NHEKs in the presence or absence of I-
BET151 or DMSO (i.e. conditions 3 vs. 4 and 7 vs. 8 (section 6.3.1). 
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A) IL-6 
Condition Time Microarray 
IL-6, fold 
change 
(Log2) 
Microarray 
IL-6, fold change 
(absolute) 
qRT-PCR 
IL-6 fold 
change 
(Log2) 
TNF + IL-17 stimulation 6h 0.5632 1.4775 2.5655 
TNF + IL-17 stimulation 24h 0.6364 1.5545 2.5069 
TNF + IL-17 stimulation + 
I-BET151 treatment 
6h -0.4496 1.3657 -1.0964 
TNF + IL-17 stimulation + 
I-BET151 treatment 
24h -0.4836 1.3982 -1.0843 
 
B) IL-8 
Condition Time Microarray 
IL-8, fold 
change 
(Log2) 
Microarray 
IL-8, fold change 
(absolute) 
qRT-PCR 
IL-8 fold 
change 
(Log2) 
TNF + IL-17 stimulation 6h 4.7150 26.2637 6.0827 
TNF + IL-17 stimulation 24h 4.6950 25.9022 6.2594 
TNF + IL-17 stimulation + 
I-BET151 treatment 
6h -1.5030 2.8343 -1.5586 
TNF + IL-17 stimulation + 
I-BET151 treatment 
24h -0.3780 1.2995 0.4056 
Table 6-4: IL-6 and IL-8 responses to TNF + IL-17 stimulation and I-BET151, as 
measured by microarray and qRT-PCR 
Table shows the effect of TNF + IL-17 stimulation compared to mock stimulated 
NHEKs at 6 and 24h (i.e. conditions 1 vs. 2 and 5 vs. 6 (section 6.3.1) as well as the 
effect of I-BET151, compared to vehicle, in TNF + IL-17 stimulated NHEKs at 6 and 
24h (i.e. conditions 3 vs. 4 and 7 vs. 8 (section 6.3.1) on A) IL-6 responses and B) IL-8 
responses.  Microarray and qRT-PCR values are mean data (N=12). 
 
 
191 
 
 Condition Time Up Down Total 
TNF + IL-17 stimulation 6h 222 38 260 
TNF + IL-17 stimulation 24h 334 102 436 
TNF + IL-17 stimulation +         
 I-BET151 treatment 
6h 1621 1993 3614 
TNF + IL-17 stimulation +          
 I-BET151 treatment 
24h 2159 2130 4289 
Table 6-5: Number of probes regulated by TNF + IL-17 stimulation and I-
BET151, with fold change ≥ 1.3 and p-value ≤ 0.01 
Table shows the number of probes regulated by TNF + IL-17 stimulation compared to 
mock stimulated NHEKs at 6 and 24h (i.e. conditions 1 vs. 2 and 5 vs. 6 (section 6.3.1) 
as well as the number of probes regulated by I-BET151 in TNF + IL-17 stimulated 
NHEKs compared to NHEKs stimulated with TNF + IL-17 + DMSO at 6 and 24h (i.e. 
conditions 3 vs. 4 and 7 vs. 8 (section 6.3.1), with fold change  ≥ 1.3 and p-value ≤ 0.01. 
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6.3.2. TNF + IL-17 stimulation of keratinocytes, upregulated expression of genes 
relevant to psoriasis 
In NHEKs, TNF + IL-17 stimulation differentially regulated expression of 260 probes 
at 6h, compared to mock stimulated NHEKs (222 upregulated and 38 downregulated) 
and 436 probes at 24h (334 upregulated and 102 downregulated) (Table 6-5).  Figure 6-
2, shows that 174 probes were upregulated at both 6 and 24h and 23 probes were 
downregulated at both 6 and 24h, demonstrating that TNF + IL-17 stimulation had 
some sustained effects.  The effect of TNF + IL-17 stimulation on keratinocytes has 
previously been investigated and was found to upregulate expression of many genes 
involved in the pathogenesis of psoriasis (Chiricozzi et al., 2011).  To understand how 
reproducible the effects of TNF + IL-17 stimulation were, the two data sets were 
compared using the same cut-offs and timepoint as those specified by Chiricozzi et al. 
(i.e. FCH ≥ 1.3, false discovery rate (FDR) = 0.3, 24h stimulation).  This comparison 
demonstrated that there was overlap of 157 probes between the 2 datasets, but over 200 
probes featured in only one or the other of the arrays (Figure 6-3).  Furthermore, 
although Chiricozzi et al. did not report on genes which were downregulated by TNF 
+ IL-17 stimulation, we found 116 probes were negatively regulated by TNF + IL-17 
stimulation (Figure 6-3).   
DEGs at 6h (217 genes) and 24h (355 genes) after TNF + IL-17 stimulation in NHEKs 
were compared to the MAD-5 transcriptome; there was an overlap of 59 genes at 6h 
(Figure 6-4) and 97 genes at 24h (Figure 6-5).  Figure 6-4 shows that of the 59 genes 
regulated by TNF + IL-17 stimulation in NHEKs at 6h, the majority (54 genes) were 
upregulated by TNF + IL-17 stimulation and also upregulated in the MAD-5 
transcriptome.  Figure 6-5 shows that of the 97 genes regulated by TNF + IL-17 
stimulation in NHEKs at 24h, the majority (80 genes) were upregulated by TNF + IL-
17 stimulation and also upregulated in the MAD-5 transcriptome; interestingly there 
were 5 genes downregulated by TNF + IL-17 stimulation which were also 
downregulated in the MAD-5 transcriptome.  These findings demonstrated that at each 
timepoint, approximately 25% of genes regulated by TNF + IL-17 stimulation, 
featured in the MAD-5 transcriptome with the same direction of expression and that 
approximately 5 and 8% of DEGs in the MAD-5 transcriptome were regulated by TNF 
+ IL-17 stimulation in NHEKs at 6h and 24h respectively. 
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Table 6-6 and Table 6-8 show the top 10 upregulated genes in response to TNF + IL-
17 stimulated NHEKs, at 6h and 24h respectively, which included a number of genes 
known to be upregulated in psoriasis, e.g. IL-8, IL-36G, DEF4A/DEF4B, CXCL1, 
CCL20 and LCN2; and a psoriasis susceptibility loci has recently been identified near 
NFKBIZ (Tsoi et al., 2015).  In addition to overlap of DEGs at 6 and 24h post-TNF + 
IL-17 stimulation, there was considerable overlap in upstream regulators of DEGs at 
these two timepoints (Table 6-7 and Table 6-9) with 4 of the 5 top upstream regulators 
featuring in both datasets (TNF, NFKB, IL1A and IFNG). 
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Figure 6-2: Overview of effects of TNF + IL-17 stimulation at 6 and 24h 
Venn diagram shows the number of probes regulated by TNF + IL-17 stimulation in 
NHEKs at 6h and 24h after stimulation, compared to mock stimulated NHKEs, with 
fold change ≥ 1.3 and p-value ≤ 0.01.   
 
 
 
Figure 6-3: Comparison of effects of 24h stimulation with TNF + IL-17 to a 
published data set using the same stimuli and timepoint 
Venn diagram shows the number of probes regulated by TNF(10ng/ml) + IL-17 
(100ng/ml) in NHEKs compared to a published data set of NHEKs stimulated with 
TNF(10ng/ml) + IL-17 (200ng/ml) (Chiricozzi et al., 2011).  For both datasets, 
NHEKs were stimulated for 24h and cut-offs were as follows: fold change ≥ 1.3 false 
discovery rate = 0.3.  N.B. Chiricozzi et al. only reported on upregulated genes. 
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Figure 6-4: Overview of genes regulated by TNF + IL-17 stimulation in 
keratinocytes at 6h and included in the MAD-5 psoriasis transcriptome 
Venn diagram shows overlap of genes regulated by TNF+ IL-17 stimulation in 
NHEKs at 6h and either A) upregulated in the MAD-5 psoriasis transcriptome (Tian et 
al., 2012) or B) downregulated in the MAD-5 psoriasis transcriptome. 
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Figure 6-5: Overview of genes regulated by TNF + IL-17 stimulation in 
keratinocytes at 24h and included in the MAD-5 psoriasis transcriptome 
Venn diagram shows overlap of genes regulated by TNF+ IL-17 stimulation in 
NHEKs at 24h and either A) upregulated in the MAD-5 psoriasis transcriptome (Tian et 
al., 2012) or B) downregulated in the MAD-5 psoriasis transcriptome. 
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Symbol Description Fold change 
(Log2) 
IL-8 Interleukin-8 4.72 
IL-36G Interleukin-36, gamma 4.17 
CXCL1 Chemokine (C-X-C motif) ligand 1 3.89 
CCL20 Chemokine (C-C motif) ligand 20 2.92 
CSF2 Colony Stimulating Factor 2 2.91 
DEFB4A/DEFB4B Defensin, beta 4A/4B 2.91 
SPRR2A Small Proline-Rich Protein 2A 2.82 
SPRR2F Small Proline-Rich Protein 2F 2.55 
NFKBIZ 
Nuclear Factor Of Kappa Light Polypeptide 
Gene Enhancer In B-Cells Inhibitor, zeta 
2.45 
ZC3H12A Zinc Finger CCCH-Type Containing 12A 2.32 
Table 6-6: Top 10 upregulated genes at 6h after TNF + IL-17 stimulation, 
compared to mock stimulated NHEK 
Upstream regulators, 6h Predicted activation or inhibition 
TNF Activated 
NFKB Activated 
IL1A Activated 
IFNG Activated 
IL1B Activated 
Table 6-7: Top 5 upstream regulators of differentially expressed genes at 6h after 
TNF + IL-17 stimulation 
Upstream regulators were predicted using IPA. 
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Symbol Description Fold change 
(Log2) 
DEFB4A/DEFB4B Defensin, beta 4A/4B 5.32 
SPRR2A Small Proline-Rich Protein 2A 5.02 
IL-36G Interleukin-36, gamma 4.78 
IL-8 Interleukin-8 4.70 
SPRR2F Small Proline-Rich Protein 2F 4.48 
CXCL1 Chemokine (C-X-C motif) ligand 1 3.90 
SPRR2E Small Proline-Rich Protein 2E 3.83 
SAA1 Serum Amyloid A1 3.55 
CCL20 Chemokine (C-C motif) ligand 20 3.01 
LCN2 Lipocalin 2 2.97 
Table 6-8: Top 10 upregulated genes at 24h after TNF + IL-17 stimulation, 
compared to mock stimulated NHEKs 
 
Upstream regulators, 24h Predicted activation or inhibition 
TNF Activated 
IL1A Activated 
NFKB Activated 
EHF Activated 
IFNG Activated 
Table 6-9: Top 5 upstream regulators of differentially expressed genes at 24h after 
TNF + IL-17 stimulation 
Upstream regulators were predicted using IPA. 
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6.3.3. I-BET151 differentially regulated expression of genes principally involved 
in p53 signalling and cell cycle, these had most relevance to cancer but also to 
dermatological diseases 
In TNF + IL-17 stimulated NHEKs, I-BET151 differentially regulated expression of 
3614 probes at 6h (1621 upregulated and 1993 downregulated) and 4289 probes at 24h 
(2159 upregulated and 2130 downregulated) (Table 6-5).  Figure 6-6, shows that 884 
probes were upregulated at both 6 and 24h and 1063 probes were downregulated at both 
6 and 24h, demonstrating that I-BET15 had some sustained effects.  In some instances 
I-BET151 had differential effects at 6 vs. 24h; 21 probes were upregulated at 6h but 
downregulated at 24h, and in 40 probes the opposite was observed.  Table 6-10 and 
Table 6-11 show the top 10 upregulated and downregulated genes in response to I-
BET151 treatment in TNF + IL-17 stimulated NHEKs, at 6h and 24h respectively.  In 
order to understand the gross functions of the ~4000 differentially regulated probes at 
each timepoint, data was mined using Ingenuity
®
 Pathway Analysis (IPA).   
As shown in Figure 6-7, at 6h post treatment with I-BET151, compared to vehicle, in 
TNF + IL-17 stimulated NHEKs, the highest canonical pathway was p53 signalling (p 
= 1.91 x 10
-8
), but canonical pathways involving cell cycle also featured very 
prominently (e.g. cell cycle: G1/S checkpoint regulation, p = 2.78 x 10
-7
; cell cycle: 
G2/M DNA damage checkpoint regulation, p = 3.95 x 10
-7
 and also cell cycle control of 
chromosomal replication, p = 2.13 x 10
-6
  amongst other pathways in cell cycle).  
Interestingly, the role of IL-17A in psoriasis also featured in the top 20 canonical 
pathways (p = 7.13 x 10
-5
) and 7 of the 8 genes regulated by I-BET151 within this 
pathway were inhibited (Figure 6-8).  Given the canonical pathways affected by I-
BET15 in TNF + IL-17 stimulated NHEKs, it was logical the top diseases and 
biological functions were related to these pathways: 839 genes were included in the cell 
death and survival dataset, and 981 genes in the cancer dataset.  Interestingly, 291 genes 
were included in the dermatological diseases and conditions dataset and 305 genes in 
the protein synthesis dataset (Figure 6-9).  IPA was also used to analyse interactions 
within the differentially regulated gene dataset at 6h, by linking genes through their 
relationships.  The most number of differentially regulated genes were included in the 
“Cell cycle, cellular assembly and organisation, DNA replication, recombination and 
repair” network, (Figure 6-10, and the majority of genes in this network were 
downregulated by I-BET151 treatment at 6h. 
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Similar to 6h, the I-BET151 DEG list at 24h included canonical pathways involving the  
cell cycle (e.g. cell cycle control of chromosomal replication, p = 2.81 x 10
-8
; role of 
CHK proteins in cell cycle checkpoint control, p = 2.02 x 10
-6
; and cell cycle: G2/M 
DNA damage checkpoint regulation, p = 2.6 x 10
-6
) (Figure 6-11).  Again cancer and 
cell death and survival were at or near the top of diseases and biological functions 
affected by I-BET151, with 1219 and 948 genes in these datasets respectively (Figure 
6-12).  Of note, the dermatological diseases and conditions dataset also featured at 24h 
(403 genes) and also a further dermatological dataset appeared: hair and skin 
development and function (124 genes).  Again, IPA was also used to analyse 
interactions within the differentially regulated gene dataset at 24h.  The most number of 
differentially regulated genes were included in the “Amino acid metabolism, small 
molecule biochemistry, post-translational modification” network (Figure 6-13) and the 
majority of genes in this network were downregulated by I-BET151 treatment at 24h.  
Interestingly downregulation of MYC, an oncogenic transcription factor involved in 
cellular proliferation and apoptosis, was at the core of this network.   
In order to understand the relationships between DEGs at 6 and 24h after I-BET151 
treatment in TNF + IL-17 stimulated NHEKs, IPA was used to predict upstream 
regulators of DEGs at 24h and these were compared to regulators of DEGs at 6h.  Table 
6-14 shows the top 10 inhibited regulators at 6h and the overlap with predicted 
regulators of DEGs at 24h after I-BET151 treatment in TNF + IL-17 stimulated 
NHEKs. Seven of the key regulators at 6h, were also predicted to be inhibited at 24h, 
based on the DEGs dataset at 24h.  It was logical that key regulators were involved in 
similar processes as DEGs e.g. inflammation (IL1A & B and NFKB1), cell cycle (e.g. 
cyclin D1, E2F2) and cancer (e.g. MYC) (Table 6-14).  The observation that IL1A, 
IL1B and NFKB1 were among the top most inhibited regulators at 6 and 24h provided 
further rationale for investigating the effects of BET inhibitors in cutaneous 
inflammation.  
Therefore, DEGs at 6h (2926 genes) and 24h (3372 genes) after I-BET151 treatment in 
TNF + IL-17 stimulated NHEKs were compared to the MAD-5 transcriptome; there 
was an overlap of 286 genes at 6h (Figure 6-14) and 365 genes at 24h (Figure 6-15).  
Figure 6-14 shows that of the 286 genes modulated by I-BET151 treatment in TNF + 
IL-17 stimulated NHEKs at 6h, the majority (190 genes) were upregulated in the MAD-
5 transcriptome but downregulated by I-BET151 and 24 genes which were  
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downregulated in the MAD-5 transcriptome were upregulated by I-BET151.  Figure 
6-15 shows that of the 365 genes modulated by I-BET151 treatment in TNF + IL-17 
stimulated NHEKs at 24h, 228 genes were upregulated in the MAD-5 transcriptome but 
downregulated by I-BET151 and 59 genes which were  downregulated in the MAD-5 
transcriptome were upregulated by I-BET151.  These findings demonstrated that of the 
1120 up or downregulated DEGs in the MAD-5 transcriptome, approximately 19% and 
26% of genes were differentially modulated by I-BET151 treatment in TNF + IL-17 
stimulated NHEKs, at 6h and 24h respectively. 
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Figure 6-6: Overview of effects of I-BET151 in TNF + IL-17 stimulated 
keratinocytes at 6 and 24h 
Venn diagram shows the number of probes regulated by I-BET151, compared to 
vehicle, in TNF + IL-17 stimulation of NHEKs at 6h and 24h, with fold change ≥ 1.3 
and p-value ≤ 0.01.  *Includes 21 probes upregulated at 6h but downregulated at 24h.  
**Includes 40 probes downregulated at 6h but upregulated at 24h. 
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Symbol Description Fold 
change 
(Log2) 
Type 
CSF2 Colony Stimulating Factor 2 -3.19 Cytokine 
FST Follistatin -3.05 Other 
DKK1 Dickkopf-related protein 1 -3.05 Growth factor 
C15orf52 
Chromosome 15 Open Reading 
Frame 52 (Uncharacterised) 
-2.89 Other 
IL-1A Interleukin-1, alpha -2.76 Cytokine 
EPN3 Epsin 3 -2.52 Other 
IL-1B Interleukin-1, beta -2.44 Cytokine 
ADAMTS1 
A disintegrin and 
metalloproteinase with 
thrombospondin motif, 1 
-2.31 Peptidase 
IL-36G Interleukin-36, gamma -2.30 Cytokine 
IFIT3 
Interferon-Induced Protein With 
Tetratricopeptide Repeats 3 
-2.14 Other 
HIST2H2AA3/HIST2H2AA4 Histone cluster 2, H2aa3 3.23 Other 
HIST1H2BD Histone cluster 1, H2bd 3.05 Other 
HCFC1R1 
Host cell factor C1 regulator 1 
(XPO1 dependent) 
2.93 Other 
HIST1H4H Histone cluster 1, H4h 2.93 Other 
HIST2H2AC Histone cluster 2, H2ac 2.78 Other 
HIST2H2BE Histone cluster 2, H2be 2.60 Other 
HIST1H1C Histone cluster 1, H1c 2.44 Other 
TRNP1 TMF1-regulated nuclear protein 1 2.31 Other 
H2AFJ H2A histone family, member J 2.31 Other 
MT1X Metallothionein 1X 2.26 Other 
Table 6-10: Top 10 down and upregulated genes at 6h after I-BET151 treatment, 
compared to vehicle, in TNF + IL-17 stimulated keratinocytes  
Molecule type was defined by IPA. 
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Symbol Description Fold 
change 
(Log2) 
Type 
FST Follistatin -5.00 Other 
UBE2C Ubiquitin-conjugating enzyme E2 
C -3.80 Enzyme 
CDC20 cell-division cycle protein 20 -3.48 Other 
DKK1 Dickkopf-related protein 1 -3.16 Growth factor 
PRC1 Protein Regulator of cytokinesis 1 -3.14 Other 
OAS2 2'-5'-oligoadenylate synthetase 2 -3.14 Enzyme 
CCNB2 cyclin B2 -3.09 Other 
SERPINB2 Serpin peptidase inhibitor, clade B, 
member 2 -3.08 Other 
TOP2A DNA topoisomerase 2-alpha -3.05 Cytokine 
KRT34 Keratin 34 -2.97 Other 
HIST2H2BE Histone cluster 2, H2be 3.28 Other 
HIST2H2AA3/HIST2H2AA4 Histone cluster 2, H2aa3 2.937 Other 
CTGF Connective tissue growth factor 2.94 Growth factor 
HIST1H2BG Histone cluster 1, H2bg 2.74 Other 
HIST1H2AC Histone cluster 1, H2ac 2.64 Other 
HIST1H2BD Histone cluster 1, H2bd 2.62 Other 
TXNIP Thioredoxin interacting protein 2.60 Other 
HIST2H2AC Histone cluster 2, H2ac 2.40 Other 
CCL20 Chemokine (C-C motif) ligand 20 2.38 Cytokine 
TUBB3 Tubulin, beta 3 class III 2.35 Other 
Table 6-11: Top 10 down and upregulated genes at 24h after I-BET151 treatment, 
compared to vehicle, in TNF + IL-17 stimulated keratinocytes 
Molecule type was defined by IPA. 
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Figure 6-7: Top 20 Ingenuity
®
 Pathway Analysis “canonical pathways” 
differentially modulated by I-BET151 in TNF + IL-17 stimulated keratinocytes at 
6h 
Expression profiles are shown as log mean values, compared to DMSO in TNF + IL-
17 stimulated keratinocytes at 6h, and were considered significant when the adjusted p-
value (threshold) was ≤ 0.01 and used as input into IPA.  The orange line depicts the 
ratio (number of pathway relevant proteins in the data set divided by the total number of 
proteins in that pathway); 35 out of 98 genes were included in the p53 signalling 
pathway and 8 out of 13 genes were included in the role of IL-17A in psoriasis pathway 
(Figure 6-8).  Bars in orange, blue or grey predict an increase, decrease or undetermined 
change in a pathway’s activity, respectively.  This is based on the activation Z-score, 
which infers the activation state of predicted transcriptional regulators of a particular 
pathway using expression patterns of differentially expressed genes within that dataset. 
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Figure 6-8: Effects of I-BET151 treatment, compared to vehicle, in TNF + IL-17 
stimulated keratinocytes in Ingenuity
®
 Pathway Analysis’ “role of IL-17A in 
psoriasis pathway” 
Squares represent cytokines, horizontal ovals are transmembrane receptors and circles 
are other molecules.  The intensity of red and green indicates the degree of up or 
downregulation, respectively, at 6h after treatment with I-BET151, compared to vehicle, 
in TNF + IL17 stimulated NHEKs. *indicates gene was represented by more than one 
probe. 
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Figure 6-9: Top 20 Ingenuity
®
 Pathway Analysis “diseases and biological 
functions” differentially modulated by I-BET151 in TNF + IL-17 stimulated 
keratinocytes at 6h 
Expression profiles are shown as log mean values, compared to DMSO in TNF + IL-
17 stimulated keratinocytes at 6h, and were considered significant when the adjusted p-
value (threshold) was ≤ 0.01 and used as input into IPA.  The yellow line indicates the 
significance, p < 0.01 (i.e. all datasets shown were significant).  839 genes were 
included in the cell death and survival dataset, 981 genes in the cancer dataset, 291 
genes in the dermatological diseases and conditions dataset and 305 genes in the protein 
synthesis dataset. 
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Figure 6-10: Interaction of genes modulated by I-BET151 in TNF + IL-17 
stimulated keratinocytes at 6h 
IPA revealed that the greatest number of differentially regulated genes grouped into the 
“Cell cycle, cellular assembly and organisation, DNA replication, recombination and 
repair” network, shown above with biological relationships between indicated.  Solid 
lines indicate direct interactions whereas dashed lines indicate indirect relationships. 
Inverted triangles represent kinases, vertical diamonds are peptidases, ovals are 
transcription regulators, trapeziums are transporters and circles are other molecules. The 
intensity of red and green indicates the degree of up or downregulation, respectively, at 
6h after treatment with I-BET151, compared to vehicle, in TNF + IL17 stimulated 
NHEKs. 
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Figure 6-11: Top 20 Ingenuity
®
 Pathway Analysis “canonical pathways” 
differentially modulated by I-BET151 in TNF + IL-17 stimulated keratinocytes at 
24h 
Expression -
17 stimulated keratinocytes at 24h, and were considered significant when the adjusted 
p-value (threshold) was ≤ 0.01 and used as input into IPA.  The orange line depicts the 
ratio (number of pathway relevant proteins in the data set divided by the total number of 
proteins in that pathway).  Bars in orange, blue or grey predict an increase, decrease or 
undetermined change in a pathway’s activity, respectively.  This is based on the 
activation Z-score, which infers the activation state of predicted transcriptional 
regulators of a particular pathway using expression patterns of differentially expressed 
genes within that dataset. 
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Figure 6-12: Top 20 Ingenuity
®
 Pathway Analysis “diseases and biological 
functions” differentially modulated by I-BET151 in TNF + IL-17 stimulated 
keratinocytes at 24h 
Expression profiles are shown as log mean values, compared to DMSO in TNF + IL-
17 stimulated keratinocytes at 6h, and were considered significant when the adjusted p-
value (threshold) was ≤ 0.01 and used as input into IPA.  The yellow line indicates the 
significance, p < 0.01 (i.e. all datasets shown were significant).  1219 genes were 
included in the cancer dataset, 403 genes in the dermatological diseases and conditions 
dataset, 948 genes in the cell death and survival dataset and 124 genes in the hair and 
skin development and function dataset. 
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Figure 6-13: Interaction of genes modulated by I-BET151 in TNF + IL-17 
stimulated keratinocytes at 24h 
IPA revealed that the greatest number of differentially regulated genes grouped into the 
“Amino acid metabolism, small molecule biochemistry, post-translational modification” 
network, shown above with biological relationships between indicated.  Solid lines 
indicate direct interactions whereas dashed lines indicate indirect relationships. Inverted 
triangles represent kinases, vertical diamonds are peptidases, horizontal diamonds are 
enzymes, ovals are transcription regulators, trapeziums are transporters and circles are 
other molecules.  The intensity of red and green indicates the degree of up or 
downregulation, respectively, at 24h after treatment with I-BET151, compared to 
vehicle, in TNF+ IL17 stimulated NHEKs. 
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Symbol Gene name Fold 
change 
(Log2), 6h 
Activation 
Z-Score, 
24h 
Inferred 
activation, 24h 
CSF2 Colony stimulating factor 2  -3.19 -7.14 Inhibited 
IL1 (A, B) Interleukin 1 (alpha, beta) 
-2.76, 
 -2.44  
 -2.95, 
 -2.11 
Inhibited 
TRIB3 Tribbles pseudokinase 3 -1.99 2.53 Activated 
TP63 Tumor protein p63 -1.85 -2.46 Inhibited 
IL1RN 
Interleukin 1 receptor 
antagonist 
-1.65 4.61 Activated 
CCND1 Cyclin D1 -1.04 -2.97 Inhibited 
E2F2 E2F transcription factor 2 -0.96 -2.18 Inhibited 
MYC 
V-myc avian 
myelocytomatosis viral 
oncogene homolog 
-0.80 -5.38 Inhibited 
IKBKE 
Inhibitor of kappa light 
polypeptide gene enhancer in 
B-cells, kinase epsilon 
-0.80 2.22 Activated 
NFKB1 
Nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 1 
-0.75 -2.47 Inhibited 
Table 6-12: Top 10 inhibited regulators at 6h, in response to I-BET151 in TNF + 
IL-17 stimulated keratinocytes, and inferred activation/activation Z-score at 24h 
predicted using Ingenuity
®
 Pathway Analysis  
Table shows top 10 regulators inhibited by I-BET151 treatment in TNF + IL-17 
stimulated NHEKs at 6h.  Inferred activation state at 24h of these regulators was based 
on the IPA-predicted activation Z-score at 24h. The activation Z-score infers the 
activation state of predicted transcriptional regulators of a particular pathway using 
expression patterns of differentially expressed genes within the (24h) dataset. 
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Figure 6-14: Overview of genes modulated by I-BET151 in TNF + IL-17 
stimulation in keratinocytes at 6h and included in the MAD-5 psoriasis 
transcriptome 
Venn diagram shows overlap of genes modulated by I-BET151 in TNF+ IL-17 
stimulated NHEKs at 6h and either A) upregulated in the MAD-5 psoriasis 
transcriptome (Tian et al., 2012) or B) downregulated in the MAD-5 psoriasis 
transcriptome. 
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Figure 6-15: Overview of genes modulated by I-BET151 in TNF + IL-17 
stimulation in keratinocytes at 24h and included in the MAD-5 psoriasis 
transcriptome 
Venn diagram shows overlap of genes modulated by I-BET151 in TNF+ IL-17 
stimulated NHEKs at 24h and either A) upregulated in the MAD-5 psoriasis 
transcriptome (Tian et al., 2012) or B) downregulated in the MAD-5 psoriasis 
transcriptome. 
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6.3.4. I-BET151 modulated a sub-set of genes, induced by TNF + IL-17 
stimulation in keratinocytes, which are known to be differentially expressed 
in psoriasis 
Having observed that I-BET151 in TNF + IL-17 stimulated NHEKs, regulated 
expression of genes involved in p53 signalling, cell cycle and cellular growth and 
proliferation, which are known to be involved in the pathogenesis of psoriasis and that 
many of the differentially regulated genes are involved in “dermatological diseases and 
conditions”, we hypothesised that there would be an overlap of genes which were 
regulated by TNF + IL-17 stimulation and sensitive to I-BET151 treatment and also 
relevant to the pathogenesis of psoriasis. 
Figure 6-16  shows that of the 260 probes regulated by TNF + IL-17 stimulation in 
NHEKs at 6h, 168 were modulated by I-BET151.  Of these 168, 121 probes were 
upregulated by TNF + IL-17 stimulation but downregulated by I-BET151 and 6 were 
downregulated by TNF + IL-17 stimulation but upregulated by I-BET151.  Figure 
6-17 shows that of the 436 probes regulated by TNF + IL-17 stimulation in NHEKs at 
24h, 280 were modulated by I-BET151.  Of these 280, 169 probes were upregulated by 
TNF + IL-17 stimulation but downregulated by I-BET151 and 25 were downregulated 
by TNF + IL-17 stimulation but upregulated by I-BET151.  These findings 
demonstrated that 48.4% and 44.4% of genes regulated by TNF + IL-17 stimulation in 
NHEKs were differentially modulated by I-BET151 treatment, at 6h and 24h 
respectively. 
Figure 6-18, shows that 174 probes were upregulated by TNF + IL-17 stimulation a 
both 6 and 24h, while 1063 probes were downregulated by I-BET151 treatment at both 
6 and 24h; with an overlap of 70 probes, which represented 59 unique genes.  To 
understand the gross functions of the 59 DEGs, data was mined using Ingenuity 
Pathway Analysis (IPA).  Perhaps unsurprisingly, the top diseases and biological 
functions, that genes grouped into was dermatological diseases and conditions dataset 
(32 genes were included in this data set) (Figure 6-19).  Interestingly, DEGs also 
grouped immune cell function trafficking and inflammatory responses, both relevant to 
the pathogenesis of psoriasis (Figure 6-19).  Of these 32 genes, 26 had roles in psoriasis 
according to analysis in IPA (Figure 6-20) which derives this information from primary 
literature, in e.g. journal articles, review articles and textbooks, as well as publicly 
available databases.  
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In comparison, 22 probes were downregulated by TNF + IL-17 stimulation a both 6 
and 24h, while 884 probes were upregulated by I-BET151 treatment at both 6 and 24h; 
with an overlap of only 1 probe, which represented the connective tissue growth factor 
gene (Figure 6-21). 
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Figure 6-16: Overview of probes modulated by I-BET151 and TNF + IL-17 
stimulation in keratinocytes at 6h  
Venn diagram shows overlap of probes modulated by I-BET151 in TNF+ IL-17 
stimulated NHEKs at 6h and either A) upregulated in TNF+ IL-17 stimulated NHEKs 
or B) downregulated in TNF+ IL-17 stimulated NHEKs. 
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Figure 6-17: Overview of probes modulated by I-BET151 and TNF + IL-17 
stimulation in keratinocytes at 24h  
Venn diagram shows overlap of probes modulated by I-BET151 in TNF+ IL-17 
stimulated NHEKs at 24h and either A) upregulated in TNF+ IL-17 stimulated 
NHEKs or B) downregulated in TNF+ IL-17 stimulated NHEKs. 
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Figure 6-18: Overview of probes positively regulated by TNF + IL-17 stimulation 
and sensitive to I-BET151 treatment 
Venn diagram shows the number of probes upregulated by TNF + IL-17 stimulation 
at both 6 and 24h and the number of probes downregulated by I-BET151 treatment at 
both 6 and 24h.  The 70 overlapping probes represented 59 unique genes.  For both 
datasets, cut-offs were as follows: fold change ≥ 1.3 and p-value ≤ 0.01. 
 
 
 
 
 
 
 
 
Figure 6-19: Top 10 Ingenuity
®
 Pathway Analysis “diseases and biological 
functions” of genes positively regulated by TNF + IL-17 stimulation and 
downregulated by I-BET151 treatment in keratinocytes (i.e. overlap of genes from 
Figure 6-18). 
The yellow line indicates the significance p < 0.01 (i.e. all datasets shown are 
significant), 32 genes were included in the dermatological diseases and conditions 
dataset. 
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Figure 6-20: Overview of the 26 genes positively regulated by TNF + IL-17 
stimulation, downregulated by I-BET151 treatment and included in a psoriasis 
network defined by Ingenuity
®
 Pathway Analysis  
Diagram shows genes, and their functions, upregulated by TNF + IL-17 stimulation at 
both 6 and 24h and downregulated by I-BET151 treatment at both 6 and 24h (i.e. 
overlap of genes from Figure 6-18 and which were included in an-IPA defined psoriasis 
network.  Squares represent cytokines, trapeziums are transporters, vertical diamonds 
are peptidases, horizontal diamonds are enzymes, interrupted squares are growth 
factors, and circles are other molecules.  The intensity of green indicates the degree of 
downregulation at 24h after treatment with I-BET151, compared to vehicle, in TNF + 
IL17 stimulated NHEKs. *indicates gene was represented by more than one probe. 
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Figure 6-21: Overview of probes differentially regulated by TNF + IL-17 
stimulation and I-BET151 treatment 
Venn diagram shows the number of probes downregulated by TNF + IL-17 
stimulation at both 6 and 24h and the number of probes upregulated by I-BET151 
treatment at both 6 and 24h.  For both datasets, cut-offs were as follows: fold change ≥ 
1.3 and p-value ≤ 0.01. 
  
222 
 
6.3.5. Overlap of genes differentially regulated by TNF + IL-17 and I-BET151 
compared to published MAD-5 psoriasis transcriptome  
In addition to investigating the overlap of genes which were upregulated by TNF + 
IL-17 stimulation at both 6 and 24h and downregulated by I-BET151 treatment at both 
6 and 24h and which were included in an IPA-defined psoriasis network, the overlap 
with a published psoriasis transcriptome was also investigated.  The meta-analysis 
derived (“MAD-5”) transcriptome is a previously published meta-analysis of 5 
transcriptomic studies, which defined a total of 677 upregulated and 443 downregulated 
genes across the 5 studies (Tian et al., 2012).  Of the 677 upregulated genes in the 
MAD-5 transcriptome, 27 overlapped with the 59 genes upregulated by TNF + IL-17 
stimulation at both 6 and 24h and downregulated by I-BET151 treatment at both 6 and 
24h (Figure 6-22 and Table 6-13). 
 
The genes upregulated by TNF + IL-17 stimulation at both 6 and 24h and 
downregulated by I-BET151 treatment at both 6 and 24h and included in the IPA 
psoriasis network (26 genes, Figure 6-20) was compared to those included in the MAD-
5 transcriptome (27 genes, Table 6-13).  This analysis identified 13 overlapping genes, 
but 13 and 14 genes featured only in the IPA or MAD-5 datasets respectively (Table 
6-14). 
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Figure 6-22: Overview of genes positively regulated by TNF + IL-17 stimulation, 
downregulated by I-BET151 treatment and included in the MAD-5 psoriasis 
transcriptome 
Venn diagram shows overlap of genes included in the MAD-5 psoriasis transcriptome 
(Tian et al., 2012) which were also upregulated by TNF+ IL-17 stimulation at both 6 
and 24h and downregulated by I-BET151 treatment at both 6 and 24h (i.e. overlap of 
genes from Figure 6-18).   
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  Fold change (Log2) 
Gene Description MAD-5 TNF+ 
IL-17 
6h 
TNF+ 
IL-17 
24h 
I-BET151  
 
6h 
I-BET151 
 
24h 
Cytokines 
IL1F9 
Interleukin 1 family, 
member 9 
5.45 4.17 4.78 -2.30 -2.28 
CXCL2 
Chemokine (C-X-C motif) 
ligand 2 
3.28 1.72 1.39 -0.91 -0.45 
IL1B Interleukin 1, beta 2.43 1.75 2.22 -2.44 -2.55 
NAMPT 
Nicotinamide 
phosphoribosyltransferase 
1.84 0.44 0.65 -0.42 -0.90 
IL1RN 
Interleukin 1 receptor 
antagonist 
1.43 1.16 1.20 -1.65 -1.36 
TNFSF10 
Tumor necrosis factor 
(ligand) superfamily, 
member 10 
1.17 0.85 0.94 -1.20 -0.93 
Enzymes 
PLAT 
Plasminogen activator, 
tissue 
2.85 0.64 0.99 -0.73 -0.91 
FUT2 Fucosyltransferase 2  2.02 0.39 0.64 -0.45 -0.62 
BIRC3 
Baculoviral IAP repeat-
containing 3 
1.11 0.97 0.84 -0.95 0.60 
CYB5R2 Cytochrome b5 reductase 2 1.01 0.49 0.97 -0.77 -1.08 
Peptidases 
KYNU Kynureninase 6.17 1.05 1.26 -1.20 -1.57 
VNN1 Vanin 1 3.4 0.41 0.53 -0.46 -0.47 
ISG20  
Interferon stimulated 
exonuclease gene 20kDa 
2.39 0.40 0.79 -0.56 -1.36 
ALDH1A3 
Aldehyde dehydrogenase 1 
family, member A3 
2.37 1.21 1.80 -1.70 -1.92 
Growth factors 
TYMP Thymidine phosphorylase 3.09 0.47 1.16 -0.89 -0.84 
225 
 
TGFA 
Transforming growth factor, 
alpha 
1.48 0.65 0.75 -0.48 -0.52 
Transporters 
RHCG Rh family, C glycoprotein 6.3 0.73 1.70 -0.69 -1.76 
Transcription regulators 
PRDM1 
PR domain containing 1, 
with ZNF domain 
1.64 0.75 0.78 -1.28 -1.25 
Other 
DEFB4A Defensin, beta 4A 7.59 2.91 5.32 -1.89 -2.27 
S100A9 
S100 calcium binding 
protein A9 
5.18 1.61 2.87 -0.93 -1.11 
MPZL2 Myelin protein zero-like 2 3.64 0.56 0.60 -1.12 -0.71 
S100A8 
S100 calcium binding 
protein A8 
2.3 1.47 2.56 -0.94 -1.40 
SERPINA3 
Serpin peptidase inhibitor, 
clade A, member 3 
2.29 0.96 0.88 -0.75 -0.71 
PDZK1IP1 PDZK1 interacting protein 1 2.29 0.52 1.41 -0.55 -1.09 
NOD2 
Nucleotide-binding 
oligomerization domain 
containing 2 
1.82 0.70 0.88 -0.80 -0.92 
MYO1B Myosin IB 1.66 0.48 0.63 -0.69 -0.68 
NDRG4 NDRG family member 4 1.26 0.63 1.17 -0.50 -0.53 
Table 6-13: Overview of the 27 genes positively regulated by TNF + IL-17 
stimulation, downregulated by I-BET151 treatment and included in the MAD-5 
psoriasis transcriptome 
Identity of the 27 genes (Figure 6-22) included in the MAD-5 psoriasis transcriptome 
(Tian et al., 2012) which were also upregulated by TNF+ IL-17 stimulation at both 6 
and 24h and downregulated by I-BET151 treatment at both 6 and 24h (i.e. overlap of 
genes from Figure 6-18).  Fold changes (Log2) are shown for each condition: “TNF + 
IL-17”  represents that effect of TNF + IL-17 stimulation compared to mock 
stimulated and “I-BET151” represents the effect of I-BET151 treatment, compared to 
vehicle, in TNF + IL-17 stimulated NHEKs, fold changes for MAD-5 were as 
published (Tian et al., 2012).  Molecule type was defined by IPA.  
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Included in IPA and 
MAD-5 datasets 
 
Included in IPA 
dataset 
 
Included in MAD-5 
dataset 
 
KYNU CXCL5 IL1F9 
VNN1 IL6 CXCL2 
ISG20 IL23A IL1RN 
ALDH1A3 IL1A TNFSF10 
IL1B IL36G FUT2 
NAMPT IL24 BIRC3 
TYMP CSF2 CYB5R2 
TGFA CXCL6 RHCG 
PLAT TNFAIP3 PRDM1 
DEFB4A PTGS2 SERPINA3 
S100A9 GJB2 NOD2 
S100A8 SERPINB2 MYO1B 
PDZK1IP1 CFLAR NDRG4 
  MPZL2 
Table 6-14: Overview of genes differentially regulated by TNF + IL-17 
stimulation and I-BET151 treatment (i.e. overlapping gene from Figure 6-18) and 
overlap with genes included in an Ingenuity
®
 Pathway Analysis-defined psoriasis 
network and/or MAD-5 psoriasis transcriptome 
Peptidases are shown in green, cytokines in red, growth factors in blue, enzymes in 
purple, transporters in orange, transcription regulators in maroon and others in black.  
Molecule type was defined by IPA. 
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6.4. Discussion 
For the first time, the effects of a BET inhibitor on global gene expression in a cell 
model of cutaneous inflammation were investigated.  In TNF + IL-17 stimulated 
NHEKs, I-BET151 modulated expression of genes involved in the cell cycle, p53 
signalling and inflammation; pathways which are involved in the pathogenesis of 
psoriasis.  Both I-BET151 and TNF + IL-17 affected expression of genes which have 
previously been shown to be differentially expressed in psoriasis.  Furthermore we 
demonstrated that many genes which were upregulated by TNF + IL-17 stimulation 
and down-regulated with I-BET151 treatment, overlapped with genes which have been 
shown to be both upregulated in psoriasis and involved in its pathogenesis.  These 
findings suggest that i) BET proteins regulate the expression of genes relevant to 
psoriasis and ii) BET proteins may represent novel targets for the treatment of psoriasis. 
The effects of TNF + IL-17 stimulation of  NHEKs have previously been investigated 
in a microarray study (Chiricozzi et al., 2011) which showed some discordance with our 
dataset.  There are number of factors which may contribute to the discrepancies.  Firstly, 
primary keratinocytes were used, therefore donor variability may account for some of 
these differences.  As our dataset had 3 times the number of donors it is likely to be 
more robust (N=4 in Chiricozzi et al.’s dataset and N=12 in our dataset) and although 
there were some heterogenic responses, for logistical reasons our array focused on 
uniform responses at this stage (section 6.3.1).  It would however be important to 
validate a sub-set of our DEGs through qRT-PCR.  Secondly, a specified FDR of 0.3 
could suggest that some of the observations reported by Chiricozzi et al. are due to 
chance and may include false positives (Chiricozzi et al., 2011).  Thirdly, Chiricozzi et 
el. used a IL-17 concentration of 200ng/ml compared to 100ng/ml in our experiments.   
Although it was previously observed that there were no signification differences in IL-6 
or IL-8 induction in response to simulation with IL-17 at concentrations between 100 – 
400 ng/ml (data from preceding MRes, as discussed in section 3.3.1), it is possible that 
other analytes showed greater sensitivity to IL-17 stimulation at increasing 
concentrations.  Finally, although Chiricozzi et al. also used Illumina human HT-12 
microarray platform for analysis, the version was not specified therefore probes may 
have varied (Chiricozzi et al., 2011).    However despite these potential differences, the 
overlap between the 2 datasets was good (157 probes) suggesting that TNF + IL-17 
stimulation had robust and reproducible effects in different hands.  Furthermore, many 
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of the genes regulated by these stimuli, which are key cytokines in the pathogenesis of 
psoriasis, were also known to be differentially expressed in psoriasis. 
In NHEKs, TNF + IL-17 stimulation regulated expression of 260 probes (217 genes) 
and 436 probes (358 genes), with a fold change ≥ 1.3 and p-value ≤ 0.01, at 6h and 24h 
post-stimulation respectively.  At each timepoint, approximately 25% of the DEGs were 
also included in the MAD-5 psoriasis transcriptome (Tian et al., 2012).  There was also 
clear overlap of probes (174 upregulated and 23 downregulated) regulated by TNF + 
IL-17 stimulation at both 6h and 24h, this demonstrated stimulation had sustained 
effects.  In keeping with this finding, 7 of the top 10 genes upregulated by TNF + IL-
17 stimulation at 6h were also in the top 10 at 24h and included both cytokines (e.g. IL-
8) and anti-microbial peptides (e.g. DEFB4A) known to be increased and to play key 
roles in psoriasis.  Consistent with the overlap of DEGs at 6 and 24h after stimulation 
with TNF and IL-17, 4 out of the top 5 predicted upstream regulators of DEGs at 6h 
(TNF, NFKB, IL1A and IFNG) were also in the top 5 predicted upstream regulators of  
DEGs at 24h, and all these factors are key drivers of the pathogenesis of psoriasis 
(Perera et al., 2012; Lowes et al., 2014).  Furthermore approximately 5 and 8% of 
DEGs in the MAD-5 transcriptome were regulated by TNF + IL-17 stimulation in 
NHEKs at 6h and 24h respectively.  These are reasonable figures given that our array 
included only one cell type whereas the MAD-5 transcriptome was derived from array 
data of whole skin.  These findings suggest the TNF + IL-17 in vitro model of 
cutaneous inflammation was a valid model to study the expression of genes known to be 
dysregulated in psoriasis.   
As BET inhibitors have previously been shown to have anti-inflammatory and anti-
proliferative effects (Filippakopoulos et al., 2010; Nicodeme et al., 2010; Dawson et al., 
2011), we hypothesised that I-BET151 would regulate the expression of some key genes 
involved in the pathogenesis of psoriasis and these would compromise genes regulated 
in other cell types (Filippakopoulos et al., 2010; Nicodeme et al., 2010; Dawson et al., 
2011) but also some novel cell-type specific genes.  This hypothesis was supported by 
the finding that, of the 1120 up or downregulated DEGs in the MAD-5 transcriptome, 
approximately 19% and 26% of genes were differentially modulated by I-BET151 
treatment in TNF + IL-17 stimulated NHEKs, at 6h and 24h respectively.  
Furthermore, approximately 10% of genes regulated by I-BET151 in the model of 
cutaneous inflammation were also included in the MAD-5 transcriptome.  DEGs were 
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compared in TNF + IL-17 stimulated NHEKs with or without I-BET151 and it was 
found that 48.4% and 44.4% of genes regulated by TNF + IL-17 stimulation in 
NHEKs were differentially modulated by I-BET151 treatment, at 6h and 24h 
respectively.    Furthermore, the top I-BET15 inhibited regulators at 6h overlapped 
considerably with predicted regulators of DEGs at 24h, demonstrating that I-BET151 
had sustained effects, and interestingly inhibited regulators (IL-1A & B, and NFKB1) 
that are known to be key regulators of inflammation in psoriasis (Perera et al., 2012; 
Lowes et al., 2014).  In addition Cyclin D1 was also one of the most inhibited regulators 
of 6 and 24h DEGs (Table 6-12).  Cyclin D1 is known to have a role in regulating the 
cell cycle, has been shown to be over expressed in lesional psoriatic skin and 
interestingly is downregulated in response to currently prescribed anti-psoriatic 
treatments, including phototherapy (Abou et al., 2010).   Furthermore TP63 was also a 
key regulator of genes inhibited by I-BET151 (Table 6-12); TP63 has been 
demonstrated to regulate keratinocyte differentiation, a process known to be 
dysregulated in psoriasis (Kouwenhoven et al., 2015).   Of particular note, two of top 
upstream regulators (IL1A and NFKB) of DEGs in TNF + IL-17 stimulated NHEKs 
(Table 6-7 and Table 6-9) were also the most sensitive to I-BET151 treatment in TNF 
+ IL-17 stimulated NHEKs (Table 6-12).  Collectively these findings support the 
hypothesis that BET proteins are involved in regulating expression of keratinocyte 
genes, which have roles in inflammation and proliferation, and suggests BET inhibitors 
may have a role in treating cutaneous inflammation.  
In addition to identifying key signalling pathways, DEGs were interrogated using R 
Software and IPA to define genes of particular interest; the subset of genes upregulated 
by TNF + IL-17 stimulation at both 6 and 24h but downregulated by I-BET151 
treatment at both 6 and 24h was compared to an IPA-defined psoriasis network as well 
as the MAD-5 psoriasis transcriptome.  Using this approach, 59 genes were found to be 
consistently upregulated by stimulation but downregulated by compound at both 
timepoints.  32 of the 59 genes grouped into IPA’s dermatological diseases and 
conditions dataset and this was the top diseases and biological functions group, 
encompassing the most number of DEGs.  The 59 DEGs were also included in other 
IPA-defined diseases and biological functions groups including immune cell function 
trafficking and inflammatory responses, both relevant to the pathogenesis of psoriasis.  
Of the 59 genes, 26 also featured in an IPA-defined psoriasis network and 27 were in 
the MAD-5 transcriptome and, perhaps of most interest, there were 13 genes common to 
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both of these two datasets.  Many of the proteins encoded by these 13 genes are known 
to have key roles in psoriasis, for example: 
 S100A8 and S100A9 encodes S100 calcium binding protein A8 and A9, 
respectively, which as the name suggests binds calcium but also has anti-
microbial and chemotactic effects as well as roles in regulating epidermal 
differentiation and activation of immune cells (Wilsmann-Theis et al., 2015).  
Interestingly S100A8/A9 have both been proposed to be biomarkers for psoriatic 
arthritis activity (Hansson et al., 2014).  S100 proteins are some of the most 
upregulated genes in psoriasis (Yao et al., 2008); stimulation with TNF + IL-
17 increased expression of S100A8 by 2.8 and 5.9 fold at 6h and 24h 
respectively and I-BET151 inhibited expression by 1.9 and 2.6 fold at 6h and 
24h respectively.  Stimulation with TNF + IL-17  had even greater effects on 
S100A9, increasing expression by 3.1 and 7.3 fold at 6h and 24h respectively 
and I-BET151 inhibited expression by 1.9 and 2.2 fold at 6h and 24h 
respectively.   
 DEFB4A encodes defensin-4, an anti-microbial peptide with broad-spectrum 
activity against bacterial, fungal, and viral pathogens. -defensins also have 
chemotactic effects on dendritic and T-cells (Ganz, 2003). -defensins are some 
of the most upregulated genes in psoriasis (Suarez-Farinas et al., 2010); 
stimulation with TNF + IL-17 increased expression of DEFB4A by 7.5 and 
39.9 fold at 6h and 24h respectively and I-BET151 inhibited expression by 3.7 
and 4.8 fold at 6h and 24h respectively.   
 TGFA encodes transforming growth factor alpha, a growth factor that has been 
shown to enhance keratinocyte migration and upregulate expression of toll-like 
receptors 5 and 9 in keratinocytes, leading to enhanced secretion of IL-8 and -
defensins (Cha et al., 1996; Miller et al., 2005); stimulation with TNF + IL-17 
increased expression of TGFA by 1.6 and 1.7 fold at 6h and 24h respectively 
and I-BET151 inhibited expression by 1.4 and 1.4 fold at 6h and 24h 
respectively.   
 KYNU encodes kynureninase, a peptidase involved in tryptophan degradation; 
upregulation of tryptophan metabolism confers anti-microbial effects in cells 
including macrophages and disruption of this pathway can affect T-cell 
proliferation (Ito et al., 2004).  KYNU is one of the most upregulated genes in 
psoriasis (Suarez-Farinas et al., 2010); stimulation with TNF + IL-17 increased 
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expression of KYNU by 2.1 and 2.4 fold at 6h and 24h respectively and I-
BET151 inhibited expression by 2.3 and 3.0 fold at 6h and 24h respectively.   
 VNNI encodes Vanin 1, a pantetheinase involved in pantetheine (the cysteamine 
amide analogue of vitamin B5) metabolism. This enzyme is induced by TH1 and 
TH17 psoriasis-associated cytokines, may have roles in inflammation and 
epidermal differentiation and has previously been described as a potential target 
in psoriasis treatment (Jansen et al., 2009); stimulation with TNF + IL-17 
increased expression of VNNI by 1.3 and 1.4 fold at 6h and 24h respectively and 
I-BET151 inhibited expression by 1.4 and 1.4 fold at 6h and 24h respectively.   
 NAMPT (PBEF1) encodes nicotinamide phosphoribosyltransferase, which is 
involved in nicotinamide adenine dinucleotide (NAD) biosynthesis thus may 
regulate inflammation and cellular proliferation, NAMPT is also known to have 
cytokine functions and induces expression of IL-6, TNF and VEGF (Xie et al., 
2014); stimulation with TNF + IL-17 increased expression of NAMPT by 1.4 
and 1.6 fold at 6h and 24h respectively and I-BET151 inhibited expression by 
1.3 and 1.9 fold at 6h and 24h respectively. 
 TYMP (PD-ECGF) encodes thymidine phosphorylase, involved in pyrimidime 
metabolism and is known to act as an angiogenic growth factor and promotes 
angiogenesis in vivo and stimulates the growth and chemotaxis of cells in vitro 
(Akiyama et al., 2004); stimulation with TNF + IL-17 increased expression of 
TYMP by 1.4 and 2.2 fold at 6h and 24h respectively and I-BET151 inhibited 
expression by 1.9 and 1.8 fold at 6h and 24h respectively. 
 
In addition to the overlapping 13 genes included in both the IPA-defined psoriasis 
network and the MAD-5 psoriasis transcriptome, 13 genes only featured in the IPA 
network and 14 genes only in the MAD-5 transcriptome (Table 6-14).  There are a 
number of reasons why there was not complete concordance between the two datasets.  
As previously discussed, the information in IPA is manually curated from a wide 
variety of published data sources.  Although IPA is not without some faults (Henderson-
Maclennan et al., 2010) and it relies on published data, and publication bias is possible, 
the careful curation is likely to mean the IPA-defined psoriasis network may define a 
broader set of genes relevant to psoriasis than a purely array-based meta-analysis 
dataset. For example, it is known that microarrays can have low sensitivity compared to 
PCR-based methods (Chiricozzi et al., 2011).  Indeed, when we compared IL-6 and IL-
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8 expression profiles, based on microarray and qRT-PCR results, qRT-PCR results 
consistently demonstrated greater sensitivity compared to array data (Table 6-4.  
Chiricozzi et al. previously reported TNF +IL-17 stimulation of NHEKs had an 
additive effect on upregulating expression of some genes (e.g. LCN2) when measured 
by microarray, but that the effect was synergistic when measured by RT-PCR, 
demonstrating the latter method had greater sensitivity.  Interestingly 8 of the 13 genes 
(i.e. CXCL5, IL6, IL13A, IL1A, IL36G, IL24, CSF2 and CXCL6 (Table 6-14) included 
in the IPA dataset but not the MAD-5 dataset are cytokines and many of these cytokines 
including IL-6, in particular, are known to have key roles in psoriasis (Perera et al., 
2012; Saggini et al., 2014).  I-BET151 inhibition of IL36G may also be of particular 
interest as deficiency in IL-36 receptor antagonist is known to underlie pustular 
psoriasis (Marrakchi et al., 2011; Sugiura et al., 2013), BET inhibitors may therefore 
represent novel therapy for this potentially life threatening endotype of psoriasis.  
Stimulation of NHEKs with TNF + IL-17 increased expression of IL36G by 17.3 and 
27.5 fold at 6h and 24h respectively and I-BET151 inhibited expression by 4.9 and 4.8 
fold at 6h and 24h respectively.  The discrepancy in cytokines being excluded in DEGs 
sets in array data has previously been addressed with the explanation that “expression of 
these (inflammatory) genes is usually low on the Affymetrix gene array platform and 
hence fold change is not accurately measured.  Most analysis pipelines filter out low 
abundance genes so they may be excluded from the statistical analysis” (Suarez-Farinas 
et al., 2010); a similar explanation for the lack of many cytokines in the MAD-5 
transcriptome was made by its authors (Tian et al., 2012).  In addition variance in DEGs 
amongst different transcriptomic studies may be a factor in excluding potentially 
relevant DEGs, as illustrated by connective tissue growth factor (CTFG), below.  
Furthermore, DEGs in psoriasis are compounded by variations in numbers of relevant 
cells, which may also be in low abundance, that express the gene in the sample (section 
1.2.7).   
The 14 genes included in the MAD-5 dataset but not included in the IPA-defined 
psoriasis network, may represent interesting candidates for further study given that they 
are also upregulated by TNF + IL-17, key psoriasis cytokines. 
Interestingly there was only one gene, CTFG, which was downregulated by TNF + 
IL-17 stimulation at both 6 and 24h and upregulated by I-BET151 treatment at both 6 
and 24h; stimulation with TNF + IL-17 decreased expression of CTFG by 1.7 and 1.9 
fold at 6h and 24h respectively and I-BET151 increased expression by 7.7 and 3.3 fold 
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at 6h and 24h respectively.  Although CTFG was not included in either the IPA-defined 
psoriasis network or in the MAD-5 transcriptome, it has previously been found to be 
downregulated in psoriatic lesional skin, compared to non-lesional skin (Manczinger 
and Kemeny, 2013), and although its role in psoriasis has not yet identified it was 
identified as a central node in a network analysis of DEGs in psoriasis (Manczinger and 
Kemeny, 2013).  Connective tissue growth factor is involved in angiogenesis and acts 
downstream of TGF- and in addition to being downregulated in psoriasis, stimulation 
with key psoriasis-related cytokines (IFN + TNF) has previously been demonstrated 
to downregulate CTFG in lung endothelial cells (Laug et al., 2012). Thus CTGF may be 
a further gene of interest to investigate in the pathogenesis of psoriasis. 
I-BET151 modulated ~ 7.7% and 9.1% of the total number of probes in the array 
(~47000) at 6 and 24 h respectively, indicating effects of the compound were discrete, 
not global.  These discrete effects were in keeping with the effects of BET inhibitors in 
other models of inflammation and cancer (Nicodeme et al., 2010; Dawson et al., 2011).  
Although I-BET151 diminished expression of many genes implicated in psoriasis, the 
majority of the compound sensitive genes (~90%) did not overlap with the MAD-5 
transcriptome.  Analysis of these genes (non-overlapping with MAD-5 transcriptome) in 
IPA revealed that many were involved in the cell cycle (e.g. cell cycle: G1/S checkpoint 
regulation and cell cycle: G2/M DNA damage checkpoint regulation; both sets had 
predicted activation scores at 6h after I-BET151 treatment in TNF + IL-17 stimulated 
NHEKs, with the latter also being predicted to the activated at 24h) and p53 signaling, 
with cancer, cell cycle and cell death and survival being some of the top disease and 
biological functions.  These findings are consistent with previously published data, 
which demonstrated that BET inhibitors have anti-cancer effects (Filippakopoulos et al., 
2010; Dawson et al., 2011) and indeed BET inhibitors are currently in phase I/II clinical 
trials for the treatment for a variety of cancers (Basheer and Huntly, 2015).  
Interestingly, IPA revealed that downregulation of MYC was the central node in the 
network featuring the most number of DEGs at 24h after I-BET151 treatment in TNF 
+ IL-17 stimulated NHEKs (Figure 6-12.  Again these findings are consistent with 
previously published data which showed that BET inhibition led to downregulation of 
MYC expression in in vitro and in vivo models of mixed-lineage leukaemia (MLL)-
fusion leukaemia, multiple myeloma and neuroblastoma (Dawson et al., 2011; Delmore 
et al., 2011; Wyce et al., 2013).  Although BET inhibitors have previously been 
demonstrated to inhibit MYC expression in other cell types, it was not necessarily 
234 
 
predictable that the same would occur in TNF + IL-17 stimulated NHEKs, as BET 
inhibitors are known to have cell-type specific effect, in particular on MYC expression.  
Thus, for example, although BET inhibitors blocked expression of MYC expression in 
leukaemic cells, as described above, there were minimal effects on MYC expression in 
fibroblasts (Zuber et al., 2011).  Inhibition of Brd4 binding, by BET inhibitors, to cell-
type specific enhancers has previously been hypothesised to account for these cell-type 
specific effects (Shi and Vakoc, 2014).  Given that I-BET151 did inhibit MYC mRNA 
expression and modulate expression of genes involved in the cell cycle and other cancer 
related pathways in keratinocytes, this could provide rationale for investigating the role 
of BET proteins and the effects of BET inhibitors in suitable models of keratinocyte-
based cancers.  In this respect, keratinocyte-derived basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC) are the most common types of non-melanoma skin 
cancer, with incidences of ~76/100, 000 person-years and ~23/100, 000 person-years, 
respectively, in England (Lomas et al., 2012).  Whereas BCCs are generally indolent, 
slow growing and rarely metastasizes, untreated SCCs can penetrate underlying tissue, 
invade lymph nodes, and metastasise to distant sites.  Over expression of MYC has 
previously been described in both BCCs and SCCs, this provides further rationale for 
investigating the effects of BET inhibitors in models of these keratinocyte-based 
cancers (Freier et al., 2006; Toll et al., 2009).  
In section 4.3.2, it was demonstrated that I-BET151 had a greater maximal effect and 
was more potent in inhibiting IL-6 protein release in response to TNF + IL-17 
stimulation in NHEKs, compared to effects on IL-6 mRNA expression.  As previously 
discussed, HDAC inhibitors have previously been shown to have differential effects on 
inhibiting IL-6 mRNA vs. protein responses which could be accounted for by the 
observation that histone deacetylase (HDAC) inhibitors decreased IL-6 mRNA stability 
(section 4.4) (Grabiec et al., 2012).  We hypothesise that BET inhibitors may have 
similar posttranscriptional effects to HDAC inhibitors, to account for the differences 
that were observed.   As discussed, these effects could have been through I-BET151 i) 
directly binding and inhibiting the function of proteins/molecules with post-
transcriptional roles e.g. mRNA translation or protein trafficking, or ii) inhibiting 
expression of these proteins/molecules.  Interestingly, I-BET151 modulated the 
expression of molecules involved the IPA-defined “protein synthesis” diseases and 
functions pathway at 6h post-treatment, Figure 6-8, and the network involving the 
greatest number of DEGs at 24h was “amino acid metabolism, small molecule 
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biochemistry, post-translational modifications”, Figure 6-12.  Further interrogation of 
the “protein synthesis” pathway in IPA at 6h post I-BET151 treatment, revealed that all 
sub-categories within this group (e.g. synthesis of protein, expression of protein and 
translation of protein) had negative activation Z-scores (-1.7, -1.7 and -1.2, respectively) 
suggesting that these pathways are all downregulated by I-BET151.  These findings 
support the hypothesis that BET inhibitors can inhibit expression of proteins involved in 
mRNA translation and may explain the differential effects of I-BET151 on IL-6 mRNA 
vs. protein.  Additionally it is possible that I-BET151 could directly bind and inhibit the 
function of these protein(s).  However, direct inhibition by I-BET151 compared to 
inhibition of expression is less likely, given the high specificity of BET inhibitors and 
the observation that no non-BET binding partners have previously been described in the 
literature, as previously discussed in section 4.4. 
I-BET151 impacted expression of ~3000 genes with ~10% included in the MAD-5 
psoriasis transcriptome.  As BET inhibitors have previously been shown to bind to BET 
proteins with high affinity without any known non-BET binding partners (Nicodeme et 
al., 2010; Klein et al., 2014), it is likely that BET proteins are involved in the regulation 
of many genes in keratinocytes, included ones relevant to psoriasis.  In sections 4.3.4 
and 4.3.5, it was demonstrated that I-BET151 inhibition of IL-6 and IL-8 expression 
could be explained by the reduction in BET proteins binding to IL-6 and IL-8 promoter 
regions in the presence of I-BET151.  Although a similar mechanism may account for 
how I-BET151 inhibits the expression of a number of these other genes in 
keratinocytes, other underlying mechanisms are possible.  For example, some will be 
secondary effects, e.g. some genes will be downstream of genes directly regulated by 
BET proteins; expression of other genes may be inhibited by I-BET-151 through 
disruption of Brd4/pTEFb and Brd4/p65 interactions (Jang et al., 2005; Huang et al., 
2009; Schroder et al., 2012).  Finally, in addition to blocking BET proteins binding to 
gene promoter regions, I-BET151 may also block BET proteins binding to keratinocyte 
enhancer regions which may result in the downregulation of a variety of cell-specific 
genes as previously demonstrated in other cell types (Delmore et al., 2011).  It would be 
of particular interest to understand the underlying mechanism(s) by which BET 
inhibitors block expression of key regulators of inflammation (e.g. IL1A & B and 
NFKB1) (Table 6-12).  Of note, as BET inhibitors modulate expression of a wide 
variety of genes, many not involved in the pathogenesis of psoriasis, topical application 
of BET inhibitors (small molecules) may be a method to avoid widespread systemic 
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effects.  In this respect, topical application of JQ1, a BET inhibitor, was recently shown 
to inhibit psoriasis-like cutaneous inflammation in an imiquimod-induced mouse model 
of psoriasis (Nadeem et al., 2015).   
6.5. Future work 
In summary I-BET151 treatment in TNF + IL-17 stimulated NHEKs altered 
expression of a variety of genes, including ones known to be upregulated in psoriasis 
and with known roles in its pathogenesis.  In addition a number of DEGs, whose 
functions have not been previously characterised in psoriasis, were also identified and 
may be interesting candidates for further investigation.  The sensitivity of psoriasis 
related genes to the BET inhibitor supports a biological model for psoriasis 
pathogenesis, in which epigenetic processes, including histone acetylation, are involved 
in the psoriasis phenotype and that these processes can be dynamic and reversible. The 
effect of the BET inhibitor highlights the potential for targeting epigenetic processes, 
and in this case specifically BET proteins are implicated as targets. Collectively the data 
highlight the area of epigenetics as a potential route to identify novel disease modifying 
therapies.  Furthermore, many DEGs sensitive to I-BET151 treatment were involved in 
the cell cycle, p53 signalling and MYC regulated pathways, in keeping with previously 
published data of BET inhibitors in other model systems, thus providing rationale for 
studying the potential effects of BET inhibitors in keratinocyte-based skin cancers. 
Using these datasets, a number of further analyses would be of interest: 
 Using IPA to interrogate datasets, what are the predicted downstream effects of 
DEGs regulated by TNF + IL-17 and I-BET151, and how do these relate to the 
pathogenesis of psoriasis and disease resolution? 
 How do genes regulated by I-BET151 treatment relate to changes in gene 
expression after psoriasis treatments which are in current use?  Such an analysis 
may provide further justification for investigating the effects of BET inhibitors 
in psoriasis, and may identify potential novel therapeutic opportunities and 
combination treatments? 
 In addition to taking a Venn diagram approach to compare DEGs to published 
datasets, e.g. to psoriasis or cancer transcriptome, using a gene set enrichment 
analysis (GSEA) approach allows whole datasets or pathways to be compared, 
not just individual genes (Suarez-Farinas et al., 2010).  Although the list of 
genes identified through the Venn diagram approach are of interest, taking a 
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GSEA approach may enrich for a wider set of genes and identify particular 
pathways or functions for further investigation into the role in psoriasis or its 
treatment.  
 qRT-PCR validation of array for IL-6 and IL-8 already performed, it would be 
important to validate array of other target genes e.g. from Table 6-14, in the 
form of qRT-PCR from the same 12 donors used in the array.  It would also be 
interesting to understand protein expression profile of validated genes in 
response to TNF + IL-17 stimulation and I-BET151 treatment. 
6.6. Conclusions 
 There was considerable overlap of DEGs regulated by TNF + IL-17 
stimulation of NHEKs at 6h and 24h post-stimulation and of the top 5 upstream 
regulators of DEGs at each timepoint, 4 were common to both datasets (TNF, 
NFKB, IL1A and IFNG) and known to regulated inflammatory responses in 
psoriasis. 
 I-BET151 treatment of TNF + IL-17 stimulated NHEKs resulted in ~3000 
DEGs at both 6 and 24h post-treatment.  DEGs were involved in cell cycle, p53 
signalling and inflammation, in keeping with previously published anti-
proliferative and anti-inflammatory effects of BET inhibitors in other in vitro 
and in vivo models of disease.  
 Regulators of I-BET151-sensitive DEGs included IL1A & B and NFBK1, which 
are known key regulators of inflammatory circuits in psoriasis.  Furthermore, of 
the 1120 up or downregulated DEGs in the MAD-5 transcriptome, 
approximately 20% of genes were differentially modulated by I-BET151 
treatment in TNF + IL-17 stimulated NHEKs, at 6h and 24h respectively.  
These findings supported the rationale for evaluating I-BET151 in a model of 
cutaneous inflammation. 
 59 genes were upregulated by TNF + IL-17 stimulation but downregulated by 
I-BET151 treatment, at both 6 and 24h.  Of these 59 genes, 26 were included in 
an IPA-defined psoriasis network and 27 were included in the MAD-5 psoriasis 
transcriptome. 13 genes were included in both datasets, with known roles in 
psoriasis, and other genes may warrant further investigation for their potential 
roles in the pathogenesis of psoriasis or as potential novel target for treatment. 
 The observation I-BET151 modulated expression of genes involved in cell 
cycle, inflammation and cancer pathways in keratinocytes could provide 
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rationale for investigating the effects of BET inhibitors in models skin cancer 
and other non-psoriatic inflammatory skin disease. 
 I-BET151 modulated expression of genes involved in protein synthesis and all  
sub-categories within this group (e.g. synthesis of protein, expression of protein 
and translation of protein) had negative activation Z-scores suggesting that these 
pathways were all downregulated by I-BET151.  This may explain the 
differential effects of I-BET151 on IL-6 mRNA vs. protein responses to TNF + 
IL-17 stimulation in NHEKs. 
 The sensitivity of psoriasis related genes to I-BET151 supports a role for 
epigenetic mechanisms in regulating the psoriasis phenotype and highlights the 
potential for targeting epigenetic processes; specifically BET proteins were 
implicated as targets in treating cutaneous inflammation. This highlights the area 
of epigenetics as potential targets for novel disease modifying treatment.   
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7. The effects of exogenous factors in the in vitro model of cutaneous 
inflammation 
 
7.1. Introduction 
Genetic susceptibility is known to contribute to inflammatory skin diseases; 
monozygotic twins show a concordance of 65–72% for psoriasis, versus 15–30% in 
dizygotic twins (Bowcock and Cookson, 2004) and genome wide association studies 
have identified 41 psoriasis susceptibility loci in individuals of European ancestry (Tsoi 
et al., 2012; Tsoi et al., 2015).  However, 36 of the 41 previously discovered psoriasis 
susceptibility loci were predicted to account for only approximately 14% of the total 
variance of psoriasis risk or approximately 22% of its estimated heritability (Tsoi et al., 
2012), which together with the observation that monozygotic twins do not show 
complete concordance for psoriasis, implies non-genetic factors must also contribute to 
disease.   
As previously discussed in section 1.4, epidemiological studies implicate environmental 
factors including alcohol and drugs, e.g. beta-blockers (-blockers) and lithium, in the 
development and exacerbation of psoriasis.  For example, the relative risk of developing 
psoriasis was 1.73 (95% confidence interval, 1.16–2.58) in those who consumed ≥ 2.3 
alcoholic drinks/week compared with those who did not drink any alcohol (Qureshi et 
al., 2010).  Many investigators also report that alcohol consumption can exacerbate pre-
existing psoriasis (Higgins, 2000) and that abstinence can induce remission (Vincenti 
and Blunden, 1987).  Incidence of lithium exacerbation or induction of psoriasis ranges 
between 3.4 – 45%, is not necessarily dose related and latency periods of  20 weeks 
(mean) for exacerbation and 48 weeks (mean) for induction of psoriasis are reported 
(Rongioletti et al., 2009).  An analysis of the UK-based General Practice Research 
Database, showed that patients who received 5 or more prescriptions of lithium had an 
odds ratio of 1.68 (95 confidence interval: 1.18-2.39) for developing psoriasis compared 
to those who did not receive lithium (Brauchli et al., 2009).  -blockers are also widely 
accepted to both provoke and exacerbate existing psoriasis, although latency can be 
over 1 year (Rongioletti et al., 2009), not all patients exposed to -blockers will develop 
psoriasis and discontinued use of the offending drug will induce remission of -blocker-
induced psoriasis in the majority of patients (Arntzen et al., 1984).  In addition to drugs, 
infections e.g. Streptococcal Group A (S pyogenes) throat infections and stress are also 
implicated as risk factors in the development and exacerbation of psoriasis (Peters et al., 
2000). 
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Specific environmental factors have also been associated with particular psoriasis 
phenotypes.  For example, patients with high alcohol intake have a tendency towards a 
more inflamed psoriasis phenotype (Higgins and du Vivier, 1992), whereas patients 
taking lithium are often reported to develop generalised plaque or pustular psoriasis 
(Lowe and Ridgway, 1978; White, 1982; Jafferany, 2008). 
Increased knowledge of genetic components may lead to greater understanding of 
psoriasis pathogenesis.  However genetic susceptibility, unlike environmental insults, 
may be irreversible and unavoidable.  Although it is unknown how environmental 
factors interact with genetic components and the adaptive and innate immune systems to 
produce the different disease phenotypes in psoriasis, greater understanding of the 
underlying mechanisms could lead to the development of novel therapies to target these 
mechanisms.  Although a variety of mechanisms may exist; it has previously been 
shown that environmental factors can alter the epigenome which may then impact on 
phenotype.  For example, Park et al. were the earliest investigators to demonstrate that 
ethanol treatment, in rat derived hepatocytes, resulted in histone hyperacetylation (Park 
et al., 2003), and ingestion of alcohol in rats in vivo also leads to enhanced histone 
acetylation in the liver and spleen but not in brain or kidney (effects in skin were not 
investigated) (Kim and Shukla, 2006).  In a macrophage model of acute alcoholic 
hepatitis, ethanol and its principal metabolite, acetate, enhanced cytokine responses to 
pro-inflammatory stimuli through hyperacetylation of histones at the promoter region of 
inflammatory genes (Kendrick et al., 2010).      
Given that environmental factors can influence the psoriasis phenotype, and therefore 
potentially gene expression, this raised the hypothesis that in the normal human 
epidermal keratinocytes (NHEKs) model of cutaneous inflammation, exogenous factors 
would potentiate expression and secretion of pro-inflammatory cytokines.  Furthermore, 
potentiation of inflammatory responses by exogenous factors might be through 
chromatin remodelling e.g. via hyperacetylation thus promoting altering gene 
expression. 
To test this hypothesis, the effects of clinically relevant concentrations of a variety of 
exogenous factors (e.g. ethanol, lithium and beta-blockers), implicated in the risk of 
developing or exacerbation of psoriasis, were examined in the NHEKs model of 
cutaneous inflammation.  Expression of pro-inflammatory cytokines in response to a 
variety of stimuli and underlying changes in chromatin were investigated. 
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7.2. Aims 
 To investigate whether exogenous factors, relevant to the psoriasis phenotype, 
can alter inflammatory responses in the NHEKs model of cutaneous 
inflammation and understand if these effects are stimulus specific (e.g. cytokine 
vs. non-cytokine stimuli). 
 To investigate epigenetic mechanisms underlying modulation of inflammatory 
responses by exogenous factors and test whether these might represent potential 
therapeutic targets. 
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7.3. Results 
7.3.1. Acetate, but not ethanol, potentiated the IL-6 response to TNF + IL-17 
stimulation 
Psoriasis patients who consume excess alcohol have a tendency towards  a more severe, 
widespread and inflamed phenotype (Monk and Neill, 1986; Higgins and Du Vivier, 
1994b).  This raised the hypothesis that ethanol would potentiate pro-inflammatory 
cytokine responses in NHEKs, as previously shown in ethanol treated macrophages 
(Kendrick et al., 2010).  To understand whether ethanol or acetate (one of ethanol’s 
principal metabolites, section 1.4.2), could potentiate responses to inflammatory stimuli, 
primary human NHEKs were incubated with ethanol or acetate for 7 days prior to 
stimulation with TNF + IL-17.  The incubation time with acetate was previously 
shown to enhance subsequent responses to stimuli in macrophages (Kendrick et al., 
2010).   Serum levels of TNF and IL-17 are both increased in patients with psoriasis 
and correlate with disease activity (Takahashi et al., 2010) and was earlier demonstrated 
to regulate expression of genes relevant to psoriasis (sections 3.3.1and 6.4).  Media 
supernatants were collected after 48h and IL-6 and IL-8 levels in the conditioned media 
were measured by ELISA.  The ethanol concentration (86mM, 0.5%, 400mg/dL) used 
was equivalent to five times the legal blood ethanol concentration for driving in the UK 
and the acetate concentration (1mM) was equivalent to the corresponding serum 
concentration observed in individuals metabolising ethanol at the concentration used 
(Mascord et al., 1992).  In a study of over 700 drunken drivers in Finland, offenders had 
blood ethanol and acetate levels similar or higher than the concentrations assayed, 
suggesting the concentrations used were clinically relevant (Roine et al., 1988).  
As shown in Figure 7-1, pre-incubation with acetate (1mM) for 7 days potentiated the 
release of IL-6 from primary human NHEKs in response to stimulation with TNF + 
IL-17 for 48h (~50% enhancement compared to control, p<0.01).  On the other hand, 
acetate did not potentiate IL-8 release in response to TNF + IL-17 stimulation.  
Although acetate appeared to have an inhibitory affect on IL-8 release, this was not 
significant.  In comparison to acetate, pre-incubation with ethanol did not significantly 
potentiate IL-6 or IL-8 responses to TNF + IL-17 stimulation.  Neither ethanol nor 
acetate affected basal IL-6 or IL-8 secretion, in unstimulated NHEKs. 
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Figure 7-1: Acetate but not ethanol potentiated IL-6 secretion in response to TNF 
+ IL-17 stimulation  
NHEKs were incubated with media, 1mM acetate (A and B) or 86mM (0.5%, 
400mg/dL) ethanol (C and D) or for 7 days prior to stimulation with TNF (10ng/ml) + 
IL-17 (100ng/ml) or mock stimulated.  Supernatants were collected 48h post-
stimulation and secreted IL-6 (A and C) and IL-8 (B and D) levels were measured by 
ELISA. (N=3, with each donor performed in triplicate repeat Analysis by one-way 
ANOVA with Dunnett’s post-test, comparing against the relevant media control; 
*p<0.05, **p<0.01, ***p<0.001.  Graphs show mean of data points (normalised to 
media/unstimulated control) ± SEM .  The absolute values for secreted IL-6 and IL-8 
(Mean ± SEM) were 613 pg/ml ± 127 and 1003 pg/ml ± 177, respectively in TNF + 
IL-17 stimulated, media treated NHEKs. 
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7.3.2. Keratinocytes demonstrated low expression of enzymes involved in ethanol 
metabolism 
Having observed that ethanol, unlike its principal metabolite acetate, did not potentiate 
the IL-6 response to TNF + IL-17 stimulation we hypothesised that NHEKs may not 
metabolise ethanol.  In vivo, ethanol is metabolised to acetaldehyde by alcohol 
dehydrogenase (ADH), mainly ADH1A, ADH1B and ADH1C. Acetaldehyde is 
subsequently oxidised to acetate by aldehyde dehydrogenase (ALDH), mainly ALDH1 
and ALDH2 (section 1.4.2). 
To investigate this hypothesis, expression of ADH and ALDH in NHEKs was 
determined by qRT-PCR using Taqman
®
 gene expression assays, with a hepatocellular 
carcinoma cell line (HepG2) as a comparative positive control. 
As shown in Figure 7-2, NHEKs demonstrated significantly lower expression of all 
isoenzymes of both ADH and ALDH involved in ethanol metabolism, compared to 
HepG2 cells suggesting that there is little metabolism of ethanol in keratinocytes. 
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Figure 7-2: Keratinocytes demonstrated low expression of enzymes involved in 
ethanol metabolism 
Taqman
®
 gene expression assays were used to compare NHEKs expression of 
isoenzymes of ADH (A) and ALDH (B) to HepG2 cells. (N=3, with each donor 
performed in triplicate repeat) Analysis by t-test; *p<0.05, **p<0.01, ***p<0.001.  
Graphs show mean of data points (relative to HepG2 positive control) ± SEM. 
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7.3.3. Acetate potentiated the IL-6, but not IL-8, mRNA responses to TNF + IL-
17 stimulation 
Incubation of NHEKs with acetate for 7 days prior to stimulation enhanced the level of 
secreted IL-6 detected in conditioned medium in response to TNF + IL-17 stimulation.  
We hypothesised that acetate-enhanced levels of IL-6 detected in conditioned medium 
following TNF + IL-17 stimulation may reflect at least in part an increase in IL-6 
mRNA production.  To test this hypothesis, primary human NHEKs were grown in the 
presence of 1mM acetate for 7 days prior to stimulation with TNF + IL-17.  As 
expression of IL-6 and IL-8 mRNA was previously demonstrated to be maximal at 6h 
after stimulation (section 3.3.2), NHEKs were harvested at various timepoints around 
6h post-stimulation (3-12h) and IL-6 and IL-8 mRNA levels measured by qRT-PCR. 
As shown in Figure 7-3, pre-treatment with acetate (1 mM) for 7 days significantly 
enhanced IL-6 mRNA production at 6-10h post TNF + IL-17 stimulation, but 
interestingly this effect was reduced at 12h post-stimulation.  In contrast, pre-treatment 
with acetate appeared to inhibit IL-8 mRNA production at all timepoints, although this 
was only significant at 6h, 10h and 12h post- TNF + IL-17 stimulation.  Pre-treatment 
with acetate did not affect basal production of IL-6 or IL-8 mRNA at any of the 
timepoints investigated, in unstimulated NHEKs.  
These findings are in keeping with the differential effect of acetate on IL-6 and IL-8 
cytokine release post-TNF + IL-17 stimulation and suggest that acetate could mediate 
this effect at least in part through transcriptional responses.  
  
248 
 
3h 6h 8h 10h 12h
0
5
10
15
20 Media
Media + acetate
Media + TNF plus IL-17
Media + acetate + TNF plus IL-17
R
e
la
ti
v
e
 I
L
-6
 m
R
N
A
e
x
p
re
s
s
io
n
(n
o
rm
a
li
s
e
d
 t
o
 r
e
le
v
a
n
t
m
e
d
ia
 c
o
n
tr
o
l)
ns ns ns ns ns
nsns * *** ***
A)
 
3h 6h 8h 10h 12h
0
10
20
30
R
e
la
ti
v
e
 I
L
-8
 m
R
N
A
e
x
p
re
s
s
io
n
(n
o
rm
a
li
s
e
d
 t
o
 r
e
le
v
a
n
t
m
e
d
ia
 c
o
n
tr
o
l)
ns ns ns ns ns
*ns *** ns **
B)
 
Figure 7-3: Pre-treatment with acetate potentiates the IL-6 mRNA response to 
TNF + IL-17 stimulation and attenuates the IL-8 mRNA response to TNF + IL-
17 stimulation in a time dependent manner 
Primary human NHEKs were incubated with or without 1mM acetate for 7 days prior to 
stimulation with TNF (10ng/ml) + IL-17 (100ng/ml) or mock stimulated.  Cells were 
harvested for mRNA at indicated timepoints post-stimulation and IL-6 (A) and IL-8 (B) 
mRNA levels were measured by qRT-PCR. (N=3, with each donor performed in 
duplicate repeat) Analysis by two-way ANOVA with Bonferroni post-test; *p<0.05, 
**p<0.01, ***p<0.001.  Graphs show mean of data points (normalised to unstimulated 
media control within each timepoint) ± SEM. 
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7.3.4. The potentiation by acetate of the IL-6 response to TNF + IL-17 
stimulation was concentration dependent 
Having observed that 7 days’ pre-treatment of primary human NHEKs with 1mM 
acetate potentiated the subsequent IL-6 response to TNF + IL-17 stimulation, we 
sought to understand the concentration range of acetate for which this potentiation could 
be observed.  NHEKs were therefore incubated with increasing concentrations of 
acetate (0.2 – 1mM) for 7 days prior to stimulation with TNF + IL-17, reflecting 
physiological concentrations observed in vivo.  Cells were harvested 6h post-TNF + 
IL-17 stimulation for mRNA extraction to determine IL-6 and IL-8 mRNA levels 
(measured by qRT-PCR).  Media supernatants were collected from parallel cultures of 
NHEKs 48h post- TNF + IL-17 stimulation and secreted IL-6 and IL-8 levels were 
measured by ELISA. 
As shown in Figure 7-4, the potentiation by acetate of IL-6 expression in response to 
TNF + IL-17 stimulation appeared to be concentration dependent.  For effects on IL-6 
mRNA, the potentiation was significant for both 0.6mM acetate (p<0.05) and 1mM 
acetate (p<0.05), but at the secreted protein level this was only significant for 1mM 
acetate (p<0.05).   Acetate did not potentiate or attenuate IL-8 mRNA production or 
secreted protein in response to TNF + IL-17 stimulation, at any of the concentrations 
of acetate assayed.  Furthermore, acetate did not potentiate or attenuate basal IL-6 or IL-
8 mRNA or secreted protein production, in unstimulated NHEKs, at any concentration. 
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Figure 7-4: Acetate demonstrated concentration-dependent potentiation of IL-6 
expression in response to TNF + IL-17 stimulation 
NHEKs were incubated with acetate (0.2 - 1mM) or media for 7 days prior to 
stimulation with TNF (10ng/ml) + IL-17 (100ng/ml) or mock stimulated.  Cells were 
harvested 6h post-stimulation and IL-6 (A) and IL-8 (B) mRNA measured by qRT-
PCR.  Media supernatants were collected 48h post-stimulation and secreted IL-6 (C) 
and IL-8 (D) levels were measured by ELISA. (for mRNA: N=3, with each donor 
performed in duplicate repeat; for protein: N=3, with each donor performed in triplicate 
repeat) Analysis by one-way ANOVA with Dunnett’s post-test, comparing against the 
relevant media control; *p<0.05, **p<0.01, ***p<0.001.  Graphs show mean of data 
points (for mRNA, levels were normalised to unstimulated media control) ± SEM.           
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7.3.5. In comparison to acetate, lithium and propranolol did not potentiate the IL-
6 response to TNF + IL-17 stimulation 
In addition to ethanol, lithium and propranolol have also been implicated in the 
development and exacerbation psoriasis (Brauchli et al., 2009; Rongioletti et al., 2009) 
and we hypothesised that these may enhance pro-inflammatory responses to TNF + 
IL-17 stimulation.  To address this, NHEKs were pre-incubated with 1mM lithium 
chloride, 1mM lithium carbonate or 150ng/ml propranolol hydrochloride (propranolol) 
for 7 days prior to stimulation with TNF + IL-17. The concentration of lithium 
assayed was equivalent to the therapeutic concentration used clinically (BNF, 2015) and 
the concentration of propranolol was equivalent to the concentration required to achieve 
physiological beta-receptor blockade (Duff et al., 1986).  As there are often long latency 
periods between lithium or -blocker exposure and development or exacerbation of 
psoriasis (Rongioletti et al., 2009), and 7 days exposure to acetate was necessary to 
demonstrate potentiation of inflammatory responses, the effects 7 days incubation with 
lithium or -blocker prior to stimulation was assayed.   Although lithium is prescribed 
as either lithium carbonate or lithium citrate, for the treatment of bipolar disorder and 
depression (BNF, 2015), lithium chloride has previously been shown to induce 
keratinocyte proliferation, a key feature of psoriasis, through inhibition of glycogen 
synthase kinase 3 (GSK-3) (Hampton et al., 2012).  For this reason, the potential effect 
of lithium chloride on inflammatory responses in NHEKs was also investigated.  
NHEKs were harvested 6h post-TNF + IL-17 stimulation for mRNA (measured by 
qRT-PCR).  Supernatants were collected 48h post-stimulation and secreted IL-6 and IL-
8 levels were measured by ELISA.    
As shown in Figure 7-5, unlike acetate, neither lithium chloride, lithium carbonate nor 
propranolol potentiated IL-6 or IL-8 responses (mRNA or secreted protein) to TNF + 
IL-17 stimulation.  Although propranolol appeared to potentiate expression of IL-6 
mRNA in response to TNF + IL-17 stimulation, this effect was not significant and this 
did not translate into potentiation of secreted IL-6 protein.  In unstimulated NHEKs, 
lithium chloride, lithium carbonate and propranolol had no significant effect on basal 
production of IL-6 or IL-8 mRNA or secreted protein.  These findings suggest that, 
while both lithium and -blockers are implicated as risk factors in the development and 
exacerbation of psoriasis, they may act through alternative mechanisms to alcohol. 
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Figure 7-5: Pre-incubation with lithium or propranolol had no significant effect on 
IL-6 or IL-8 cytokine secretion in response to TNF + IL-17 stimulation 
NHEKs were incubated with acetate (1mM), lithium chloride (1mM), lithium carbonate 
(1mM) or propranolol (150ng/ml) or media for 7 days prior to stimulation with TNF 
(10ng/ml) + IL-17 (100ng/ml) or mock stimulated.  Cells were harvested 6h post-
stimulation and IL-6 (A) and IL-8 (B) mRNA measured by qRT-PCR.  Supernatants 
were collected 48h post-stimulation and secreted IL-6 (C) and IL-8 (D) levels were 
measured by ELISA. (for mRNA: N=3, with each donor performed in duplicate repeat; 
for protein: N=3, with each donor performed in triplicate repeat) Analysis by one-way 
ANOVA with Dunnett’s post-test, comparing against the relevant media control; 
*p<0.05, **p<0.01, ***p<0.001.  Graphs show mean of data points (for mRNA, levels 
were normalised to unstimulated media control) ± SEM.        
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7.3.6. IL-6 responses were more sensitive to potentiation by acetate compared to 
IL-8 responses 
To determine whether potentiation by acetate of inflammation was specific to TNF + 
IL-17 stimulation, NHEKs were grown in the presence of 1mM acetate for 7 days prior 
to stimulation with cytokine or non-cytokine stimuli including TNF, IL-17, TNF + 
IL-17, UVB or poly:IC or mock.  Supernatants were collected 48h post-stimulation and 
secreted IL-6 and IL-8 levels were measured by MSD
®
.  
As shown in Figure 7-6, IL-6 and IL-8 were both induced by all stimuli.  In addition to 
acetate potentiating the secretion of IL-6 in response to TNF + IL-17 stimulation 
(p<0.01), as previously observed, acetate also significantly potentiated IL-6 secretion in 
responses to TNF alone (p<0.05) and IL-17 alone (p<0.001).  Interestingly acetate also 
potentiated IL-6 secretion in response to non-cytokine stimuli (UVB; p<0.01, but not 
poly:IC).  In comparison, acetate potentiated the secretion of IL-8 in response to TNF 
alone (p<0.05) and UVB (p<0.01), but not IL-17 alone or TNF + IL-17, as previous 
demonstrated. 
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Figure 7-6: Acetate potentiated secretion of IL-6 and IL-8 in response to cytokine 
and non-cytokine stimuli; IL-6 was more sensitive to potentiation 
NHEKs were incubated with or without 1mM acetate for 7 days prior to stimulation 
with TNF (10ng/ml),  IL-17 (100ng/ml), TNF (10ng/ml) + IL-17 (100ng/ml), UVB 
(3SED) or poly:IC (0.5g/ml).   Supernatants were collected 48h post-stimulation and 
secreted IL-6 (A) and IL-8 (B) levels were measured by MSD
®
. (N=6, with each donor 
performed in triplicate repeat)  Analysis by two-way ANOVA with Bonferroni post-
test; *p<0.05, **p<0.01, ***p<0.001; *p<0.05, **p<0.01, ***p<0.001.  Graphs show 
mean of data points (normalised to media/unstimulated control) ± SEM. 
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7.3.7. Prolonged exposure of NHEKs to acetate prior to stimulation with TNF + 
IL-17 is necessary for potentiation of IL-6 secretion 
Previously, incubation of NHEKs with acetate for 7 days was shown to enhance IL-6 
inflammatory response to TNF + IL-17 stimulation (Figure 7-1), in keeping with 
acetate’s effect in a macrophages (Kendrick et al., 2010).  In order to understand time-
dependent effects of acetate exposure, NHEKs were grown in the presence of 1mM 
acetate for 2 days prior to stimulation with TNF, IL-17 or TNF + IL-17.  
Supernatants were collected after a further 48h and secreted IL-6 and IL-8 levels were 
measured by ELISA.  
As shown in Figure 7-7 and in contrast to acetate exposure for 7 days (Figure 7-1) 
exposure of NHEKs to acetate for only 2 days, was insufficient to demonstrate 
potentiation of the IL-6 secreted protein response to TNF, IL-17, or TNF + IL-17 
stimulation, although there were trends for enhancement these were not significant.  
Equally, although there were general trends for inhibition, there were no significant 
effects on IL-8 responses after 2 days of exposure to acetate, in the presence or absence 
of subsequent stimulation. 
  
256 
 
 
0
200
400
600
800
Unstimulated
ns
A)
Media
Media + acetate
TNF IL-17 TNF  + IL-17
ns
ns
ns
IL
-6
 p
ro
te
in
 (
p
g
/m
l)
 
0
500
1000
1500
Unstimulated
B)
TNF IL-17 TNF  + IL-17
ns
ns ns
ns
IL
-8
 p
ro
te
in
 (
p
g
/m
l)
 
Figure 7-7: Exposure to acetate for 2 days was insufficient to significantly affect 
pro-inflammatory responses 
NHEKs were incubated with or without 1mM acetate for 2 days prior to stimulation 
with TNF (10ng/ml), IL-17 (100ng/ml) or TNF (10ng/ml) + IL-17 (100ng/ml).  
Supernatants were collected 48h post-stimulation and secreted IL-6 (A) and IL-8 (B) 
levels were measured by ELISA. (N=3, with each donor performed in triplicate repeat) 
Analysis by one-way ANOVA with Dunnett’s post-test, comparing against the relevant 
media control; *p<0.05, **p<0.01, ***p<0.001.  Graphs show mean of data points ± 
SEM. 
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7.3.8. Acetate reduced keratinocyte metabolism and total protein in the presence 
of specific pro-inflammatory stimuli  
In addition to excessive inflammation, psoriasis is also characterised by excessive 
epidermal keratinocyte proliferation.  We therefore hypothesised that acetate may 
enhance NHEKs proliferation and cellular metabolism. To test this hypothesis, NHEKs 
were grown in the presence of 1mM acetate for 7 days prior to stimulation with both 
cytokine and non-cytokine stimuli including TNF, IL-17, TNF + IL-17, UVB or 
poly:IC.  48h later effects on cellular metabolism (measured by MTT) and total protein 
(measured by SRB, which is highly correlated with cell density) (Skehan et al., 1990), 
were determined. 
As shown in Figure 7-8: The effects of acetate on cellular metabolism and total protein 
were stimulus specific, pre-incubation with acetate had no effect on total protein or 
cellular metabolism in unstimulated NHEKs compared to control.  On the other hand, 
pre-incubation with acetate had a significant inhibitory effect on total protein (p<0.001), 
but not cellular metabolism in TNF + IL-17 stimulated cells.  In the presence of 
poly:IC stimulation, acetate inhibited both cellular metabolism (p<0.01) and total 
protein (p<0.01).   
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Figure 7-8: The effects of acetate on cellular metabolism and total protein were 
stimulus specific 
NHEKs were pre-incubated with or without 1mM acetate for 7 days prior to stimulation 
with TNF (10ng/ml),  IL-17 (100ng/ml), TNF (10ng/ml) +  IL-17 (100ng/ml), UVB 
(3SED) or poly:IC (0.5g/ml) or mock.   48h post-stimulation effects on NHEKs 
metabolism (A) (measured by MTT) and total protein (B) (measured by SRB) were 
determined.  (N=6, with each donor performed in triplicate repeat)  Analysis by two-
way ANOVA with Bonferroni post-test; *p<0.05, **p<0.01, ***p<0.001; *p<0.05, 
**p<0.01, ***p<0.001.  Graphs show mean of data points (normalised to 
media/unstimulated control) ± SEM.  
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7.3.9. At the IL-6 promoter, acetate exposure prior to stimulation resulted in 
enhancement of active epigenetic epitopes and RNA polymerase II 
recruitment in TNF + IL-17 stimulated NHEKs 
The observation that exposure of NHEKs to acetate for 7 days, prior to stimulation with 
TNF + IL-17, enhanced IL-6 expression (mRNA and protein) raised the hypothesis 
that an epigenetic mechanism was involved, as previously demonstrated in a 
macrophage model of acute alcoholic hepatitis (Kendrick et al., 2010).  Since TNF + 
IL-17 stimulation of NHEKs resulted in an increase in permissive epigenetic epitopes 
(acetyl-H3, H3K9ac, H3K27ac and H3K4me3) but not a repressive epitope (H3K4me1) 
at the IL-6 promoter (section 5.3.1), and acetate enhanced IL-6 responses to TNF + IL-
17 stimulation, it was hypothesised that acetate treatment would lead to an increase in 
permissive marks at the IL-6 promoter thus facilitating gene expression. 
To explore this hypothesis, chromatin immunoprecipitation (ChIP) studies were 
undertaken to understand acetate’s effects on the epigenome.  NHEKs were grown in 
the presence of 1mM acetate for 7 days prior to stimulation with TNF + IL-17.  As IL-
6 (and IL-8) mRNA expression was maximal at 6h post-TNF + IL-17 exposure 
(Figure 7-3), and it is likely that any chromatin remodelling and epigenetic changes 
would precede maximal transcription, NHEKs were harvested at 1h and 4h post-TNF 
+ IL-17 stimulation for ChIP studies.  We were particularly interested to investigate 
whether acetate modulated the following permissive epigenetic marks that were 
identified to be increased by TNF + IL-17 stimulation (sections 5.3.1 and 5.3.2): 
global acetylation of histone H3, Acetyl-H3; acetylation of the lysine 9 residue on 
histone H3, H3K9ac; acetylation of the lysine 27 residue on histone H3, H3K27ac; and 
tri-methylation of the lysine 4 residue on histone H3, H3K4me3.  Chromatin was 
selectively immunoprecipitated with antibodies to:  
 RNA polymerase II, phosphorylated (and therefore activated) at its serine 2 
residue (pol II (S2P)) 
 epigenetic epitopes known to positively regulate gene expression: Acetyl-H3, 
H3K9ac, H3K27ac and H3K4me3 
 epigenetic epitopes known to have repressive effects on gene expression: mono-
methylation of the lysine 4 residue on histone H3, H3K4me1  
 IgG was used as a negative control and -pan H3 a positive control 
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Co-immunoprecipitated DNA was assayed by real-time PCR (qPCR) for enrichment of 
the IL-6 promoter region, using specifically designed primers directed at the IL-6 
promoter region (Qiao et al., 2013), in media + acetate treated NHEKs compared to 
media alone.  Enrichment of a particular region of DNA (e.g. IL-6 promoter) reflects the 
extent to which this region was associated with the histone modification or transcription 
factor/protein of interest. 
As previously discussed in (section 5.3.1), we observed enrichment of pol II (S2P) at 
the IL-6 promoter after TNF + IL-17 stimulation (4h, p<0.05), Figure 7-9.   Perhaps 
more notably, pre-incubation with acetate enhanced the recruitment of pol II (S2P) to 
the IL-6 promoter (4h, p<0.05) in TNF + IL-17 stimulated NHEKs.  In addition pre-
incubation with acetate also significantly enhanced the TNF + IL-17 stimulated active 
epigenetic epitopes at 4h (Acetyl-H3, p<0.001; H3K9ac, p<0.01; H3K27ac, P<0.001; 
H3K4me3, P<0.001) in TNF + IL-17 stimulated NHEKs.    By comparison, pre-
incubation with acetate had no significant effect on the repressive H3K4me1 mark. 
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Figure 7-9: At the IL-6 promoter, pre-incubation with acetate enhanced active 
epigenetic epitopes and pol II (S2P) recruitment  
NHEKs were incubated with or without 1mM acetate for 7 days prior to stimulation 
with TNF (10ng/ml) + IL-17 (100ng/ml) or mock stimulated.  NHEKs were harvested 
at 1h and 4h post-stimulation and ChIP undertaken using antibodies to pol II (S2P) (A), 
epigenetic epitopes that positively regulate gene expression, highlighted in green (B) 
and epigenetic epitopes with repressive effects on gene expression, highlighted in red 
(C).  Quantification of co-immunoprecipitated DNA was performed by qPCR, using 
primers to the IL-6 promoter region.    (N=3)  Analysis by one-way ANOVA with 
Dunnett’s post-test, comparing against the unstimulated media control; +p<0.05, 
++
p<0.01, 
+++
p<0.001.  Analysis by two-way ANOVA with Bonferroni post-test, 
comparing against the relevant media control; *p<0.05, **p<0.01, ***p<0.001.  Data 
points show mean (after subtracting background/non-specific binding and normalised to 
an input control) ± SEM.  
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7.3.10. In comparison to effects at the IL-6 promoter, at the IL-8 promoter acetate 
exposure decreased active epigenetic epitopes and RNA polymerase II 
recruitment in TNF + IL-17 stimulated keratinocytes  
Having observed that NHEKs exposed to acetate for 7 days prior to stimulation with 
TNF + IL-17 reduced IL-8 mRNA expression (at 6h post stimulation, p<0.001, Figure 
7-3) it was hypothesised that, in contrast to the positive effects at the IL-6 promoter, 
acetate would have an inhibitory effect on pol II (S2P) recruitment and overall 
repressive effects on the epigenome at the IL-8 promoter.  In particular it was 
hypothesised that acetate would augment enrichment of the epigenetic marks that were 
identified to be altered by TNF + IL-17 stimulation at the IL-8 promoter (section 
5.3.2). 
Co-immunoprecipitated, purified DNA samples (prepared as per section 7.3.9) were 
assayed by qPCR for enrichment of the IL-8 promoter region (using specifically 
designed primers, (Costa et al., 2013)) in media + acetate treated NHEKs compared to 
media alone.   
As shown in Figure 7-10, acetate significantly reduced recruitment of pol II (S2P) to the 
IL-8 promoter post-TNF + IL-17 stimulation (1h, p<0.05).  In addition, acetate 
significantly reduced the TNF + IL-17 stimulated increase in active epigenetic 
epitopes at 1h (Acetyl-H3, P<0.05; and H3K4me3, P<0.05).  Acetate also reduced the 
TNF + IL-17 stimulated increase in H3K9ac and H3K17ac; although not significant, 
this trend was observed at both 1h and 4h post-TNF + IL-17 stimulation.  Interestingly 
acetate significantly reduced the repressive H3K4me1 mark (1h, p<0.05, although this 
was not significant at 4h). 
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Figure 7-10: At the IL-8 promoter, pre-incubation with acetate decreased active 
epigenetic epitopes and pol II (S2P) recruitment 
See Figure 7-9 for experimental details.  NHEKs were harvested at 1h and 4h post-
stimulation and ChIP undertaken using antibodies to pol II (S2P) (A), epigenetic 
epitopes that positively regulate gene expression, highlighted in green (B) and 
epigenetic epitopes with repressive effects on gene expression, highlighted in red (C).  
Quantification of co-immunoprecipitated DNA was performed by qPCR, using primers 
to the IL-8 promoter region.    (N=3)  Analysis by one-way ANOVA with Dunnett’s 
post-test, comparing against the unstimulated media control; 
+
p<0.05, 
++
p<0.01, 
+++
p<0.001.  Analysis by two-way ANOVA with Bonferroni post-test, comparing 
against the relevant media control; *p<0.05, **p<0.01, ***p<0.001.  Data points show 
mean (after subtracting background/non-specific binding and normalised to an input 
control) ± SEM. 
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7.3.11. At the IL-6 enhancer, acetate had little effect on epigenetic epitopes and no 
effect on pol II (S2P) recruitment 
Having observed that in ChIP studies at the IL-6 promoter acetate enhanced recruitment 
of pol II (S2P) as well as an increase in active epigenetic epitopes, which could explain 
the potentiation of IL-6 expression in response to TNF + IL17 stimulation, we 
hypothesised that similar mechanisms might occur at the IL-6 enhancer region.  As an 
IL-6 enhancer has not been previously described in keratinocytes, we assayed the 
effects of acetate at a region previously described as an IL-6 enhancer in macrophages 
(Qiao et al., 2013) 
Co-immunoprecipitated, purified DNA samples (prepared as per section 7.3.9) were 
assayed by qPCR for enrichment of a region previously described as an IL-6 enhancer 
in macrophages, using specifically designed primers directed at this region (Qiao et al., 
2013) in media + acetate treated NHEKs compared to media alone.   
As shown in  
Figure 7-11, and in contrast to effects at the IL-6 promoter, acetate had little significant 
effect at the IL-6 enhancer, only the active epitope H3K27ac demonstrated a significant 
enhancement at 1h and 4h post-TNF + IL-17 stimulation (p<0.05 at both timepoints) 
and recruitment of pol II (S2P) to this region was not affected by acetate. 
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Figure 7-11: At a region previously defined as an IL-6 enhancer in macrophages, 
pre-incubation with acetate had relatively little effect  
See Figure 7-9 for experimental details.  NHEKs were harvested at 1h and 4h post-
stimulation and ChIP undertaken using antibodies to pol II (S2P) (A) and epigenetic 
epitopes that positively regulate gene expression, highlighted in green (B).  
Quantification of co-immunoprecipitated DNA was performed by qPCR, using primers 
to the potential IL-6 enhancer region.    (N=3)  Analysis by one-way ANOVA with 
Dunnett’s post-test, comparing against the unstimulated media control; +p<0.05, 
++
p<0.01, 
+++
p<0.001.  Analysis by two-way ANOVA with Bonferroni post-test, 
comparing against the relevant media control; *p<0.05, **p<0.01, ***p<0.001. Data 
points show mean (after subtracting background/non-specific binding and normalised to 
an input control) ± SEM. 
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7.3.12. Exposure of NHEKs to acetate did not alter histone acetyl transferase 
(HAT) or histone deacetylase (HDAC) enzyme activity or expression of acetyl-
coA synthetase (ACSS) enzymes 
Since acetate treatment resulted in hyperacetylation of histones and specific lysine 
residues at the IL-6 promoter, we hypothesised that acetate might upregulate expression 
of ACSS enzymes or alter the balance of HAT versus HDAC activity to favour 
hyperacetylation, similar to the mechanism observed in a model of acute alcoholic 
hepatitis (Kendrick et al., 2010).  To test this hypothesis, NHEKs were incubated with 
1mM acetate for 7 days, nuclear extracts were prepared and HAT and HDAC enzyme 
activity determined.  HAT activity was measured using a kit that detects acetylation of a 
substrate by HAT enzymes, using acetyl-coA as a substrate; the release of co-A in the 
reaction can be detected as a measurable colour change (section 2.10).  HDAC activity 
was measured using a kit that detects deacetylation of an acetylated lysine residue; in 
subsequent reactions the deacetylated lysine residue results in release of a chromophore 
or fluorophore which can be detected by a quantifiable colour change (HDAC 
1,2,6,10,11) or fluorescence (HDAC 1,2,6,8,10,11) (section 2.10).  Acetate effects on 
ACSS1 and ACSS2 expression were quantified by qRT-PCR/Taqman
®
 gene expression 
assays. 
As shown in Figure 7-12, acetate exposure had no significant effect on total HAT or 
HDAC enzyme activity, compared to control NHEKs grown in media alone.  
Furthermore, acetate exposure did not have any significant effect on ACSS1 or ACSS2 
expression, compared to control NHEKs grown in media alone (Figure 7-13). 
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Figure 7-12: pre-incubation with acetate had no significant effect on HAT or 
HDAC enzyme activity  
NHEKs were incubated with or without 1mM acetate for 7 days and effects on HAT (A) 
enzyme activity was determined using a kit based on colour change  after release of co-
A from acetyl-coA by HAT enzymes.  HDAC (B) enzyme activity was measured using 
a kit producing a change in colour (HDAC 1,2,6,10,11) or fluorescence (HDAC 
1,2,6,8,10,11)  after deacetylation of an acetylated substrate by HDAC enzymes.  (N=3, 
with each donor performed in triplicate repeat) Analysis by t-test; *p<0.05, **p<0.01, 
***p<0.001.  Graphs show mean of data points (normalised to media control) ± SEM.    
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Figure 7-13: Pre-incubation with acetate did not affect ACSS expression  
NHEKs were incubated with or without 1mM acetate for 7 days and ACSS mRNA 
expression was measured by qRT-PCR/Taqman
®
 gene expression assays.  (N=3, with 
each donor performed in triplicate repeat) Analysis by t-test; *p<0.05, **p<0.01, 
***p<0.001.  Graphs show mean of data points (normalised to media control) ± SEM.           
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7.3.13. I-BET151 attenuated acetate’s potentiation of the IL-6 response to TNF + 
IL-17 stimulation 
Potentiation of the IL-6 response to TNF + IL-17 stimulation together with 
hyperacetylation of histone residues at the IL-6 promoter, following pre-incubation with 
acetate, suggests histone hyperacetylation is a key component of the underlying 
mechanism that modulates gene expression.  In sections 4.3.4 and 4.3.5, it was 
demonstrated that BET proteins were involved in the TNF + IL-17 induced IL-6 and 
IL-8 expression.  These finding raised the hypothesis that BET proteins might also be 
involved in the acetate potentiated phenotype. To test this hypothesis we utilised I-
BET151, which specifically inhibits binding of BET proteins to acetyl lysine residues 
(section 1.3.7), to investigate whether I-BET151 would inhibit acetate’s potentiation of 
the IL-6 response to TNF + IL-17 stimulation.    
NHEKs were incubated with 1mM acetate for 7 days prior to stimulation with TNF + 
IL-17, either in the presence or absence of I-BET151 or vehicle (DMSO).  Paired 
cultures of NHEKs were harvested 6h post-TNF + IL-17 stimulation for mRNA 
(measured by qRT-PCR).  Supernatants were collected 48h post-stimulation and 
secreted IL-6 and IL-8 levels were measured by ELISA. 
A shown in Figure 7-14, acetate treatment enhanced the expression of IL-6 in response 
to TNF + IL-17 stimulation (p<0.01) although interestingly the effect was less 
significant in vehicle (DMSO) treated NHEKs (p<0.05), for both IL-6 mRNA and 
protein.  I-BET151 reduced IL-6 expression with a greater effect on protein than 
mRNA, as previously shown (section 4.3.2), but also in NHEKs pre-treated with 1mM 
acetate for 7 days prior to stimulation (P<0.001).  Furthermore, I-BET151 treatment 
blocked potentiation of IL-6 by acetate in the TNF + IL-17 stimulated model.  
Interestingly the inhibition of protein secretion appeared maximal with 0.3M I-
BET151 as inhibition was comparable for both concentrations of I-BET151. 
I-BET151 also had an inhibitory effect on expression of IL-8 in response to TNF + IL-
17 stimulation, although the inhibition was not as great as for IL-6 at the protein level, 
as previously demonstrated.  IL-8 protein was inhibited in acetate treated cells (p<0.01 
for 0.3M I-BET151) and the inhibition of IL-8 was more significant at a higher 
concentration of I-BET151 (p<0.001 for 1M I-BET151).  There was also inhibition of 
IL-8 mRNA in response to TNF + IL-17 stimulation in both acetate exposed and non-
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exposed NHEKs (p<0.05).  Consistent with our previous results, acetate did not 
significantly affect basal IL-6 or IL-8 mRNA or secreted protein in NHEKs not 
stimulated with TNF + IL-17.   Furthermore, I-BET151 had no significant effect on 
basal levels of IL-6 or IL-8, in unstimulated NHEKs (either in the presence or absence 
of acetate). 
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Figure 7-14: I-BET151 an inhibitor of BET protein interaction with acetylated 
lysine residues blocks acetate's potentiation of the IL-6 and IL-8 response to TNF 
+ Il-17 stimulation 
NHEKs were incubated with or without 1mM acetate for 7 days prior to stimulation 
with TNF (10ng/ml) + IL-17 (100ng/ml) or mock, in the presence or absence of I-
BET151 or vehicle (DMSO, 1:1200).  Secreted IL-6 (A) and IL-8 (C) protein was 
measured by ELISA, 48h post-stimulation (for protein: N=3, with each donor performed 
in triplicate repeat).  IL-6 (B) and IL-8 (D) mRNA was measured by qRT-PCR, 6h post-
stimulation, (for mRNA: N=3, with each donor performed in duplicate repeat).  
Analysis by two-way ANOVA with Bonferroni post-test, comparing against media 
control; *p<0.05, **p<0.01, ***p<0.001.  Analysis by one-way ANOVA with 
Dunnett’s post-test, comparing against vehicle control; +p<0.05, ++p<0.01, +++p<0.001.    
Graphs show mean of data points (normalized to media/untreated for mRNA) ± SEM. 
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7.4. Discussion 
For the first time in a model of cutaneous inflammation relevant to psoriasis we 
demonstrate that pre-incubation with acetate, a principal metabolite of ethanol, used at 
clinically relevant concentrations significantly enhanced the keratinocyte IL-6, but not 
IL-8, response to TNF + IL-17 stimulation, at both the mRNA and secreted protein 
level.  These findings could be accounted for by the chromatin changes, induced by 
acetate, at the IL-6 promoter, which facilitated recruitment of pol II (S2P) thus 
enhancing IL-6 expression.   In contrast acetate did not enhance permissive epigenetic 
epitopes or pol II (S2P) recruitment to the IL-8 promoter.  These findings provide 
mechanistic insight into how environmental factors, implicated in disease, interact with 
the genome to influence the disease phenotype.  Specifically this may explain how 
alcohol predisposes patients to an exaggerated inflammatory responses resulting in 
development or exacerbation of psoriasis, could lead to identification of novel targets 
for therapy and could be used to educate patients about the hazards associated with 
excess alcohol consumption. 
Our finding that acetate could modify epigenetic epitopes is in keeping with previously 
published data, where it has been shown that ethanol can mediate its effects on the 
epigenome through acetate (Park et al., 2003; Park et al., 2005).  Our data showed that 
in NHEKs, ethanol had no significant effect on IL-6 or IL-8 responses to TNF + IL-17 
stimulation and it was demonstrated that NHEKs showed low expression of enzymes, 
ADH and ALDH, involved in ethanol metabolism. This finding is consistent with 
previously published data which showed expression of class 1 ADH proteins, measured 
by western blot analysis, was approximately 30-fold higher in the liver compared to the 
skin (Cheung et al., 1999).   Furthermore, class 1 and 2 ALDH protein expression was 
also higher in the liver compared to the skin; approximately 22-fold and 12-fold, 
respectively (Cheung et al., 1999; Cheung et al., 2003).  In addition it has previously 
been calculated that ~96 to 98.8% of total ADH activity in the human body is confined 
to the liver and only 0.05% occurs in the whole of the skin and that the specific enzyme 
activity of skin derived ADH is ~190 fold lower than in liver for ethanol metabolism 
(Saleem et al., 1984).  Together these findings suggests there is very little metabolism 
ethanol in skin as a whole, compared to the liver, and therefore very little/negligible in 
individual keratinocytes.  This is likely to explain why ethanol had no effect on pro-
inflammatory responses, unlike its principle metabolite acetate. 
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We found that the magnitude of enhancement of IL-6 expression in response to TNF + 
IL-17 stimulation was dependent on the concentration of acetate, during the pre-
incubation period prior to stimulation.  This suggests that potentiation of the cutaneous 
inflammatory response may correlate with the degree of alcohol consumption and 
interestingly, in support of this suggestion, the severity of psoriasis has previously been 
shown to correlate with alcohol intake (Zou et al., 2015).  In addition, psoriatic skin and 
serum is rich in both TNF and IL-17 and has also been shown to correlate with disease 
severity (Takahashi et al., 2010), thus the cytokine milieu in psoriasis provides the 
necessary environment for acetate enhancement of cutaneous inflammation. 
The enhancement of IL-6 expression by acetate is in keeping with a model of acute 
alcoholic hepatitis in which it was shown that acetate enhanced the IL-6 response to 
lipopolysaccharide (LPS) in a human monoblastic cell line (Kendrick et al., 2010).  
However, Kendrick et al. also observed potentiation of IL-8 (and TNF) in responses to 
LPS, which we did not observe in our system.  Furthermore, Kendrick et al. only 
described potentiation effects of ethanol and acetate; no inhibitory effects or null effects 
on gene expression were described, the specificity of ethanol/acetate effects on different 
genes was therefore unclear.   These differences could be due to the differences in cell 
type or the stimulus.  For example, in our system we demonstrated that in NHEKs 
stimulated with TNF alone or UVB, pre-incubation with acetate could potentiate both 
IL-6 and IL-8 expression; LPS may have had a similar effect in our model system.  
However, as LPS is derived from gram negative bacteria, it would be difficult to justify 
the clinical relevance of investigating LPS in a cutaneous inflammatory model relevant 
to psoriasis.  It is interesting that in the KC model acetate potentiated IL-6 expression in 
response to TNF + IL-17 stimulation, but not IL-8 as this could be consistent with 
what is observed clinically.   As previously discussed, psoriasis patients with high 
alcohol consumption tend to have a more inflammatory phenotype, which would fit 
with enhanced IL-6 release.  In psoriasis, IL-6 is involved in differentiation and 
activation of naïve T-cells into TH17 cells, resulting in IL-17 release; IL-17 can induce 
further IL-6 production from non-immune cells, including keratinocytes and fibroblasts 
(Saggini et al., 2014).  Thus, ethanol/acetate could enhance the positive feedback loop 
between the adaptive and innate immune system.  On the other hand IL-8 is important 
in neutrophil recruitment in psoriasis (Gillitzer et al., 1996).  Therefore if alcohol or its 
metabolites potentiated IL-8 production in vivo, one might expect to more commonly 
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observe a pustular psoriasis phenotype in patients with high alcohol consumption, 
which is not the case (Higgins and du Vivier, 1992). 
Our results showed that lithium, although implicated as a risk factor in the development 
and exacerbation of psoriasis, did not potentiate the IL-6 or IL-8 response to TNF+ Il-
17 stimulated NHEKs, nor basal IL-6 and IL-8 levels in unstimulated NHEKs.  These 
findings are in keeping with previously published data, where it was shown that lithium 
chloride did not potentiate release of IL-6 or IL-8 protein in unstimulated keratinocytes 
derived from patients with psoriasis or healthy controls (Ockenfels et al., 1996).  
However the authors did demonstrate that lithium potentiated basal levels of 
transforming growth factor alpha (TGF) in keratinocytes derived from healthy 
controls.  We did not assay the effects of acetate on TGF; it is therefore difficult to 
make any direct comparisons for this particular response.  However these results may 
need to be interpreted with caution, as the concentration of lithium used by Ockenfels et 
al. was 1.5mM;  in vivo a serum-lithium concentration over 1.5mM is associated with 
toxicity (BNF, 2015).  Additionally, recently it was reported lithium chloride increased 
keratinocyte proliferation, through inhibition of glycogen synthase kinase 3 (GSK-3) 
(Ohteki et al., 2000; Hampton et al., 2012).  Hampton et al. demonstrated that clinically 
relevant concentrations of lithium lead to increased keratinocyte proliferation and that 
this could be reproduced by either pharmacological inhibition of GSK-3 or retroviral 
transduction of GSK-binding protein, a known endogenous inhibitory binding partner of 
GSK-3, which resulted in both increased nuclear translocation of Nuclear factor of 
activated T cells 2 (NFAT2) and transcriptional activation of NFAT (Hampton et al., 
2012).  These findings suggest that while both lithium and ethanol can exacerbate or 
provoke psoriasis, this may be through different underlying mechanisms.  However, 
these findings may need to be interpreted with caution as Ockenfels et al. and Hampton 
et al. both investigated the effects of lithium chloride and not the compounds which are 
used clinically i.e. lithium carbonate and lithium citrate.   
We also observed that propranolol did not potentiate pro-inflammatory responses to 
TNF and IL-17 stimulation.  Although beta-blockers are implicated as a risk factor for 
the development of psoriasis, the underlying mechanism is unknown. It is suggested 
that it may be through decreased levels of cyclic adenosine monophosphate, as a result 
of beta-blockade.  This is thought to lead to decreased levels of intracellular calcium 
and therefore reduced differentiation and increased proliferation, as seen in psoriasis 
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(Wu et al., 2014).  Therefore beta-blockers may influence the psoriasis phenotype 
through positive effects on proliferation rather than inflammation as we had initially 
hypothesised. 
Interestingly, acetate enhanced both IL-6 and IL-8 secreted protein secretion in response 
to UVB stimulation.  Epidemiological studies suggest that alcohol consumption is a risk 
factor for sunburn, as well as non-melanoma and melanoma skin (Saladi et al., 2010).  
Furthermore it has been shown that alcohol consumption causes a significant decrease 
in minimal erythemal dose (MED) (Darvin et al., 2013).  An MED is defined as the 
smallest amount of UV irradiation required to achieve just perceptible erythema 
(redness) of the skin, 24h after exposure, and is widely used in clinical practice as a 
visible indicator of a biological response. A reduction in MED therefore indicates that 
less irradiation is required to cause erythema of the skin.  The precise mechanism by 
which alcohol sensitises the skin to UV irradiation and contributes to skin cancer is 
unknown but it has been hypothesised that metabolites of ethanol, especially 
acetaldehyde, form highly reactive molecules which generate reactive oxygen species 
(ROS) upon UVB exposure which can lead to DNA damage (Saladi et al., 2010).  Our 
in vitro data showing that pre-incubation of keratinocytes with acetate sensitises them to 
UVB supports the clinical finding that ethanol, or its metabolites, sensitises the skin to 
UV irradiation and a reduction in MED in vivo.  Although we have shown that acetate 
induced enhancement of the IL-6 response to TNF+ IL-17 stimulation can be 
explained by changes to the epigenome, we have not shown that this is necessarily the 
case with the potentiation by acetate of the inflammatory response to UVB stimulation. 
We showed that NHEKs exposure to acetate for only 2 days was insufficient to 
potentiate a subsequent IL-6 response to TNF + IL-17 stimulation.  In a model of 
acute alcoholic hepatitis, it was shown that prolonged exposure to ethanol (6 days) or 
acetate (2 days) was necessary for the induction of ACSS enzymes, responsible for the 
conversion of acetate to acetyl-coA, which the authors found was essential for the 
facilitation of histone hyperacetylation (Kendrick et al., 2010).  However in our system 
prolonged acetate exposure for 7 days had no effect on ACSS expression, HAT or 
HDAC activity.  In contrast to Kendrick et al.’s observations in a monoblastic cell line, 
ethanol nor acetate treatment did not significantly affect total HDAC activity in rat-
derived hepatocytes (Park et al., 2005).  This suggests that either i) changes in HDAC 
activity are not responsible for ethanol/acetate induced changes in acetylation or ii) 
because individual HDACs (and HATs) target particular histone residues, it is plausible 
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that specific HDAC(s) may be inhibited by ethanol/acetate thereby contributing to the 
net increase in acetylation of specific lysine residues.    
Our mechanistic ChIP studies showed that the differential effects of acetate on IL-6 and 
IL-8 responses to TNF + IL-17 stimulation could be explained by the changes seen at 
the promoter regions of these two genes.  In NHEKs, incubation with acetate for 7 days 
had no effect on basal expression of IL-6 or IL-8, in unstimulated cells.  Entirely in 
keeping with this finding, acetate also had no significant effects on epigenetic marks or 
pol II (S2P) recruitment to IL-6 or IL-8 promoters in unstimulated cells.  Pre-incubation 
with acetate only had an effect on the epigenome in conjunction with stimulation.  At 
the IL-6 promoter, acetate treatment prior to TNF + IL-17 stimulation resulted in 
significant enhancement of acetylation of histone H3 (as well as H3K9ac and 
H3K27ac), H3K4me3 and recruitment of pol II (S2P).  It has previously been shown 
that there is a degree of specificity to ethanol-induced histone acetylation; ethanol 
treatment of hepatocytes increased acetylation of histone H3 at lysine residue 9, but had 
little effect on acetylation of lysine residues 14, 18 and 23 (Park et al., 2005).  This 
specificity was also demonstrated in vivo in rats exposed to ethanol; and acetate was 
shown to have similar effects (Park et al., 2005).  Park et al. also demonstrated that 
H3K9ac was increased at the ADH I promoter, this is consistent with their finding that 
ethanol exposure upregulates expression of this gene and consistent with our finding 
that acetate mediates its effects, in part, through increased H3K9ac at target gene 
promoters. 
Interestingly in a model of acute alcoholic hepatitis, the authors demonstrated that 
ethanol exposure alone (without LPS stimulation) lead to increased histone acetylation 
at the IL-6 promoter (Kendrick et al., 2010).  Kendrick et al. did not investigate the 
effects of acetate on histone acetylation at gene promoter regions; it may therefore be 
difficult to make direct comparisons with our results.  However, in our system we 
showed that acetate enhanced pol II (S2P) recruitment and histone and lysine (residues 
9 and 27) acetylation at the IL-6 promoter only in the presence of stimulation (TNF + 
IL-17), but not in baseline unstimulated cells as demonstrated in the acute alcoholic 
hepatitis model.  Our findings are internally consistent; acetate did not potentiate basal 
IL-6 production in unstimulated cells, which is in keeping with the observation that 
acetate had no effect on pol II (S2P) recruitment or histone acetylation at the IL-6 
promoter in unstimulated cells.  In contrast to effects at the IL-6 promoter, at the IL-8 
promoter pre-incubation with acetate had the opposite effect in that there was a decrease 
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in histone and lysine acetylation and inhibition of pol II (S2P) recruitment following 
stimulation with IL-17 + TNF.  As previously discussed (section 1.3.6) BET proteins 
are known to bind acetylated lysine residues found on histones, orchestrate recruitment 
of transcription factors  and proteins involved in RNA polymerase II activation, thus 
BET proteins can regulate gene expression.  Since the modulation of inflammatory 
responses by acetate could be explained by changes in histone acetylation and pol II 
(S2P) recruitment, BET proteins may also be involved in underlying mechanisms. 
Of interest, in addition to modulating histone acetylation, pre-incubation with acetate 
also affected histone methylation, in TNF + IL-17 NHEKs.  For example, at the IL-6 
promoter acetate significantly enhanced H3K4me3, a permissive epigenetic mark, but 
significantly decreased H3K4me3 at the IL-8 promoter.  Our observation that acetate 
can affect histone methylation is supported by the finding that ethanol treatment of rat-
derived hepatocytes has been shown to alter the methylation status of lysine residues on 
histones (Pal-Bhadra et al., 2007).  Interestingly, Pal-Bhadra et al. demonstrated that 
ethanol affected methylation patterns in a lysine-residue specific manner; ethanol 
induced an increase in global dimethylation on lysine 4 on histone-H3 (H3K4me2) but a 
decrease in global dimethylation on lysine 9 on histone-H3 (H3K9me2).  The local 
effects of acetate on histone acetylation and methylation at IL-6 and IL-8 promoters are 
entirely consistent with the differential effects of acetate on IL-6 and IL-8 responses to 
TNF + IL-17 stimulation and provide mechanistic insight into how environmental 
stimuli regulate cutaneous inflammation.   
As an IL-6 enhancer has not been defined in keratinocytes, we investigated the effects 
of acetate at a region previously defined as an IL-6 enhancer in macrophages (Qiao et 
al., 2013); pre-incubation with acetate had little significant effect on the epigenome at 
this region and had no effect on pol II (S2P) recruitment.  However, as this region 
demonstrated little enrichment of H3K27ac, H3K4me1 and Brd4, it is unlikely to 
function as IL-6 enhancer region in keratinocytes, as previously discussed in sections 
4.4 and 5.4.  It is therefore difficult to conclude if the effects of acetate were solely 
through chromatin remodelling at the IL-6 promoter region and not at other regulatory 
regions. 
As a global change in ACSS expression, or indeed HAT or HDAC activity, could not 
necessarily explain the potentiation of IL-6 versus the repression of IL-8 responses by 
acetate nor the changes in histone methylation in our data, we hypothesised that local 
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changes at the level of individual gene promoters or enhancers driven by acetate 
induced activation or inhibition of specific epigenetic writers (e.g. acetylases or 
methylases) and/or erasers (e.g. deacetylases or demethylases) would be necessary to 
account for these differences.  Our finding that acetate had a differential effect on the 
epigenome at the IL-6 versus IL-8 promoters is consistent with a model of alcohol-
induced cardiac hypertrophy, in which ethanol-exposed mice demonstrated increased 
expression of the transcription factor NKX2.5 involved in cardiac development and 
hypertrophy with a corresponding increase in H3K9ac at the NKX2.5 promoter(Peng et 
al., 2015). In contrast, there was no increase in H3K9ac at the RPL13A promoter, a 
gene whose expression was not enhanced with ethanol treatment (Peng et al., 2015).  
This supports our hypothesis that the phenotypic effects of ethanol, or its metabolites, 
can be explained by localised chromatin remodelling at individual gene promoters.  To 
account for the differential epigenetic modifications at the IL-6 versus IL-8 promoters, 
we hypothesise that acetate modulated the recruitment of epigenetic writers (e.g. HATs) 
and erasers (e.g. HDACs) to individual gene promoters.  In support of this hypothesis, it 
has previously been shown that in nuclear extracts prepared from rat derived 
hepatocytes, both ethanol and acetate exposure lead to the selective enhancement of 
acetylation of H3 at lysine 9 (H3K9ac), suggesting that ethanol or acetate could 
selectively modulate activity of epigenetic writers and erasers with specificity for 
particular histone residues (Park et al., 2005).  More recently, in a mouse model of 
alcohol-induced cardiac hypertrophy, ethanol-induced localisation of specific members 
of the HAT family (p300, CBP, PCAF, SRC1 and GCB5) to the NKX2.5 promoter and 
that ethanol enhanced the binding of a specific subset of these (p300, CBP, PCAF and 
SRC1 but not GCB5), corresponding to enhance expression of NKX2.5.  In addition 
anacardic acid, a pan-HAT inhibitor, reduced binding of p300 and PCAF with 
corresponding attenuation of H3K9ac. (Peng et al., 2015).  To explain the finding that 
acetate also had a differential effect on histone methylation at IL-6 and IL-8 promoters, 
we hypothesised that acetate would also affect recruitment of methylases and 
demethylases to specific genes.  Consistent with this hypothesis, in ChIP studies of 
ethanol treated rat-derived hepatocytes showed that H3K4me2 was enriched at the 
promoter region of genes which were upregulated with ethanol treatment, whereas 
H3K9me2 was enriched at the promoter region of genes which were downregulated 
with ethanol treatment, although the underlying mechanism could not be explained (Pal-
Bhadra et al., 2007).  Together these findings suggest ethanol, or acetate, can induce a 
variety of epigenetic modifications at the promoter region of specific genes by directing 
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recruitment of particular epigenetic writers (and potentially erasers).  This mechanism 
could explain the differential effects of acetate (on both histone acetylation and 
methylation) at IL-6 and IL-8 promoters that we observed. 
Interestingly, similar to the effects of acetate, IFN enhanced IL-6, but not IL-8, protein 
response to TNF + IL-17 stimulation in NHEKs (section 3.3.1).  As discussed in 
section 3.4, in macrophages, pre-treatment with IFN synergistically upregulated 
subsequent LPS-induced response of IL-6 (Qiao et al., 2013).  Qiao et al. demonstrated 
this was mediated through IFN induced recruitment of HAT enzymes (p300 and CBP) 
to the IL-6 promoter, resulting in increased acetylation of H3K27, thus facilitating IL-6 
expression; the effects of IFN on IL-8 responses to LPS stimulation were not 
investigated. Together these findings demonstrate that IL-6 response is more sensitive 
to potentiation by added stimuli, e.g. acetate and IFN, and that these different stimuli 
mediate their potentiation through a common pathway i.e. histone hyperacetylation (e.g. 
H3K27ac) at the IL-6 promoter, this likely to be through the recruitment of particular 
HAT enzymes (e.g. p300 and CBP) specifically to the IL-6 promoter, ultimately 
resulting in increased IL-6 expression.  
I-BET151 treatment inhibited acetate enhancement of IL-6 response (mRNA and 
protein) to TNF + IL-17 stimulation. Whilst this finding does not necessarily provide 
additional understanding of the underlying mechanisms involved, it supports the 
hypothesis that these involve BET proteins which are a key, rate-limiting step and a 
potential therapeutic target in alcohol-provoked psoriasis  In this respect I-BET151, 
may block BET proteins binding either to the acetylated histones at gene regulatory 
regions or to other proteins involved in transcription e.g. acetyl-p65 or pTEFb, as 
previously discussed (section 4.4).  The hypothesis that histone hyperacetylation (which 
may involve BET proteins) plays a key role in enhancing gene expression in response to 
ethanol/acetate treatment is supported by the observation that anacardic acid (a pan-
HAT inhibitor) attenuated alcohol-induced enhancement of NKX2.5 expression in a 
model of alcohol-induced cardiac hypertrophy (Peng et al., 2015). Peng et al. 
demonstrated anacardic acid decreased hyperacetylation of H3K9 as well as p300 and 
PCAF binding at the NKX2.5 promoter.  Interestingly our results showed that the 
vehicle (DMSO) also reduced the potentiation of the IL-6 response in TNF + IL-17 
stimulated NHEKs.  Two studies implicate DMSO in affecting histone acetylation, or 
binding to the acetyl-lysine residue, and potentially may explain effects of DMSO in the 
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acetate/TNF + IL-17 model.  Firstly DMSO may have HDAC inhibitor activity; it has 
previously been shown that DMSO can induce cellular differentiation and it was 
through this observation that HDAC inhibitors were developed, based initially on the 
structure of DMSO (Marks and Breslow, 2007).  Secondly, DMSO has been shown to 
bind within the acetyl-lysine binding cavity of BET proteins. However as the 
concentration of DMSO used in our studies (11.8mM) was low compared to the DMSO 
IC50 for Brd2 and Brd4, 255.9mM and 218mM respectively, based on peptide 
displacement assays (Philpott et al., 2011), this second possible explanation is perhaps 
less likely to account for the effects of DMSO in the acetate/TNF + IL-17 model. 
7.5. Future work 
It would be interesting to understand in our system the localised, underlying 
mechanisms at the IL-6 versus IL-8 promoter regions which give rise to the observed 
differences on the epigenome and pol II (S2P) recruitment to these two regions.  We 
propose a number of possible underlying hypotheses/future work: 
1) We demonstrated that exposure to acetate for only 2 days was insufficient to 
potentiate the IL-6 response.  Could acetate affect the expression or activation of 
transcription factors or co-factors involved in IL-6 or IL-8 expression? In 
addition to histone acetylation, could acetate act as a substrate (through the 
conversion to acetyl-coA by ACSS) for the acetylation of other transcription 
factors (e.g. p65) involved in gene expression?   Does any delay in expression or 
activation explain why 2 days’ exposure of NHEKs to acetate is insufficient to 
observe acetate’s effects on responses to stimulation?   
2) We showed that acetate’s potentiation of inflammatory responses was both gene 
and stimulus specific, and demonstrated differential effects at target gene 
promoters.  What are the underlying mechanisms; do particular stimuli have 
localised effects at the level of gene promoters (or enhancers) e.g. through 
differential recruitment of epigenetic writers (e.g. HATs) and erasers (e.g. 
HDACs)? 
3) BET proteins are known to bind acetylated lysine residues on histones, which 
are augmented by acetate. Therefore, are BET proteins involved in underlying 
mechanisms which might explain how acetate affects gene expression? 
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4) Which other genes, other than IL-6 and IL-8, are enhanced or repressed by 
acetate treatment prior to TNF + IL-17 stimulation in our model and how do 
these genes relate to psoriasis pathogenesis? 
 
7.6. Conclusions 
 Acetate, a principal metabolite of ethanol, potentiated IL-6, but not IL-8 
expression in response to TNF + IL-17 stimulation. 
 Ethanol did not potentiate IL-6 or IL-8 expression in response to TNF + IL-17 
stimulation; NHEKs demonstrated low expression of enzymes involved in 
ethanol metabolism.   
 Lithium and propranolol did not potentiate IL-6 or IL-8 expression in response 
to TNF + IL-17 stimulation. 
 IL-6 expression induced by both cytokine and non-cytokine stimuli, were more 
sensitive to potentiation by supra-basal exposure to acetate, compared to IL-8. 
 In the TNF + IL-17 stimulation model, at the IL-6 promoter, acetate exposure 
resulted in chromatin remodelling with histone hyperacetylation and 
enhancement of pol II (S2P) recruitment, thus promoting IL-6 expression.  This 
was consistent with the effect of acetate to potentiate IL-6 mRNA expression.  
Acetate had little effect at the IL-6 enhancer. 
 In comparison in the TNF + IL-17 stimulation model, at the IL-8 promoter 
acetate exposure resulted in chromatin remodelling with histone deacetylation 
and inhibition of pol II (S2P) recruitment, thus inhibiting IL-8 expression.  This 
was consistent with acetate’s inhibitory effects on IL-8 mRNA expression. 
 The effect of acetate on pro-inflammatory responses, through epigenetic 
modifications, may explain how alcohol predisposes patients to an exaggerated 
inflammatory response resulting in exacerbation of their psoriasis and provide 
mechanistic insight into the regulation of cutaneous inflammation by defined 
environmental signals. 
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8. Concluding remarks 
Psoriasis represents a complex interplay between genetic predisposition, the 
environment and inflammatory responses.  Although how these factors interact to 
influence the psoriasis phenotype is incompletely understood, there is increasing 
evidence that alterations in the epigenome, including aberrant histone acetylation, plays 
an important role in regulating inflammatory skin conditions, including psoriasis.  In 
addition, there is little documentation about the function of BET proteins or the effects 
of BET inhibition in keratinocytes.  However, given that psoriasis is characterised by 
chronic inflammation and excessive keratinocyte proliferation, and that BET inhibitors 
are known to have anti-proliferative and anti-inflammatory effects in other cell types, it 
was hypothesised that epigenetic modifications and BET proteins would be involved in 
regulating inflammatory gene responses to cytokines relevant to psoriasis and that BET 
inhibitors would block the pathogenic inflammatory response to stimuli in 
keratinocytes. 
This project set out to evaluate the role that epigenetics, including histone acetylation 
and BET epi-reader proteins, plays in regulating cutaneous inflammation and 
inflammatory skin disease and how exogenous factors relevant to disease might alter 
inflammatory responses through underlying changes in the epigenome of effector genes.   
The main tool used to investigate epigenetic modifications was an in-vitro keratinocyte 
model of cutaneous inflammation (Chiricozzi et al., 2011) which was further developed 
by investigating the effects of TNF + IL-17 stimulation on secreted cytokine responses 
and evaluating the model for pre-clinical testing of potential therapeutic compounds.  
This work demonstrated that stimulation of normal human epidermal keratinocytes 
(NHEKs) with TNF + IL-17, key cytokines in the pathogenesis of psoriasis, induced 
expression of IL-6 and IL-8 (mRNA and protein).  Consistent with these findings we 
demonstrated through chromatin immunoprecipitation (ChIP) studies, for the first time, 
that TNF + IL-17 stimulation induced histone modifications including global 
hyperacetylation of histone-H3, as well as acetylation of specific lysine residues 
associated with active promoters (e.g. H3K9ac and H3K27ac), at the promoter regions 
of IL-6 and IL-8.   In contrast, TNF + IL-17 stimulation had no significant effect on a 
repressive epigenetic epitope, H3K4me1.  Collectively these data demonstrate that there 
is dynamic, gene-specific modulation of the epigenome, inducible by disease relevant 
stimuli, regulating gene expression in human keratinocytes. 
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The model of cutaneous inflammation was then used to study potential new therapies. 
We initially demonstrated ciclosporin, a compound used clinically to treat psoriasis, 
inhibited IL-6 and IL-8 induction in response to TNF + IL-17 stimulation, illustrating 
that the in vitro model of cutaneous inflammation could be used for pre-clinical 
evaluation of compound effects.   Following on from this, we chose to explore the role 
of the BET epi-reader proteins in the model, which are known to bind acetylated lysine 
residues, found on histones via bromodomains and recruit transcription factors, thereby 
regulating gene expression.  We showed that TNF + IL-17 stimulation resulted in 
transient and co-ordinated recruitment of BET proteins (Brd2, Brd3 and Brd4) and RNA 
polymerase II to the promoter regions of IL-6 and IL-8, consistent with the positive 
effects of stimulation on histone acetylation and IL-6 and IL-8 mRNA expression.  
Small molecule BET bromodomain inhibitors have been discovered which exhibit anti-
proliferative and anti-inflammatory effects in in vitro and in vivo models of cancer and 
inflammation, therefore we hypothesised that BET inhibitors would inhibit 
inflammatory responses in keratinocytes.  I-BET151, a specific small molecule BET 
inhibitor, potently inhibited IL-6 induction by TNF+ IL-17 but had a weaker and 
more variable effect on IL-8.  Moreover, chromatin immunoprecipitation (ChIP) studies 
showed that I-BET151 reduced recruitment of Brd4 to the IL-6 promoter and Brd3/4 to 
the IL-8 promoter, with corresponding decreases in RNA polymerase II binding at both 
promoters, in TNF + IL-17 stimulated NHEKs; these findings were consistent with the 
inhibitory effects of I-BET151 on IL-6 and IL-8 mRNA expression.  Additionally, we 
hypothesised that I-BET151 would be most effective during the phase of chromatin 
remodelling induced by the TNFα + IL-17 stimulation, and thus be active even when 
added after stimulation. This mechanism is in contrast to drugs which block the 
stimulation event or proximal cytokine receptor-signalling.  In support of this 
hypothesis, I-BET151 continued to have an inhibitory effect on IL-6 and IL-8 
expression when added after stimulation (up to 2h for IL-6/-8 mRNA and up to 24h for 
IL-6 protein), which also more realistically reflects how psoriasis treatments are used 
clinically.  In addition, given that levels of IL-6 and IL-8 are high in lesional psoriatic 
skin, reflecting active transcription of these genes, then chromatin around the promoter 
region of IL-6 and IL-8 is likely to be in an “active/open” (euchromatin) state and 
accessible to compound.  These novel findings demonstrate that stimuli relevant to 
disease induce chromatin remodelling, provide mechanistic insight into the role of BET 
proteins in regulating cutaneous inflammatory responses and highlight that BET 
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proteins could represent novel targets for psoriasis treatment.  This concept is supported 
by recently published findings that JQ-1, another BET inhibitor, inhibited psoriasis-like 
cutaneous inflammation in an imiquimod-induced mouse model of psoriasis (Nadeem et 
al., 2015).    
Global gene expression array experiments were also undertaken to investigate the wider 
effects of TNF + IL-17 stimulation in NHEKs and I-BET151 treatment in the model, 
and to place the results for IL-6 and IL-8 into a broader context.  Comparisons of genes 
regulated by TNF + IL-17 in NHEKs to a previously published psoriasis datasets (the 
MAD-5 psoriasis transcriptome), demonstrated that > 25% of genes regulated by these 
stimuli were also differentially expressed in psoriasis (Tian et al., 2012).  In TNF + 
IL-17 stimulated NHEKs, I-BET151 modulated expression of genes mainly involved in 
cell cycle, p53 signalling and inflammation, and of the 1120 up or downregulated genes 
in the MAD-5 transcriptome ~20% of genes were differentially modulated by I-BET151 
treatment in TNF + IL-17 stimulated NHEKs.  Specifically, I-BET151 inhibited 
expression of key regulators of inflammation in psoriasis, including IL1A, IL1B and 
NFKB.  Comparisons of genes regulated by TNF + IL-17 stimulation and sensitive to 
I-BET151 treatment, with an Ingenuity
®
 Pathway Analysis (IPA)-defined psoriasis 
network and the MAD-5 psoriasis transcriptome, revealed a number of overlapping 
genes as well as ones which were regulated by stimulation and differentially expressed 
in psoriasis but have not previously been characterised in the pathogenesis of psoriasis. 
These genes may represent interesting candidates for further investigation.  Together 
these findings suggest the in vitro model of cutaneous inflammation is a valid cell 
model for studying pathogenic pathways, regulation of expression of genes involved in 
cutaneous inflammatory responses relevant to psoriasis and supports the hypothesis that 
BET proteins are involved in regulating cutaneous inflammation and that BET 
inhibitors may represent novel therapy for the treatment of psoriasis. 
The global gene expression array studies with I-BET151 in TNF + IL-17 stimulated 
NHEKs, also showed that I-BET151 inhibited expression of genes encoding proteins 
involved in protein synthesis and post-translational modification.  These findings may 
explain the differential effects of I-BET151 on IL-6 mRNA versus protein responses to 
TNF + IL-17 stimulation, and support the hypothesis that BET inhibitors impair 
expression of molecules with post-transcriptional roles, as previously suggested with 
HDAC inhibitors (Grabiec et al., 2012).  In addition to I-BET151 regulating expression 
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of genes involved in the cell cycle and p53, downregulation of MYC was at the centre 
of an IPA network encompassing the most number of I-BET151-sensitive genes, in 
keeping with previously published effects on BET inhibitors on MYC expression 
(Dawson et al., 2011; Delmore et al., 2011; Wyce et al., 2013).  The role of BET 
proteins and BET inhibitors in keratinocyte-derived cancers, including basal cell 
carcinoma and squamous cell carcinoma, the most common non-melanoma skin cancers 
in which over-expression of MYC is implicated, therefore warrants further 
investigation. 
Exogenous factors, including alcohol, are implicated in the development and 
exacerbation of psoriasis.  Alcohol and its principal metabolite, acetate, was previously 
shown to enhance pro-inflammatory responses to stimuli in macrophages, through 
epigenetic modifications and we hypothesised similar processes existed in 
keratinocytes.  Pre-treatment with acetate resulted in concentration-dependent 
potentiation of IL-6 expression, but not IL-8, in response to TNF + IL-17 stimulation 
compared to control. Consistent with this, chromatin immunoprecipitation studies 
showed pre-treatment of keratinocytes with acetate significantly enhanced the TNF + 
IL-17 stimulated increase in permissive epigenetic epitopes and RNA polymerase II 
recruitment to the IL-6 promoter, but not to the IL-8 promoter.  On the other hand, 
ethanol did not significantly potentiate IL-6 or IL-8 responses to TNF + IL-17 
stimulation in keratinocytes. Keratinocytes exhibited low expression of enzymes 
involved in ethanol metabolism, which probably accounted for the lack of effect of 
ethanol in the model.  Although lithium and propranolol have also been implicated in 
the development and exacerbation of psoriasis, pre-treatment of NHEKs with these 
compounds did not result in any potentiation of subsequent inflammatory responses, 
suggesting these factors may act through alternative mechanisms to ethanol/acetate.  
The enhancement of pro-inflammatory responses by acetate, through epigenetic 
modifications, may explain how alcohol predisposes patients to an exaggerated 
inflammatory response resulting in development or exacerbation of psoriasis and could 
be used to educate patients about the hazards associated with excess alcohol 
consumption. These data provide mechanistic insight into the regulation of cutaneous 
inflammation by defined environmental signals and could lead to identification of novel 
targets for therapy.  In addition, these findings could explain how environmental factors 
interact with genetic predisposition in other common complex diseases e.g. cancer, 
diabetes and cardiovascular disease. 
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TNF + IL-17 stimulation had a consistently synergistic effect on IL-8 mRNA 
induction in all donors, but donor-dependent effects on IL-6 induction.  In addition, we 
showed that both acetate and IFN enhanced the IL-6, but not IL-8, response to TNF + 
IL-17 stimulation.  These findings suggest that i) IL-6 responses are more sensitive to 
enhancement by additional disease relevant stimuli and ii) IL-6 and IL-8 are 
differentially regulated at the transcriptional level.  Interestingly, TNF + IL-17 
simulated NHEKs demonstrated greater enrichment of Brd4 and p65 at the IL-6 
promoter than at the IL-8 promoter, and changes in p65 binding tracked with the 
kinetics of Brd4 binding at the IL-6 promoter.  These findings could suggest NF-B 
plays a greater role in regulating IL-6 expression, compared to IL-8 expression, 
consistent with previous findings in Jurkat T cells (Khalaf et al., 2013). They also raise 
the hypothesis that NF-B (p65)-regulated genes are more sensitive to enhancement by 
additional stimuli and that Brd4/p65 may mediate enhancement of gene expression 
through binding to the promoter, of effectors genes, which are hyperacetylated in 
response to pathogenic stimuli e.g. acetate or IFN (Qiao et al., 2013). 
In summary we have further developed an in vitro keratinocyte model of cutaneous 
inflammation to study the regulation of genes involved in pathogenic pathways and to 
evaluate novel targets/drugs.  Disease relevant stimuli induced dynamic, gene-specific 
epigenetic changes, with co-ordinated recruitment of BET proteins (Brd2, Brd3 and 
Brd4) and RNA polymerase II, at the promoter region of effector genes.  In addition 
acetate a principal metabolite of ethanol, which is implicated in the pathogenesis of 
psoriasis, modulated pro-inflammatory responses to stimulation through gene-specific 
changes in the epigenome.  IL-6 and IL-8 responses to stimuli were found to be 
differentially sensitive to potentiation by additional disease relevant factors, e.g. acetate 
and IFN, and it was observed that there was increased enrichment of Brd4/p65 at the 
IL-6 promoter than at the IL-8 promoter, raising the hypothesis that NF-B (p65)-
regulated genes are more sensitive to additional stimuli and that Brd4/p65 are involved 
in underlying mechanisms in alcohol provoked-inflammatory skin disease, consistent 
with previous findings in IFN+ LPS stimulated macrophages (Qiao et al., 2013).  
Pharmacological profiling of a specific BET inhibitor was supported by gene array data 
and putative mechanisms validated through ChIP studies.  The sensitivity of psoriasis 
related genes to BET inhibition, supports a biological model in which epigenetic 
process are involved in the pathogenesis of psoriasis and that these processes can be 
dynamic, subject to reversal and potentially targetable by compounds thereby altering 
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the phenotype.  In addition drugs currently used in the treatment of psoriasis to induce 
remission are associated with changes in the epigenome (Roberson et al., 2012; Gu et 
al., 2015), relapse in disease may therefore also be associated with potentially reversible 
epigenetic processes.  The effect of BET inhibition highlights the potential for targeting 
epigenetic processes, and in this case specifically BET proteins are implicated as 
targets. Collectively the data highlight the area of epigenetics as a potential route to 
discover novel disease modifying therapies. 
8.1. Future directions 
It would be interesting to investigate whether there are specific expression quantitative 
trait loci (eQTLs) associated with donor-dependent variability in keratinocyte 
inflammatory responses, whether these are associated with particular disease endotypes 
or whether these represent potential biomarkers for sensitivity to therapy. In the UK, the 
British Association of Dermatologists' Biologic Interventions Register (BADBIR) and 
Psoriasis Stratification to Optimise Relevant Therapy (PSORT) 
(http://www.psort.org.uk/; Burden et al., 2012) studies could provide suitably large 
cohorts to link  genome wide association studies (GWAS) and epigenome wide 
association studies (EWAS) to gene expression data for specific genes.   
ChIP-sequencing (ChIP-Seq) could be an informative screening method to investigate 
where, for example, Brd4 (other BET proteins), p65 or acetyl marks map within the 
genome in order to further understand their regulatory roles. Advances in ChIP-Seq 
technology using low cell numbers could allow this to be performed in activated 
primary keratinocytes in future (Mundade et al., 2014; Jakobsen et al., 2015). 
Future investigations into how disease relevant cytokine stimuli e.g. TNF, IL-17 and 
IFNγ, influence the balance between epigenetic writers and erasers to regulate the 
epigenome, how environment factors affects this balance and which genes are most 
sensitive to exogenous stimuli, this may reveal novel targets for therapy. 
Further data-mining of the gene array analysis generated here may identify candidates 
for further investigation into the pathogenesis of psoriasis or as novel targets for its 
treatment.  In addition this may provide further rationale for investigating the role of 
BET proteins and BET inhibitors in suitable models of keratinocyte-derived skin 
cancers.  
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